fluorouracil has been researched along with Head and Neck Neoplasms in 1265 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 9.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 9.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "We measured the effectiveness of the prophylactic administration of a polaprezinc suspension dispersed in sodium alginate solution (P-AG) by dividing it into two courses in the same patients, and measured the stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy." | 9.15 | [Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer]. ( Fujiki, Y; Hama, T; Hatake, K; Ishibashi, M; Kawakami, K; Kawata, K; Mishima, Y; Nemoto, M; Sugisaki, T; Takahashi, S; Yokoyama, M, 2011) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 9.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 7.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin." | 7.80 | Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 6.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| "Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)." | 6.69 | Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 5.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery." | 5.32 | Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. ( Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K, 2004) |
| "This study compared the efficacy and toxicity of Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil (5-FU) in patients of recurrent squamous cell carcinoma of head and neck (SCCHN) treated with palliative intent." | 5.20 | Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. ( Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP, 2015) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 5.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "To evaluate the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of the head and neck (SCCHN)." | 5.15 | Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study. ( Birzgalis, A; Homer, J; Jegannathen, A; Lee, L; Mais, K; Ryder, WD; Slevin, N; Sykes, A; Yap, B, 2011) |
| "We measured the effectiveness of the prophylactic administration of a polaprezinc suspension dispersed in sodium alginate solution (P-AG) by dividing it into two courses in the same patients, and measured the stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy." | 5.15 | [Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer]. ( Fujiki, Y; Hama, T; Hatake, K; Ishibashi, M; Kawakami, K; Kawata, K; Mishima, Y; Nemoto, M; Sugisaki, T; Takahashi, S; Yokoyama, M, 2011) |
| " At CDDP 50 mg/m2, raltitrexed 3 mg/m2, 5-FU 900 mg/m2, four out of six patients showed DLT, which was in all cases grade 4 neutropenia." | 5.09 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG). ( Avallone, A; Budillon, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Di Gennaro, E; Ionna, F; Manzione, L; Mozzillo, N; Rivellini, F, 2000) |
| "We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity." | 5.09 | Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F, 2001) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 5.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| " The combination chemotherapy with CDDP and 5-fluorouracil (5-FU), which has great efficacy for head and neck cancer, induces nausea and vomiting as side effects." | 5.08 | [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1997) |
| "The effects of weekly subcutaneous recombinant human erythropoietin (r-hEPO) administration on anemia during chemotherapy including cisplatin and 5-fluorouracil in patients with head and neck carcinomas were examined." | 5.08 | Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. ( Itoh, K; Kawai, S; Kohno, H; Kokatsu, T; Tsukuda, M; Yuyama, S, 1998) |
| " Leukopenia was severe in the first two steps of treatment, with WHO grade IV toxicity occurring in 41% of patients; however, this decreased to 10% when vindesine was deleted from the chemotherapy regimen in the last two steps." | 5.07 | Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study. ( Bauer, J; Bernasconi, S; Leyvraz, S; Monnier, P; Pasche, P, 1994) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| "Recent studies suggest that 5-fluorouracil (5-FU) dosing by use of pharmacokinetic (PK) parameters is superior to the traditional body surface area (BSA) method in colorectal cancer therapy." | 4.93 | Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis. ( Han, Y; Lyu, Y; Tong, Q; Yang, P; Yang, R; Zhang, P; Zhang, Y; Zhou, H, 2016) |
| "At this juncture in the development of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), knowledge about the agent's pharmacologic behavior and clinical antitumor activity in less common neoplasms is being elucidated." | 4.79 | Paclitaxel pharmacology and other tumor types. ( Rowinsky, EK, 1997) |
| "The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 3.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
| "The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF)." | 3.83 | Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone. ( Ejima, Y; Hasegawa, S; Hashikawa, K; Kenji, Y; Kiyota, N; Kohmura, E; Nibu, K; Nomura, T; Otsuki, N; Sakakibara, S; Sasaki, R; Shinomiya, H; Yamashita, D, 2016) |
| "The use of cetuximab in combination with platinum (P) plus 5-fluorouracil (F) has previously been demonstrated to be effective in the treatment of metastatic squamous cell cancer of head and neck (SCCHN)." | 3.80 | Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution. ( Alves, MP; Avezedo, I; de Mello, RA; Dinis, J; Gerós, S; Moreira, F, 2014) |
| "Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin." | 3.80 | Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014) |
| "Oropharyngeal cancers were most responsive, whereas results were less satisfactory for oral cancers." | 3.76 | Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers. ( Bassot, V; Brasnu, D; Jacquillat, C; Lacau St Guily, J; Laccourreye, H; Weil, M, 1986) |
| "Head and neck cancer is a term that encompasses heterogeneous groups of patients." | 3.76 | Clinical trials with fluorinated pyrimidines in patients with head and neck cancer. ( al-Sarraf, M, 1989) |
| "This monoinstitutional retrospective study compares the results of both treatment schedules: 315 patients with locally advanced carcinoma (UICC stage III and IV) of the oral cavity and the orohypopharynx were treated from January 1990 to March 2006 with a radiochemotherapy combination based on mitomycin C and fluorouracil (HART-CC: 203 patients, CFRT-CC: 112 patients, total dose: 70-72 Gy) with curative intent." | 3.75 | Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. ( Abu Jawad, J; Budach, V; Jahnke, K; Lehnerdt, G; Pöttgen, C; Sack, H; Stüben, G; Stuschke, M; Welz, H; Wierlemann, A; Wittig, A, 2009) |
| " In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected." | 3.75 | Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. ( Glick, JH; Taylor, SG; Zehngebot, LM, 1980) |
| "Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR)." | 3.67 | Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. ( Braakhuis, BJ; de Bruijn, EA; Laurensse, EJ; Peters, GJ; Pinedo, HM; van Walsum, M, 1989) |
| " Ten patients developed grade 3-4 adverse events, including neutropenia (31." | 3.01 | Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. ( Doi, K; Fumita, S; Haratani, K; Hayashi, H; Ishikawa, K; Iwasa, T; Kanemura, H; Kitano, M; Kurosaki, T; Mitani, S; Nakagawa, K; Nishimura, Y; Otsuki, N; Suzuki, S; Tanaka, K; Yoshida, T, 2021) |
| "A prospective open-label phase II trial was conducted to evaluate the efficacy of hyperthermia combined with induction chemotherapy in patients with locally advanced resectable oral squamous cell carcinoma (OSCC)." | 3.01 | A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma. ( Chen, Y; Ge, M; Guo, W; He, Y; Ju, H; Ma, X; Meng, J; Qiu, W; Ren, G; Song, H; Wu, Y; Zhuang, Q, 2021) |
| "Pantoprazole prevented the increase in acute kidney injury biomarkers in cisplatin-treated patients." | 3.01 | Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial. ( El-Haggar, S; Ghonaim, E; Gohar, S, 2021) |
| " Treatment-emergent adverse events of maximum grade 3 or 4 occurred in 61." | 3.01 | First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. ( Bai, C; Chang, X; Chen, W; Feng, J; Ge, M; Guo, Y; He, X; Huang, X; Li, Z; Lin, T; Liu, Y; Luo, Y; Shen, L; Sun, Y; Wang, L; Xue, K; Yang, K; Zeng, Y; Zhang, Q; Zhu, X, 2021) |
| "Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) often requires postoperative chemoradiation with high risk of toxicity." | 2.94 | Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. ( Betz, CS; Binder, M; Boettcher, A; Bokemeyer, C; Busch, CJ; Moeckelmann, N; Muenscher, A; Schafhausen, P; Vettorazzi, E; Zech, HB, 2020) |
| "Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response." | 2.90 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. ( Basté, N; Bratland, Å; Burtness, B; Cheng, JD; de Castro, G; Fuereder, T; González Mendoza, R; Greil, R; Gumuscu, B; Harrington, KJ; Hong, RL; Hughes, BGM; Jin, F; Mesía, R; Neupane, P; Ngamphaiboon, N; Psyrri, A; Rischin, D; Rordorf, T; Roy, A; Soulières, D; Tahara, M; Wan Ishak, WZ; Zhang, Y, 2019) |
| "Data of 179 patients with N3 HNSCC from two GORTEC randomized trials (96-01 and 99-02) were pooled." | 2.84 | Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. ( Alfonsi, M; Aupérin, A; Bardet, E; Bourhis, J; Calais, G; Deprez, P; Geoffrois, L; Gery, B; Graff, P; Grégoire, V; Lapeyre, M; Maingon, P; Martin, L; Pignon, T; Rives, M; Sire, C; Tao, Y; Verrelle, P, 2017) |
| "Patients with LAHNSCC were randomized to receive concomitant treatment alone [CCRT (Arm A1) or CET/RT (Arm A2)], or three cycles of induction docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1) or followed by CET/RT (Arm B2)." | 2.84 | Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. ( Alterio, D; Azzarello, G; Bertoni, F; Bidoli, P; Bonetti, A; Bunkheila, F; Campostrini, F; Casanova, C; Chiappa, F; Cipani, T; Codecà, C; D'Ambrosio, C; Da Corte, D; Emiliani, E; Ferrari, D; Foa, P; Frattegiani, A; Gava, A; Ghi, MG; Guaraldi, M; Koussis, H; Loreggian, L; Massa, E; Mastromauro, C; Mione, CA; Morelli, F; Niespolo, RM; Nolè, F; Orecchia, R; Paccagnella, A; Parisi, S; Pieri, G; Polsinelli, M; Rossetto, C; Rulli, E; Valduga, F; Verri, E, 2017) |
| " The primary outcome was all-grade, all-cause treatment-emergent adverse events (TEAEs)." | 2.82 | Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. ( Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D, 2016) |
| "Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up." | 2.82 | nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. ( Adkins, D; Daly, M; Gay, HA; Jackson, R; Ley, J; Michel, L; Nussenbaum, B; Paniello, R; Rich, J; Thorstad, W; Trinkaus, K; Uppaluri, R; Wildes, TM, 2016) |
| "Patients with stage III/IV resectable head and neck squamous cell carcinoma were randomized to surgery followed by RT or CCRT." | 2.80 | Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. ( Ang, MK; Hwang, J; Iyer, NG; Lim, WT; Sivanandan, R; Soo, KC; Tan, DS; Tan, EH; Tan, HK; Tan, NC; Tan, VK; Wang, W; Wee, J, 2015) |
| "Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses αvβ5 integrin." | 2.79 | Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). ( Bethe, U; Brümmendorf, TH; Clement, PM; Delord, JP; Erfán, J; Gauler, TC; Hicking, C; Iglesias, L; Keilholz, U; Krauss, J; Mesía, R; Peyrade, F; Remenar, E; Schafhausen, P; Vermorken, JB, 2014) |
| "Nab-paclitaxel (A) is a novel albumin-bound paclitaxel with a superior therapeutic index to docetaxel." | 2.79 | Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. ( Bayley, A; Chan, K; Chen, EX; Chin, S; Diaz-Padilla, I; Hope, A; Hossain, M; Kim, J; Loong, HH; Palma, D; Razak, AR; Read, N; Siu, LL; Waldron, J; Wang, L; Winquist, E, 2014) |
| "Resistant HNSCC cell lines were generated by exposure to an EGFR TKI, gefitinib, in vitro." | 2.78 | A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. ( Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A, 2013) |
| " This study evaluated the efficacy and feasibility of induction nab-paclitaxel and cetuximab given with PF (ACPF) followed by definitive chemoradiation (CRT) in a phase 2 trial." | 2.78 | A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. ( Adkins, D; Dehdashti, F; Gay, H; Lewis, J; Ley, J; Mehan, P; Nussenbaum, B; Siegel, BA; Thorstad, W; Trinkaus, K; Wildes, T, 2013) |
| "This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)." | 2.78 | Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Brümmendorf, TH; Delord, JP; Forssmann, U; Goddemeier, T; Kaminsky, MC; Keller, U; Machiels, JP, 2013) |
| "Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients." | 2.77 | Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012) |
| "Patients with stage III-IV HNSCC received hyperfractionated radiation (72-74." | 2.77 | Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. ( Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG, 2012) |
| "We performed a prospective phase II trial to investigate the safety and efficacy of radiotherapy combined with capecitabine in patients suffering from a recurrence of a squamous cell carcinoma of the head and neck (SCCHN) within a previously irradiated field." | 2.77 | Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial. ( Kornek, G; Lemaire, C; Radonjic, D; Selzer, E; Vormittag, L, 2012) |
| "The numbers of circulating tumor cells (CTCs) and their expression/activation of epidermal growth factor receptor (EGFR) during the course of combined chemo- or bioradiotherapy regimens as potential biomarkers of treatment efficacy in squamous cell carcinoma of the head and neck (SCCHN) were determined." | 2.77 | Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. ( Budach, V; Hristozova, T; Keilhoiz, U; Stromberger, C; Tinhofer, I, 2012) |
| "Locally advanced head and neck squamous cell carcinoma (HNSCC) has a high rate of recurrence." | 2.77 | Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. ( Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G, 2012) |
| "Forty cases of resectable HNSCC were treated with nimotuzumab (400 mg on day 1) combined with PF regimens (cisplatin 75 mg/m² on days 1 and 5-Fu 750 mg/m² on days 1-5 q3wks)." | 2.77 | [Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma]. ( Guo, Y; Hu, CS; Ji, QH; Wang, Y; Zhao, XY; Zhu, GP; Zhu, YX, 2012) |
| " In this group, six patients (9%) experienced severe toxicities, none of them being life threatening, and no toxic death was encountered." | 2.76 | DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. ( Bagarry-Liegey, D; Blesius, A; Brunet, C; Chefrour, M; Ciccolini, J; Dahan, L; Duffaud, F; Favre, R; Ferri-Dessens, RM; Frances, N; Giovanni, A; Lacarelle, B; Marouani, H; Mercier, C; Seitz, JF; Varoquaux, A; Yang, CG; Zanaret, M, 2011) |
| "Eligible patients had newly diagnosed HNSCC." | 2.76 | A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. ( Blair, EA; Cohen, EE; Haraf, DJ; Kunnavakkam, R; Salama, JK; Seiwert, T; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2011) |
| "In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival." | 2.75 | Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. ( Cho, BC; Choi, EC; Choi, HJ; Kim, GE; Kim, JH; Lee, CG; Lee, YJ; Sohn, JH, 2010) |
| "Patients with locally advanced head and neck cancer, and who had not previously undergone surgery, were randomly assigned to one of four groups in a 3:2:2:2 ratio, stratified by centre and chemotherapy regimen: radical radiotherapy alone (n=233); radiotherapy with two courses of chemotherapy given simultaneously on days 1 and 14 of radiotherapy (SIM alone; n=166); or 14 and 28 days after completing radiotherapy (SUB alone, n=160); or both (SIM+SUB; n=154)." | 2.75 | Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. ( Glaholm, J; Gupta, N; Hackshaw, A; Hutchison, I; Kadalayil, L; Macdougall, H; Monson, K; Tobias, JS, 2010) |
| "Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules." | 2.75 | Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. ( Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J, 2010) |
| "The peak prevalence of grade 3 dysphagia was higher and the recovery was slower in patients with lower OTT (median 38 days vs." | 2.75 | Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. ( Bhide, SA; Fowler, J; Gulliford, S; Harrington, KJ; Newbold, K; Nutting, CM; Rosenfelder, N, 2010) |
| "Gefitinib was continued while patients received concurrent weekly docetaxel and radiation therapy." | 2.74 | Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. ( Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR, 2009) |
| "Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "This concurrent chemoradiotherapy with PFML was safe and well tolerated." | 2.73 | Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. ( Katori, H; Taguchi, T; Tsukuda, M, 2007) |
| " The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion." | 2.73 | [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007) |
| "Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | 2.73 | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
| "Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible." | 2.73 | Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008) |
| "To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)." | 2.73 | Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. ( Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008) |
| "Acute mucositis is a dose-limiting toxicity of concurrent chemoradiotherapy regimens for locally advanced head and neck cancer." | 2.73 | Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. ( Berger, D; Brizel, DM; Brizel, HE; Chen, MG; Glück, S; Mendenhall, W; Meredith, RF; Murphy, BA; Pandya, KJ; Rosenthal, DI, 2008) |
| "Treatment comprised cetuximab (initial dose 400 mg/m2 with subsequent weekly doses of 250 mg/m2) in combination with 3-week cycles of either cisplatin (100 mg/m2) or carboplatin (area under the curve, 5), each in combination with a 5-day infusion of fluorouracil (FU) at escalating doses of 600, 800, and 1,000 mg/m2/d." | 2.72 | Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ( Amellal, N; Awada, A; Borel, C; Bourhis, J; Duck, L; Geoffrois, L; Harstrick, A; Hitt, R; Humblet, Y; Lopez-Pousa, A; Mesia, R; Rivera, F; Rosine, D; Schueler, A; Vega Villegas, ME, 2006) |
| "Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate." | 2.72 | Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. ( Bonomi, M; Cabalar, ME; Castro, MA; Cerchietti, LC; Kirchuk, R; Lutteral, MA; Navigante, AH; Negretti, G; Roth, B; Sheinker, B; Uchima, P, 2006) |
| "Patients with intermediate-stage squamous cell carcinoma of the head and neck traditionally have been treated with initial surgical resection followed by radiotherapy (RT) alone or chemoradiotherapy." | 2.72 | High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. ( Brockstein, B; Cohen, EE; Haraf, DJ; Kies, MS; Kocherginsky, M; List, MA; Mittal, BB; Rosen, F; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2006) |
| "Twenty patients with squamous cell carcinoma (SCC) of the head and neck were included in the study." | 2.71 | FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. ( Kitagawa, Y; Nakamura, M; Nishizawa, S; Ogasawara, T; Sadato, N; Sano, K; Yonekura, Y, 2003) |
| "Capecitabine (Xeloda) is an oral fluoropyrimidine that is preferentially activated at the tumoral level, exploiting the higher thymidine phosphorylase activity in tumoral tissue." | 2.71 | Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. ( Chamorey, E; Giroux, B; Guardiola, E; Magné, N; Milano, G; Mouri, Z; Otto, J; Pivot, X; Schneider, M; Thyss, A, 2003) |
| " The purpose of this study was to evaluate the efficacy and toxicity of a modified TPFL regimen (m-TPFL) for locally advanced SCCHN, consisting of a modified dosage with docetaxel, cisplatin, 5-FU and l-leucovorin (l-LV) designed for Japanese patients." | 2.71 | Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. ( Sasaki, S; Taniguchi, M; Watanabe, A, 2003) |
| "Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible." | 2.71 | Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. ( Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE, 2004) |
| "Gemcitabine was dose escalated, 50-300 mg/m(2) on day 1." | 2.71 | Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. ( Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME, 2004) |
| "Grade 4 neutropenia was observed in one patient." | 2.71 | Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. ( Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A; Millán, JM, 2004) |
| "Neutropenia was the only grade-4 toxicity that occurred in 2 patients." | 2.71 | Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity. ( Ernst-Stecken, A; Grabenbauer, G; Iro, H; Plasswilm, L; Sauer, R, 2004) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 2.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| " Patients in arm B were given cisplatin and 5-FU in the same dosage and schedule as in arm A." | 2.70 | Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients. ( Babović, N; Gavrilović, D; Jelić, S; Jovanović, N; Kreacić, M; Mikić, A; Petrović, Z; Stamatović, Lj; Vucićević, S, 2002) |
| "25 patients with locally advanced head and neck cancer were treated with 4 cycles of vinorelbine (20 mg i." | 2.70 | Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. ( Catalano, G; Chiesa, F; De Braud, F; De Paoli, F; De Pas, T; DePas, T; Jereczek-Fossa, BA; Krengli, M; Marrocco, E; Masci, G; Orecchia, R; Robertson, C; Vavassori, A, 2002) |
| "Raltitrexed has been shown to be devoid of clinical activity against SCCHN when used alone; however, both preclinical and early clinical data regarding the combination raltitrexed-CDDP hold promise." | 2.70 | Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Lucia, L; De Rosa, P; De Rosa, V; Rosati, G, 2002) |
| "Sixty-five patients with advanced head and neck cancer underwent a definitive (53 patients) or a postoperative adjuvant (12 patients) chemoradiation treatment." | 2.70 | Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer. ( Arcangeli, G; Arcangeli, S; Carlini, P; Cognetti, F; Danesi, DT; De Campora, E; Giovinazzo, G; Mecozzi, A; Saracino, B, 2002) |
| "The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery." | 2.70 | Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001) |
| "Complete responses were observed in squamous carcinomas from various primary sites including head and neck, esophagus, cervix, vagina, anus, and unknown primary." | 2.70 | Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. ( Baker, MN; Burris, HA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH, 2001) |
| "Patients with recurrent squamous cell cancer of the head and neck (SCH&N) are generally treated with systemic chemotherapy." | 2.70 | RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. ( Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2001) |
| "Gemcitabine has shown in vitro and in vivo radiosensitizing properties, synergistic activity with cisplatin, and cytotoxic activity against SCC-HN." | 2.70 | Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. ( Benasso, M; Corvò, R; Marchetti, G; Merlano, M; Numico, G; Pallestrini, E; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V, 2001) |
| "The first-line chemotherapy for head and neck cancer is reported to be the combination of CDDP and 5-FU." | 2.69 | [Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1998) |
| "Patients with locoregionally advanced head and neck cancer were treated either with RT alone (arm A) or simultaneous RT plus CT (RCT; arm B)." | 2.69 | Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. ( Aydin, H; Grabenbauer, GG; Iro, H; Popella, C; Rödel, CM; Rohloff, R; Schalhorn, A; Thiel, HJ; Wendt, TG; Wustrow, TP, 1998) |
| "Patients with advanced head and neck cancer who were treated only with hyperfractionated irradiation received 125 cGy twice daily, for a total of 7500 cGy." | 2.69 | Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. ( Albers, ME; Brizel, DM; Fisher, SR; George, SL; Hars, V; Huang, AT; Prosnitz, LR; Richtsmeier, WJ; Scher, RL, 1998) |
| "For patients with squamous cell carcinoma of the head and neck (HNSCC), persistence of cervical adenopathy following organ-preservation therapy is a strong predictor of locoregional failure." | 2.69 | Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy. ( Eisele, DW; Forastiere, AA; Lee, DJ; Westra, WH, 1998) |
| " Dose adjustment based on pharmacokinetic follow-up has been proposed to decrease hematological and digestive toxicities, but the clinical impact of this approach has not yet been demonstrated." | 2.69 | Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. ( Barberi-Heyob, M; Campion, L; Conroy, T; Etienne, MC; Fety, R; Hardouin, A; Merlin, JL; Milano, G; Perrocheau, G; Rivière, A; Rolland, F, 1998) |
| "Ifosfamide was given initially to 12 patients in combination with standard fixed doses of cisplatin and 5-fluorouracil, at 1,000 mg/m2 daily on days 2, 3, and 4." | 2.69 | Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma. ( Abad, T; Alvárez, I; Churruca, C; Egana, L; Guimón, E; Lacasta, A; López de Argumedo, G; Paredes, A; Piera, JM; Sánchez Parra, M, 1999) |
| "Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing." | 2.69 | Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. ( Brockstein, B; Dolan, ME; Haraf, DJ; Humerickhouse, RA; Kies, M; Ratain, MJ; Stenson, K; Sulzen, L; Vokes, EE, 1999) |
| "In head-and-neck cancer, chemosensitivity is inconstant, and no marker is available to predict response to treatment." | 2.69 | Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. ( Beaune, P; Blons, H; Brasnu, D; Cabelguenne, A; Carnot, F; de Waziers, I; Hamelin, R; Laccourreye, O; Laurent-Puig, P, 1999) |
| "Twenty-three patients with advanced head and neck cancer, mainly Stage III and IV, were treated with preoperative radiation (n = 1), pre- as well as postoperative radiotherapy (n = 5), postoperative radiation (n = 9) or combined postoperative radio-chemotherapy (n = 6)." | 2.69 | [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. ( Altmann, S; Hoffmanns, H, 1999) |
| "Paclitaxel has exhibited single-agent activity in patients with this disease." | 2.69 | Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. ( Du, W; Ensley, J; Gadgeel, S; Hussain, M; Kucuk, O; Salwen, W, 1999) |
| "Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)." | 2.69 | Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999) |
| "For locally unresectable recurrent squamous cell carcinoma of the head and neck, we investigated two salvage chemotherapy regimens as second-line chemotherapy." | 2.69 | Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck. ( Kawaida, M; Kitahara, S; Kohno, N; Ohmuma, T, 1999) |
| "Thirty two patients with inoperable head and neck cancer seen at Jichi Medical School Hospital during the period 1978 to 1995 were analyzed." | 2.69 | [A clinical study of inoperable head and neck cancers]. ( Ishikawa, K; Kanazawa, T; Kitamura, K; Miyata, M; Morita, M; Nishino, H, 1999) |
| "Forty-two patients with advanced head and neck cancer entered this phase II trial of long-term continuous 5-fluorouracil (5-FU) infusion at a dose of 300 mg/m2/day for a maximum of 16 weeks." | 2.69 | Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer. ( Andersen, LJ; Bastholt, L; Hansen, O; Sørensen, P, 1999) |
| "To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy." | 2.69 | Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. ( Dolan, ME; Haraf, DJ; Hsieh, YC; Humerickhouse, R; Kies, MS; List, M; Mittal, BB; Pelzer, H; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RR; Witt, ME, 2000) |
| "Febrile neutropenia was recorded in 15% of courses." | 2.69 | Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. ( Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E, 2000) |
| "All patients had advanced but operable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx." | 2.69 | The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03. ( Aref, A; Berkey, BA; Ensley, J; Ervin, TJ; Haselow, RE; Laramore, GE; Schuller, DE; Schwade, JG, 2000) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | 2.69 | The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| "In patients with locally unresectable head and neck cancer with large nodal involvement, the expected five-year survival is as low as 1-2%." | 2.69 | [Concurrent chemoradiotherapy for locally unresectable head and neck cancer]. ( Furukawa, T; Itoh, Y; Kitahara, S; Kohno, N; Murata, Y; Nakanoboh, M; Tamura, E; Tanabe, T, 2000) |
| "Recurrent squamous cell carcinoma of the head and neck is poorly responsive to most chemotherapy regimens." | 2.68 | Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer. ( Baez, L; Benner, SE; Brooks, J; Dimery, IW; Earley, CL; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M; Winn, RJ, 1995) |
| "Oral mucositis is a frequent side effect of cancer therapy." | 2.68 | A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. ( Burkhead, T; Garewal, HS; Koenig, LM; Vaughn, B; Verdi, CJ, 1995) |
| "Intra-arterial drug therapy for head and neck cancer has been used for over 30 years." | 2.68 | Palliative intra-arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port-systems. ( Eckardt, A; Kelber, A; Pytlik, C, 1995) |
| "Twenty patients with stage IV squamous cell carcinoma of head and neck were studied." | 2.68 | Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. ( Chan, WK; Chang, CY; Chao, JY; Chen, CH; Chen, KY; Chen, SY; Chi, KH; Chow, KC; Yen, SH, 1995) |
| "Forty-two patients with head and neck cancer were treated with tegafur suppository for 7 days preoperatively and clinical value of this treatment was assessed." | 2.68 | [High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories]. ( Itokazu, T; Kochi, A; Koja, S; Maeda, H; Maeshiro, N; Matsumura, J; Noda, Y; Yasuda, S, 1995) |
| "N&V and leukopenia were the major side effects." | 2.68 | Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995) |
| "Chemotherapy for squamous cell carcinoma with unknown primary (SCUP) has not been prospectively studied." | 2.68 | Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. ( Allred, C; Anand, V; Khansur, T; Little, D, 1995) |
| "Patients with advanced, inoperable head and neck cancers have cure rates of approximately 10-15%." | 2.68 | Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study. ( Barzan, L; Boz, G; De Paoli, A; Franchin, G; Gobitti, C; Lamon, S; Mascarin, M; Minatel, E; Trovò, MG, 1995) |
| " Individualized 5-FU dosing to obtain higher 5-FU plasma concentrations may be indicated." | 2.68 | Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. ( Athanasiadis, I; Dolan, ME; Haraf, DJ; Kies, MS; Kozloff, M; Malone, D; Mick, R; Ratain, MJ; Vokes, EE; Weichselbaum, RR, 1996) |
| "Recurrent cancer of the head and neck after primary therapy is almost always fatal." | 2.68 | Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. ( Benedetti, J; Ensley, J; Hussain, M; Rodriguez, GI; Schuller, D; Smith, RE, 1995) |
| "Stage IV inoperable head and neck cancer has a 2-year mortality rate of greater than 70% when treated with conventional radiotherapy." | 2.68 | Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer. ( Benninger, MS; Boyd, SB; Carlson, ER; Doyle, TJ; Dragovic, J; Jacobsen, GR; Nichols, RD; Tilchen, EJ, 1995) |
| "8%)." | 2.68 | Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer. ( Bishop, JF; Hughes, PG; Narayan, K; Olver, IN; Smith, JG, 1996) |
| "Eighty patients with advanced squamous carcinoma of the head and neck were entered into a study using a 2-day, inpatient, intravenous regimen." | 2.68 | Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck. ( Canney, PA; Hatton, MQ; Junor, EJ; McGurk, FM; Paul, J; Robertson, AG; Symonds, RP; Yosef, H, 1996) |
| "Eligible patients had Stage III or IV squamous cell carcinoma of the head and neck with no distant metastases." | 2.68 | Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. ( Athanasiadis, I; Blough, R; Ganzenko, N; Kies, MS; Lester, EP; Mittal, BB; Pelzer, HJ; Rademaker, A; Taylor, S; Vokes, EE, 1997) |
| "The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease." | 2.68 | Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997) |
| "Adenoid cystic carcinoma is a relatively rare tumour which arises in the parotid and submandibular salivary glands." | 2.68 | Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. ( A'Hern, RP; Archer, D; Breach, N; Constenla, DO; Gore, ME; Henk, JM; Hill, ME; Rhys-Evans, P, 1997) |
| "Patients with localized esophageal cancer also received radiation therapy beginning on day 1 (1." | 2.68 | Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial. ( Greco, FA; Hainsworth, JD; Meluch, AA, 1997) |
| "The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck." | 2.67 | Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a ( Cappelaere, P; Clavel, M; Clerico, M; Cognetti, F; de Mulder, PH; Schornagel, JH; Tueni, EA; Vermorken, JB; Verweij, J; Wildiers, J, 1994) |
| "Leukopenia was more frequent in the simultaneous than in the sequential arm (p = 0." | 2.67 | A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. ( Carlini, P; Cercato, MC; Cognetti, F; Del Vecchio, MR; Giannarelli, D; Impiombato, FA; Marzetti, F; Milella, M; Pinnarò, P, 1994) |
| "The maximum tolerated 5-fluorouracil dosage was 300 mg/m2 i." | 2.67 | Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study. ( Benasso, M; Blengio, F; Cavallari, M; Merlano, M; Rosso, M; Rosso, R; Sguotti, C, 1994) |
| "In the first study by the "Kinki Head and Neck Tumor Study Group," we performed a comparative study to investigate intergroup difference between a control group consisting of patients given radical treatment only, and a HCFU group consisting of patients receiving long-term administration of HCFU after radical treatment." | 2.67 | [A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group]. ( Kozuka, T; Matsunaga, T; Matsuoka, H; Miyaguchi, M; Nakai, Y; Nishimura, T; Sakai, S; Sato, T; Tanabe, M; Yoshino, K, 1994) |
| " The radiation therapy dosage planned to the whole neck, nasopharynx, and supraclavicular area was 45 Gy in 24 daily fractions in 5 weeks, increasing to 60-70 Gy to the metastatic site." | 2.67 | Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study. ( Jeremic, B; Marinkovic, J; Matovic, M; Zivic, DJ, 1993) |
| "Patients with head and neck cancer who continue to smoke during radiation therapy have lower rates of response and survival than patients who do not smoke during radiation therapy." | 2.67 | Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. ( Browman, GP; Hodson, I; Levine, MN; McAlpine, L; Russell, R; Sathya, J; Skingley, P; Wong, G, 1993) |
| "IL 2 in advanced head and neck squamous cell carcinoma (HNSCC)." | 2.67 | Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study. ( Bianchi, A; Curreli, L; Ghiani, M; Mantovani, G; Proto, E; Puxeddu, P; Santona, MC, 1994) |
| "For advanced stages of head and neck cancers (T3, T4, N2, N3), we recently launched a pilot study combining platinum and irradiation, but according to a concomitant schedule." | 2.67 | [Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients]. ( Asselain, B; Blaszka, B; Brunin, F; Jaulerry, C; Jouve, M; Mosseri, V; Point, D; Rodriguez, J; Validire, P; Zafrani, B, 1992) |
| "The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy." | 2.67 | Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; McEvilly, JM; Mick, R; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "Forty Stage IV head and neck cancer patients were entered on a multimodality trial of induction chemotherapy (cisplatin + infusional 5-fluorouracil), surgery, and radiation." | 2.67 | Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics. ( Ashayeri, E; Gumbs, RV; Myers, EM; Pressoir, R; White, RM, 1992) |
| "Twenty-eight patients with previously untreated Stage IV squamous cell carcinoma of the head and neck received 2 cycles of cisplatin 100 mg/m2 on day 1 followed by a 5-day continuous infusion of 5-FU at 800 mg/m2/day and 100 mg of leucovorin administered orally every 4 hours." | 2.67 | Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. ( Clendeninn, NJ; Collier, MA; Goldman, MD; Haraf, DJ; Kozloff, MF; McEvilly, JM; Mick, R; Moran, WJ; Vokes, EE; Weichselbaum, RR, 1992) |
| "Thirty-four patients (22 NSCLC, 12 head/neck cancer) were registered in the study." | 2.67 | Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. ( Aronson, FR; Deisseroth, AB; Gandara, DR; Luce, J; Paradise, C; Perez, EA; Rayner, A; Valone, FH, 1991) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "59 patients with histological verified squamous cell carcinoma of the head and neck, 39 with primary disease and 20 with relapse were given carboplatin and 5-fluorouracil (5-FU) in escalated carboplatin doses." | 2.67 | Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma. ( Evensen, JF; Gundersen, S; Høst, H; Kaasa, S; Tausjø, J; Thorud, E; Wist, E, 1991) |
| "route, in various types of cancer disease such as non-small cell lung cancer and advanced breast cancer." | 2.67 | Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors. ( Bouffard, P; Caty, A; Fournier, C; Hecquet, B; Krikorian, A; Lefebvre, JL; Merle, S; Vanseymortier, L; Vert, M; Vilain, MO, 1991) |
| "Among 13 patients with colorectal cancer, 4 partial responses were observed." | 2.67 | Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. ( Comis, RL; Cornfeld, MJ; O'Dwyer, PJ; Peter, R, 1990) |
| "The patients all had previously untreated squamous cell carcinoma of the head and neck (SCCHN)." | 2.66 | Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study. ( Benasso, M; Bonelli, L; Corvó, R; Gardin, G; Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Scarpati, D; Sertoli, MR, 1988) |
| "The histopathology of 54 squamous carcinomas of the head and neck was evaluated by qualitative grading and morphometry in order to identify those features which predicted a good response to cisplatinum chemotherapy." | 2.66 | Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck. ( Atkinson, MW; Cooke, LD; Cooke, TG; Helliwell, TR; Stell, PM, 1989) |
| "The eligible patients with an advanced head and neck cancer were paired off successively on the basis of the tumour site and the UICC stage." | 2.66 | Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil. ( Coninx, P; Garbe, E; Lebrun, D; Legros, M; Lucas, P; Nasca, S; Panis, X, 1988) |
| "Stomatitis was more frequent on the infusion arm but it was mild and reversible." | 2.66 | A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985) |
| "Among patients with primary head and neck cancer, the stage of the disease influenced the response rate." | 2.65 | Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. ( Archibald, SD; Browman, GP; Hryniuk, WM; Kiehl, K; Levine, MN; Russell, R; Young, JE, 1983) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with methotrexate (250 mg/m2) followed 1 hour later by 5-FU (600 mg/m2)." | 2.65 | Use of methotrexate and 5-FU for recurrent head and neck cancer. ( Jacobs, C, 1982) |
| "Standard treatment for locally advanced head and neck squamous cell carcinoma (LAHNSCC) consists mainly of concurrent chemoradiation (CCR) but induction chemotherapy (IC) by docetaxel-cisplatin-fluorouracil (TPF), followed by CCR, is a strong option." | 2.61 | Induction chemotherapy in head and neck cancers: Results and controversies. ( Fayette, J; Gau, M; Karabajakian, A; Neidhardt, EM; Reverdy, T, 2019) |
| "The Tax-PF induction chemotherapy improved PFS and OS, and the ORR was better as compared to PF-based therapy regimens at the cost of a higher incidence of adverse events." | 2.53 | [Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a Meta-analysis of the efficacy and safety]. ( Jian, J; Li, G; Tian, L; Yu, Z, 2016) |
| "Head and neck cancer, mostly squamous cell carcinoma, ranks sixth among the most common cancers." | 2.49 | Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials. ( Ben-Aharon, I; Perl, G; Popovtzer, A; Stemmer, SM; Vidal, L, 2013) |
| "In head and neck squamous cell carcinoma (HNSCC), the inhibition of epidermal growth factor receptor (EGFR) signaling as a central step in carcinogenesis, progression, and metastasis is the predominant approach." | 2.49 | Molecular targeting agents in the context of primary chemoradiation strategies. ( Knecht, R; Laban, S; Münscher, A; Schafhausen, P; Tribius, S; Wang, CJ, 2013) |
| "Head and neck squamous cell carcinoma is now the 8th most common cancer affecting men in the United States largely due to a rising epidemic of oropharynx cancer (tonsil and tongue base) associated with the human papillomavirus (HPV)." | 2.48 | Current treatment options for metastatic head and neck cancer. ( Cohen, EE; Price, KA, 2012) |
| "The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors." | 2.48 | Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. ( Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N, 2012) |
| "The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR)." | 2.47 | Cetuximab in the treatment of squamous cell carcinoma of the head and neck. ( Specenier, P; Vermorken, JB, 2011) |
| " A number of orally bioavailable tyrosine kinase inhibitors have been tested or are undergoing trials in SCCHN." | 2.47 | Management of recurrent head and neck cancer: recent progress and future directions. ( Brockstein, BE, 2011) |
| "As therapy for locoregionally advanced head and neck cancer (HNC) has evolved, treatment has become increasingly aggressive and cure rates have risen." | 2.44 | Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. ( Posner, M; Vermorken, JB, 2008) |
| "Induction chemotherapy for squamous cell carcinoma of the head and neck has long been known to be highly active with tumor responses observed in a high percentage of patients." | 2.44 | Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). ( Kies, MS, 2007) |
| "Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor prognosis." | 2.44 | Recurrent head and neck cancer: current treatment and future prospects. ( Specenier, PM; Vermorken, JB, 2008) |
| "Advanced squamous cell carcinomas of the oral cavity, oro-, hypopharynx and larynx often have to be categorised as non resectable disease." | 2.43 | [Decision making in non resectable head and neck tumours]. ( Dietz, A; Dollner, R; Hildebrandt, G; Weber, A, 2005) |
| "Although a decrease in distant metastases has frequently been observed, an improvement in survival from induction has been difficult to demonstrate." | 2.43 | Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? ( Adelstein, DJ; Leblanc, M, 2006) |
| "Patients with locally recurrent head and neck cancer previously treated with radiation have a poor prognosis." | 2.43 | Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? ( Li, Y; Machtay, M; Wong, SJ, 2006) |
| " The administration of the conventional dose of S-1 including dihydropyrimidine dehydrogenase (DPD), an metabolic inhibitor of 5-FU, results in exceeding the critical plasma concentration of 5-FU, and the long-term administration with high plasma concentration of 5-FU is considered to show clinical effectiveness in head and neck cancer." | 2.43 | [Clinical efficacy of administration with S-1 alone for head and neck carcinoma]. ( Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T, 2006) |
| "Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival." | 2.42 | Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. ( Lefebvre, JL; Posner, MR, 2003) |
| "The systemic therapy of head and neck cancer has gained momentum in recent years." | 2.42 | Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. ( Argiris, A; Haraf, DJ; Kies, MS; Vokes, EE, 2003) |
| "Standard treatment for squamous cell carcinomas in the head and neck consists of surgery and/or radiotherapy." | 2.41 | [Recent regimen of chemotherapy for advanced head and neck carcinomas]. ( Tsukuda, M, 2000) |
| "For head and neck cancer, a recent meta-analysis of published randomized trial results showed that concurrent chemoradiotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy may increase absolute survival by 12." | 2.41 | [Role of Chemotherapy in head and neck cancer]. ( Kitahara, S; Kohno, N, 2001) |
| "Cases with head and neck squamous cell carcinoma (HNSCC) have clinically advanced tumors." | 2.41 | [Preoperative chemotherapy for patients with advanced head and neck cancer]. ( Tsukuda, M, 2001) |
| "Many head and neck cancers have been found to overexpress the receptor to epidermal growth factor (EGFR)." | 2.41 | [Current and future state of chemoradiotherapy for head and neck cancer]. ( Fuwa, N, 2002) |
| "Both protocols are responsive to squamous cell carcinoma of the head and neck." | 2.40 | [Head and neck cancer]. ( Fukuda, S; Inuyama, Y; Satoh, N, 1997) |
| "At diagnosis of head and neck cancer, over half of all patients show advanced stages." | 2.40 | [Chemoradiotherapy for patients with advanced head and neck cancer]. ( Tsukuda, M, 1997) |
| "The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)." | 2.40 | Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998) |
| "The standard chemotherapy of squamous cell carcinomas of the head and neck is cisplatin and 5-FU." | 2.39 | [A critical consideration of the combined radiochemotherapy of head and neck tumors]. ( Hainz, A; Schlappack, O; Springer, B, 1994) |
| "5-fluorouracil is a widely used chemotherapeutic agent." | 2.39 | 5-fluorouracil plus radiation for head and neck cancer. ( Stupp, R; Vokes, EE, 1995) |
| "Among studies in recurrent head and neck cancer, the most effective chemotherapy regimens appear to be variations of the program consisting of cisplatin followed by a 5-day infusion of 5-fluorouracil." | 2.38 | Current chemotherapy of head and neck cancer. ( Amrein, P, 1991) |
| "This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities." | 2.35 | Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975) |
| "The treatment of oral squamous cell carcinoma (OSCC) includes systemic chemotherapy and is associated with aggressive side effects on patients." | 1.91 | A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma. ( Aboushelib, MN; Al-Wakeel, E; Badawi, MF; Elsaady, SA, 2023) |
| "Treatment decisions for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are complicated, and multi-modal treatments are usually indicated." | 1.72 | Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). ( Ahn, HK; Choi, JH; Kang, EJ; Keam, B; Kim, HJ; Kim, HR; Kim, JS; Kim, MK; Kim, SB; Kwon, JH; Lee, JB; Lee, KE; Lee, KW; Lee, YG; Park, KU; Shin, SH; Yun, HJ, 2022) |
| "To evaluate the efficacy and safety of ultrasound hyperthermia combined with TPF chemotherapy for advanced oral squamous cell carcinoma in the elderly." | 1.62 | [Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma]. ( Ge, LY; Gu, QP; Li, L; Li, XD; Li, ZP; Meng, J; Zhuang, QW, 2021) |
| " There was also no difference in the incidence of grade 3/4 adverse events between groups." | 1.62 | Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. ( Fujiwara, Y; Fukuda, N; Hayashi, N; Mitani, H; Nakano, K; Ohmoto, A; Ono, M; Sato, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yunokawa, M, 2021) |
| "The rate of toxic deaths related to induction chemotherapy in the treatment of locally advanced head and neck cancers is unacceptable and calls into question this therapeutic strategy, which is however highly effective in terms of rate and speed of response." | 1.62 | Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. ( Bernadach, M; Biau, J; Casile, M; Dillies, AF; Durando, X; Ginzac, A; Lapeyre, M; Miroir, J; Molnar, I; Moreau, J; Pham-Dang, N; Saroul, N, 2021) |
| "In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor." | 1.62 | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. ( Amorim, C; Domingues, I; Felix, R; Garcia, AR; João Sousa, M; Mariano, M; Pontes, F; Salgueiro, F; Teixeira, M, 2021) |
| "Although the continuation of cetuximab in combination with paclitaxel after EXTREME provides moderate benefit, it could be an interesting option for selected patients." | 1.62 | Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. ( Alfonsi, M; Chevalier, T; Daste, A; Dupuis, C; Fakhry, N; Fayette, J; Huguet, F; Lambert, T; Le Tourneau, C; Loundou, A; Peyrade, F; Peyraud, F; Reure, J; Saada-Bouzid, E; Salas, S; Toullec, C, 2021) |
| "Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54-67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0-1; 32% had oral cavity and 30% oropharyngeal cancers." | 1.56 | Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. ( Ahn, MJ; Auclair, V; Berrocal, A; Bertolini, F; Castro, G; Cheung, WY; Chirovsky, D; Grünwald, V; Guillaume, X; Harrington, K; Joo, S; Kuyas, H; Shah, R; Sjoquist, K; Yang, MH, 2020) |
| "Forty patients with LAHNSCC were included and 50% received induction chemotherapy." | 1.56 | Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance. ( A Moez, M; Abo-Madyan, Y; Atef, H; Mashhour, K; Selim, A; Zawam, H, 2020) |
| "A total of 445 LA-HNSCC patients were analyzed." | 1.56 | Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). ( Ahn, HK; Choi, JH; Kang, EJ; Keam, B; Kim, HR; Kim, JS; Kim, MK; Kim, SB; Kwon, JH; Lee, KE; Lee, KW; Lee, YG; Park, KU; Shin, SH; Yun, HJ, 2020) |
| "Taste disorders are common adverse effects of cancer chemotherapy that can reduce quality of life and impair nutritional status." | 1.56 | Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice. ( Hirayama, A; Hirose, F; Iwata, S; Kawabata, Y; Oike, A; Osaki, A; Sanematsu, K; Shigemura, N; Takai, S; Wada, N; Watanabe, Y; Yamada, Y; Yamazoe, J, 2020) |
| "Adult patients with R/M-HNSCC, who initiated systemic therapy between 1 September 2011 and 31 December 2014 and followed through 31 December 2015, were identified from iKnowMed electronic-health-records database (McKesson Specialty Health) supplemented with manual chart-abstraction." | 1.51 | Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E, 2019) |
| "Tumor volume in locally advanced head and neck squamous cell carcinomas (LAHNSCC) treated by induction chemotherapy (ICT) and followed by radiochemotherapy (RCT) was measured." | 1.51 | Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas. ( Berliner, C; Bier, J; Bohlen, M; Busch, C-; Bußmann, L; Forterre, F; Münscher, A; Sehner, S, 2019) |
| "Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive." | 1.51 | Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. ( Fushimi, C; Hanyu, K; Katsube, Y; Kondo, T; Miura, K; Okada, T; Okamoto, I; Sato, H; Shimizu, A; Tsukahara, K, 2019) |
| "5% objective response) but an important morbidity with 10% toxic deaths in our very symptomatic population with a very important tumor burden." | 1.51 | [Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. ( Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N, 2019) |
| "Induction chemotherapy (IC) for head and neck cancer (HNC) often causes severe side-effects." | 1.51 | Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients. ( Ikari, Y; Imanishi, Y; Ito, F; Mikoshiba, T; Nakahara, N; Ogawa, K; Ozawa, H; Saito, S; Sekimizu, M; Watanabe, Y, 2019) |
| "Human papillomavirus-associated oropharyngeal cancer was associated with a significant improved overall survival, locoregional, distant and overall tumor control rates in multivariate analysis." | 1.48 | Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". ( Baumeister, P; Belka, C; Ganswindt, U; Hess, J; Kirchner, T; Macht, C; Maihoefer, C; Pflugradt, U; Schneider, L; Schüttrumpf, L; Walch, A; Woischke, C; Zitzelsberger, H, 2018) |
| " Nephrotoxicity that developed within 14 days following CDDP administration was evaluated in accordance with Common Terminology Criteria for Adverse Events ver." | 1.46 | Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. ( Enokiya, T; Ikemura, K; Ishinaga, H; Iwamoto, T; Katayama, N; Mizuno, T; Muraki, Y; Oda, H; Okamoto, A; Okuda, M; Oshima, K; Takeuchi, K, 2017) |
| "Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world." | 1.46 | Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics. ( Hyun, H; Kim, B; Kim, D; Kim, O; Ko, Y; Lee, J; Lim, W; Moon, YL; Park, M; Sohn, H, 2017) |
| "The responsiveness of head and neck squamous cell carcinoma (HNSCC) to chemotherapy widely affects prognosis." | 1.46 | Livin enhances chemoresistance in head and neck squamous cell carcinoma. ( Chung, IJ; Joo, YE; Kim, SA; Lee, DH; Lee, JK; Lee, KH; Lim, SC; Park, YL; Yoon, TM, 2017) |
| "The involvement of S-1 chemotherapy in ATLL development suggests that a test for HTLV-1 antibody should be performed before treatment and that S-1 should not be administered in HTLV-1 positive patients with head and neck carcinoma." | 1.46 | Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy. ( Kurono, Y; Matushita, K; Nagano, H, 2017) |
| " There was no difference in adverse effects or response rate between the two groups." | 1.46 | Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. ( Dosaka-Akita, H; Honma, R; Iseki, K; Kasashi, K; Kinoshita, I; Kobayashi, M; Saito, Y; Shimizu, Y; Takeuchi, S; Yamada, T, 2017) |
| "We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database." | 1.46 | Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. ( Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS, 2017) |
| "In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months." | 1.43 | Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. ( Carp, L; Corthouts, B; Specenier, P; Szturz, P; Van Den Weyngaert, D; Van Laer, C; Van Marck, E; Vanderveken, O; Vermorken, JB, 2016) |
| "Globally, head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer and represents approximately 6% of all diagnosed cancers." | 1.43 | Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways. ( Krishnan, UM; Sethuraman, S; Sivanantham, B, 2016) |
| "We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC." | 1.43 | Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. ( Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG, 2016) |
| "Many patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) receive cisplatin-based radiochemotherapy." | 1.43 | Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. ( Bajrovic, A; Hakim, SG; Janssen, S; Kazic, N; Rades, D; Schild, SE; Seidl, D; Strojan, P; Wollenberg, B, 2016) |
| "Oral squamous cell carcinoma (OSCC), one of the most deadliest malignancies in the world, is caused primarily by areca nut chewing in Southeast Asia." | 1.43 | Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline. ( Chang, YC; Chou, MY; Lee, SS; Peng, CY; Wang, TY; Yu, CC, 2016) |
| "Head and neck squamous cell carcinomas from 81 patients were analyzed; clinical factors, histologic parameters, and expression of p16 and p53 were correlated with response to chemotherapy and prognosis." | 1.43 | Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. ( Dumollard, JM; Forest, F; Fournel, P; Froudarakis, M; Gavid, M; Giroult, JB; Karpathiou, G; Monaya, A; Peoc'h, M; Prades, JM, 2016) |
| "Since the prognosis of head and neck squamous cell carcinoma (HNSCC) still remains poor, identifying novel chemotherapeutic agents is of outmost importance." | 1.42 | Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines. ( Brunner, M; Enzenhofer, E; Haymerle, G; Heiduschka, G; Kadletz, L; Kotowski, U; Stanisz, I; Thurnher, D, 2015) |
| "The treatment of head and neck squamous cell carcinoma (HNSCC) with N3 (>6cm) lymph nodes remains difficult, and the best treatment strategy has not been elucidated." | 1.42 | Role of induction chemotherapy for N3 head and neck squamous cell carcinoma. ( Hanai, N; Hasegawa, Y; Hirakawa, H; Nakashima, T; Nishikawa, D; Ozawa, T; Suzuki, H, 2015) |
| "Docetaxel-cisplatin and 5-fluorouracil (TPF) chemotherapy (days 1-21) represents a standard but toxic regimen for advanced head and neck cancer (HNC)." | 1.42 | Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. ( Breheret, R; Capitain, O; Laccourreye, L; Linot, B; Peyraga, G; Yossi, S, 2015) |
| "Using two head and neck squamous cell carcinoma cell lines, Hep-2 (larynx) and CAL-27 (oral cavity), the present study sequentially exposed these cells to increasing concentrations of the combination of docetaxel, cisplatin and 5-FU (TPF) to generate triple drug-resistant cells, termed Hep-2 TPF resistant (TPFR) and CAL-27 TPFR." | 1.42 | Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines. ( Das, D; Govindan, SV; Hicks, W; Kulsum, S; Kuriakose, MA; Pandian, RS; Seshadri, M; Suresh, A, 2015) |
| "A cohort of 78 patients with advanced head and neck cancer treated with induction chemotherapy was assessed for clinical outcome and toxicity during treatment with curative intention." | 1.42 | CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. ( Egle, A; Gaggl, A; Greil, R; Hufnagl, C; Hutarew, G; Magnes, T; Melchardt, T; Moser, G; Neureiter, D; Schlattau, A; Tränkenschuh, W; Weiss, L, 2015) |
| "Survival, distant metastasis and local control rates are expressed as percentages at two years using the Kaplan-Meier method." | 1.40 | Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes. ( Correa, P; Grose, D; Haslett, K; James, A; Paterson, C; Rizwanullah, M; Sanders, IW, 2014) |
| "Distant metastasis accounted for the predominant cause of death." | 1.40 | [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment]. ( Guo, Y; Ji, Q; Qian, W; Wang, Y; Zhu, G, 2014) |
| "Early administration of G-CSF is safe and seems to be more effective than D7." | 1.40 | Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. ( Augereau, P; Breheret, R; Capitain, O; Laccourreye, L; Linot, B, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide." | 1.40 | INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1. ( Liu, P; Shu, Y; Xu, B, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide." | 1.40 | Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. ( Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Stern-Straeter, J; Umbreit, C, 2014) |
| "Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial." | 1.40 | Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma. ( Chen, CH; Lin, SF; Liu, YC; Sun, Y; Tang, JY; Wu, CF; Yang, WC, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world." | 1.40 | Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro. ( Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C, 2014) |
| "Fifteen cancer patients (head and neck cancer (n=11), colon cancer (n=4)) were enrolled." | 1.39 | Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil. ( Hino-Shishikura, A; Horiuchi, C; Ichikawa, Y; Inoue, T; Minamimoto, R; Oka, T; Shizukuishi, K; Sugae, S; Suzuki, A; Tateishi, U, 2013) |
| "We studied head and neck cancer patients (n=23) on 5-FU and cisplatin combination therapy attending a tertiary care cancer research institute in Gujarat, India, to understand the effect of a particular genotype on toxicity." | 1.39 | Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study. ( Dhawan, D; Padh, H; Panchal, H; Shukla, S, 2013) |
| " Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer." | 1.39 | Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ( Chen, H; Cohen, MH; Fuchs, C; He, K; Keegan, P; Pazdur, R; Shord, S; Sickafuse, S; Zhao, H, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) is the most common malignant epithelial tumor in the upper aerodigestive tract." | 1.39 | Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. ( Aderhold, C; Birk, R; Erben, P; Faber, A; Hofheinz, RD; Hörmann, K; Sauter, A; Schultz, JD; Sommer, JU; Stern-Straeter, J; Umbreit, C, 2013) |
| "Head and neck carcinomas are among the most frequent tumor diseases and, because of different multimodal therapy options, cause enormous costs." | 1.39 | Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. ( Guntinas-Lichius, O; Hartmann, M; Himmel, M, 2013) |
| "Head and neck cancer patients treated with a platinum-based regimen were included in the analysis." | 1.39 | Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. ( Cho, H; Inohara, H; Nakahara, S; Takenaka, Y; Yamamoto, M; Yamamoto, Y, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer worldwide." | 1.39 | Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. ( Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Sommer, JU; Stern-Sträter, J; Umbreit, C, 2013) |
| " National Cancer Institute Common Toxicity Criteria (version 4) for classification of adverse events." | 1.39 | Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer. ( Atrash, F; Billan, S; Doweck, I; Haim, N; Kaidar-Person, O; Kuten, A; Ronen, O, 2013) |
| " The aim of the study was to assess the benefit of ICT with docetaxel, cisplatin and 5-fluorouracil (5-FU) (TPF) when combined with concurrent cisplatin chemoradiotherapy (CRT) for HNSCC." | 1.39 | The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis. ( Coyle, C; Dyker, KE; Karakaya, E; Prestwich, RJ; Sen, M; Teo, M; Young, CA, 2013) |
| "5 Gy resulted in a similar pharmacokinetic profile, with a 17% and 33% reduction in the AUC of 5-FU and CDDP, respectively." | 1.39 | Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin. ( Chen, YJ; Chiang, MH; Hou, ML; Hsieh, CH; Tai, HC; Tien, HJ; Tsai, TH; Wang, LY, 2013) |
| "Induction chemotherapy in head and neck squamous cell carcinoma does not compromise delivery of definitive radiotherapy with or without concurrent chemotherapy." | 1.39 | Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck. ( Geropantas, K; Loo, SW; Martin, C; Roques, TW; Tasigiannopoulos, Z, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) represents more than 5% of all cancers diagnosed annually in United States and around the world." | 1.39 | Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. ( Bi, ZG; Cheng, L; Gu, B; Ji, C; Lu, CC; Wang, R; Yang, YL, 2013) |
| "In the majority of cases, HNSCC overexpress the epidermal growth factor receptor (EGFR), and its presence is associated with a poor outcome." | 1.38 | Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. ( Bossow, S; Grossardt, C; Kalle, Cv; Leber, MF; Plinkert, PK; Springfeld, C; Ungerechts, G; Zaoui, K, 2012) |
| "Ten patients had disease progression." | 1.38 | Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer. ( Bi, CP; Chang, TH; Chen, MK; Lai, GM; Lin, JT; Liu, MT; Wang, JW, 2012) |
| "The optimal dosage and frequency of platinum-based chemoradiotherapy (CRT) regimen for treating advanced head and neck squamous cell carcinoma remains unresolved." | 1.38 | Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Fan, KY; Gogineni, H; Ha, PK; Lake, S; Levine, MA; Messing, B; Pai, SI; Saunders, JR; Tang, M; Zaboli, D; Zahurak, ML; Zinreich, ES, 2012) |
| "In case of Head and Neck Squamous Cell Carcinoma, chromosomal changes are detectable at all stages of tumor development providing excellent opportunity for chromosomal prognosis and therapy." | 1.38 | Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents. ( Desai, B; Gadhia, P, 2012) |
| "Apigenin has an antioxidant capacity as well as the ability to inhibit lipid peroxidation." | 1.38 | Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin. ( Chan, LP; Chen, PR; Chiang, FY; Chou, TH; Ding, HY; Kuo, PL; Liang, CH, 2012) |
| " Boosted high dosing to metastatic lymph nodes can increase the relapse-free survival rate." | 1.38 | Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma. ( Chen, XF; Han, JH; Li, T; Yu, CH; Zhou, K; Zhu, WG, 2012) |
| "Capecitabine seems to be an active and well-tolerated regimen, even in heavily pretreated, frail patients." | 1.38 | Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. ( Ceruse, P; Fayette, J; Girodet, D; Péron, J; Poupart, M; Ramade, A; Zrounba, P, 2012) |
| "A total of 45 patients with primary squamous cell carcinoma of the tongue were included in the study." | 1.38 | Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. ( Asakawa, T; Furusaka, T; Ikeda, M; Matsuda, H; Tanaka, A, 2012) |
| " Data for 203 treatment courses were evaluated using the JCOG/JSCO National Cancer Institute-Common Terminology Criteria for Adverse Events(v 4." | 1.38 | Digestive symptoms as side effects of combination chemotherapy of docetaxel, nedaplatin and 5-fluorouracil for head and neck cancer. ( Iwabuchi, H; Nakayama, S; Sugiyama, K; Uchiyama, K; Yamada, M, 2012) |
| "Paclitaxel was identified as a potent inducer of numerous drug transporters and phenotypic MDR in HNSCC." | 1.37 | Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. ( Bertholet, V; Dyckhoff, G; Efferth, T; Haefeli, WE; Herold-Mende, C; Ketabi-Kiyanvash, N; Theile, D; Weiss, J, 2011) |
| "Fatigue was a prominent long-lasting symptom in these patients." | 1.37 | Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011) |
| "World Health Organization scores for oral mucositis were documented weekly and correlated with DSB repair." | 1.37 | The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. ( Derschang, S; Fleckenstein, J; Fricke, A; Gräber, S; Kühne, M; Melchior, P; Rübe, C; Rübe, CE; Seegmüller, K, 2011) |
| "Furthermore, HNSCC-driven squamospheres appeared to be chemoresistant to cisplatin, 5-fluorouracil (FU), paclitaxel and doxetaxel, and showed increased levels of ABCG2, one of the ATP-binding cassette (ABC) transporters." | 1.37 | Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. ( Cha, YY; Jin, X; Kim, H; Kim, SH; Lim, YC; Oh, SY, 2011) |
| "Head and neck squamous cell carcinoma (HNSCC) is one prevalent human cancer worldwide." | 1.37 | Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. ( Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH, 2011) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| "Patients receiving C-IMRT for head-and-neck cancer had repeat CT scans at weeks 2, 3, 4, and 5 during radiotherapy." | 1.36 | Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. ( Barbachano, Y; Bhide, SA; Burke, K; Davies, M; El-Hariry, IA; Hansen, V; Harrington, KJ; McNair, HA; Newbold, K; Nutting, CM, 2010) |
| "Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy between December 1998 and March 2006 were reviewed retrospectively." | 1.36 | Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2010) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "In patients with advanced squamous cell head and neck cancer, the haemoglobin level prior to induction chemotherapy is significantly related to outcome including response and survival." | 1.35 | Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients. ( Baghi, M; Gstoettner, W; Hambek, M; Knecht, R; Moertel, S; Strebhardt, K; Wagenblast, J, 2008) |
| "5-Fluorouracil (5-FU) is a widely used drug in head and neck squamous cell carcinoma (HNSCC)." | 1.35 | Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. ( Ayada, T; Fukushima, M; Kogo, R; Komune, S; Masuda, M; Nakashima, T; Uryu, H; Wakasaki, T; Yasumatsu, R, 2009) |
| " Since all these measures are accompanied by relatively low risks of chronic bleeding a choice of palliative or radical dosage of radiation is possible." | 1.35 | [Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck]. ( Korytova, LI; Sokurenko, VP; Suvorova, IuV; Tarazov, PG, 2008) |
| " Chemotherapy with cisplatin plus 5-FU (PF) is widely used, but the standard dosage, PF (100/1000; cisplatin 100 mg/m(2) day 1 and 5-FU 1000 mg/m(2)/24 h by continuous intravenous infusion on days 1 through 4), is relatively toxic for palliative use, and PF (80/800; cisplatin 80 mg/m(2) day 1 and 5-FU 800 mg/m(2)/24 h by continuous intravenous infusion on days 1 through 5) is more commonly used in Japan, albeit without clear comparative data." | 1.35 | Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. ( Doi, T; Fuse, N; Kadowaki, S; Kiyota, N; Minami, H; Ohtsu, A; Tahara, M, 2009) |
| "Severe dysphagia (Grade 3-4) was observed in 22 patients (47%) as an acute toxic event." | 1.35 | Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2009) |
| "Seven of the 45 had distant metastasis." | 1.35 | [Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer]. ( Enomoto, T; Enomoto, Y; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T, 2009) |
| "Chemoradiation for head and neck cancer may produce severe glucose metabolism alteration during treatment." | 1.35 | Altered glucose metabolism during chemoradiation for head and neck cancer. ( Borok, TL; Dutta, S; Jo, BH; Karlsson, U; Lee, H; Martinez, T; Nguyen, LM; Nguyen, N; Nguyen, NP; Sallah, S; Vinh-Hung, V; Vos, P, 2009) |
| "The present study supports the toxic effect of 5-FU on the myocardium, which is largely schedule-dependent, whereas a low but finite risk of such toxicity has been observed with oral capecitabine." | 1.35 | Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. ( Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N, 2008) |
| "Unknown primary head and neck cancers often require comprehensive mucosal and bilateral neck irradiation." | 1.35 | Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. ( Klem, ML; Kraus, D; Lee, NY; Mechalakos, JG; Pfister, DG; Shah, J; Shaha, A; Singh, B; Wolden, SL; Zelefsky, MJ, 2008) |
| "4-year local-regional control, distant metastasis-free survival, disease-free survival and overall survival rates were 76." | 1.35 | Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings. ( Chan, KY; Chen, YH; Cheng, JC; Cheng, SH; Jian, JJ; Tsai, SY; Yen, KC, 2008) |
| "Since human head and neck cancer cells highly express the antiapoptotic protein myeloid cell leukemia-1 (Mcl-1), the aim of this study was to explore the efficacy of the Mcl-1 suppression in combination with various cytotoxic agents in the head and neck cancer cell line SCC9." | 1.35 | Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. ( Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F, 2008) |
| "Fifty patients with advanced squamous cell carcinoma of the head and neck (SSCHN) who underwent MRI volumetry before and after neoadjuvant chemotherapy consisting of docetaxel, cisplatin, and 5-fluorouracil (TPF) were included in this study." | 1.34 | Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. ( Baghi, M; Bisdas, S; Gstoettner, W; Hambek, M; Knecht, R; Mack, MG; Muerthel, R; Vogl, T; Wagenblast, J, 2007) |
| "Head and neck cancer patients are treated with various therapeutic regimens, including chemotherapy with 5-FU at a dose of 600 mg m(-2) day(-1) with radiotherapy." | 1.34 | Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy. ( Beneton, M; Blasco, H; Boisdron-Celle, M; Calais, G; Chapet, S; Denis, F; Deporte-Fety, R; Giraudeau, B; Le Guellec, C; Narcisso, B, 2007) |
| "Recent studies on polychemotherapy of head and neck cancer showed an improved remission rate on adding taxanes to the standard cytotoxic drugs cisplatin and 5-fluorouracil (5-FU)." | 1.33 | EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. ( Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Peters, S; Solbach, C, 2005) |
| "Based on laboratory data, we diagnosed acute renal failure caused by MTX and added the infusion of Ringer and LV." | 1.33 | [A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator]. ( Matsuda, H; Mikami, Y; Nagao, J; Sakuma, N; Tsukuda, M; Yoshida, T, 2005) |
| "Unknown primary squamous cell carcinoma in the neck has been treated by combination therapy consisting of chemotherapy, radiation therapy and surgery." | 1.33 | [A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil]. ( Fujitani, K; Hirao, M; Ikenaga, M; Kashiwazaki, M; Masuda, N; Mishima, H; Nakamori, S; Sawamura, T; Tsujinaka, T; Yamashita, S, 2005) |
| "Patients complaining from taste disorders during RCT exhibited a significant decrease of taste function assessed with both natural and electric stimuli." | 1.33 | Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy. ( Bombor, I; Fietkau, R; Guthoff, RF; Hummel, T; Just, T; Pau, HW, 2005) |
| " Overall, the present study supports the clinical development of HTP in combination with low-dose PTX against HNSCC." | 1.33 | Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. ( Cho, YB; Kim, SY; Kuh, HJ; Lee, JW; Lee, SH; Park, JK, 2006) |
| "Most of the head and neck tumors are squamous cell carcinomas (SCCs), which are relatively sensitive to chemotherapeutic agents." | 1.33 | [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer]. ( Horiuchi, C; Kawakami, M; Kondo, N; Masuda, Y; Matsuda, H; Mikami, Y; Nagao, J; Nishimura, G; Taguchi, T; Tsukuda, M; Yabuki, K; Yoshida, T, 2006) |
| "77." | 1.33 | Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. ( Hernández, JL; Macías, JG; Olmos, JM; Rivera, F; Valero, C; Vega, ME, 2006) |
| "In order to cure head and neck cancer without resection, chemotherapy (superselective intra-arterial infusion therapy with DCF) was conducted by anterograde, superselective intra-arterial infusion of 50-60 mg/m(2) of DOC and 50-60 mg/m(2) of CDDP via the femoral artery on day 1 followed by continuous intravenous instillation of 600-750 mg/m(2)/day of 5-FU for 5 days from day 2." | 1.33 | [Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies]. ( Furusaka, T, 2006) |
| "Six patients had recurrent head and neck cancer, and 13 had newly diagnosed disease." | 1.32 | [Combined MTX.5-FU.CDGP for the treatment of head and neck cancer]. ( Dake, Y; Enomoto, T; Ikeda, H; Kawano, A; Kitano, H; Saitoh, Y; Sakoda, T; Seno, S, 2003) |
| "Colorectal carcinomas are well known to highly express COX-2 and their growth is markedly inhibited by COX-2 inhibitors, but little is known about head and neck carcinomas." | 1.32 | Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. ( Hashitani, S; Maeda, T; Nishimura, N; Noguchi, K; Sakurai, K; Takaoka, K; Urade, M, 2003) |
| "Twenty-five cases with head and neck cancers in Guangzhou Tumor Hospital from January 1999 to June 2002 were reviewed." | 1.32 | [Combined usage of taxotere in induction chemotherapy of head and neck neoplasms]. ( Liu, WW; Yu, QW; Zeng, J; Zeng, ZY, 2003) |
| "We used a human head and neck cancer cell line (CAL33) to examine the influence of cell cycle modifications on TS, TP, and dihydropyrimidine dehydrogenase activity." | 1.32 | ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. ( Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C, 2003) |
| "We used KB cell that an oral floor squamous cell carcinoma, vitamins as all-trans retinoic acid (ATRA), 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), 1alpha,25(OH)(2)D(3) (calcitriol) and 22-oxa-1,25-(OH)(2)D(3) (OCT)." | 1.32 | Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. ( Imagawa, Y; Ishii, A; Kato, Y; Kimura, Y; Satake, K; Takagi, E; Tsukuda, M, 2003) |
| "An analysis of chromosomal abnormalities in 10 head and neck cancer cell lines by comparative genomic hybridization was performed." | 1.32 | Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. ( Aldosari, N; Cullen, KJ; Haddad, BR; Newkirk, KA; Rone, JD; Schumaker, LM, 2003) |
| "Patients with locally advanced squamous carcinoma of the head and neck who also presented with nodal disease and underwent hyperfractionated radiotherapy and concurrent cisplatin/5-fluorouracil chemotherapy constituted the study population." | 1.32 | Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. ( Brizel, DM; Clough, RL; Downey, MA; Fisher, SR; Hunter, S; Prosnitz, RG; Scher, RL, 2004) |
| "Treatment of head and neck cancer often associates different therapeutic modalities, including surgery, radiotherapy, and chemotherapy." | 1.32 | Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. ( Beaune, P; Beauregard, J; Blons, H; Brasnu, D; Gad, S; Laccourreye, O; Laurent-Puig, P; Manière, I; Tregouet, D; Zinzindohoué, F, 2004) |
| "To evaluate the efficacy and toxic effects of intensive chemoradiotherapy as a primary modality for organ preservation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and to define the patterns of treatment failure associated with this therapy." | 1.32 | Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. ( Alexiou, M; Badley, J; Breau, R; Fan, CY; Hanna, E; Maddox, AM; Morgan, J; Penagaricano, J; Suen, J, 2004) |
| "Locoregionally advanced, stage IV head and neck cancer has traditionally carried a poor prognosis." | 1.32 | Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. ( Brockstein, B; Fung, BB; Haraf, DJ; Kies, MS; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, F; Stenson, KM; Vokes, EE; Weichselbaum, RW; Wenig, B; Witt, ME, 2004) |
| "Avascular-differentiated regions in squamous cell carcinoma offer sanctuary to some hypoxic but viable tumor cells (carbonic anhydrase IX and Ki67 positive) that escape therapy because of limited drug delivery." | 1.32 | Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. ( Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K, 2004) |
| "In the present study we adapted 4 colon cancer (C26-A, C26-10, C26-G and WiDr) and 3 squamous cell carcinoma of the head and neck (HNSCC) cell lines (11B, 14C and 22B) to culture medium with low folate (LF) levels (2." | 1.31 | Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. ( Backus, HH; Jansen, G; Molders, N; Padrón, JM; Peters, GJ; Pinedo, HM; van Der Wilt, CL; van Groeningen, CJ; Wouters, D, 2000) |
| "Occasionally in head and neck cancer patients treated surgically after induction chemotherapy, the histologic analysis of the excised tissue does not show evidence of viable tumor cells, a situation that the authors named "negative specimen." | 1.31 | Histologically negative specimens after induction therapy: frequency and impact on survival. ( de Juan, M; León, X; López-Pousa, A; Orús, C; Quer, M; Sancho, FJ, 2000) |
| "In most new cases of head and neck squamous cell carcinoma, especially in the pharynx and oral cavity, the tumors are advanced." | 1.31 | [Development of new treatment modalities for advanced head and neck carcinomas]. ( Tsukuda, M, 2001) |
| "Patients with advanced squamous cell head and neck cancer were treated with hyperfractionated radiation therapy (72 Gy at 1." | 1.31 | Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. ( Adelstein, DJ; Carroll, MA; Esclamado, RM; Lavertu, P; Rybicki, LA; Saxton, JP; Strome, M; Wood, BG, 2002) |
| "Six head and neck cancer cell lines were used to study the cytotoxic effects of combining ZD1839 ('Iressa'), a new selective epidermal growth factor receptor tyrosine kinase inhibitor, and radiation." | 1.31 | Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. ( Dubreuil, A; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G, 2002) |
| "Most of them (n = 40) were squamous cell carcinomas." | 1.30 | [Therapy pf cervical lymph node metastases of unknown primary tumor]. ( Fietkau, R; Iro, H; Kirschner, MJ; Sauer, R; Waldfahrer, F, 1997) |
| "Disease control for this advanced head and neck cancer population was excellent." | 1.30 | Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. ( Blendowski, C; Caldarelli, DD; Campanella, RS; Chen, S; Griem, KL; Hurst, PB; Hutchinson, JC; Kiel, K; Murthy, AK; Recine, DC; Showel, JT; Taylor, SG, 1997) |
| "Thrombocytopenia was the major dose-limiting toxicity in this study." | 1.30 | [Importance of AUC of carboplatin in head and neck cancer]. ( Makishima, K; Shimizu, T; Yoshida, M, 1998) |
| "Reirradiation of head and neck cancer with 5-fluorouracil and hydroxyurea offers acceptable acute toxicity and minimal late effects." | 1.30 | Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. ( Beenken, SW; Conner, W; Meredith, RF; Peters, GE; Salter, MM; Smith, J; Spencer, SA; Wheeler, RH, 1999) |
| " The findings indicate that a method is available to rationally address the design of dosing schedules in concurrent therapy regimens." | 1.30 | Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. ( Bachert, P; Becker, M; Dietz, A; Knopp, MV; Rudat, V; Schlemmer, HP; van Kaick, G; Vanselow, B; Wannenmacher, M; Weidauer, H; Wollensack, P; Zuna, I, 1999) |
| "Patients with head and neck cancer who chewed betel quid habitually seem to experience more severe chemotherapy-induced mucositis in our clinical practice." | 1.30 | Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent. ( Chen, IH; Chen, JS; Liao, CT; Su, CL; Wang, CH; Wang, HM, 1999) |
| "These guidelines for management of Bowen's disease have been prepared for dermatologists on behalf of the British Association of Dermatologists." | 1.30 | Guidelines for management of Bowen's disease. British Association of Dermatologists. ( Cox, NH; Eedy, DJ; Morton, CA, 1999) |
| "In patients with locally advanced head and neck cancer a high initial rate of anemia was registered (41%): This rate was nearly doubled during chemoradiation (76%)." | 1.30 | [Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors]. ( Carl, UM; Hartmann, KA; Lammering, G; Pape, H, 1999) |
| "Intraarterial drug therapy for head and neck cancer has been used for more than 30 years." | 1.29 | Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system. ( Eckardt, A; Kelber, A, 1994) |
| " This therapy is easy to make the dosage adjustment and can apply drugs directly to the tumor residue at the high concentration." | 1.29 | [Local chemotherapy by a sustained-release preparation with fibrin seal against the operative wound in head and neck cancer]. ( Kubota, T; Matsui, K; Ohtani, M; Takasaki, S, 1995) |
| "Histologically, aneuploidy was detected in 71." | 1.29 | [Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck]. ( Miyagi, M; Nakashima, T; Soda, T, 1994) |
| "Cardiotoxicity is a serious but relatively unknown side-effect of treatment with 5-fluorouracil (5-FU)." | 1.29 | Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity? ( Albertsson, M; Cwikiel, M; Eskilsson, J; Larsson, H; Persson, SU, 1995) |
| "The tegafur suppository was useful because of the high concentration in cancer tissue and metastatic lymph nodes without any obvious side effects in the head and neck region." | 1.29 | [Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue]. ( Esu, H; Itokazu, T; Kamiya, S; Kanazawa, T; Koja, S; Maeshiro, N; Noda, Y; Simoji, Y; Yamauchi, M, 1994) |
| " The optimal scheduling and dosage of concomitant chemoradiotherapy should be further researched." | 1.29 | Concomitant chemoradiotherapy for advanced head and neck cancer. ( Hsu, CY; Jan, JS; Lin, JC, 1994) |
| " In a first step, the 5-FU pharmacokinetic and pharmacodynamic analysis of 25 cycles for 14 patients revealed that both the time-concentration product (ASC) for the entire cycle and the half-cycle were predictive of cycle toxicity and a dose adjustment diagram was established." | 1.29 | [Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion]. ( Klein, T; Levêque, D; Velten, M; Wihlm, J, 1993) |
| "A total of 48 patients with squamous cell carcinomas (SCC) of the head and neck were examined with positron emission tomography (PET) and 18Fluor-deoxyglucose (FDG)." | 1.29 | The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. ( Haberkorn, U; Reisser, C; Strauss, LG, 1993) |
| " Adverse reactions to chemotherapy were documented for all 164 patients included in the study." | 1.29 | Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas. ( Bachaud, JM; Boussin, G; Daly-Schveitzer, NJ; David, JM; De Forni, M; Perineau, D; Pessey, JJ; Serrano, E; Shubinski, RE, 1993) |
| "Twenty-six patients with advanced squamous carcinoma of the head and neck or local recurrence after surgery and/or radiotherapy received carboplatin 300 mg/m2 intravenously on day 1 and 5-fluorouracil 1 gm/m2 by continuous intravenous infusion for 4 days." | 1.29 | Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck. ( Canney, P; Junor, E; Yosef, H, 1993) |
| "The chemosensitivity of various head and neck cancers was investigated with the 5-day rapid thymidine incorporation assay in soft agar culture." | 1.28 | Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application. ( Fujieda, S; Ohtsubo, T; Saito, H; Tanigawa, N, 1992) |
| "We previously have shown that pharmacokinetic monitoring of 5-fluorouracil (5-FU) could significantly improve the 5-FU therapeutic index when given in continuous venous infusion (Br J Cancer 59, 287-290, 1989)." | 1.28 | [Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance]. ( Demard, F; Etienne, MC; Fleming, RA; Milano, G; Renée, N; Schneider, M; Thyss, A, 1992) |
| " Significant interpatient variability for various 5-FU pharmacokinetic parameters was observed including an almost ten-fold range in 5-FU clearance (5-FU Cl, ml min-1 m-2 = 791-7769, mean 2820." | 1.28 | No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. ( Demard, F; Etienne, MC; Fleming, RA; Milano, GA; Renée, N; Schneider, M; Thyss, A, 1992) |
| "Twenty-two cases of early squamous cell carcinoma of the arytenoid cartilage staged as T1 according to the 1983 American Joint Committee for Cancer Staging Classification system were reviewed." | 1.28 | T1 squamous cell carcinoma of the arytenoid. ( Brasnu, D; Chabardes, E; Housset, M; Laccourreye, H; Laccourreye, O; Weinstein, G, 1992) |
| "Head and neck cancer locally recurrent after previous irradiation and surgery presents a difficult management problem." | 1.28 | Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. ( Kim, RY; Meredith, RF; Peters, GE; Salter, MM; Spencer, SA; Weppelmann, B; Wheeler, RH, 1992) |
| "A cohort of 26 patients with head and neck cancer of all histologies were entered into a broad phase I study investigating simultaneous radiation therapy, 5-FU (with or without leucovorin), HU, and infusional cisplatin administered on an alternate-week schedule." | 1.28 | Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| " Age and sex are among the host factors that have been implicated in the pharmacokinetic variability of drugs." | 1.28 | Influence of sex and age on fluorouracil clearance. ( Cassuto-Viguier, E; Demard, F; Etienne, MC; Frenay, M; Milano, G; Renee, N; Santini, J; Schneider, M; Thyss, A, 1992) |
| "Hydroxyurea is an active single agent in squamous cell cancer of the head and neck." | 1.28 | Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992) |
| " Administration of LV by repeated oral dosing resulted in total reduced folate plasma concentrations of 5." | 1.28 | Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. ( Kozloff, MF; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1990) |
| "Patients with cancer of nasopharynx had a better survival than those with other primaries (P = 0." | 1.28 | Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. ( Daniilidis, J; Destouni-Salem, E; Fountzilas, G; Kalogera-Fountzila, A; Sombolos, K; Sridhar, KS; Tourkantonis, A; Vritsios, A; Zaramboukas, T, 1990) |
| "Chemotherapy for head and neck cancer has made great progress after CDDP was introduced at the clinical level." | 1.28 | [Neoadjuvant chemotherapy of head and neck cancer]. ( Fujii, M; Kawasaki, K, 1991) |
| "Thirty-six patients with advanced squamous cell carcinoma of the head and neck (SCCHN) were treated with a regimen including cisplatinum (CP) 30 mg/m2 i." | 1.28 | 5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma. ( Caliceti, U; Dall'Olio, D; Guaraldi, M; Laudadio, P; Martoni, A; Occhiuzzi, L; Pannuti, F; Tononi, A, 1991) |
| "Fifty patients of advanced squamous cell carcinoma of head and neck received infusions of cisplatin 50 mg and 5-FU 500 mg weekly for 4 wk." | 1.28 | Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients. ( Sharma, AK; Sharma, SC; Singhal, KC, 1990) |
| "Hypercalcemia was previously considered a terminal phenomenon in advanced head and neck squamous-cell carcinoma." | 1.28 | Hypercalcemia in head and neck squamous-cell carcinoma. ( Hussein, AM; Sridhar, KS, 1990) |
| "Neutropenic enterocolitis is a recognized complication of immunosuppression or chemotherapy for leukemia." | 1.28 | Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy. ( de Vries, EJ; Johnson, JT; Petruzzelli, GJ, 1990) |
| "And our data are presented in head and neck cancer with multi-drug chemotherapy containing cisplatin." | 1.28 | [Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy]. ( Asano, K; Kagami, Y; Narimatsu, N; Nishio, M; Sanbe, S; Somekawa, Y, 1989) |
| "Six patients developed distant metastases." | 1.28 | Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study. ( Hartenstein, RC; Lissner, J; Wendt, TG; Wustrow, TP, 1989) |
| "Twenty patients with stage III-IV squamous cell carcinoma of the head and neck were treated with the combination of a multidrug cytotoxic regimen CMF-B (cyclophosphamide, methotrexate, 5-fluorouracil, bleomycin) and radical radiotherapy." | 1.27 | Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma. ( Corvò, L; Merlano, M; Rosso, R; Tatarek, R, 1984) |
| "Twenty-seven patients with squamous cell carcinoma of the head and neck were treated with bleomycin 7." | 1.27 | Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck. ( Biller, H; Brooks, S; Holland, JF; Ohnuma, T; Plasse, TF; Saponaro, E, 1984) |
| "30 patients with advanced squamous cell carcinoma of the head and neck received initial chemotherapy with Cisplatin (100 mg/m2 i." | 1.27 | [Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region]. ( Nagel, GA; Scherpe, A; Schröder, M; von Heyden, HW, 1984) |
| "Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate-5-fluorouracil followed by leucovorin rescue." | 1.27 | Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck. ( Ewert, G; Kinnman, J; Lundqvist, PG; Ringborg, U; Strander, H, 1983) |
| "All of them were squamous cell carcinoma except a case presenting parotid lesion caused by adenocarcinoma." | 1.27 | [Clinical study of HCFU and radiation therapy for head and neck cancer]. ( Honda, T, 1983) |
| "Average survival for advanced head and neck cancer (AHNC) is 18 months." | 1.27 | Pretreatment with chemotherapy in patients with advanced head and neck cancer. ( Barron, P; Cripps, C; Danjoux, C; de la Bastide, Y; Hardie, J; Nichol, J; Odell, P, 1985) |
| "In patients with locally advanced head and neck cancer, the results of standard definitive treatments of surgery, radiotherapy, or both were disappointing." | 1.27 | Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer. ( Ahmad, K; Al-Sarraf, M; Crissman, J; Ensley, JF; Jacobs, JR; Kish, J; Weaver, A, 1986) |
| " Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion." | 1.27 | Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. ( Dodge, RK; Forastiere, AA; Goren, MP; Horowitz, ME; Kamen, BA; Pratt, CB; Viar, MJ; Wright, RK, 1987) |
| "A case of retrobulbar neuritis which developed in association with intraarterial continuous infusion cisplatin is presented." | 1.27 | Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer. ( Forastiere, AA; Urba, S, 1988) |
| "Since 1984, a new method for intra-arterial administration of anti-cancer drug and radiosensitizer, named 'superselective continuous intra-arterial infusion therapy' has been used in combination with simultaneous irradiation, for the treatment of 67 patients with the head and neck tumors." | 1.27 | [Continuous superselective intra-arterial infusion with BUdR and 5 FU in combination with radiotherapy in the treatment of head and neck tumors]. ( Hattori, T; Hirano, T; Murata, M; Nakagawa, T; Sakakura, Y; Tashiro, T; Toyota, S; Yamaguchi, N, 1988) |
| "In advanced inoperable head and neck cancer radiotherapy alone is unsatisfying." | 1.27 | 5-Fluorouracil/folinic acid/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer. ( Hartenstein, R; Kastenbauer, ER; Wendt, TG, 1988) |
| " Dose-response curves for cisplatin or fluorouracil on MTS cells closely followed those from monolayer cells, indicating good drug penetration into the MTS core." | 1.27 | Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids. ( Biller, HF; Holland, JF; Kohno, N; Ohnuma, T, 1988) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with an outpatient schedule: cisplatin (100 mg/m2) day 1 and an 8-hour infusion of 5-fluorouracil (1000 mg/m2) on days 1-4 every 28 days." | 1.27 | Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1988) |
| " Using an intensive adjuvant treatment, the overall toxicity was tolerable allowing the application of the full therapeutic dosage in 95% without any interruptions." | 1.27 | [Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma]. ( Hartenstein, RC; Wendt, TG; Wustrow, TP, 1987) |
| " 5-FU dosage was decreased in ten patients (36%) for grade 2 or greater stomatitis or diarrhea." | 1.27 | A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck. ( Forastiere, AA; Goren, MP; Kudla-Hatch, V; Natale, RB; Takasugi, BJ; Vogel, WC, 1987) |
| "Among 30 patients with squamous cell carcinoma, five achieved complete response (CR) (17%) and 13 achieved partial response (PR) (43%)." | 1.27 | Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study. ( DeConti, RC; Marsh, JC; Milner, LM; O'Donnell, MR; Rowland, KM; Showel, J; Spiers, AS; Stott, PB; Taylor, SG, 1986) |
| "Thirty-two patients with squamous cell carcinomas of the head and neck and three patients with parotid gland carcinomas were treated with methotrexate 40 mg/m2 followed 1 h later by 5-fluorouracil 600 mg/m2." | 1.27 | Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck. ( Cripps, C; Gerin-Lajoie, J; Laframboise, G; Maroun, JA; Stewart, DJ; Young, V, 1986) |
| "Treatment of the head and neck cancer has surprisingly developed in the last decade." | 1.27 | [Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application]. ( Komiyama, S; Kudo, S; Kuwano, N; Yanagita, T, 1986) |
| "9 g carmofur (HCFU) in combination with a mean total dose of 49." | 1.27 | [Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck]. ( Fukukita, K; Harada, T; Ito, Y; Kubo, M; Sakakura, Y; Yamagiwa, M, 1986) |
| "One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment." | 1.27 | Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. ( Caldani, C; Chauvel, P; Demard, F; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1986) |
| "The treatment of 192 patients with cancer of the larynx, 60 patients with hypopharyngeal and cervical esophageal cancer, and 23 patients with epipharyngeal cancer with FAR therapy during 6 years from 1972 to 1977 resulted in highly effective synergism, and the improved points of this therapy were considered." | 1.27 | Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A. ( Komiyama, S; Kudoh, S; Kuwano, M; Yanagita, T, 1985) |
| "Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results." | 1.27 | [Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture]. ( Hattori, Y; Horiuchi, M; Miyake, H; Murakami, T; Otake, H; Sawaki, S; Takahashi, H; Takeyama, I; Tamamushi, N; Yao, K, 1985) |
| "Seventy-five cases of head and neck cancer except of maxillary sinus, 27 cases of mesopharyngeal cancer, 6 cases of oral cancer, 9 cases of thyroid cancer and 9 cases of the other cancer, were treated with this multi-disciplinary treatment and the results were evaluated in this series." | 1.27 | [An evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy of head and neck cancer]. ( Maehara, Y; Makino, S; Matsuura, S; Miyama, J; Nakamura, Y; Sakaino, K; Satake, B; Shimizu, R, 1985) |
| "Thirty patients with squamous cell carcinoma of the head and neck were treated with a combination of cisplatin (20 mg/m2) and 5-FU (400-200 mg/m2) by iv push on Days 1-5 every 21 days." | 1.27 | Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule. ( Grimaldi, A; Margarino, G; Merlano, M; Rosso, R; Tatarek, R, 1985) |
| " They received 5FU and cisplatin in the same dosage every 28 days for either recurrent or metastatic disease." | 1.27 | A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck. ( Citrin, P; Dasmahapatra, KS; Hill, GJ; Mohit-Tabatabai, MA; Rush, BF; Yee, R, 1985) |
| "Fifteen patients with advanced squamous cell carcinoma of the head and neck were treated with the six-drug Price-Hill regimen (vincristine, bleomycin, methotrexate, hydrocortisone, 5-fluorouracil, and leucovorin)." | 1.26 | Combination chemotherapy for advanced squamous cell carcinoma of the head and neck. ( Oster, MW; Raafat, J, 1980) |
| "Twenty-five patients with advanced squamous cell carcinoma of the head and neck were entered into this study." | 1.26 | Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A. ( Blackledge, G; Crowther, D; Thatcher, N, 1980) |
| " Radiation dosage must not be reduced." | 1.26 | [Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)]. ( Ammon, J; Schwab, W; zum Winkel, K, 1976) |
| "Palliation of unresectable head and neck cancer remains a difficult problem." | 1.26 | Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation. ( Armstrong, AL; Meeker, WR, 1978) |
| "A total of 77 patients with cancer of the head and neck area were treated with five different drug combination regimens." | 1.26 | Combination chemotherapy of head and neck cancer. ( Byers, RM; Gard, DA; Goepfert, H; Guillamondegui, OM; Holoye, PY; Jesse, RH, 1978) |
| "The treatment of 33 patients with cancer of larynx and 15 patients with hypopharyngeal or cervical esophageal cancer with FAR therapy during three years from 1972 to 1974 resulted in highly effective synergism in vivo, and the improved points of this therapy were presented." | 1.26 | Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors. ( Endo, H; Hiroto, I; Komiyama, S; Kuwano, M; Nakashima, T; Ryu, S, 1978) |
| "Generally, metastases responded better than the advanced primaries from which they were derived, except for those from breast tumours." | 1.25 | The influence of site of metastasis on tumour growth and response to chemotherapy. ( Bross, ID; Slack, NH, 1975) |
| "All 14 patients with breast carcinoma underwent remission and in 6 this was complete." | 1.25 | Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime. ( Hanham, IW; Newton, KA; Westbury, G, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 272 (21.50) | 18.7374 |
| 1990's | 309 (24.43) | 18.2507 |
| 2000's | 306 (24.19) | 29.6817 |
| 2010's | 319 (25.22) | 24.3611 |
| 2020's | 59 (4.66) | 2.80 |
| Authors | Studies |
|---|---|
| Almeida, LY | 1 |
| Moreira, FDS | 1 |
| Santos, GASD | 1 |
| Cuadra Zelaya, FJM | 1 |
| Ortiz, CA | 1 |
| Agostini, M | 1 |
| Mariano, FS | 1 |
| Bastos, DC | 1 |
| Daher, URN | 1 |
| Kowalski, LP | 1 |
| Coletta, RD | 1 |
| Graner, E | 1 |
| Li, L | 1 |
| Li, XD | 1 |
| Zhuang, QW | 1 |
| Ge, LY | 1 |
| Li, ZP | 1 |
| Gu, QP | 1 |
| Meng, J | 2 |
| Goerling, U | 1 |
| Gauler, T | 1 |
| Dietz, A | 6 |
| Grünwald, V | 2 |
| Knipping, S | 1 |
| Guntinas-Lichius, O | 3 |
| Frickhofen, N | 1 |
| Lindeman, HW | 1 |
| Fietkau, R | 4 |
| Haxel, B | 1 |
| Große-Thie, C | 1 |
| Maschmeyer, G | 1 |
| Zipfel, M | 1 |
| Martus, P | 1 |
| Knoedler, M | 1 |
| Keilholz, U | 4 |
| Klinghammer, K | 2 |
| Kang, EJ | 3 |
| Lee, YG | 3 |
| Keam, B | 5 |
| Choi, JH | 3 |
| Kim, JS | 3 |
| Park, KU | 3 |
| Lee, KE | 3 |
| Kim, HJ | 2 |
| Lee, KW | 3 |
| Kim, MK | 3 |
| Ahn, HK | 3 |
| Shin, SH | 3 |
| Lee, JB | 1 |
| Kwon, JH | 2 |
| Kim, HR | 4 |
| Kim, SB | 3 |
| Yun, HJ | 3 |
| Cao, L | 1 |
| Zhou, MJ | 1 |
| Ding, YM | 1 |
| Gao, R | 1 |
| Chen, XH | 1 |
| Patil, VM | 1 |
| Kolkur, M | 1 |
| Kumar Chinthala, S | 1 |
| Waratkar, G | 1 |
| Menon, N | 1 |
| Noronha, V | 1 |
| Ghosh Laskar, S | 1 |
| Simha, V | 1 |
| Talreja, V | 1 |
| Dhumal, S | 1 |
| Chandrasekharan, A | 1 |
| Prabhash, K | 1 |
| Saada-Bouzid, E | 2 |
| Peyrade, F | 5 |
| Guigay, J | 4 |
| Fu, JY | 1 |
| Yue, XH | 1 |
| Dong, MJ | 1 |
| Li, J | 2 |
| Zhang, CP | 1 |
| Li, R | 2 |
| Ye, L | 1 |
| Zhu, Y | 1 |
| Ding, H | 1 |
| Wang, S | 1 |
| Ying, H | 1 |
| Wu, C | 1 |
| Zhou, L | 2 |
| Wang, X | 2 |
| Tian, S | 1 |
| Hitt, R | 14 |
| Mesía, R | 12 |
| Lozano, A | 2 |
| Iglesias Docampo, L | 1 |
| Grau, JJ | 5 |
| Taberna, M | 2 |
| Rubió-Casadevall, J | 1 |
| Martínez-Trufero, J | 5 |
| Morillo, EDB | 1 |
| García Girón, C | 1 |
| Vázquez Estévez, S | 1 |
| Cirauqui, B | 1 |
| Cruz-Hernández, JJ | 3 |
| Yu, X | 1 |
| Su, X | 2 |
| Fang, L | 1 |
| Zhang, H | 2 |
| Chen, X | 3 |
| Pu, Y | 1 |
| Liu, H | 2 |
| Guo, R | 1 |
| Takahashi, S | 5 |
| Oridate, N | 2 |
| Tanaka, K | 2 |
| Shimizu, Y | 3 |
| Fujimoto, Y | 3 |
| Matsumoto, K | 1 |
| Yokota, T | 3 |
| Yamazaki, T | 2 |
| Takahashi, M | 5 |
| Ueda, T | 1 |
| Hanai, N | 8 |
| Yamaguchi, H | 1 |
| Hara, H | 1 |
| Yoshizaki, T | 1 |
| Yasumatsu, R | 4 |
| Nakayama, M | 1 |
| Shiga, K | 4 |
| Fujii, T | 3 |
| Mitsugi, K | 1 |
| Takahashi, K | 1 |
| Nohata, N | 1 |
| Gumuscu, B | 2 |
| Swaby, RF | 1 |
| Tahara, M | 10 |
| Kusaka, T | 3 |
| Katagiri, K | 3 |
| Saito, D | 3 |
| Oikawa, SI | 3 |
| Ikeda, A | 3 |
| Tsuchida, K | 3 |
| Miyaguchi, J | 3 |
| Ohashi, YU | 3 |
| Ariga, H | 3 |
| Tanno, K | 3 |
| Dhaka, S | 2 |
| Jakhar, SL | 2 |
| Sharma, N | 2 |
| Kumar, HS | 2 |
| Kumar, R | 2 |
| Liao, AH | 1 |
| Lee, YA | 1 |
| Lin, DL | 1 |
| Chuang, HC | 2 |
| Wang, JK | 1 |
| Chang, CE | 1 |
| Li, HT | 1 |
| Wu, TY | 1 |
| Shih, CP | 1 |
| Wang, CH | 3 |
| Chu, YH | 1 |
| Tang, H | 1 |
| Yang, D | 2 |
| Luo, G | 1 |
| He, J | 1 |
| Yi, G | 1 |
| Chen, Z | 2 |
| Li, H | 1 |
| Luo, Q | 2 |
| Huang, N | 1 |
| Luo, H | 1 |
| De Felice, F | 1 |
| Mahdavi, H | 1 |
| Le Tourneau, C | 3 |
| Ghiani, M | 3 |
| Cau, MC | 1 |
| Depenni, R | 1 |
| Ronzino, G | 1 |
| Bonomo, P | 1 |
| Montesarchio, V | 1 |
| Leo, L | 1 |
| Schulten, J | 1 |
| Salmio, S | 1 |
| Messinger, D | 1 |
| Sbrana, A | 1 |
| Borcoman, E | 1 |
| Ghi, MG | 5 |
| Elsaady, SA | 1 |
| Aboushelib, MN | 1 |
| Al-Wakeel, E | 1 |
| Badawi, MF | 1 |
| Yamada, A | 1 |
| Shinomiya, H | 2 |
| Uehara, N | 1 |
| Iritani, K | 1 |
| Tatehara, S | 1 |
| Furukawa, T | 3 |
| Teshima, M | 1 |
| Miyawaki, D | 1 |
| Fujita, T | 1 |
| Kakigi, A | 1 |
| Kiyota, N | 3 |
| Sasaki, R | 2 |
| Nibu, KI | 1 |
| Xiao, Q | 1 |
| Dong, P | 1 |
| Ying, X | 1 |
| Liu, Y | 3 |
| Chen, L | 3 |
| Ding, J | 1 |
| Rognoni, C | 2 |
| Quaglini, S | 2 |
| Vermorken, JB | 23 |
| De Cecco, L | 1 |
| Licitra, L | 6 |
| Bossi, P | 2 |
| Burtness, B | 1 |
| Harrington, KJ | 6 |
| Greil, R | 4 |
| Soulières, D | 4 |
| de Castro, G | 1 |
| Psyrri, A | 3 |
| Basté, N | 2 |
| Neupane, P | 1 |
| Bratland, Å | 1 |
| Fuereder, T | 1 |
| Hughes, BGM | 1 |
| Ngamphaiboon, N | 1 |
| Rordorf, T | 1 |
| Wan Ishak, WZ | 1 |
| Hong, RL | 1 |
| González Mendoza, R | 1 |
| Roy, A | 1 |
| Zhang, Y | 6 |
| Cheng, JD | 1 |
| Jin, F | 1 |
| Rischin, D | 5 |
| Moro, Y | 1 |
| Kogashiwa, Y | 2 |
| Sakurai, H | 1 |
| Takahashi, R | 1 |
| Kimura, T | 1 |
| Hirasaki, M | 1 |
| Matsumoto, Y | 1 |
| Sugasawa, M | 1 |
| Kohno, N | 13 |
| Chirovsky, D | 2 |
| Cheung, WY | 1 |
| Bertolini, F | 1 |
| Ahn, MJ | 3 |
| Yang, MH | 5 |
| Castro, G | 1 |
| Berrocal, A | 3 |
| Sjoquist, K | 1 |
| Kuyas, H | 1 |
| Auclair, V | 1 |
| Guillaume, X | 1 |
| Joo, S | 2 |
| Shah, R | 1 |
| Harrington, K | 2 |
| Lim, SH | 1 |
| Sun, JM | 1 |
| Hong, J | 1 |
| Oh, D | 1 |
| Ahn, YC | 1 |
| Chung, MK | 1 |
| Jeong, HS | 1 |
| Son, YI | 1 |
| Baek, CH | 1 |
| Park, K | 2 |
| Mashhour, K | 1 |
| Atef, H | 1 |
| Selim, A | 1 |
| A Moez, M | 1 |
| Zawam, H | 1 |
| Abo-Madyan, Y | 1 |
| Maniglia, MP | 1 |
| Russo, A | 4 |
| Biselli-Chicote, PM | 1 |
| Oliveira-Cucolo, JG | 1 |
| Rodrigues-Fleming, GH | 1 |
| -Maniglia, JV | 1 |
| Pavarino, ÉC | 1 |
| Goloni-Bertollo, EM | 1 |
| Shirasu, H | 1 |
| Kawakami, T | 1 |
| Hamauchi, S | 2 |
| Onozawa, Y | 4 |
| Ogawa, H | 2 |
| Onoe, T | 1 |
| Mori, K | 1 |
| Onitsuka, T | 2 |
| Iglesias, L | 2 |
| López-Pousa, A | 8 |
| Berrocal-Jaime, A | 1 |
| García-Girón, C | 2 |
| Guix, M | 1 |
| Lambea-Sorrosal, J | 1 |
| Del Barco-Morillo, E | 1 |
| León-Vintró, X | 1 |
| Cunquero-Tomas, AJ | 1 |
| Ocaña, A | 1 |
| Zhao, Z | 1 |
| Wen, Y | 1 |
| Liao, D | 1 |
| Miao, J | 1 |
| Gui, Y | 1 |
| Cai, H | 1 |
| Chen, Y | 2 |
| Wei, M | 1 |
| Jia, Q | 1 |
| Tian, H | 1 |
| Sun, M | 1 |
| Feng, G | 1 |
| Du, X | 1 |
| Hsieh, CY | 1 |
| Lein, MY | 1 |
| Yang, SN | 1 |
| Wang, YC | 1 |
| Lin, YJ | 1 |
| Lin, CY | 1 |
| Hua, CH | 1 |
| Tsai, MH | 1 |
| Lin, CC | 1 |
| Tomita, R | 1 |
| Sasabe, E | 1 |
| Tomomura, A | 1 |
| Yamamoto, T | 3 |
| Zech, HB | 1 |
| Moeckelmann, N | 1 |
| Boettcher, A | 1 |
| Muenscher, A | 1 |
| Binder, M | 2 |
| Vettorazzi, E | 1 |
| Bokemeyer, C | 4 |
| Schafhausen, P | 3 |
| Betz, CS | 1 |
| Busch, CJ | 2 |
| Mezi, S | 2 |
| Pomati, G | 1 |
| Botticelli, A | 2 |
| Roberto, M | 1 |
| Cerbelli, B | 2 |
| Cirillo, A | 2 |
| Di Gioia, C | 1 |
| Corsi, A | 1 |
| Vullo, F | 1 |
| De Vincentiis, M | 1 |
| Polimeni, A | 2 |
| Tombolini, V | 1 |
| Valentini, V | 3 |
| Marchetti, P | 2 |
| Kurosaki, T | 1 |
| Mitani, S | 1 |
| Suzuki, S | 4 |
| Kanemura, H | 1 |
| Haratani, K | 1 |
| Fumita, S | 1 |
| Iwasa, T | 1 |
| Hayashi, H | 1 |
| Yoshida, T | 9 |
| Ishikawa, K | 3 |
| Kitano, M | 1 |
| Otsuki, N | 2 |
| Nishimura, Y | 1 |
| Doi, K | 1 |
| Nakagawa, K | 1 |
| Huang, YF | 1 |
| Liu, SP | 1 |
| Muo, CH | 1 |
| Chen, HJ | 1 |
| Liao, YF | 1 |
| Chiu, KM | 1 |
| Chen, CC | 3 |
| Tsai, CH | 1 |
| Hong, HH | 1 |
| Chang, CT | 1 |
| Inukai, D | 1 |
| Nishimura, K | 2 |
| Okamoto, H | 3 |
| Sano, R | 1 |
| Ueda, H | 2 |
| Ota, A | 1 |
| Karnan, S | 1 |
| Hosokawa, Y | 1 |
| Yoshikawa, K | 3 |
| Ueda, R | 2 |
| Murotani, K | 1 |
| Bradford, CR | 4 |
| Ogawa, T | 7 |
| Tron, C | 1 |
| Lemaitre, F | 1 |
| Boisteau, E | 1 |
| Sourd, SL | 1 |
| Lièvre, A | 2 |
| Osaki, A | 1 |
| Sanematsu, K | 1 |
| Yamazoe, J | 1 |
| Hirose, F | 2 |
| Watanabe, Y | 2 |
| Kawabata, Y | 1 |
| Oike, A | 1 |
| Hirayama, A | 1 |
| Yamada, Y | 1 |
| Iwata, S | 1 |
| Takai, S | 1 |
| Wada, N | 1 |
| Shigemura, N | 1 |
| Fukuda, N | 1 |
| Yunokawa, M | 1 |
| Fujiwara, Y | 1 |
| Ohmoto, A | 1 |
| Hayashi, N | 1 |
| Urasaki, T | 1 |
| Sato, Y | 2 |
| Nakano, K | 2 |
| Ono, M | 2 |
| Tomomatsu, J | 1 |
| Mitani, H | 2 |
| Singh, K | 1 |
| Sunku, R | 1 |
| Rathi, AK | 1 |
| Pradhan, GS | 1 |
| Shen, Q | 1 |
| Zhu, H | 1 |
| Lei, Q | 1 |
| Sui, W | 1 |
| de Lima, JM | 1 |
| Castellano, LRC | 1 |
| Bonan, PRF | 1 |
| de Medeiros, ES | 1 |
| Hier, M | 1 |
| Bijian, K | 1 |
| Alaoui-Jamali, MA | 1 |
| da Cruz Perez, DE | 1 |
| da Silva, SD | 1 |
| Hwang, M | 1 |
| Seiwert, TY | 6 |
| Bernadach, M | 2 |
| Lapeyre, M | 3 |
| Dillies, AF | 2 |
| Miroir, J | 2 |
| Casile, M | 1 |
| Moreau, J | 2 |
| Molnar, I | 1 |
| Ginzac, A | 1 |
| Pham-Dang, N | 2 |
| Saroul, N | 2 |
| Durando, X | 2 |
| Biau, J | 2 |
| Pontes, F | 1 |
| Garcia, AR | 1 |
| Domingues, I | 1 |
| João Sousa, M | 1 |
| Felix, R | 2 |
| Amorim, C | 1 |
| Salgueiro, F | 1 |
| Mariano, M | 1 |
| Teixeira, M | 1 |
| Keil, F | 2 |
| Hartl, M | 1 |
| Altorjai, G | 1 |
| Berghold, A | 2 |
| Riedl, R | 2 |
| Pecherstorfer, M | 1 |
| Mayrbäurl, B | 1 |
| De Vries, A | 3 |
| Schuster, J | 1 |
| Hackl, J | 1 |
| Füreder, T | 1 |
| Melchardt, T | 2 |
| Burian, M | 2 |
| Chevalier, T | 1 |
| Daste, A | 1 |
| Loundou, A | 1 |
| Peyraud, F | 1 |
| Lambert, T | 1 |
| Dupuis, C | 2 |
| Alfonsi, M | 4 |
| Fayette, J | 8 |
| Reure, J | 1 |
| Huguet, F | 3 |
| Fakhry, N | 2 |
| Toullec, C | 1 |
| Salas, S | 2 |
| Ren, G | 1 |
| Ju, H | 1 |
| Wu, Y | 1 |
| Song, H | 1 |
| Ma, X | 1 |
| Ge, M | 2 |
| Qiu, W | 1 |
| He, Y | 1 |
| Zhuang, Q | 1 |
| Guo, W | 1 |
| Sun, W | 1 |
| Zhao, T | 1 |
| Aladelusi, TO | 1 |
| Ju, W | 1 |
| Zhang, Z | 3 |
| Zhong, L | 1 |
| Zhu, D | 1 |
| Meirovitz, A | 1 |
| Bergerson, S | 1 |
| Hirshoren, N | 1 |
| Weinberger, JM | 1 |
| Bersudski, E | 1 |
| Daniel, S | 1 |
| Sheva, K | 1 |
| Perez, CA | 1 |
| Iqbal, MS | 1 |
| Kovarik, J | 1 |
| Patil, R | 1 |
| Kelly, CG | 1 |
| Nakaya, S | 1 |
| Ogawa, R | 1 |
| Hayakawa, S | 1 |
| Fujihata, S | 1 |
| Okubo, T | 1 |
| Sagawa, H | 1 |
| Tanaka, T | 1 |
| Takahashi, H | 4 |
| Matsuo, Y | 1 |
| Takiguchi, S | 1 |
| Ghonaim, E | 1 |
| El-Haggar, S | 1 |
| Gohar, S | 1 |
| Guo, Y | 5 |
| Luo, Y | 1 |
| Zhang, Q | 2 |
| Huang, X | 2 |
| Li, Z | 2 |
| Shen, L | 2 |
| Feng, J | 2 |
| Sun, Y | 2 |
| Yang, K | 1 |
| Zhu, X | 2 |
| Wang, L | 2 |
| He, X | 1 |
| Bai, C | 1 |
| Xue, K | 1 |
| Zeng, Y | 1 |
| Chang, X | 1 |
| Chen, W | 1 |
| Lin, T | 1 |
| Szturz, P | 2 |
| Vinches, M | 1 |
| Remenár, É | 8 |
| van Herpen, CML | 2 |
| Abdeddaim, C | 1 |
| Stewart, JS | 3 |
| Fortpied, C | 3 |
| Strigari, L | 1 |
| Valentini, F | 1 |
| Scagnoli, S | 1 |
| Cerbelli, E | 1 |
| Zizzari, IG | 1 |
| Rocca, CD | 1 |
| D'Amati, G | 1 |
| Nuti, M | 1 |
| Merlano, MC | 2 |
| Yang, M | 1 |
| Chen, F | 1 |
| Ikemura, K | 1 |
| Oshima, K | 1 |
| Enokiya, T | 1 |
| Okamoto, A | 1 |
| Oda, H | 1 |
| Mizuno, T | 1 |
| Ishinaga, H | 1 |
| Muraki, Y | 1 |
| Iwamoto, T | 1 |
| Takeuchi, K | 1 |
| Katayama, N | 1 |
| Okuda, M | 1 |
| Lee, J | 3 |
| Park, M | 1 |
| Ko, Y | 1 |
| Kim, B | 1 |
| Kim, O | 1 |
| Hyun, H | 1 |
| Kim, D | 1 |
| Sohn, H | 1 |
| Moon, YL | 1 |
| Lim, W | 1 |
| Alterio, D | 2 |
| Cossu Rocca, M | 1 |
| Russell-Edu, W | 1 |
| Dicuonzo, S | 1 |
| Fanetti, G | 1 |
| Marvaso, G | 1 |
| Preda, L | 1 |
| Zorzi, S | 1 |
| Verri, E | 2 |
| Nole', F | 1 |
| Jereczek-Fossa, BA | 2 |
| Burgy, M | 2 |
| Barthélémy, P | 1 |
| Lefevre, F | 1 |
| Dupret-Bories, A | 2 |
| Truntzer, P | 1 |
| Korenbaum, C | 1 |
| Flesch, H | 1 |
| Bronner, G | 1 |
| Borel, C | 5 |
| Yoon, TM | 1 |
| Kim, SA | 1 |
| Lee, DH | 1 |
| Lee, JK | 1 |
| Park, YL | 1 |
| Lee, KH | 1 |
| Chung, IJ | 1 |
| Joo, YE | 1 |
| Lim, SC | 1 |
| Lin, JC | 2 |
| Chen, KW | 1 |
| Otto, R | 1 |
| Raguse, JD | 2 |
| Albers, AE | 1 |
| Tinhofer, I | 2 |
| Fichtner, I | 1 |
| Leser, U | 1 |
| Hoffmann, J | 1 |
| Koutsodontis, G | 1 |
| Avgeris, M | 1 |
| Kroupis, C | 1 |
| Goutas, N | 1 |
| Menis, J | 2 |
| Herman, L | 1 |
| Giurgea, L | 1 |
| Degardin, M | 3 |
| Pateras, IS | 1 |
| Langendijk, JA | 2 |
| Awada, A | 5 |
| Germà-Lluch, JR | 1 |
| Kienzer, HR | 3 |
| Tao, Y | 1 |
| Aupérin, A | 1 |
| Graff, P | 1 |
| Grégoire, V | 3 |
| Maingon, P | 1 |
| Geoffrois, L | 2 |
| Verrelle, P | 2 |
| Calais, G | 9 |
| Gery, B | 3 |
| Martin, L | 2 |
| Deprez, P | 1 |
| Bardet, E | 3 |
| Pignon, T | 2 |
| Rives, M | 1 |
| Sire, C | 2 |
| Bourhis, J | 7 |
| Pointreau, Y | 4 |
| Schick, U | 2 |
| Specenier, PM | 3 |
| Buter, J | 1 |
| Schrijvers, DL | 1 |
| Bergamini, C | 2 |
| Licitra, LF | 1 |
| Clement, PM | 2 |
| Paccagnella, A | 9 |
| Ferrari, D | 1 |
| Foa, P | 2 |
| Codecà, C | 1 |
| Nolè, F | 1 |
| Orecchia, R | 3 |
| Morelli, F | 1 |
| Parisi, S | 1 |
| Mastromauro, C | 3 |
| Mione, CA | 3 |
| Rossetto, C | 1 |
| Polsinelli, M | 1 |
| Koussis, H | 2 |
| Loreggian, L | 3 |
| Bonetti, A | 2 |
| Campostrini, F | 2 |
| Azzarello, G | 1 |
| D'Ambrosio, C | 1 |
| Bertoni, F | 1 |
| Casanova, C | 1 |
| Emiliani, E | 1 |
| Guaraldi, M | 4 |
| Bunkheila, F | 1 |
| Bidoli, P | 1 |
| Niespolo, RM | 1 |
| Gava, A | 5 |
| Massa, E | 3 |
| Frattegiani, A | 1 |
| Valduga, F | 1 |
| Pieri, G | 1 |
| Cipani, T | 1 |
| Da Corte, D | 1 |
| Chiappa, F | 1 |
| Rulli, E | 1 |
| Hirakawa, H | 5 |
| Suzuki, H | 6 |
| Nishikawa, D | 3 |
| Matayoshi, S | 1 |
| Hasegawa, Y | 13 |
| Suzuki, M | 2 |
| Nishio-Nagai, M | 1 |
| Kazaoka, Y | 1 |
| Leblanc, J | 1 |
| Lowe, NM | 1 |
| Kershaw, LE | 1 |
| Bernstein, JM | 1 |
| Withey, SB | 1 |
| Mais, K | 3 |
| Homer, JJ | 1 |
| Slevin, NJ | 2 |
| Bonington, SC | 1 |
| Carrington, BM | 1 |
| West, CM | 1 |
| Chen, J | 1 |
| Qi, J | 1 |
| Yu, B | 1 |
| Peng, XH | 1 |
| Wang, F | 1 |
| Tan, JJ | 1 |
| Chen, QQ | 1 |
| Peng, XY | 1 |
| Zeng, FF | 1 |
| Liu, X | 1 |
| Maihoefer, C | 1 |
| Schüttrumpf, L | 1 |
| Macht, C | 1 |
| Pflugradt, U | 1 |
| Hess, J | 1 |
| Schneider, L | 1 |
| Woischke, C | 1 |
| Walch, A | 1 |
| Baumeister, P | 1 |
| Kirchner, T | 1 |
| Zitzelsberger, H | 1 |
| Belka, C | 2 |
| Ganswindt, U | 1 |
| Tamura, T | 1 |
| Taniguchi, N | 1 |
| Otsuki, K | 1 |
| Narai, T | 1 |
| Kawasaki, M | 1 |
| Fujii, N | 1 |
| Doi, R | 2 |
| Kodani, I | 1 |
| Elkashty, OA | 1 |
| Ashry, R | 1 |
| Elghanam, GA | 1 |
| Pham, HM | 1 |
| Stegen, C | 1 |
| Tran, SD | 1 |
| Zhong, Q | 1 |
| Fang, J | 1 |
| Huang, Z | 1 |
| Yang, Y | 2 |
| Lian, M | 1 |
| Ye, J | 1 |
| Hui, X | 1 |
| Wang, Y | 5 |
| Ying, Y | 1 |
| Cheng, Y | 2 |
| Saba, NF | 2 |
| Mendenhall, WM | 2 |
| Hutcheson, K | 1 |
| Suárez, C | 1 |
| Wolf, G | 1 |
| Ferlito, A | 1 |
| Nadler, E | 1 |
| Boyd, M | 1 |
| Black-Shinn, J | 1 |
| Bastit, V | 2 |
| Bon-Mardion, N | 1 |
| Picquenot, JM | 1 |
| Rainville, V | 1 |
| Moldovan, C | 2 |
| François, A | 1 |
| Loeb, A | 1 |
| Thureau, S | 2 |
| Manu, D | 1 |
| Jardin, F | 1 |
| Marie, JP | 1 |
| Di Fiore, F | 2 |
| Clatot, F | 2 |
| Killock, D | 1 |
| Bohlen, M | 1 |
| Busch, C- | 1 |
| Sehner, S | 1 |
| Forterre, F | 1 |
| Bier, J | 3 |
| Berliner, C | 1 |
| Bußmann, L | 1 |
| Münscher, A | 2 |
| Sato, H | 1 |
| Tsukahara, K | 1 |
| Okamoto, I | 1 |
| Katsube, Y | 1 |
| Shimizu, A | 2 |
| Kondo, T | 1 |
| Hanyu, K | 1 |
| Fushimi, C | 1 |
| Okada, T | 2 |
| Miura, K | 1 |
| Le Louedec, F | 1 |
| Alix-Panabières, C | 1 |
| Lafont, T | 1 |
| Allal, BC | 1 |
| Garrel, R | 1 |
| Digue, L | 1 |
| Cupissol, D | 5 |
| Delord, JP | 4 |
| Lallemant, B | 3 |
| Aubry, K | 1 |
| Mazel, M | 1 |
| Becher, F | 1 |
| Perriard, F | 1 |
| Chatelut, E | 2 |
| Thomas, F | 1 |
| Dalwadi, C | 1 |
| Patel, G | 1 |
| Rambeau, A | 1 |
| Thariat, J | 1 |
| Roge, M | 1 |
| Babin, E | 1 |
| Florescu, C | 1 |
| Kwiatkowski, F | 1 |
| Mikoshiba, T | 1 |
| Ozawa, H | 1 |
| Saito, S | 2 |
| Ikari, Y | 1 |
| Nakahara, N | 1 |
| Ito, F | 1 |
| Sekimizu, M | 1 |
| Imanishi, Y | 5 |
| Ogawa, K | 1 |
| Landgraf, V | 1 |
| Griessmann, M | 1 |
| Roller, J | 1 |
| Polednik, C | 1 |
| Schmidt, M | 1 |
| Gau, M | 1 |
| Karabajakian, A | 1 |
| Reverdy, T | 1 |
| Neidhardt, EM | 2 |
| Seto, A | 1 |
| Sasaki, T | 2 |
| Shimbashi, W | 1 |
| Fukushima, H | 1 |
| Yonekawa, H | 2 |
| Faivre, S | 3 |
| Albert, S | 1 |
| Raymond, E | 2 |
| Haddad, R | 4 |
| O'Neill, A | 1 |
| Rabinowits, G | 2 |
| Tishler, R | 4 |
| Khuri, F | 1 |
| Adkins, D | 4 |
| Clark, J | 2 |
| Sarlis, N | 2 |
| Lorch, J | 2 |
| Beitler, JJ | 2 |
| Limaye, S | 1 |
| Riley, S | 1 |
| Posner, M | 6 |
| Hino-Shishikura, A | 1 |
| Suzuki, A | 2 |
| Minamimoto, R | 1 |
| Shizukuishi, K | 1 |
| Oka, T | 1 |
| Tateishi, U | 1 |
| Sugae, S | 1 |
| Ichikawa, Y | 1 |
| Horiuchi, C | 8 |
| Inoue, T | 2 |
| Perri, F | 1 |
| Muto, P | 1 |
| Argenone, A | 1 |
| Ionna, F | 3 |
| Longo, F | 1 |
| Fulciniti, F | 1 |
| Sandomenico, F | 1 |
| Daponte, A | 1 |
| Caponigro, F | 7 |
| Miyazaki, T | 2 |
| Ozawa, T | 3 |
| Harata, I | 1 |
| Rigalli, JP | 2 |
| Reuter, T | 1 |
| Herold-Mende, C | 3 |
| Dyckhoff, G | 3 |
| Haefeli, WE | 2 |
| Weiss, J | 3 |
| Theile, D | 3 |
| Yoshino, T | 1 |
| Monden, N | 2 |
| Homma, A | 4 |
| Okami, K | 1 |
| Fujii, M | 12 |
| Taguchi, T | 12 |
| de Blas, B | 1 |
| Beier, F | 1 |
| Dhawan, D | 1 |
| Panchal, H | 1 |
| Shukla, S | 1 |
| Padh, H | 1 |
| Gupta, S | 2 |
| Khan, H | 2 |
| Barik, S | 1 |
| Negi, MP | 2 |
| Bonnin, N | 1 |
| Ferlay, C | 1 |
| Ramade, A | 5 |
| Favrel, V | 2 |
| Zrounba, P | 4 |
| Chabaud, S | 2 |
| Pommier, P | 2 |
| Poupart, M | 4 |
| Céruse, P | 5 |
| Cohen, MH | 1 |
| Chen, H | 2 |
| Shord, S | 1 |
| Fuchs, C | 1 |
| He, K | 1 |
| Zhao, H | 1 |
| Sickafuse, S | 1 |
| Keegan, P | 1 |
| Pazdur, R | 1 |
| Box, C | 1 |
| Mendiola, M | 1 |
| Gowan, S | 1 |
| Box, GM | 1 |
| Valenti, M | 1 |
| Brandon, Ade H | 1 |
| Al-Lazikani, B | 1 |
| Rogers, SJ | 1 |
| Wilkins, A | 1 |
| Eccles, SA | 1 |
| Magnani, E | 1 |
| Farnetti, E | 1 |
| Nicoli, D | 1 |
| Casali, B | 1 |
| Savoldi, L | 1 |
| Focaccetti, C | 1 |
| Boni, C | 1 |
| Albini, A | 1 |
| Banzi, M | 1 |
| Kua, VF | 1 |
| Ismail, F | 1 |
| Chee Ee Phua, V | 1 |
| Aslan, NM | 1 |
| McPartlin, AJ | 1 |
| Barker, C | 1 |
| Swindell, R | 1 |
| Mitchell, K | 1 |
| Sykes, A | 2 |
| Lee, L | 2 |
| Yap, B | 2 |
| Aderhold, C | 4 |
| Umbreit, C | 4 |
| Faber, A | 5 |
| Sauter, A | 4 |
| Sommer, JU | 3 |
| Birk, R | 2 |
| Erben, P | 1 |
| Hofheinz, RD | 3 |
| Stern-Straeter, J | 2 |
| Hörmann, K | 3 |
| Schultz, JD | 5 |
| Tallon, B | 1 |
| Turnbull, N | 1 |
| Himmel, M | 1 |
| Hartmann, M | 1 |
| Goto, Y | 1 |
| Kodaira, T | 6 |
| Furutani, K | 3 |
| Tachibana, H | 4 |
| Tomita, N | 1 |
| Ito, J | 1 |
| Stöhlmacher-Williams, J | 1 |
| Davidenko, I | 1 |
| Winquist, E | 3 |
| Villanueva, C | 1 |
| Rottey, S | 4 |
| Skladowski, K | 1 |
| Pai, VR | 1 |
| Blajman, CR | 2 |
| Forastiere, AA | 12 |
| Stein, BN | 1 |
| Oliner, KS | 1 |
| Pan, Z | 1 |
| Bach, BA | 1 |
| Takenaka, Y | 3 |
| Cho, H | 2 |
| Yamamoto, M | 1 |
| Nakahara, S | 3 |
| Yamamoto, Y | 3 |
| Inohara, H | 3 |
| Stern-Sträter, J | 1 |
| Hoermann, K | 2 |
| Reers, S | 1 |
| Pfannerstill, AC | 1 |
| Rades, D | 7 |
| Maushagen, R | 1 |
| Andratschke, M | 1 |
| Pries, R | 1 |
| Wollenberg, B | 4 |
| Blanchard, P | 1 |
| Lacas, B | 1 |
| Posner, MR | 20 |
| Cruz Hernandez, JJ | 1 |
| Bourredjem, A | 1 |
| Pignon, JP | 2 |
| Billan, S | 1 |
| Kaidar-Person, O | 1 |
| Atrash, F | 1 |
| Doweck, I | 1 |
| Haim, N | 1 |
| Kuten, A | 2 |
| Ronen, O | 1 |
| Magliocca, KR | 1 |
| Kim, S | 2 |
| Muller, S | 1 |
| Owonikoko, TK | 1 |
| Sarlis, NJ | 3 |
| Eggers, C | 1 |
| Phelan, V | 1 |
| Grist, WJ | 1 |
| Chen, AY | 1 |
| Ramalingam, SS | 1 |
| Chen, ZG | 1 |
| Shin, DM | 5 |
| Khuri, FR | 3 |
| Marcus, AI | 1 |
| Graham, CM | 1 |
| Elci, O | 1 |
| Griswold, ME | 1 |
| Zhang, X | 2 |
| Khan, MA | 1 |
| Pitman, K | 1 |
| Caudell, JJ | 2 |
| Hamilton, RD | 2 |
| Ganeshan, B | 1 |
| Smith, AD | 1 |
| Teo, M | 1 |
| Karakaya, E | 2 |
| Young, CA | 1 |
| Dyker, KE | 2 |
| Coyle, C | 3 |
| Sen, M | 3 |
| Prestwich, RJ | 3 |
| Olson, R | 1 |
| Karam, I | 1 |
| Wilson, G | 1 |
| Bowman, A | 1 |
| Lee, C | 1 |
| Wong, F | 1 |
| Suzuki, K | 4 |
| Hayashi, R | 3 |
| Ebihara, M | 1 |
| Miyazaki, M | 2 |
| Shinozaki, T | 1 |
| Daiko, H | 1 |
| Sakuraba, M | 2 |
| Zenda, S | 2 |
| Fujii, S | 1 |
| Herman, LC | 1 |
| Garnett, A | 1 |
| Feldman, LE | 2 |
| Smith, B | 1 |
| Weichselbaum, RR | 38 |
| Spiotto, MT | 1 |
| Denaro, N | 2 |
| Russi, EG | 2 |
| Hsieh, CH | 1 |
| Hou, ML | 1 |
| Chiang, MH | 1 |
| Tai, HC | 1 |
| Tien, HJ | 1 |
| Wang, LY | 1 |
| Tsai, TH | 1 |
| Chen, YJ | 3 |
| Scardina, GA | 1 |
| Cacioppo, A | 1 |
| Messina, P | 1 |
| Strojan, P | 4 |
| Grašič Kuhar, C | 1 |
| Žumer, B | 1 |
| Kadivec, M | 1 |
| Karner, K | 1 |
| Fajdiga, I | 1 |
| Jančar, B | 1 |
| Gale, N | 1 |
| Poljak, M | 1 |
| Kocjan, BJ | 1 |
| Zakotnik, B | 1 |
| Gratieri, T | 1 |
| Kalia, YN | 1 |
| Irigoyen, A | 3 |
| Sastre, J | 2 |
| Brandariz Castelo, JA | 1 |
| Verger, E | 1 |
| Bank, PC | 1 |
| Guchelaar, HJ | 1 |
| Swen, JJ | 1 |
| Noda, S | 1 |
| Kashiwagi, S | 1 |
| Kawajiri, H | 1 |
| Takashima, T | 1 |
| Onoda, N | 1 |
| Hirakawa, K | 1 |
| Téllez-Gabriel, M | 1 |
| Arroyo-Solera, I | 1 |
| León, X | 3 |
| Gallardo, A | 1 |
| López, M | 2 |
| Céspedes, MV | 1 |
| Casanova, I | 1 |
| Quer, M | 3 |
| Mangues, MA | 1 |
| Barnadas, A | 1 |
| Mangues, R | 1 |
| Pavón, MA | 1 |
| Sanders, IW | 1 |
| Haslett, K | 1 |
| Correa, P | 1 |
| Paterson, C | 2 |
| James, A | 1 |
| Rizwanullah, M | 2 |
| Grose, D | 2 |
| Gal, Z | 1 |
| Warta, R | 1 |
| Lahrmann, B | 1 |
| Grabe, N | 1 |
| de Mello, RA | 1 |
| Gerós, S | 1 |
| Alves, MP | 1 |
| Moreira, F | 1 |
| Avezedo, I | 1 |
| Dinis, J | 1 |
| Krauss, J | 3 |
| Gauler, TC | 1 |
| Erfán, J | 3 |
| Brümmendorf, TH | 3 |
| Bethe, U | 2 |
| Hicking, C | 1 |
| Mak, MP | 1 |
| Glisson, BS | 4 |
| Peguero, J | 1 |
| Khanfar, A | 1 |
| Mannem, S | 1 |
| Willis, M | 1 |
| Markowtiz, A | 1 |
| Komatsu, M | 4 |
| Shiono, O | 2 |
| Sakuma, Y | 4 |
| Nishimura, G | 7 |
| Sano, D | 2 |
| Sakuma, N | 2 |
| Yabuki, K | 2 |
| Arai, Y | 3 |
| Isitoya, J | 1 |
| Shi, M | 1 |
| Yang, A | 1 |
| Choi, YJ | 1 |
| Hu, G | 1 |
| Pan, J | 2 |
| Hu, C | 1 |
| Luo, R | 1 |
| Lüpfert, C | 1 |
| Cai, J | 1 |
| Shi, Y | 1 |
| Qian, W | 1 |
| Zhu, G | 1 |
| Ji, Q | 1 |
| Linot, B | 3 |
| Augereau, P | 1 |
| Breheret, R | 3 |
| Laccourreye, L | 4 |
| Capitain, O | 4 |
| Fujii, H | 2 |
| Yana, I | 1 |
| Otani, S | 1 |
| Xu, B | 2 |
| Shu, Y | 1 |
| Liu, P | 2 |
| Zhou, G | 1 |
| Wang, J | 2 |
| Zhao, M | 1 |
| Xie, TX | 1 |
| Tanaka, N | 1 |
| Patel, AA | 1 |
| Ward, AM | 1 |
| Sandulache, VC | 1 |
| Jasser, SA | 1 |
| Skinner, HD | 1 |
| Fitzgerald, AL | 1 |
| Osman, AA | 1 |
| Wei, Y | 1 |
| Xia, X | 1 |
| Songyang, Z | 1 |
| Mills, GB | 1 |
| Hung, MC | 1 |
| Caulin, C | 1 |
| Liang, J | 1 |
| Myers, JN | 2 |
| Ijichi, K | 7 |
| Adachi, M | 4 |
| Murakami, S | 2 |
| Konda, S | 1 |
| Patel, VA | 1 |
| O'Bryan, KW | 1 |
| Ratner, D | 1 |
| Sato, K | 2 |
| Kubota, A | 6 |
| Furukawa, M | 6 |
| Kitani, Y | 1 |
| Nakayama, Y | 1 |
| Nonaka, T | 1 |
| Mizoguchi, N | 1 |
| Shiomi, M | 1 |
| Loong, HH | 1 |
| Waldron, J | 1 |
| Chen, EX | 2 |
| Kim, J | 1 |
| Palma, D | 1 |
| Read, N | 1 |
| Razak, AR | 1 |
| Diaz-Padilla, I | 1 |
| Chan, K | 1 |
| Bayley, A | 1 |
| Hossain, M | 1 |
| Chin, S | 2 |
| Siu, LL | 1 |
| Hope, A | 1 |
| Yang, WC | 1 |
| Chen, CH | 3 |
| Tang, JY | 1 |
| Wu, CF | 1 |
| Liu, YC | 1 |
| Lin, SF | 1 |
| Mizumachi, T | 2 |
| Kakizaki, T | 1 |
| Sakashita, T | 2 |
| Kano, S | 2 |
| Hatakeyama, H | 2 |
| Tsuchiya, K | 2 |
| Yasuda, K | 2 |
| Onimaru, R | 2 |
| Shirato, H | 3 |
| Taguchi, J | 1 |
| Kinoshita, I | 2 |
| Akita, H | 1 |
| Fukuda, S | 3 |
| Péron, J | 3 |
| Polivka, V | 1 |
| Girodet, D | 2 |
| Tsuchiya, Y | 1 |
| Gosho, M | 1 |
| Fukayama, M | 1 |
| Carey, TE | 1 |
| Cohen, EE | 9 |
| Karrison, TG | 1 |
| Kocherginsky, M | 3 |
| Mueller, J | 1 |
| Egan, R | 1 |
| Huang, CH | 1 |
| Brockstein, BE | 8 |
| Agulnik, MB | 1 |
| Mittal, BB | 14 |
| Yunus, F | 1 |
| Samant, S | 1 |
| Raez, LE | 2 |
| Mehra, R | 1 |
| Kumar, P | 1 |
| Ondrey, F | 1 |
| Marchand, P | 1 |
| Braegas, B | 1 |
| Villaflor, VM | 2 |
| Haraf, DJ | 37 |
| Vokes, EE | 63 |
| Perl, G | 1 |
| Ben-Aharon, I | 1 |
| Popovtzer, A | 2 |
| Stemmer, SM | 1 |
| Vidal, L | 1 |
| Mohan, A | 1 |
| Narayanan, S | 1 |
| Sethuraman, S | 2 |
| Krishnan, UM | 2 |
| Shapiro, LQ | 1 |
| Sherman, EJ | 1 |
| Riaz, N | 1 |
| Setton, J | 1 |
| Koutcher, L | 1 |
| Shi, W | 1 |
| Fury, MG | 2 |
| Wolden, SL | 2 |
| Pfister, DG | 3 |
| Morris, L | 1 |
| Lee, N | 1 |
| Shigeishi, H | 1 |
| Biddle, A | 1 |
| Gammon, L | 1 |
| Rodini, CO | 1 |
| Yamasaki, M | 1 |
| Seino, S | 1 |
| Sugiyama, M | 2 |
| Takechi, M | 1 |
| Mackenzie, IC | 1 |
| Izawa, N | 1 |
| Hikosaka, T | 1 |
| Tsushima, T | 1 |
| Todaka, A | 1 |
| Machida, N | 1 |
| Haraguchi, Y | 1 |
| Nishimura, T | 3 |
| Nakagawa, M | 1 |
| Fuke, T | 1 |
| Iida, Y | 1 |
| Kamijo, T | 1 |
| Boku, N | 1 |
| Yasui, H | 1 |
| Wu, W | 1 |
| Ma, L | 1 |
| Liu, M | 1 |
| Zhao, F | 1 |
| Huang, D | 1 |
| Syed, N | 2 |
| Chavan, S | 1 |
| Sahasrabuddhe, NA | 1 |
| Renuse, S | 1 |
| Sathe, G | 1 |
| Nanjappa, V | 1 |
| Radhakrishnan, A | 1 |
| Raja, R | 1 |
| Pinto, SM | 1 |
| Srinivasan, A | 1 |
| Prasad, TS | 1 |
| Srikumar, K | 1 |
| Gowda, H | 1 |
| Santosh, V | 1 |
| Sidransky, D | 1 |
| Califano, JA | 2 |
| Pandey, A | 1 |
| Chatterjee, A | 1 |
| Lynggaard, CD | 1 |
| Therkildsen, MH | 1 |
| Kristensen, CA | 1 |
| Specht, L | 1 |
| Haymerle, G | 1 |
| Thurnher, D | 2 |
| Kadletz, L | 1 |
| Stanisz, I | 1 |
| Brunner, M | 1 |
| Kotowski, U | 1 |
| Enzenhofer, E | 1 |
| Heiduschka, G | 2 |
| Yunaiyama, D | 1 |
| Saito, K | 2 |
| Funatsu, T | 1 |
| Nakayama, H | 1 |
| Ito, H | 1 |
| Akata, S | 1 |
| Tokuuye, K | 1 |
| Wopken, K | 1 |
| Bijl, HP | 1 |
| van der Schaaf, A | 1 |
| van der Laan, HP | 1 |
| Chouvalova, O | 1 |
| Steenbakkers, RJ | 1 |
| Doornaert, P | 1 |
| Slotman, BJ | 1 |
| Oosting, SF | 1 |
| Christianen, ME | 1 |
| van der Laan, BF | 1 |
| Roodenburg, JL | 1 |
| Leemans, CR | 1 |
| Verdonck-de Leeuw, IM | 1 |
| Zhu, DW | 1 |
| Yuan, YX | 1 |
| Qiao, JK | 1 |
| Yu, C | 1 |
| Yang, X | 1 |
| Wang, LZ | 1 |
| Zhang, ZY | 3 |
| Zhong, LP | 2 |
| Agüero, A | 1 |
| García, J | 2 |
| Farré, N | 1 |
| Nakashima, T | 10 |
| Ishimaru, K | 1 |
| Takano, A | 1 |
| Katsura, M | 1 |
| Yamaguchi, N | 2 |
| Kaneko, K | 1 |
| Yossi, S | 3 |
| El Alouani, C | 1 |
| Gustin, P | 2 |
| Peyraga, G | 3 |
| Septans, AL | 2 |
| Jadaud, É | 2 |
| Vinchon-Petit, S | 1 |
| Cellier, P | 1 |
| Autret, D | 1 |
| Tuchais, C | 1 |
| Iyer, NG | 1 |
| Tan, DS | 1 |
| Tan, VK | 1 |
| Wang, W | 1 |
| Hwang, J | 1 |
| Tan, NC | 1 |
| Sivanandan, R | 1 |
| Tan, HK | 1 |
| Lim, WT | 1 |
| Ang, MK | 1 |
| Wee, J | 2 |
| Soo, KC | 2 |
| Tan, EH | 3 |
| Budach, V | 7 |
| Stromberger, C | 2 |
| Poettgen, C | 1 |
| Baumann, M | 2 |
| Budach, W | 5 |
| Grabenbauer, G | 3 |
| Marnitz, S | 1 |
| Olze, H | 1 |
| Wernecke, KD | 2 |
| Ghadjar, P | 1 |
| Nishiike, S | 1 |
| Yasui, T | 3 |
| Hanamoto, A | 2 |
| Nakamaru, Y | 2 |
| Terasaka, S | 1 |
| Yoshida, D | 1 |
| Furusawa, J | 1 |
| Kushwaha, VS | 1 |
| Husain, N | 1 |
| Jamal, N | 1 |
| Ghatak, A | 1 |
| Ma, SR | 3 |
| Wang, WM | 1 |
| Huang, CF | 3 |
| Zhang, WF | 3 |
| Sun, ZJ | 3 |
| Sachdev, S | 1 |
| Refaat, T | 1 |
| Bacchus, ID | 1 |
| Sathiaseelan, V | 1 |
| Li, SH | 2 |
| Lin, WC | 2 |
| Huang, TL | 3 |
| Chiu, TJ | 3 |
| Fang, FM | 3 |
| Huang, WT | 1 |
| Hsu, CM | 2 |
| Luo, SD | 2 |
| Lai, CC | 2 |
| Su, YY | 2 |
| Chien, CY | 3 |
| Govindan, SV | 1 |
| Kulsum, S | 1 |
| Pandian, RS | 1 |
| Das, D | 1 |
| Seshadri, M | 1 |
| Hicks, W | 1 |
| Kuriakose, MA | 1 |
| Suresh, A | 1 |
| Hasegawa, S | 1 |
| Yamashita, D | 1 |
| Ejima, Y | 1 |
| Kenji, Y | 1 |
| Sakakibara, S | 1 |
| Nomura, T | 2 |
| Hashikawa, K | 1 |
| Kohmura, E | 1 |
| Nibu, K | 1 |
| de Souza Viana, L | 1 |
| de Aguiar Silva, FC | 1 |
| Andrade Dos Anjos Jacome, A | 1 |
| Calheiros Campelo Maia, D | 1 |
| Duarte de Mattos, M | 1 |
| Arthur Jacinto, A | 1 |
| Elias Mamere, A | 1 |
| Boldrini Junior, D | 1 |
| de Castro Capuzzo, R | 1 |
| Roberto Santos, C | 1 |
| Lopes Carvalho, A | 1 |
| Specenier, P | 3 |
| Van Laer, C | 2 |
| Van Den Weyngaert, D | 4 |
| Corthouts, B | 1 |
| Carp, L | 1 |
| Van Marck, E | 1 |
| Vanderveken, O | 1 |
| Ryoo, I | 1 |
| Kim, JH | 4 |
| Choi, SH | 1 |
| Sohn, CH | 1 |
| Kim, SC | 1 |
| Kun, M | 1 |
| Xinxin, Z | 1 |
| Feifan, Z | 1 |
| Lin, M | 1 |
| Haxel, BR | 1 |
| Berg, S | 1 |
| Boessert, P | 1 |
| Mann, WJ | 1 |
| Fruth, K | 1 |
| Yang, R | 1 |
| Zhou, H | 1 |
| Zhang, P | 2 |
| Yang, P | 1 |
| Tong, Q | 1 |
| Lyu, Y | 1 |
| Han, Y | 1 |
| Kitamura, K | 2 |
| Honma, K | 1 |
| Morii, E | 1 |
| Niwa, Y | 1 |
| Koike, M | 1 |
| Oya, H | 1 |
| Iwata, N | 1 |
| Nishio, N | 1 |
| Hiramatsu, M | 1 |
| Kanda, M | 1 |
| Kobayashi, D | 1 |
| Tanaka, C | 1 |
| Yamada, S | 1 |
| Nakayama, G | 1 |
| Sugimoto, H | 1 |
| Nomoto, S | 1 |
| Fujiwara, M | 1 |
| Kodera, Y | 1 |
| Otter, S | 1 |
| Gulliford, S | 2 |
| Lal, P | 1 |
| Franceschini, D | 1 |
| Newbold, K | 4 |
| Nutting, C | 1 |
| Bhide, S | 1 |
| Hufnagl, C | 1 |
| Magnes, T | 1 |
| Weiss, L | 1 |
| Hutarew, G | 1 |
| Neureiter, D | 1 |
| Schlattau, A | 1 |
| Moser, G | 1 |
| Gaggl, A | 1 |
| Tränkenschuh, W | 1 |
| Egle, A | 1 |
| Uchiyama, K | 3 |
| Yamada, M | 2 |
| Komatsu, S | 1 |
| Souma, T | 1 |
| Iwabuchi, H | 3 |
| Onizawa, K | 1 |
| Nakayama, S | 3 |
| Franco, P | 1 |
| Potenza, I | 1 |
| Schena, M | 3 |
| Riva, G | 1 |
| Pecorari, G | 1 |
| Garzino Demo, P | 1 |
| Fasolis, M | 1 |
| Moretto, F | 1 |
| Garzaro, M | 1 |
| Di Muzio, J | 1 |
| Melano, M | 1 |
| Airoldi, M | 4 |
| Ragona, R | 3 |
| Rampino, M | 2 |
| Ricardi, U | 2 |
| Sivanantham, B | 1 |
| Bu, LL | 2 |
| Zhao, ZL | 2 |
| Liu, JF | 2 |
| Liu, B | 2 |
| Kim, R | 1 |
| Hahn, S | 1 |
| Shin, J | 1 |
| Ock, CY | 2 |
| Kim, M | 1 |
| Kim, TM | 3 |
| Kim, DW | 4 |
| Heo, DS | 6 |
| Bölke, E | 2 |
| Kammers, K | 1 |
| Gerber, PA | 1 |
| Orth, K | 1 |
| Gripp, S | 2 |
| Matuschek, C | 1 |
| Bozec, A | 2 |
| Ebran, N | 1 |
| Radosevic-Robin, N | 1 |
| Sudaka, A | 2 |
| Monteverde, M | 2 |
| Toussan, N | 1 |
| Etienne-Grimaldi, MC | 3 |
| Nigro, CL | 1 |
| Merlano, M | 24 |
| Penault-Llorca, F | 1 |
| Milano, G | 29 |
| Driessen, CM | 1 |
| de Boer, JP | 1 |
| Gelderblom, H | 1 |
| Rasch, CR | 1 |
| de Jong, MA | 1 |
| Verbist, BM | 1 |
| Melchers, WJ | 1 |
| Tesselaar, ME | 1 |
| van der Graaf, WT | 1 |
| Kaanders, JH | 1 |
| van Herpen, CM | 2 |
| Casanova, M | 1 |
| Özyar, E | 1 |
| Patte, C | 1 |
| Orbach, D | 1 |
| Ferrari, A | 1 |
| Veyrat-Follet, C | 1 |
| Errihani, H | 1 |
| Zhang, L | 2 |
| Grzegorzewski, KJ | 1 |
| Varan, A | 1 |
| Vázquez, S | 1 |
| García-Sáenz, JA | 1 |
| García, C | 1 |
| Carles, J | 2 |
| Mañós, M | 1 |
| García-Paredes, B | 1 |
| del Barco, E | 1 |
| Escobar, Y | 1 |
| Cruz, JJ | 7 |
| Janoray, G | 1 |
| Garaud, P | 1 |
| Chapet, S | 2 |
| Jambusaria-Pahlajani, A | 1 |
| Ortman, S | 1 |
| Schmults, CD | 1 |
| Liang, C | 1 |
| Masloub, SM | 1 |
| Elmalahy, MH | 1 |
| Sabry, D | 1 |
| Mohamed, WS | 1 |
| Ahmed, SH | 1 |
| Aguilar, JL | 1 |
| Chen, E | 1 |
| Misiukiewicz, K | 2 |
| Ernst, S | 1 |
| Lee, HJ | 1 |
| Bryant, K | 1 |
| He, S | 1 |
| Obasaju, CK | 1 |
| Chang, SC | 1 |
| Dhawan, A | 1 |
| Ruwali, M | 1 |
| Pant, MC | 4 |
| Rahman, Q | 1 |
| Parmar, D | 1 |
| Lee, CG | 2 |
| Choi, EC | 2 |
| Koh, YW | 1 |
| Cho, BC | 2 |
| Ahn, D | 1 |
| Sohn, JH | 3 |
| Lee, JE | 1 |
| Park, SH | 1 |
| Kim, JC | 2 |
| Calderon, B | 1 |
| Guerder, C | 1 |
| Resbeut, M | 1 |
| Cowen, D | 1 |
| Han, DH | 1 |
| Won, TB | 1 |
| Lee, SH | 4 |
| Hah, JH | 5 |
| Kwon, TK | 3 |
| Kim, DY | 1 |
| Rhee, CS | 3 |
| Wu, HG | 4 |
| Sung, MW | 5 |
| Miyawaki, Y | 1 |
| Nakajima, Y | 1 |
| Kawada, K | 1 |
| Tokairin, Y | 1 |
| Kawano, T | 2 |
| Chen, YH | 2 |
| Dang, RP | 1 |
| LE, VH | 1 |
| Miles, BA | 1 |
| Teng, MS | 2 |
| Genden, EM | 3 |
| Bakst, RL | 1 |
| Gupta, V | 3 |
| Zhang, DY | 1 |
| Demicco, EG | 1 |
| Misiukiewicz, KJ | 1 |
| Schmaltz, H | 1 |
| Ciftci, S | 1 |
| Takeda-Raguin, C | 1 |
| Debry, C | 1 |
| Schultz, P | 1 |
| Sato, M | 3 |
| Nakano, T | 1 |
| Kogo, R | 2 |
| Hashimoto, K | 1 |
| Sawatsubashi, M | 1 |
| Nakagawa, T | 2 |
| Yu, GT | 1 |
| Gutkind, JS | 2 |
| Kulkarni, AB | 1 |
| Fontaine-Delaruelle, C | 1 |
| Ambrun, A | 1 |
| Daveau, C | 1 |
| Diallo, A | 1 |
| Braig, F | 1 |
| Voigtlaender, M | 1 |
| Schieferdecker, A | 1 |
| Laban, S | 4 |
| Grob, T | 1 |
| Kriegs, M | 1 |
| Knecht, R | 7 |
| Seidl, D | 4 |
| Janssen, S | 4 |
| Hakim, SG | 5 |
| Schild, SE | 6 |
| Bajrovic, A | 3 |
| Ameri, A | 1 |
| Mortazavi, N | 1 |
| Khoshbakht Ahmadi, H | 1 |
| Novin, K | 1 |
| Sakakura, K | 1 |
| Mito, I | 1 |
| Ida, S | 1 |
| Chikamatsu, K | 1 |
| Brower, V | 1 |
| Rumley, CN | 1 |
| Nedev, N | 1 |
| Sharples, K | 1 |
| Lamb, DS | 1 |
| Jian, J | 1 |
| Li, G | 2 |
| Yu, Z | 1 |
| Tian, L | 1 |
| Ahn, PH | 1 |
| Machtay, M | 5 |
| Anne, PR | 1 |
| Cognetti, D | 1 |
| Keane, WM | 1 |
| Wuthrick, E | 1 |
| Dicker, AP | 1 |
| Axelrod, RS | 1 |
| Rusz, O | 1 |
| Pál, M | 1 |
| Szilágyi, É | 1 |
| Rovó, L | 1 |
| Varga, Z | 1 |
| Tomisa, B | 1 |
| Fábián, G | 1 |
| Kovács, L | 1 |
| Nagy, O | 1 |
| Mózes, P | 1 |
| Reisz, Z | 1 |
| Tiszlavicz, L | 1 |
| Deák, P | 1 |
| Kahán, Z | 1 |
| Nakata, Y | 1 |
| Shimizu, T | 2 |
| Kazic, N | 3 |
| Sun, X | 1 |
| Xiao, D | 1 |
| Xu, T | 1 |
| Yuan, Y | 1 |
| Nagano, H | 2 |
| Kurono, Y | 1 |
| Matushita, K | 1 |
| Burnstein, H | 1 |
| Stemmer, S | 1 |
| Limon, D | 1 |
| Hili, O | 1 |
| Bachar, G | 1 |
| Sopov, V | 1 |
| Feinmesser, R | 1 |
| Groshar, D | 1 |
| Shvero, J | 1 |
| Wang, TY | 1 |
| Peng, CY | 1 |
| Lee, SS | 1 |
| Chou, MY | 1 |
| Yu, CC | 1 |
| Chang, YC | 2 |
| Rousseau, D | 1 |
| Rives, P | 1 |
| Ley, J | 2 |
| Michel, L | 1 |
| Wildes, TM | 1 |
| Thorstad, W | 2 |
| Gay, HA | 1 |
| Daly, M | 1 |
| Rich, J | 1 |
| Paniello, R | 1 |
| Uppaluri, R | 1 |
| Jackson, R | 1 |
| Trinkaus, K | 2 |
| Nussenbaum, B | 2 |
| Karpathiou, G | 1 |
| Giroult, JB | 1 |
| Forest, F | 1 |
| Fournel, P | 1 |
| Monaya, A | 1 |
| Froudarakis, M | 1 |
| Dumollard, JM | 1 |
| Prades, JM | 1 |
| Gavid, M | 1 |
| Peoc'h, M | 1 |
| Saito, Y | 1 |
| Kobayashi, M | 1 |
| Yamada, T | 1 |
| Kasashi, K | 1 |
| Honma, R | 1 |
| Takeuchi, S | 1 |
| Dosaka-Akita, H | 1 |
| Iseki, K | 1 |
| Miceli, R | 1 |
| Cova, A | 1 |
| Orlandi, E | 1 |
| Resteghini, C | 1 |
| Locati, L | 1 |
| Alfieri, S | 1 |
| Imbimbo, M | 1 |
| Granata, R | 1 |
| Mariani, L | 1 |
| Iacovelli, NA | 1 |
| Huber, V | 1 |
| Cavallo, A | 1 |
| Rivoltini, L | 1 |
| Chen, JH | 1 |
| Yen, YC | 1 |
| Chen, TM | 1 |
| Yuan, KS | 1 |
| Lee, FP | 1 |
| Lin, KC | 1 |
| Lai, MT | 1 |
| Wu, CC | 1 |
| Chang, CL | 1 |
| Wu, SY | 1 |
| Hui, L | 1 |
| Zhang, J | 2 |
| Ding, X | 1 |
| Guo, X | 1 |
| Jiang, X | 1 |
| Salama, JK | 6 |
| Stenson, KM | 8 |
| Kistner, EO | 1 |
| Argiris, A | 9 |
| Witt, ME | 17 |
| Rosen, F | 4 |
| Baghi, M | 3 |
| Wagenblast, J | 2 |
| Hambek, M | 4 |
| Moertel, S | 1 |
| Gstoettner, W | 2 |
| Strebhardt, K | 1 |
| Bhide, SA | 4 |
| Ahmed, M | 1 |
| Barbachano, Y | 2 |
| Nutting, CM | 4 |
| Uryu, H | 2 |
| Masuda, M | 4 |
| Hirakawa, N | 2 |
| Shiratsuchi, H | 1 |
| Tomita, K | 2 |
| Fukushima, M | 3 |
| Komune, S | 3 |
| Chang, PM | 2 |
| Teng, HW | 1 |
| Chen, PM | 2 |
| Chang, SY | 4 |
| Chu, PY | 4 |
| Tsai, TL | 4 |
| Tai, SK | 4 |
| Wang, YF | 4 |
| Huang, JL | 2 |
| Brake, R | 1 |
| Starnes, C | 1 |
| Lu, J | 1 |
| Chen, D | 1 |
| Yang, S | 1 |
| Radinsky, R | 1 |
| Borges, L | 1 |
| Rivera, F | 7 |
| Kawecki, A | 3 |
| Zabolotnyy, D | 2 |
| Benasso, M | 21 |
| Vynnychenko, I | 1 |
| De Raucourt, D | 3 |
| Schueler, A | 2 |
| Amellal, N | 2 |
| Janot, F | 5 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Bensadoun, RJ | 2 |
| Hamoir, M | 2 |
| Julieron, M | 2 |
| Castaing, M | 1 |
| Kamnerdsupaphon, P | 1 |
| Chitapanarux, I | 1 |
| Lorvidhaya, V | 3 |
| Sumitsawan, Y | 2 |
| Tharavichitkul, E | 1 |
| Sukthomya, V | 1 |
| Ayada, T | 1 |
| Wakasaki, T | 1 |
| Sokurenko, VP | 1 |
| Korytova, LI | 1 |
| Tarazov, PG | 1 |
| Suvorova, IuV | 1 |
| Su, YX | 1 |
| Zheng, JW | 1 |
| Zheng, GS | 1 |
| Liao, GQ | 1 |
| Tanvetyanon, T | 1 |
| Khan, K | 1 |
| Yu, SZ | 1 |
| Ronson, S | 1 |
| Rhee, J | 1 |
| Van Echo, D | 1 |
| Suntharalingam, M | 1 |
| O'Malley, BW | 1 |
| Li, D | 1 |
| Kadowaki, S | 1 |
| Fuse, N | 1 |
| Doi, T | 1 |
| Minami, H | 1 |
| Ohtsu, A | 1 |
| Boshoff, C | 1 |
| Hainsworth, JD | 3 |
| Spigel, DR | 1 |
| Burris, HA | 3 |
| Markus, TM | 1 |
| Shipley, D | 1 |
| Kuzur, M | 1 |
| Lunin, S | 1 |
| Greco, FA | 3 |
| Lee, JJ | 1 |
| Im, SA | 1 |
| Kim, SY | 2 |
| Kim, KH | 4 |
| Koiwai, K | 2 |
| Shikama, N | 2 |
| Sasaki, S | 3 |
| Shinoda, A | 2 |
| Kadoya, M | 2 |
| Welz, H | 1 |
| Pöttgen, C | 1 |
| Abu Jawad, J | 1 |
| Wierlemann, A | 1 |
| Wittig, A | 1 |
| Stüben, G | 1 |
| Lehnerdt, G | 1 |
| Jahnke, K | 3 |
| Sack, H | 2 |
| Stuschke, M | 3 |
| Chung, WH | 1 |
| Sung, BH | 1 |
| Kim, SS | 1 |
| Rhim, H | 1 |
| Kuh, HJ | 2 |
| Koh, Y | 1 |
| Jeon, YK | 1 |
| Kim, CW | 1 |
| Lindel, K | 1 |
| Helmke, B | 1 |
| Simon, C | 2 |
| Weber, KJ | 1 |
| Debus, J | 3 |
| de Villiers, EM | 1 |
| Massaccesi, M | 2 |
| Balducci, M | 1 |
| Mantini, G | 1 |
| Micciché, F | 1 |
| Mattiucci, GC | 1 |
| Dinapoli, N | 1 |
| Meduri, B | 1 |
| D'Agostino, GR | 1 |
| Salvi, G | 1 |
| Nardone, L | 1 |
| Adelstein, DJ | 19 |
| Moon, J | 2 |
| Hanna, E | 2 |
| Giri, PG | 1 |
| Mills, GM | 1 |
| Wolf, GT | 5 |
| Urba, SG | 3 |
| Lee, YJ | 1 |
| Kim, GE | 1 |
| Choi, HJ | 1 |
| Thomas, CY | 1 |
| Read, P | 1 |
| Petroni, G | 1 |
| Reibel, J | 1 |
| Levine, PA | 2 |
| Peñagarícano, JA | 1 |
| Moros, EG | 1 |
| Ratanatharathorn, V | 1 |
| Yan, Y | 1 |
| Corry, P | 1 |
| Haddad, RI | 6 |
| Tishler, RB | 12 |
| Norris, C | 1 |
| Goguen, L | 4 |
| Balboni, TA | 1 |
| Costello, R | 10 |
| Wirth, L | 3 |
| Andreozzi, B | 1 |
| Annino, D | 1 |
| Parthan, A | 1 |
| Brammer, C | 1 |
| Beltran, P | 1 |
| Jansen, JP | 1 |
| Cals, L | 1 |
| Hans, S | 2 |
| Saint-Guily, JL | 1 |
| Lagarde, F | 1 |
| Rolland, F | 4 |
| Lefebvre, JL | 4 |
| Sakoda, T | 2 |
| Morizane, R | 1 |
| Nakahara, K | 1 |
| Enomoto, Y | 1 |
| Nosaka, A | 1 |
| Enomoto, T | 2 |
| Kitano, H | 2 |
| Buiret, G | 1 |
| Combe, C | 1 |
| Ecochard, R | 1 |
| Tartas, S | 1 |
| García-Castaño, A | 1 |
| Vega, N | 1 |
| Vega-Villegas, ME | 2 |
| Gutiérrez-Sanz, L | 1 |
| Tobias, JS | 2 |
| Monson, K | 1 |
| Gupta, N | 1 |
| Macdougall, H | 1 |
| Glaholm, J | 1 |
| Hutchison, I | 1 |
| Kadalayil, L | 1 |
| Hackshaw, A | 1 |
| Cullen, KJ | 4 |
| Schumaker, L | 1 |
| Nikitakis, N | 1 |
| Goloubeva, O | 2 |
| Tan, M | 2 |
| Buffoli, A | 1 |
| Gardani, G | 1 |
| Ardizzoia, A | 1 |
| Dondi, D | 1 |
| Cavallo, R | 1 |
| Tomio, L | 3 |
| Nguyen, NP | 1 |
| Vos, P | 1 |
| Vinh-Hung, V | 1 |
| Borok, TL | 1 |
| Dutta, S | 1 |
| Karlsson, U | 1 |
| Lee, H | 1 |
| Martinez, T | 1 |
| Jo, BH | 1 |
| Nguyen, LM | 1 |
| Nguyen, N | 1 |
| Sallah, S | 1 |
| Tsukuda, M | 28 |
| Ishitoya, J | 5 |
| Matsuda, H | 9 |
| Kawakami, M | 2 |
| Watanabe, M | 1 |
| Niho, T | 1 |
| Ikeda, Y | 6 |
| Bhupalam, L | 1 |
| Miller, DM | 1 |
| Kloecker, GH | 1 |
| Laber, DA | 1 |
| Furukawa, MK | 1 |
| Maillard, S | 1 |
| Merol, JC | 2 |
| Chays, A | 1 |
| Nguyen, TD | 2 |
| Yang, CG | 1 |
| Ciccolini, J | 4 |
| Blesius, A | 1 |
| Dahan, L | 1 |
| Bagarry-Liegey, D | 1 |
| Brunet, C | 1 |
| Varoquaux, A | 1 |
| Frances, N | 1 |
| Marouani, H | 1 |
| Giovanni, A | 2 |
| Ferri-Dessens, RM | 1 |
| Chefrour, M | 1 |
| Favre, R | 2 |
| Duffaud, F | 2 |
| Seitz, JF | 1 |
| Zanaret, M | 2 |
| Lacarelle, B | 2 |
| Mercier, C | 2 |
| Kienzer, H | 1 |
| Koralewski, P | 1 |
| Curran, D | 1 |
| Gross, A | 1 |
| Davies, M | 1 |
| Burke, K | 1 |
| McNair, HA | 1 |
| Hansen, V | 1 |
| El-Hariry, IA | 1 |
| Fujita, Y | 1 |
| Yagi, H | 1 |
| Dias, JD | 1 |
| Liikanen, I | 1 |
| Guse, K | 1 |
| Foloppe, J | 1 |
| Sloniecka, M | 1 |
| Diaconu, I | 1 |
| Rantanen, V | 1 |
| Eriksson, M | 1 |
| Hakkarainen, T | 1 |
| Lusky, M | 1 |
| Erbs, P | 1 |
| Escutenaire, S | 1 |
| Kanerva, A | 1 |
| Pesonen, S | 1 |
| Cerullo, V | 1 |
| Hemminki, A | 1 |
| Wolff, HA | 2 |
| Bosch, J | 1 |
| Jung, K | 1 |
| Overbeck, T | 1 |
| Hennies, S | 1 |
| Matthias, C | 2 |
| Hess, CF | 5 |
| Roedel, RM | 1 |
| Christiansen, H | 3 |
| Morganti, AG | 1 |
| Mignogna, S | 1 |
| Deodato, F | 1 |
| Cilla, S | 1 |
| Calista, F | 1 |
| Serafini, G | 1 |
| Digesú, C | 1 |
| Macchia, G | 1 |
| Picardi, V | 1 |
| Caravatta, L | 1 |
| Di Lullo, L | 1 |
| Giglio, G | 1 |
| Sallustio, G | 1 |
| Piermattei, A | 1 |
| Cellini, N | 1 |
| Isla, D | 3 |
| Adansa, JC | 1 |
| Gil-Arnaiz, I | 1 |
| Lambea, J | 1 |
| Lecumberri, MJ | 1 |
| Clavel, S | 2 |
| Fortin, B | 2 |
| Després, P | 2 |
| Donath, D | 1 |
| Khaouam, N | 1 |
| Charpentier, D | 1 |
| Bélair, M | 2 |
| Guertin, L | 2 |
| Nguyen-Tan, PF | 2 |
| Rödel, RM | 1 |
| Urba, S | 4 |
| Foster, J | 1 |
| Worden, F | 1 |
| Kronemann, S | 1 |
| Meyners, T | 1 |
| Bohlen, G | 1 |
| Tribius, S | 2 |
| Schroeder, U | 1 |
| Dunst, J | 2 |
| Watanabe, A | 2 |
| Taniguchi, M | 2 |
| Tsujizakae, H | 1 |
| Toyama, T | 1 |
| Shinoto, M | 1 |
| Shioyama, Y | 2 |
| Nakamura, K | 2 |
| Ohura, H | 1 |
| Toh, Y | 1 |
| Higaki, Y | 2 |
| Yamaguchi, T | 1 |
| Ohnishi, K | 1 |
| Atsumi, K | 1 |
| Hirata, H | 1 |
| Honda, H | 1 |
| Won, YW | 1 |
| Park, YH | 1 |
| Do, IG | 1 |
| Ko, YH | 1 |
| Mladkova, J | 1 |
| Sanda, M | 1 |
| Matouskova, E | 1 |
| Selicharova, I | 1 |
| Hill, A | 1 |
| Bergin, P | 1 |
| Hanning, F | 1 |
| Thompson, P | 1 |
| Findlay, M | 1 |
| Damianovich, D | 1 |
| McKeage, MJ | 1 |
| Ketabi-Kiyanvash, N | 1 |
| Efferth, T | 1 |
| Bertholet, V | 1 |
| Hurmuzlu, M | 1 |
| Aarstad, HJ | 1 |
| Aarstad, AK | 1 |
| Hjermstad, MJ | 1 |
| Viste, A | 1 |
| Fowler, J | 1 |
| Rosenfelder, N | 1 |
| Kao, J | 4 |
| Policarpio, EL | 1 |
| Burri, RJ | 1 |
| Rivera, M | 2 |
| Gurudutt, V | 2 |
| Som, PM | 1 |
| Teng, M | 1 |
| Packer, SH | 2 |
| Mauer, ME | 1 |
| Jelic, S | 4 |
| Coens, C | 1 |
| Betka, J | 2 |
| Bernier, J | 3 |
| Preiss, JH | 2 |
| Bottomley, A | 1 |
| Bran, G | 1 |
| Anders, C | 1 |
| Sadick, H | 1 |
| Fleckenstein, J | 1 |
| Kühne, M | 1 |
| Seegmüller, K | 1 |
| Derschang, S | 1 |
| Melchior, P | 1 |
| Gräber, S | 1 |
| Fricke, A | 1 |
| Rübe, CE | 1 |
| Rübe, C | 1 |
| Jegannathen, A | 1 |
| Birzgalis, A | 1 |
| Homer, J | 1 |
| Ryder, WD | 1 |
| Slevin, N | 1 |
| D'Amanzo, P | 2 |
| Störkel, S | 1 |
| Senger, S | 1 |
| Stroh, C | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 2 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Wisniewska-Jarosinska, M | 1 |
| Sliwinski, T | 1 |
| Kasznicki, J | 1 |
| Kaczmarczyk, D | 1 |
| Krupa, R | 1 |
| Bloch, K | 1 |
| Drzewoski, J | 1 |
| Chojnacki, J | 1 |
| Blasiak, J | 1 |
| Morawiec-Sztandera, A | 1 |
| Isaev, PA | 1 |
| Medvedev, VS | 1 |
| Pasov, VV | 1 |
| Semin, DIu | 1 |
| Derbugov, DN | 1 |
| Pol'kin, VV | 1 |
| Terekhov, OV | 1 |
| Lim, YC | 1 |
| Oh, SY | 1 |
| Cha, YY | 1 |
| Kim, SH | 1 |
| Jin, X | 1 |
| Kim, H | 1 |
| Li, WY | 1 |
| Hsieh, SL | 1 |
| Lorch, JH | 1 |
| Cullen, K | 2 |
| Fasciano, J | 1 |
| Sammartino, DE | 1 |
| Corry, J | 4 |
| Jansen, JF | 1 |
| Schöder, H | 1 |
| Lee, NY | 2 |
| Stambuk, HE | 1 |
| Patel, SG | 1 |
| Shah, JP | 1 |
| Koutcher, JA | 1 |
| Shukla-Dave, A | 1 |
| Boscolo-Rizzo, P | 3 |
| Muzzi, E | 1 |
| Trabalzini, F | 1 |
| Stellin, M | 1 |
| Da Mosto, MC | 3 |
| Marchiori, C | 2 |
| Baggio, V | 2 |
| Luo, Z | 1 |
| Chang, J | 1 |
| Yu, H | 1 |
| Lu, F | 1 |
| Wu, X | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Sher, DJ | 1 |
| Holupka, EJ | 1 |
| Devlin, PM | 2 |
| Charron, MP | 1 |
| Delouya, G | 1 |
| Filion, E | 1 |
| Blair, EA | 4 |
| Williams, R | 2 |
| Kunnavakkam, R | 1 |
| Seiwert, T | 1 |
| Mücke, T | 1 |
| Konen, M | 1 |
| Wagenpfeil, S | 1 |
| Kesting, MR | 1 |
| Wolff, KD | 1 |
| Hölzle, F | 1 |
| Devisetty, K | 1 |
| Wong, SJ | 2 |
| Mell, LK | 1 |
| Atean, I | 1 |
| Trigo, JM | 1 |
| Kerber, A | 1 |
| Picard, M | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Oliver, M | 1 |
| Peytel, E | 1 |
| Sugisaki, T | 1 |
| Kawakami, K | 1 |
| Nemoto, M | 1 |
| Kawata, K | 1 |
| Ishibashi, M | 1 |
| Fujiki, Y | 1 |
| Mishima, Y | 1 |
| Yokoyama, M | 1 |
| Hatake, K | 1 |
| Hama, T | 1 |
| Öksüz, DÇ | 2 |
| Dyker, K | 1 |
| Rau, KM | 1 |
| Choe, KS | 1 |
| Solanki, A | 1 |
| Portugal, L | 6 |
| Kawaguchi, K | 1 |
| Yamada, H | 1 |
| Horie, A | 1 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Nakatani, Y | 1 |
| Hamada, Y | 1 |
| Yen, SH | 2 |
| Wang, LW | 3 |
| Lin, YH | 1 |
| Jen, YM | 1 |
| Chung, YL | 1 |
| Brunstein, MC | 1 |
| Fischel, JL | 11 |
| Lirng, JF | 1 |
| Murata, S | 1 |
| Kioi, M | 1 |
| Torigoe, S | 1 |
| Bhayani, MK | 1 |
| Lai, SY | 1 |
| Mitsudo, K | 1 |
| Tohnai, I | 2 |
| Saâda, E | 1 |
| Benezery, K | 1 |
| Hebert, C | 1 |
| Dassonville, O | 6 |
| Jensen, AD | 2 |
| Weichert, W | 1 |
| Bergmann, ZP | 1 |
| Freier, K | 1 |
| Münter, MW | 2 |
| Huang, CE | 1 |
| Lu, CH | 1 |
| Chen, PT | 1 |
| Chan, CH | 1 |
| Chen, WC | 1 |
| Wang, WH | 1 |
| Wu, JY | 1 |
| Kuan, FC | 1 |
| Lee, KD | 1 |
| Hattersley, SM | 1 |
| Sylvester, DC | 1 |
| Dyer, CE | 1 |
| Stafford, ND | 1 |
| Haswell, SJ | 1 |
| Greenman, J | 1 |
| Su, NW | 1 |
| Leu, YS | 1 |
| Lee, JC | 2 |
| Chen, HW | 1 |
| Liu, CJ | 1 |
| Chang, YF | 1 |
| Michal, SA | 1 |
| Rybicki, LA | 5 |
| Rodriguez, CP | 2 |
| Saxton, JP | 8 |
| Wood, BG | 9 |
| Scharpf, J | 2 |
| Ives, DI | 2 |
| Robertson, AG | 2 |
| Correa, PD | 1 |
| Zaoui, K | 1 |
| Bossow, S | 1 |
| Grossardt, C | 1 |
| Leber, MF | 1 |
| Springfeld, C | 1 |
| Plinkert, PK | 1 |
| Kalle, Cv | 1 |
| Ungerechts, G | 1 |
| Kawashima, M | 2 |
| Arahira, S | 2 |
| Ogino, T | 2 |
| Xiang, Q | 1 |
| Zhou, Z | 1 |
| Zhou, D | 1 |
| Jin, Y | 1 |
| Huang, Y | 1 |
| Liberato, NL | 1 |
| Rubrichi, S | 1 |
| Marchetti, M | 1 |
| Gorlia, T | 2 |
| Schroeder, P | 1 |
| Lindemann, C | 1 |
| Dettmar, K | 1 |
| Brieger, J | 1 |
| Gosepath, J | 1 |
| Pogorzelski, B | 1 |
| Seimetz, D | 1 |
| Atz, J | 1 |
| Soltys, SG | 1 |
| Choi, CY | 1 |
| Fee, WE | 3 |
| Pinto, HA | 3 |
| Le, QT | 3 |
| Lin, JT | 1 |
| Lai, GM | 2 |
| Chang, TH | 1 |
| Liu, MT | 1 |
| Bi, CP | 1 |
| Wang, JW | 1 |
| Chen, MK | 1 |
| Lorenz, RR | 2 |
| Bacigalupo, A | 8 |
| Russi, E | 2 |
| Lastrucci, L | 1 |
| Iotti, C | 1 |
| Reali, A | 1 |
| Musu, A | 1 |
| Balcet, V | 1 |
| Piva, C | 1 |
| Bustreo, S | 1 |
| Munoz, F | 1 |
| Corvò, R | 11 |
| Chitose, S | 1 |
| Chijiwa, H | 1 |
| Maeda, A | 1 |
| Umeno, H | 1 |
| Kiyokawa, K | 1 |
| Hayabuchi, N | 1 |
| Fujita, H | 1 |
| Price, KA | 1 |
| Wang, CJ | 1 |
| Fan, KY | 1 |
| Gogineni, H | 1 |
| Zaboli, D | 1 |
| Lake, S | 1 |
| Zahurak, ML | 1 |
| Best, SR | 1 |
| Levine, MA | 1 |
| Tang, M | 1 |
| Zinreich, ES | 1 |
| Saunders, JR | 1 |
| Blanco, RG | 1 |
| Pai, SI | 1 |
| Messing, B | 1 |
| Ha, PK | 1 |
| Vormittag, L | 2 |
| Lemaire, C | 1 |
| Radonjic, D | 1 |
| Kornek, G | 2 |
| Selzer, E | 3 |
| Tong, CC | 1 |
| Lau, KH | 1 |
| Cannan, D | 1 |
| Aguirre-Ghiso, J | 1 |
| Sikora, AG | 1 |
| Forsythe, K | 1 |
| Ko, EC | 1 |
| Vivenza, D | 1 |
| Gasco, M | 2 |
| Lattanzio, L | 1 |
| Colantonio, I | 3 |
| Natoli, G | 1 |
| Comino, A | 1 |
| Crook, T | 1 |
| Lo Nigro, C | 1 |
| Kurzweg, T | 1 |
| Möckelmann, N | 1 |
| Mumme, AM | 1 |
| Potthoff, K | 1 |
| Nikoghosyan, AV | 1 |
| Lossner, K | 1 |
| Desai, B | 1 |
| Gadhia, P | 1 |
| Hidaka, T | 1 |
| Fujimura, T | 1 |
| Watabe, A | 1 |
| Hashimoto, A | 1 |
| Haga, T | 1 |
| Onami, K | 1 |
| Mizuashi, M | 1 |
| Aiba, S | 1 |
| Loo, SW | 1 |
| Geropantas, K | 1 |
| Tasigiannopoulos, Z | 1 |
| Martin, C | 1 |
| Roques, TW | 1 |
| Chan, LP | 1 |
| Chou, TH | 1 |
| Ding, HY | 1 |
| Chen, PR | 1 |
| Chiang, FY | 1 |
| Kuo, PL | 1 |
| Liang, CH | 1 |
| Hristozova, T | 1 |
| Keilhoiz, U | 1 |
| Zhu, WG | 1 |
| Zhou, K | 1 |
| Yu, CH | 1 |
| Han, JH | 1 |
| Li, T | 1 |
| Chen, XF | 1 |
| Ma, J | 1 |
| Huang, XL | 1 |
| Neskey, DM | 1 |
| Lupato, V | 1 |
| Romeo, S | 1 |
| Spinato, G | 1 |
| Addonisio, G | 1 |
| Yokoyama, J | 1 |
| Ito, S | 1 |
| Ohba, S | 1 |
| Fujimaki, M | 1 |
| Ikeda, K | 1 |
| Hanaguri, M | 1 |
| Yetmen, O | 1 |
| Abgral, R | 1 |
| Le Roux, PY | 1 |
| Keromnes, N | 1 |
| Rousset, J | 1 |
| Valette, G | 1 |
| Gouders, D | 1 |
| Leleu, C | 1 |
| Mollon, D | 1 |
| Nowak, E | 1 |
| Querellou, S | 1 |
| Salaün, PY | 1 |
| Zhao, XY | 1 |
| Zhu, YX | 1 |
| Zhu, GP | 1 |
| Hu, CS | 1 |
| Ji, QH | 1 |
| Reinisch, S | 1 |
| Kapp, KS | 1 |
| Bachtiary, B | 1 |
| Tinchon, C | 1 |
| Anderhuber, W | 1 |
| Kasparek, AK | 1 |
| Elsäßer, W | 1 |
| Kainz, H | 1 |
| Kopp, M | 1 |
| Lewis, J | 1 |
| Wildes, T | 1 |
| Siegel, BA | 1 |
| Dehdashti, F | 1 |
| Gay, H | 1 |
| Mehan, P | 1 |
| Furusaka, T | 4 |
| Asakawa, T | 1 |
| Tanaka, A | 1 |
| Ikeda, M | 1 |
| Aguilar-Ponce, JL | 1 |
| Granados-García, M | 1 |
| Cruz López, JC | 1 |
| Maldonado-Magos, F | 1 |
| Alvarez-Avitia, MA | 1 |
| Arrieta, O | 1 |
| González-Ramírez, I | 1 |
| Lara-Cruz, G | 1 |
| Martinez-Juárez, I | 1 |
| Medina-Santillan, R | 1 |
| Castillo-Hernández, C | 1 |
| De la Garza-Salazar, J | 1 |
| Tomkiewicz, C | 1 |
| Mucchielli, MH | 1 |
| Agier, N | 1 |
| Delacroix, H | 1 |
| Marisa, L | 1 |
| Brasnu, D | 7 |
| Aggerbeck, LP | 1 |
| Badoual, C | 1 |
| Barouki, R | 1 |
| Aggerbeck, M | 1 |
| Darga, T | 1 |
| Haraf, D | 3 |
| Stenson, K | 14 |
| Villaflor, V | 1 |
| Lingen, MW | 1 |
| Sugiyama, K | 1 |
| Qin, H | 1 |
| Luo, J | 1 |
| Zhu, YP | 1 |
| Xie, HL | 1 |
| Yang, WQ | 1 |
| Lei, WB | 1 |
| Clark, JI | 2 |
| Greene, JB | 1 |
| Lau Clark, A | 1 |
| Dalal, JS | 1 |
| Hofmeister, CC | 1 |
| Otto, KJ | 1 |
| Jennelle, RL | 1 |
| Pitman, KT | 2 |
| Vijayakumar, S | 1 |
| Monnier, L | 1 |
| Touboul, E | 1 |
| Durdux, C | 1 |
| Lang, P | 1 |
| St Guily, JL | 2 |
| Yang, YL | 1 |
| Ji, C | 1 |
| Bi, ZG | 1 |
| Lu, CC | 1 |
| Wang, R | 1 |
| Gu, B | 1 |
| Cheng, L | 1 |
| Machiels, JP | 1 |
| Kaminsky, MC | 1 |
| Keller, U | 1 |
| Goddemeier, T | 1 |
| Forssmann, U | 1 |
| Stamatović, Lj | 1 |
| Vucićević, S | 1 |
| Petrović, Z | 1 |
| Kreacić, M | 1 |
| Babović, N | 1 |
| Jovanović, N | 1 |
| Mikić, A | 1 |
| Gavrilović, D | 1 |
| Mirjolet, JF | 3 |
| Didelot, C | 3 |
| Barberi-Heyob, M | 4 |
| Merlin, JL | 4 |
| Ramacci, C | 1 |
| Norris, CM | 13 |
| Colevas, AD | 11 |
| Lamb, CC | 2 |
| Karp, D | 1 |
| Busse, PM | 6 |
| Nixon, A | 2 |
| Frankenthaler, R | 1 |
| Lake-Willcutt, B | 2 |
| Case, M | 2 |
| Catalano, G | 3 |
| Chiesa, F | 1 |
| De Pas, T | 1 |
| Masci, G | 1 |
| Krengli, M | 1 |
| Vavassori, A | 1 |
| De Paoli, F | 1 |
| Robertson, C | 1 |
| Marrocco, E | 1 |
| De Braud, F | 1 |
| DePas, T | 1 |
| Kitahara, S | 5 |
| Tamura, E | 3 |
| Tanabe, T | 3 |
| Rosati, G | 1 |
| De Rosa, P | 1 |
| Avallone, A | 7 |
| De Rosa, V | 3 |
| De Lucia, L | 3 |
| Comella, P | 7 |
| Comella, G | 7 |
| Arcangeli, G | 1 |
| Saracino, B | 1 |
| Danesi, DT | 1 |
| De Campora, E | 1 |
| Giovinazzo, G | 1 |
| Cognetti, F | 7 |
| Carlini, P | 3 |
| Arcangeli, S | 1 |
| Mecozzi, A | 1 |
| Fouret, P | 2 |
| Temam, S | 3 |
| Charlotte, F | 1 |
| Lacau-St-Guily, J | 1 |
| Fuwa, N | 5 |
| Kamata, M | 1 |
| Matsumoto, A | 1 |
| Ito, Y | 2 |
| Vanselow, B | 2 |
| Rudat, V | 4 |
| Conradt, C | 1 |
| Weidauer, H | 3 |
| Kallinowski, F | 1 |
| Dollner, R | 2 |
| Kitagawa, Y | 2 |
| Sano, K | 2 |
| Nishizawa, S | 2 |
| Nakamura, M | 2 |
| Ogasawara, T | 2 |
| Sadato, N | 2 |
| Yonekura, Y | 2 |
| Li, Y | 7 |
| Adams, GL | 2 |
| Wagner, H | 2 |
| Kish, JA | 7 |
| Ensley, JF | 6 |
| Schuller, DE | 6 |
| Spencer, S | 1 |
| Wheeler, R | 2 |
| Peters, G | 1 |
| Meredith, R | 3 |
| Beenken, S | 1 |
| Nabel, L | 1 |
| Wooten, A | 1 |
| Soong, SJ | 1 |
| Salter, M | 1 |
| Busse, P | 2 |
| Sullivan, C | 3 |
| Case, MA | 2 |
| Rosen, FR | 3 |
| Kies, MS | 13 |
| Rademaker, AW | 5 |
| List, MA | 4 |
| Fung, BB | 2 |
| Pelzer, H | 10 |
| Yoshida, M | 2 |
| Datta, NR | 2 |
| Nagar, YS | 1 |
| Singh, S | 1 |
| Naryan, L | 1 |
| Erol, MK | 1 |
| Acikel, M | 1 |
| Senocak, H | 1 |
| Mahadevan, A | 2 |
| Goguen, LA | 2 |
| Sullivan, CA | 1 |
| Iguchi, H | 1 |
| Kusuki, M | 1 |
| Nakamura, A | 2 |
| Nishiura, H | 1 |
| Kanazawa, A | 1 |
| Yamane, H | 1 |
| Kovacs, MS | 1 |
| Dorie, MJ | 1 |
| Koong, A | 2 |
| Terris, DJ | 1 |
| Goffinet, DR | 4 |
| Nowels, K | 1 |
| Bloch, D | 2 |
| Brown, JM | 1 |
| Saitoh, Y | 1 |
| Seno, S | 1 |
| Ikeda, H | 1 |
| Dake, Y | 1 |
| Kawano, A | 1 |
| Morris, CG | 1 |
| Amdur, RJ | 1 |
| Hinerman, RW | 1 |
| Mancuso, AA | 1 |
| Loré, JM | 3 |
| Kaufman, S | 2 |
| Sundquist, N | 4 |
| Chary, KK | 1 |
| Focan, C | 1 |
| Focan-Henrard, D | 1 |
| Kreutz, F | 1 |
| Moeneclaey, N | 1 |
| Chan, SW | 1 |
| Mukesh, BN | 2 |
| Sizeland, A | 2 |
| Magné, N | 5 |
| Pivot, X | 4 |
| François, E | 3 |
| Renée, N | 18 |
| Thyss, A | 16 |
| Schneider, M | 21 |
| Demard, F | 19 |
| Tiffon, C | 2 |
| Formento, P | 12 |
| Dubreuil, A | 3 |
| Formento, JL | 4 |
| Francoual, M | 2 |
| Etienne, MC | 20 |
| Hashitani, S | 1 |
| Urade, M | 2 |
| Nishimura, N | 1 |
| Maeda, T | 1 |
| Takaoka, K | 1 |
| Noguchi, K | 1 |
| Sakurai, K | 1 |
| Zeng, J | 1 |
| Yu, QW | 1 |
| Liu, WW | 1 |
| Zeng, ZY | 1 |
| McHam, SA | 1 |
| Lavertu, P | 7 |
| Esclamado, RM | 4 |
| Strome, M | 7 |
| Carroll, MA | 3 |
| WATKINS, E | 1 |
| SULLIVAN, RD | 1 |
| JESSE, RH | 3 |
| VILLARREAL, R | 1 |
| LETAYF, V | 1 |
| RUFINO, C | 1 |
| HICKEY, RC | 1 |
| LEVINE, LA | 1 |
| GOLLIN, FF | 2 |
| ANSFIELD, FJ | 3 |
| VERMUND, H | 2 |
| GASTPAR, H | 1 |
| SCHREINER, L | 1 |
| HELSPER, JT | 1 |
| DEMOSS, EV | 1 |
| RIEHL, JL | 1 |
| BROWN, WJ | 1 |
| BAKER, RR | 1 |
| GAERTNER, RA | 1 |
| Nemunaitis, J | 3 |
| Cunningham, C | 1 |
| Senzer, N | 1 |
| Kuhn, J | 1 |
| Cramm, J | 1 |
| Litz, C | 1 |
| Cavagnolo, R | 1 |
| Cahill, A | 1 |
| Clairmont, C | 1 |
| Sznol, M | 1 |
| Chamorey, E | 1 |
| Guardiola, E | 1 |
| Otto, J | 1 |
| Giroux, B | 1 |
| Mouri, Z | 1 |
| Schäfer, U | 2 |
| Micke, O | 3 |
| Müller, SB | 1 |
| Schüller, P | 2 |
| Willich, N | 3 |
| Schmidberger, H | 1 |
| Rave-Fränk, M | 1 |
| Hille, A | 2 |
| Pradier, O | 3 |
| Marchetti, S | 1 |
| Satake, K | 3 |
| Takagi, E | 1 |
| Ishii, A | 1 |
| Kato, Y | 2 |
| Imagawa, Y | 1 |
| Kimura, Y | 1 |
| Newkirk, KA | 1 |
| Schumaker, LM | 1 |
| Aldosari, N | 1 |
| Rone, JD | 1 |
| Haddad, BR | 1 |
| Baba, Y | 1 |
| Tanigaki, Y | 4 |
| Mochimatsu, I | 4 |
| Murphy, BA | 3 |
| Langer, CJ | 2 |
| Katori, H | 8 |
| Mochimatu, I | 1 |
| Kawai, S | 4 |
| Mikami, Y | 8 |
| Hirose, S | 2 |
| Yamamoto, K | 2 |
| Ilc, K | 1 |
| Laurent-Puig, P | 5 |
| Cheradame, S | 5 |
| Azrak, RG | 1 |
| Cao, S | 3 |
| Slocum, HK | 2 |
| Tóth, K | 2 |
| Durrani, FA | 2 |
| Yin, MB | 1 |
| Pendyala, L | 2 |
| Zhang, W | 1 |
| McLeod, HL | 1 |
| Rustum, YM | 3 |
| Maguire, PD | 1 |
| Meyerson, MB | 1 |
| Neal, CR | 1 |
| Hamann, MS | 1 |
| Bost, AL | 1 |
| Anagnost, JW | 1 |
| Ungaro, PC | 1 |
| Pollock, HD | 1 |
| McMurray, JE | 1 |
| Wilson, EP | 1 |
| Kotwall, CA | 1 |
| Schrijvers, D | 2 |
| Van Herpen, C | 2 |
| Kerger, J | 1 |
| Joosens, E | 1 |
| Nguyen, H | 1 |
| Le Bouder, C | 1 |
| Castelijns, JA | 1 |
| Kaanders, J | 1 |
| De Mulder, P | 1 |
| Brizel, DM | 6 |
| Prosnitz, RG | 2 |
| Hunter, S | 1 |
| Fisher, SR | 3 |
| Clough, RL | 1 |
| Downey, MA | 1 |
| Scher, RL | 2 |
| Allal, AS | 3 |
| Taussky, D | 1 |
| Mach, N | 1 |
| Becker, M | 2 |
| Bieri, S | 2 |
| Dulguerov, P | 2 |
| Syz, N | 1 |
| Olivares, R | 2 |
| Le Lann, L | 1 |
| Yver, A | 1 |
| Dunant, A | 1 |
| Lewin, F | 2 |
| Dalley, DN | 1 |
| Taylor, SG | 11 |
| Domenge, C | 10 |
| Mazumdar, M | 1 |
| Rosenthal, DI | 2 |
| Chalian, AA | 1 |
| Lustig, R | 1 |
| Hershock, D | 1 |
| Miller, L | 1 |
| Weinstein, GS | 1 |
| Weber, RS | 1 |
| Blons, H | 4 |
| Gad, S | 1 |
| Zinzindohoué, F | 1 |
| Manière, I | 1 |
| Beauregard, J | 1 |
| Tregouet, D | 1 |
| Beaune, P | 4 |
| Laccourreye, O | 5 |
| Fasan, S | 1 |
| Paro, S | 1 |
| Carnuccio, R | 1 |
| Turcato, G | 1 |
| Gatti, C | 1 |
| Pallini, A | 1 |
| Nascimben, O | 1 |
| Biason, R | 1 |
| Oniga, F | 1 |
| Medici, M | 1 |
| Rossi, F | 1 |
| Fila, G | 2 |
| Martone, T | 1 |
| Bellone, G | 1 |
| Pagano, M | 1 |
| Beatrice, F | 1 |
| Palonta, F | 1 |
| Emanuelli, G | 1 |
| Cortesina, G | 2 |
| Garden, AS | 2 |
| Harris, J | 3 |
| Ridge, JA | 3 |
| Jones, C | 1 |
| Horwitz, EM | 1 |
| Nabell, L | 1 |
| Cooper, JS | 1 |
| Demas, W | 1 |
| Gore, E | 1 |
| Alexiou, M | 1 |
| Morgan, J | 1 |
| Badley, J | 1 |
| Maddox, AM | 1 |
| Penagaricano, J | 1 |
| Fan, CY | 1 |
| Breau, R | 1 |
| Suen, J | 1 |
| Brockstein, B | 6 |
| Wenig, B | 6 |
| Weichselbaum, RW | 2 |
| Kwong, M | 1 |
| DiStasio, S | 1 |
| Lekakis, L | 1 |
| Kassar, M | 1 |
| Sasaki, C | 1 |
| Wilson, LD | 1 |
| Haffty, BG | 1 |
| Son, YH | 1 |
| Ross, DA | 1 |
| Weinberger, PM | 1 |
| Chung, GG | 1 |
| Zelterman, D | 1 |
| Burtness, BA | 1 |
| Cooper, DL | 1 |
| Kazakin, J | 1 |
| Adak, S | 5 |
| Clark, JR | 3 |
| Milano, MT | 3 |
| Eng, C | 1 |
| Kozloff, MF | 4 |
| Jimeno, A | 2 |
| Millán, JM | 2 |
| Castellano, D | 1 |
| Cortés-Funes, H | 4 |
| Hermann, RM | 1 |
| Weiss, E | 2 |
| Nitsche, M | 1 |
| Martin, A | 1 |
| Forastiere, A | 2 |
| Akst, LM | 1 |
| Chan, J | 1 |
| Elson, P | 1 |
| Saxton, J | 1 |
| Adelstein, D | 1 |
| Bhattacharya, A | 1 |
| Mazurchuk, R | 1 |
| Spernyak, JA | 1 |
| Azrak, R | 1 |
| Ernst-Stecken, A | 1 |
| Iro, H | 4 |
| Plasswilm, L | 1 |
| Sauer, R | 3 |
| Barone, C | 1 |
| Birocco, N | 1 |
| Dongiovanni, D | 1 |
| Numico, G | 8 |
| Bertetto, O | 1 |
| Genet, D | 1 |
| Bontemps, P | 1 |
| Bourgeois, H | 1 |
| Dutin, JP | 1 |
| Philippi, MH | 1 |
| Bendahmane, B | 1 |
| Mallard-Carre, M | 1 |
| Tubiana-Mathieu, N | 1 |
| Rodríguez-Pinilla, M | 2 |
| Rodríguez-Peralto, JL | 2 |
| López-Martín, A | 1 |
| Brandariz, A | 1 |
| Peña, C | 1 |
| Peters, S | 1 |
| Solbach, C | 1 |
| Gstöttner, W | 1 |
| Sanchez, JJ | 2 |
| Ballestin, C | 2 |
| Diez, A | 1 |
| Sanchez-Verde, L | 1 |
| Alameda, F | 1 |
| Sanchez-Cespedes, M | 1 |
| Arnheim, K | 1 |
| Peters, L | 1 |
| Fisher, R | 1 |
| Macann, A | 1 |
| Denham, J | 1 |
| Poulsen, M | 2 |
| Jackson, M | 2 |
| Kenny, L | 1 |
| Penniment, M | 1 |
| Lamb, D | 1 |
| McClure, B | 1 |
| Ciruelos, E | 1 |
| Amador, ML | 1 |
| Benito, A | 1 |
| Marti, A | 1 |
| Rixe, O | 1 |
| Gatineau, M | 1 |
| Armand, JP | 8 |
| Luboinski, B | 4 |
| Geismar, D | 1 |
| Lammert, I | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Wust, P | 2 |
| Hinkelbein, W | 1 |
| Yao, B | 1 |
| Farrell, CL | 1 |
| Clough, R | 1 |
| Kimura, M | 1 |
| Sato, N | 1 |
| Weber, A | 1 |
| Hildebrandt, G | 1 |
| Porceddu, S | 1 |
| Peters, LJ | 3 |
| Mazeron, JJ | 3 |
| Franchin, G | 2 |
| Vaccher, E | 2 |
| Gobitti, C | 2 |
| Minatel, E | 2 |
| Politi, D | 1 |
| Talamini, R | 1 |
| Di Gennaro, G | 1 |
| Savignano, G | 1 |
| Trovò, MG | 3 |
| Tirelli, U | 3 |
| Barzan, L | 4 |
| Fonseca, E | 5 |
| García-Gómez, JM | 1 |
| Rueda, A | 2 |
| Pastor, M | 1 |
| Lara, MA | 1 |
| Navalón, M | 1 |
| Tisaire, JL | 1 |
| Gibson, MK | 1 |
| Murphy, B | 1 |
| Hussain, MH | 2 |
| DeConti, RC | 4 |
| Ensley, J | 10 |
| Jayaram, P | 2 |
| Pichardo, D | 2 |
| Kuratomi, Y | 2 |
| Umezaki, T | 1 |
| Nagao, J | 2 |
| Nozawa, A | 1 |
| Herbst, RS | 1 |
| Arquette, M | 1 |
| Dicke, K | 1 |
| Azarnia, N | 1 |
| Hong, WK | 9 |
| Lim, D | 1 |
| Tai, BC | 1 |
| Khoo, ML | 1 |
| Goh, C | 1 |
| Leong, SS | 1 |
| Tan, T | 1 |
| Fong, KW | 1 |
| Lu, P | 1 |
| See, A | 1 |
| Machin, D | 1 |
| Abdel-Wahab, M | 3 |
| Abitbol, A | 3 |
| Lewin, A | 3 |
| Troner, M | 3 |
| Hamilton, K | 1 |
| Markoe, A | 3 |
| Prévost, A | 1 |
| Aimé, P | 1 |
| Moutel, K | 1 |
| Roger-Liautaud, F | 1 |
| Nasca, S | 2 |
| Legros, M | 3 |
| Coninx, P | 3 |
| Garrone, O | 1 |
| Pelissero, A | 1 |
| Granetto, C | 1 |
| Di Costanzo, G | 1 |
| Heouaine, A | 1 |
| Vigna Taglianti, R | 1 |
| Cipolat, M | 1 |
| Lin, A | 1 |
| Jabbari, S | 1 |
| Worden, FP | 3 |
| Chepeha, DB | 2 |
| Teknos, TN | 2 |
| Liao, JJ | 1 |
| Nyquist, GG | 1 |
| Tsien, C | 2 |
| Schipper, MJ | 1 |
| Eisbruch, A | 3 |
| Fountzilas, G | 8 |
| Tolis, C | 1 |
| Kalogera-Fountzila, A | 5 |
| Misailidou, D | 1 |
| Tsekeris, P | 1 |
| Karina, M | 1 |
| Nikolaou, A | 2 |
| Samantas, E | 1 |
| Makatsoris, T | 1 |
| Athanassiou, E | 1 |
| Skarlos, D | 2 |
| Bamias, A | 1 |
| Zamboglou, N | 1 |
| Economopoulos, T | 1 |
| Karanastassi, S | 1 |
| Pavlidis, N | 1 |
| Daniilidis, J | 4 |
| Yamashita, S | 1 |
| Hirao, M | 1 |
| Tsujinaka, T | 1 |
| Sawamura, T | 1 |
| Nakamori, S | 1 |
| Mishima, H | 1 |
| Fujitani, K | 1 |
| Ikenaga, M | 1 |
| Kashiwazaki, M | 1 |
| Masuda, N | 1 |
| Rastogi, M | 3 |
| Srivastava, M | 3 |
| Chufal, KS | 3 |
| Srivastava, K | 2 |
| Bhatt, MB | 1 |
| Harvey, M | 1 |
| Hamilton-Nelson, K | 1 |
| Wu, J | 1 |
| Chmura, SJ | 1 |
| Kim, JG | 1 |
| Sohn, SK | 1 |
| Kim, DH | 1 |
| Baek, JH | 1 |
| Jeon, SB | 1 |
| Chae, YS | 1 |
| Lee, KB | 1 |
| Park, JS | 1 |
| Park, IK | 1 |
| Escrig, V | 1 |
| Rizo, A | 1 |
| Vega, ME | 2 |
| Martí, JL | 1 |
| Lobo, F | 1 |
| Pastor, P | 1 |
| Valentí, V | 1 |
| Belón, J | 1 |
| Sánchez, MA | 1 |
| Chaib, C | 1 |
| Pallarés, C | 1 |
| Antón, A | 1 |
| Cervantes, A | 1 |
| Paz-Ares, L | 1 |
| King, MM | 1 |
| Osswald, MB | 1 |
| Just, T | 1 |
| Pau, HW | 1 |
| Bombor, I | 1 |
| Guthoff, RF | 1 |
| Hummel, T | 1 |
| Shord, SS | 1 |
| Thompson, DM | 1 |
| Krempl, GA | 1 |
| Hanigan, MH | 1 |
| Hehr, T | 1 |
| Dietz, K | 1 |
| Bhatt, ML | 2 |
| Gath, HJ | 1 |
| Oettle, H | 1 |
| Houllier, AM | 2 |
| Taira, A | 2 |
| Budenz, S | 1 |
| Jo Dorie, M | 1 |
| Goode, R | 1 |
| Martin Brown, J | 1 |
| Ponzanelli, A | 2 |
| Ricci, I | 4 |
| Vigo, V | 2 |
| Grossi, F | 1 |
| Amadori, D | 2 |
| Cavallo, G | 1 |
| Capaccetti, B | 1 |
| Taveggia, P | 1 |
| Boni, L | 1 |
| Rosso, R | 17 |
| Lee, JW | 1 |
| Park, JK | 1 |
| Cho, YB | 1 |
| Gelbard, A | 1 |
| Garnett, CT | 1 |
| Abrams, SI | 1 |
| Patel, V | 1 |
| Palena, C | 1 |
| Tsang, KY | 1 |
| Schlom, J | 1 |
| Hodge, JW | 1 |
| Kondo, N | 1 |
| Masuda, Y | 1 |
| Hanamura, H | 1 |
| Kiss-László, Z | 1 |
| Nagy, B | 1 |
| Thurzó, L | 1 |
| Szabó, J | 1 |
| Wirth, LJ | 1 |
| Stowell, S | 1 |
| Sammartino, D | 1 |
| Humblet, Y | 2 |
| Vega Villegas, ME | 1 |
| Duck, L | 1 |
| Rosine, D | 1 |
| Harstrick, A | 1 |
| Kaneda, Y | 1 |
| Shimamoto, H | 1 |
| Matsumura, K | 1 |
| Arvind, R | 1 |
| Zhang, S | 1 |
| Sakai, E | 1 |
| Omura, K | 1 |
| Tsuchida, N | 1 |
| Rapidis, AD | 1 |
| Trichas, M | 1 |
| Stavrinidis, E | 1 |
| Roupakia, A | 1 |
| Ioannidou, G | 1 |
| Kritselis, G | 1 |
| Liossi, P | 1 |
| Giannakouras, G | 1 |
| Douzinas, EE | 1 |
| Katsilieris, I | 1 |
| Leblanc, M | 1 |
| Cerchietti, LC | 1 |
| Navigante, AH | 1 |
| Lutteral, MA | 1 |
| Castro, MA | 1 |
| Kirchuk, R | 1 |
| Bonomi, M | 1 |
| Cabalar, ME | 1 |
| Roth, B | 2 |
| Negretti, G | 1 |
| Sheinker, B | 1 |
| Uchima, P | 1 |
| Samlowski, W | 1 |
| Dakhil, SR | 1 |
| Williamson, S | 1 |
| Lu, JI | 1 |
| Carhart, RL | 1 |
| Graziano, SL | 1 |
| Gajra, A | 1 |
| O'Donnell, L | 1 |
| Valero, C | 1 |
| Olmos, JM | 1 |
| Hernández, JL | 1 |
| Macías, JG | 1 |
| Hrovatin, E | 1 |
| Viel, E | 1 |
| Lestuzzi, C | 1 |
| Tartuferi, L | 1 |
| Zardo, F | 1 |
| Brieda, M | 1 |
| Dametto, E | 1 |
| Piazza, R | 1 |
| Antonini-Canterin, F | 1 |
| Meneguzzo, N | 1 |
| Nicolosi, GL | 1 |
| Feng, FY | 1 |
| Wu, LY | 1 |
| Hu, Y | 1 |
| Liu, JW | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Toth, G | 1 |
| Nozawa, H | 1 |
| Tadakuma, T | 1 |
| Ono, T | 2 |
| Hiroi, S | 1 |
| Masumoto, K | 1 |
| Schwentner, I | 1 |
| Schmutzhard, J | 1 |
| Andrle, J | 1 |
| Haidenberger, A | 1 |
| Thumfart, WF | 1 |
| Sprinzl, GM | 1 |
| Watai, K | 1 |
| Bentzen, JD | 1 |
| Hansen, HS | 3 |
| Allen, AM | 1 |
| Elshaikh, M | 1 |
| Dawson, LA | 1 |
| Normolle, D | 1 |
| Mack, MG | 1 |
| Bisdas, S | 1 |
| Muerthel, R | 1 |
| Vogl, T | 1 |
| Goto, M | 2 |
| Terada, A | 2 |
| Hyodo, I | 2 |
| Choi, YM | 1 |
| Mafee, MF | 1 |
| Stadler, P | 2 |
| Putnik, K | 1 |
| Kreimeyer, T | 1 |
| Sprague, LD | 1 |
| Koelbl, O | 1 |
| Schäfer, C | 1 |
| Tulunay, OE | 1 |
| Enamorado, II | 1 |
| Kucuk, O | 3 |
| Heilbrun, LK | 1 |
| Otero, JE | 1 |
| Korkmaz, H | 1 |
| Blumberg, R | 1 |
| Jacobs, JR | 9 |
| Nakamura, T | 3 |
| Daimon, T | 2 |
| Larsen, S | 1 |
| Serup-Hansen, E | 1 |
| Andersen, LJ | 2 |
| Lindeløv, B | 2 |
| McCulloch, T | 1 |
| Adimi, P | 1 |
| Bastholt, L | 2 |
| Beneton, M | 1 |
| Blasco, H | 1 |
| Giraudeau, B | 1 |
| Boisdron-Celle, M | 2 |
| Deporte-Fety, R | 1 |
| Denis, F | 1 |
| Narcisso, B | 1 |
| Le Guellec, C | 1 |
| Di Gennaro, E | 2 |
| Bruzzese, F | 1 |
| Laus, G | 1 |
| Delrio, P | 1 |
| Caraglia, M | 1 |
| Pepe, S | 1 |
| Budillon, A | 4 |
| Kosmas, C | 1 |
| Kallistratos, MS | 1 |
| Kopterides, P | 1 |
| Syrios, J | 1 |
| Skopelitis, H | 1 |
| Mylonakis, N | 1 |
| Karabelis, A | 1 |
| Tsavaris, N | 1 |
| Fehlauer, F | 1 |
| Sheikh-Sarraf, M | 1 |
| Basic, H | 1 |
| Poorter, R | 1 |
| Nasu, K | 1 |
| Tomita, Y | 1 |
| Spencer, SA | 6 |
| Wheeler, RH | 6 |
| Schultz, C | 2 |
| Spanos, W | 2 |
| Rotman, M | 2 |
| Ang, KK | 2 |
| Partridge, M | 1 |
| Costea, DE | 1 |
| Jeong, WJ | 1 |
| Jung, EJ | 1 |
| Mauer, A | 1 |
| Dekker, A | 2 |
| López-Brea, M | 1 |
| Mayorga, M | 1 |
| Galdós, P | 1 |
| Rubio, A | 1 |
| Del Valle, A | 1 |
| García-Reija, F | 1 |
| García-Montesinos, B | 1 |
| Rodríguez-Iglesias, J | 1 |
| Mayordomo, J | 1 |
| Rama, J | 1 |
| Saiz-Bustillo, R | 1 |
| Sanz-Ortiz, J | 1 |
| Lee, BJ | 1 |
| Lee, BH | 1 |
| Wang, SG | 1 |
| Roh, HJ | 1 |
| Goh, EK | 1 |
| Kim, CM | 1 |
| Jun, ES | 1 |
| Rikimaru, F | 1 |
| Rey, A | 1 |
| Desaunois, I | 1 |
| Hershock, DM | 1 |
| Mickiewicz, E | 1 |
| Gorbounova, V | 1 |
| Tjulandin, S | 1 |
| Ervin, TJ | 3 |
| Cohen, RB | 1 |
| Spaulding, M | 3 |
| Viroglio, Rdel C | 1 |
| Venkatesan, V | 1 |
| Romanov, I | 1 |
| Agarwala, S | 1 |
| Harter, KW | 1 |
| Dugan, M | 1 |
| Cmelak, A | 1 |
| Markoe, AM | 3 |
| Read, PW | 1 |
| Steinbrenner, L | 1 |
| Cho, YH | 1 |
| Klem, ML | 1 |
| Mechalakos, JG | 1 |
| Zelefsky, MJ | 1 |
| Singh, B | 2 |
| Kraus, D | 1 |
| Shaha, A | 1 |
| Shah, J | 2 |
| Nakamura, H | 1 |
| Kudoh, A | 1 |
| Yasui, Y | 1 |
| Ishizaki, K | 1 |
| Lin, D | 1 |
| Glastonbury, CM | 1 |
| Rafaelian, O | 1 |
| Eisele, DW | 2 |
| Wang, SJ | 1 |
| Peiper, M | 1 |
| Weber, R | 1 |
| Ang, K | 1 |
| Trotti, A | 1 |
| Pajak, TF | 5 |
| Deville, JL | 1 |
| Giorgi, R | 1 |
| Bagarry, D | 1 |
| Barrau, K | 1 |
| Bourgeois, A | 1 |
| Chen, HX | 1 |
| Marcenaro, M | 1 |
| Margarino, G | 9 |
| Fabrício, Vde C | 1 |
| Amado, F | 1 |
| Del Giglio, A | 1 |
| Jian, JJ | 1 |
| Chan, KY | 1 |
| Tsai, SY | 1 |
| Cheng, SH | 1 |
| Yen, KC | 1 |
| Cheng, JC | 1 |
| Pandya, KJ | 1 |
| Glück, S | 1 |
| Brizel, HE | 1 |
| Meredith, RF | 5 |
| Berger, D | 1 |
| Chen, MG | 1 |
| Mendenhall, W | 1 |
| Skoda, C | 1 |
| Erovic, BM | 1 |
| Wachek, V | 1 |
| Wrba, F | 1 |
| Martinek, H | 1 |
| Kloimstein, P | 1 |
| Lehnert, M | 2 |
| Jakse, R | 3 |
| Seewann, HL | 1 |
| Al-Sarraf, M | 22 |
| Tatarek, R | 3 |
| Corvò, L | 1 |
| Price, LA | 4 |
| Hill, BT | 3 |
| Raafat, J | 1 |
| Oster, MW | 1 |
| Thatcher, N | 1 |
| Blackledge, G | 1 |
| Crowther, D | 1 |
| Smith, BL | 1 |
| Franz, JL | 1 |
| Mira, JG | 1 |
| Gates, GA | 2 |
| Sapp, J | 1 |
| Cruz, AB | 4 |
| Glick, JH | 1 |
| Zehngebot, LM | 1 |
| Cortes, EP | 1 |
| Kalra, J | 1 |
| Amin, VC | 1 |
| Attie, J | 1 |
| Eisenbud, L | 1 |
| Khafif, R | 1 |
| Wolk, D | 1 |
| Aral, I | 1 |
| Sciubba, J | 1 |
| Akbiyik, N | 1 |
| Heller, K | 1 |
| Veronesi, A | 3 |
| Magri, MD | 3 |
| Galligioni, E | 2 |
| Tumolo, S | 2 |
| Comoretto, R | 2 |
| Grigoletto, E | 2 |
| Deregibus, P | 1 |
| Battezzati, G | 1 |
| Ringborg, U | 4 |
| Bagger-Sjöbäck, D | 1 |
| Ewert, G | 3 |
| Kinnman, J | 3 |
| Strander, H | 3 |
| Werner, B | 1 |
| Mead, GM | 1 |
| Jacobs, C | 4 |
| MacRae, K | 1 |
| Frustaci, S | 1 |
| Crivellari, D | 1 |
| Plasse, TF | 1 |
| Ohnuma, T | 3 |
| Brooks, S | 1 |
| Saponaro, E | 1 |
| Holland, JF | 2 |
| Biller, H | 1 |
| Weaver, A | 11 |
| Kinzie, J | 7 |
| Crissman, J | 6 |
| Cummings, G | 4 |
| Fleming, S | 1 |
| Jacobs, J | 8 |
| Inuyama, Y | 5 |
| Horiuchi, M | 4 |
| Mashino, S | 1 |
| Ozu, R | 1 |
| Asaoka, K | 1 |
| Pitman, SW | 1 |
| Kowal, CD | 1 |
| Bertino, JR | 2 |
| Browman, GP | 5 |
| Archibald, SD | 2 |
| Young, JE | 2 |
| Hryniuk, WM | 1 |
| Russell, R | 4 |
| Kiehl, K | 1 |
| Levine, MN | 5 |
| Coates, AS | 2 |
| Tattersall, MH | 3 |
| Swanson, C | 2 |
| Hedley, D | 1 |
| Fox, RM | 1 |
| Raghavan, D | 1 |
| Takaku, F | 1 |
| Scherpe, A | 1 |
| Schröder, M | 3 |
| von Heyden, HW | 1 |
| Nagel, GA | 1 |
| Fukuyo, K | 1 |
| Eura, S | 1 |
| Kato, T | 1 |
| Soda, T | 2 |
| Kusama, M | 1 |
| Utsunomiya, Y | 1 |
| Nagura, H | 1 |
| Enomoto, S | 1 |
| Mizutani, Y | 1 |
| Marzecki, Z | 1 |
| Krygier-Stojałowska, A | 1 |
| Zaborek, B | 1 |
| Wasilewska, M | 1 |
| Meyer, A | 1 |
| Jarema, A | 1 |
| Warczygłowa, D | 1 |
| Wiktor, A | 1 |
| Bahadur, S | 1 |
| Tandon, DA | 1 |
| Kacker, SK | 1 |
| Conte, PF | 1 |
| Scarsi, P | 1 |
| Barbieri, A | 1 |
| Benedetti, G | 2 |
| Lundquist, PG | 1 |
| Lundqvist, PG | 1 |
| Dillaha, CJ | 1 |
| Jansen, GT | 1 |
| Honeycutt, WM | 1 |
| Bradford, AC | 1 |
| Decker, DA | 1 |
| Drelichman, A | 2 |
| Hoschner, J | 2 |
| Loh, JJ | 1 |
| Spaulding, MB | 1 |
| Vasquez, J | 1 |
| Khan, A | 2 |
| Byfield, JE | 1 |
| Sharp, TR | 1 |
| Frankel, SS | 1 |
| Tang, SG | 1 |
| Callipari, FB | 1 |
| Albright, SD | 1 |
| Tomioka, M | 1 |
| Usami, M | 1 |
| Sakamoto, A | 1 |
| Honda, T | 2 |
| Flemming, S | 1 |
| Kish, J | 7 |
| Vandenberg, H | 1 |
| Jacob, J | 1 |
| Loh, J | 1 |
| Ohyama, W | 1 |
| Tokashiki, T | 1 |
| Hirokawa, T | 1 |
| Takada, K | 1 |
| Konno, T | 1 |
| Takeda, C | 1 |
| Stupp, R | 5 |
| Malone, D | 3 |
| Levin, J | 1 |
| Diaz-Ordaz, E | 1 |
| Chary, K | 1 |
| Lawrence, W | 1 |
| Hong, F | 1 |
| Gerold, T | 1 |
| Barrali, RA | 1 |
| Clavel, M | 3 |
| Cappelaere, P | 4 |
| de Mulder, PH | 3 |
| Schornagel, JH | 2 |
| Tueni, EA | 1 |
| Verweij, J | 4 |
| Wildiers, J | 1 |
| Clerico, M | 2 |
| Mick, R | 13 |
| McEvilly, JM | 4 |
| Eckardt, A | 2 |
| Kelber, A | 2 |
| Huber, MH | 2 |
| Lippman, SM | 4 |
| Benner, SE | 1 |
| Shirinian, M | 2 |
| Dimery, IW | 6 |
| Earley, CL | 1 |
| Winn, RJ | 1 |
| Brooks, J | 1 |
| Baez, L | 1 |
| Verdi, CJ | 1 |
| Garewal, HS | 1 |
| Koenig, LM | 1 |
| Vaughn, B | 1 |
| Burkhead, T | 1 |
| Codacci-Pisanelli, G | 1 |
| van der Wilt, CL | 2 |
| Pinedo, HM | 4 |
| Franchi, F | 1 |
| Noordhuis, P | 1 |
| Braakhuis, BJ | 5 |
| van Laar, JA | 1 |
| Peters, GJ | 5 |
| Pytlik, C | 1 |
| Chi, KH | 1 |
| Chan, WK | 1 |
| Chow, KC | 1 |
| Chen, SY | 1 |
| Chao, JY | 1 |
| Chang, CY | 1 |
| Chen, KY | 1 |
| Moran, W | 1 |
| Sweeney, P | 1 |
| Koja, S | 2 |
| Itokazu, T | 2 |
| Maeshiro, N | 2 |
| Matsumura, J | 1 |
| Maeda, H | 1 |
| Yasuda, S | 1 |
| Kochi, A | 1 |
| Noda, Y | 2 |
| Wang, HM | 2 |
| Chen, JS | 2 |
| Chang, HK | 1 |
| Kiu, MC | 1 |
| Liaw, CC | 1 |
| Ng, KT | 1 |
| Ichikawa, G | 1 |
| Shirasaka, T | 2 |
| Kawaida, M | 2 |
| Kohno, H | 2 |
| Enomoto, H | 2 |
| Yago, T | 1 |
| Ikema, Y | 1 |
| Makino, Y | 1 |
| Pannuti, F | 2 |
| Martoni, A | 2 |
| Melotti, B | 1 |
| Morritti, MG | 1 |
| Abram, AC | 1 |
| Nabizadeh, S | 1 |
| Feldman, PS | 1 |
| Cantrell, RW | 2 |
| Kies, M | 4 |
| Moran, WJ | 8 |
| Kozloff, M | 4 |
| Mittal, B | 3 |
| Panje, W | 3 |
| Sacks, PG | 1 |
| Harris, D | 1 |
| Chou, TC | 1 |
| Khansur, T | 1 |
| Allred, C | 1 |
| Little, D | 1 |
| Anand, V | 1 |
| De Andrés, L | 1 |
| Brunet, J | 1 |
| Burgués, J | 1 |
| Vega, M | 1 |
| Tabernero, JM | 1 |
| López, JJ | 1 |
| Kubota, T | 1 |
| Matsui, K | 1 |
| Ohtani, M | 1 |
| Takasaki, S | 1 |
| Bellman, B | 1 |
| Gregory, NA | 1 |
| Silvers, D | 1 |
| Fountain, KS | 1 |
| Beck, A | 3 |
| Guillot, T | 5 |
| De Paoli, A | 1 |
| Boz, G | 1 |
| Mascarin, M | 1 |
| Lamon, S | 1 |
| Miyagi, M | 2 |
| Cwikiel, M | 1 |
| Persson, SU | 1 |
| Larsson, H | 1 |
| Albertsson, M | 3 |
| Eskilsson, J | 2 |
| Furukawa, S | 2 |
| Kokatsu, T | 3 |
| Satoh, H | 1 |
| Sakumoto, M | 1 |
| Reisser, C | 2 |
| Haberkorn, U | 2 |
| Dimitrakopoulou-Strauss, A | 1 |
| Seifert, E | 1 |
| Strauss, LG | 2 |
| Frankenthaler, RA | 1 |
| Pinnarò, P | 2 |
| Cercato, MC | 1 |
| Giannarelli, D | 2 |
| Del Vecchio, MR | 1 |
| Impiombato, FA | 2 |
| Marzetti, F | 1 |
| Milella, M | 1 |
| O'Brien, M | 1 |
| Schofield, JB | 1 |
| Lorentzos, A | 1 |
| Moore, J | 1 |
| Atkinson, H | 1 |
| Henk, JM | 2 |
| MacLennan, KA | 1 |
| Gore, ME | 2 |
| Lagrange, JL | 5 |
| Fleming, R | 2 |
| Cavallari, M | 3 |
| Blengio, F | 4 |
| Sguotti, C | 1 |
| Rosso, M | 2 |
| Cripps, C | 5 |
| Hodson, DI | 3 |
| Eapen, L | 2 |
| Sathya, J | 3 |
| Ebeling, O | 1 |
| Eckel, HE | 2 |
| Volling, P | 4 |
| Heitmann, K | 1 |
| Vössing, M | 1 |
| Kamiya, S | 1 |
| Yamauchi, M | 1 |
| Esu, H | 1 |
| Simoji, Y | 1 |
| Kanazawa, T | 3 |
| Hartsell, WF | 1 |
| Thomas, CR | 1 |
| Murthy, AK | 7 |
| Haselow, RE | 4 |
| Leyvraz, S | 2 |
| Pasche, P | 2 |
| Bauer, J | 2 |
| Bernasconi, S | 1 |
| Monnier, P | 1 |
| Vannetzel, JM | 1 |
| Colin, P | 1 |
| Dray, M | 1 |
| Caldarelli, DD | 7 |
| Shott, S | 1 |
| Vokes, E | 3 |
| Showel, JL | 3 |
| Hutchinson, JC | 6 |
| Tamura, Y | 1 |
| Miyake, H | 3 |
| Iizuka, K | 1 |
| Orlando, A | 1 |
| Zorat, PL | 2 |
| Cavaniglia, G | 2 |
| Sileni, VC | 1 |
| Jirillo, A | 1 |
| Fede, A | 2 |
| Jan, JS | 1 |
| Hsu, CY | 1 |
| McLaughlin, PW | 1 |
| Thornton, AF | 1 |
| Wihlm, J | 1 |
| Levêque, D | 1 |
| Velten, M | 1 |
| Klein, T | 1 |
| Wong, WW | 1 |
| Casiano, RR | 2 |
| Laramore, GE | 4 |
| Yoshino, K | 2 |
| Sato, T | 2 |
| Nakai, Y | 2 |
| Tanabe, M | 2 |
| Matsunaga, T | 2 |
| Kozuka, T | 2 |
| Sakai, S | 2 |
| Miyaguchi, M | 2 |
| Matsuoka, H | 2 |
| Ramaioli, A | 2 |
| Reyt, E | 3 |
| Lavieille, JP | 2 |
| Brambilla, E | 1 |
| Barra, Y | 1 |
| Riva, C | 2 |
| Galliani, S | 1 |
| Bardon, M | 1 |
| Kalish, LA | 1 |
| Oken, MM | 1 |
| Remick, SC | 1 |
| Mansour, EG | 1 |
| Jeremic, B | 2 |
| Zivic, DJ | 1 |
| Matovic, M | 1 |
| Marinkovic, J | 1 |
| Depondt, J | 2 |
| Gehanno, P | 2 |
| Martin, M | 4 |
| Lelievre, G | 3 |
| Guerrier, B | 2 |
| Peytral, C | 3 |
| Schott, H | 1 |
| Pellae-Cosset, B | 1 |
| Toma, S | 4 |
| Bachaud, JM | 1 |
| David, JM | 1 |
| Shubinski, RE | 1 |
| Perineau, D | 1 |
| Boussin, G | 1 |
| Serrano, E | 1 |
| De Forni, M | 2 |
| Pessey, JJ | 1 |
| Daly-Schveitzer, NJ | 1 |
| Leopold, KA | 1 |
| Panella, TJ | 1 |
| Fine, RL | 1 |
| Bedrosian, CL | 1 |
| Kenan, PD | 1 |
| Huang, A | 1 |
| Womack, T | 1 |
| Bjurstrom, T | 1 |
| Au, JL | 1 |
| Wientjes, MG | 1 |
| Rosol, TJ | 1 |
| Koolemans-Beynen, A | 1 |
| Goebel, EA | 1 |
| Cascinu, S | 1 |
| Fedeli, A | 1 |
| Luzi Fedeli, S | 1 |
| Schlappack, O | 1 |
| Springer, B | 1 |
| Hainz, A | 1 |
| Gomez, A | 2 |
| Sanchez, P | 4 |
| Martin, G | 3 |
| Santos, P | 1 |
| Muñoz, A | 4 |
| Nieto, A | 3 |
| Segati, R | 2 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Chiarion-Sileni, V | 1 |
| Favaretto, A | 1 |
| Itaya, S | 1 |
| Tsuge, I | 1 |
| Motai, H | 1 |
| Kobayashi, T | 1 |
| Shimada, J | 1 |
| Baba, S | 1 |
| Wong, G | 2 |
| Hodson, I | 1 |
| McAlpine, L | 1 |
| Skingley, P | 2 |
| Junor, E | 1 |
| Canney, P | 1 |
| Yosef, H | 2 |
| Ratain, MJ | 8 |
| Hamasaki, V | 1 |
| Panje, WR | 15 |
| Jassem, J | 1 |
| Gyergyay, F | 1 |
| Kerpel-Fronius, S | 1 |
| Nagykálnai, T | 1 |
| Baumöhl, J | 1 |
| Vuletic, L | 1 |
| Mechl, Z | 1 |
| Drozd-Lula, M | 1 |
| Fleming, RA | 4 |
| Milano, GA | 2 |
| Gaspard, MH | 1 |
| Bargnoux, PJ | 1 |
| Plagne, R | 1 |
| Girard, A | 1 |
| Bajard, F | 1 |
| Fety, R | 2 |
| Panadero, A | 1 |
| Garcia, MJ | 1 |
| Hecquet, B | 3 |
| Meeus, L | 3 |
| Krakowski, I | 2 |
| De Gislain, C | 3 |
| Chauvergne, J | 2 |
| Dufour-Esquerré, F | 2 |
| Carde, P | 1 |
| Somekawa, Y | 2 |
| Asano, K | 2 |
| Imai, R | 1 |
| Zhou, T | 1 |
| Zeng, Z | 1 |
| Vikram, B | 1 |
| Haaz, MC | 1 |
| Vitale, V | 6 |
| Bonelli, L | 3 |
| Santi, L | 1 |
| Alba, E | 1 |
| Sanchez-Chaparro, MA | 1 |
| Alonso, L | 1 |
| Ribelles, N | 1 |
| Ramon Delgado, J | 1 |
| Pablo Tenllado, P | 1 |
| Solano, J | 1 |
| Urquiza, R | 1 |
| Stahl, H | 1 |
| Dieckmann, K | 1 |
| Scheller, S | 1 |
| Löffel, J | 1 |
| Riess, H | 1 |
| Jahnke, V | 1 |
| Dolan, ME | 4 |
| Athanasiadis, I | 3 |
| Kosmidis, P | 3 |
| Sridhar, KS | 6 |
| Banis, K | 2 |
| Dimitriadis, A | 1 |
| Avramidis, V | 2 |
| Zaramboukas, T | 2 |
| Vritsios, A | 4 |
| Daniilidis, I | 1 |
| Hussain, M | 3 |
| Benedetti, J | 1 |
| Smith, RE | 1 |
| Rodriguez, GI | 1 |
| Schuller, D | 1 |
| Johnson, JT | 7 |
| Wagner, RL | 5 |
| Myers, EN | 6 |
| Dragovic, J | 1 |
| Doyle, TJ | 1 |
| Tilchen, EJ | 1 |
| Nichols, RD | 1 |
| Benninger, MS | 1 |
| Carlson, ER | 1 |
| Boyd, SB | 1 |
| Jacobsen, GR | 1 |
| Bensmaine, ME | 1 |
| Azli, N | 2 |
| Cvitkovic, E | 9 |
| Wibault, P | 5 |
| Bensmaine, MA | 1 |
| Tellez Bernal, E | 2 |
| Recondo, G | 5 |
| Eschwege, F | 2 |
| Olver, IN | 2 |
| Hughes, PG | 1 |
| Smith, JG | 2 |
| Narayan, K | 1 |
| Bishop, JF | 2 |
| Bernal, ET | 1 |
| Sigal, R | 1 |
| Haddad, E | 1 |
| Vergnes, L | 2 |
| Brun, B | 1 |
| Piedbois, P | 1 |
| Coste, A | 1 |
| Peynegre, R | 3 |
| Le Bourgeois, JP | 1 |
| Nakazawa, E | 1 |
| Kusunoki, M | 1 |
| Nishiya, M | 1 |
| Starr, S | 1 |
| Gebbia, V | 7 |
| Mantovani, G | 5 |
| Agostara, B | 2 |
| Contu, A | 1 |
| Farris, A | 3 |
| Colucci, G | 1 |
| Restivo, G | 1 |
| Speciale, R | 1 |
| Ferrero, B | 1 |
| Ito, K | 2 |
| Ito, T | 1 |
| Fournier, C | 2 |
| Pion, JM | 1 |
| Bianchi, A | 2 |
| Curreli, L | 3 |
| Santona, MC | 1 |
| Proto, E | 3 |
| Puxeddu, P | 1 |
| Ohno, Y | 4 |
| Tokumaru, Y | 4 |
| Kanke, M | 5 |
| Kumar, S | 1 |
| Ahuja, RC | 1 |
| Mali, HR | 1 |
| Agarwal, GN | 1 |
| Ayyagari, S | 1 |
| Coudert, B | 1 |
| Beltramo, JL | 1 |
| Guigues, B | 1 |
| Mayer, F | 1 |
| Bruchon, Y | 1 |
| Riedinger, JM | 1 |
| Fargeot, P | 1 |
| Dumas, M | 1 |
| Guerrin, J | 1 |
| Hatton, MQ | 1 |
| Junor, EJ | 1 |
| Paul, J | 1 |
| Canney, PA | 1 |
| McGurk, FM | 1 |
| Symonds, RP | 1 |
| Taylor, S | 2 |
| Pelzer, HJ | 1 |
| Rademaker, A | 2 |
| Ganzenko, N | 1 |
| Blough, R | 1 |
| Lester, EP | 2 |
| List, M | 3 |
| Johnston, PG | 3 |
| Recant, W | 1 |
| Behan, KA | 1 |
| Beckmann, E | 1 |
| Allegra, CJ | 2 |
| Nollert, J | 1 |
| Flentje, M | 2 |
| Maiei, H | 1 |
| Wannenmacher, M | 3 |
| Desogus, A | 1 |
| Moschella, F | 1 |
| Di Gregorio, C | 1 |
| Bajetta, E | 1 |
| Gebbia, N | 4 |
| Harari, PM | 1 |
| Damber, L | 1 |
| Jonsson, H | 1 |
| Andersson, T | 2 |
| Berthelsen, A | 2 |
| Biörklund, A | 3 |
| Blomqvist, E | 1 |
| Evensen, JF | 2 |
| Hansen, O | 3 |
| Jetlund, O | 1 |
| Mercke, C | 4 |
| Modig, H | 1 |
| Overgaard, M | 1 |
| Rosengren, B | 1 |
| Tausjö, J | 1 |
| Cheung, AY | 1 |
| Rinehart, J | 1 |
| Ruff, T | 1 |
| Abitbol, AA | 2 |
| Lewin, AA | 2 |
| Schwade, JG | 4 |
| Raub, W | 1 |
| Wolfson, A | 1 |
| Gonzalez-Angulo, C | 1 |
| Adessa, A | 1 |
| Goodwin, WJ | 1 |
| Zidan, J | 1 |
| Rosenblatt, E | 1 |
| Robinson, E | 1 |
| Kanzaki, J | 3 |
| Devriendt, D | 1 |
| Klastersky, J | 1 |
| Kirschner, MJ | 1 |
| Waldfahrer, F | 1 |
| Andersen, JW | 2 |
| Dreyfuss, AI | 2 |
| Rossi, RM | 1 |
| Poulin, MD | 1 |
| Lucarini, JW | 2 |
| Lucarini, D | 1 |
| Thornhill, L | 1 |
| Lackey, M | 1 |
| Peters, E | 1 |
| Miralbell, R | 1 |
| Bardina, A | 1 |
| Lehmann, W | 1 |
| Kurtz, JM | 1 |
| Rodríguez, CA | 1 |
| Gómez-Bernal, A | 1 |
| Pardal, JL | 1 |
| Hill, ME | 1 |
| Constenla, DO | 1 |
| A'Hern, RP | 1 |
| Rhys-Evans, P | 1 |
| Breach, N | 1 |
| Archer, D | 1 |
| Eliachar, I | 4 |
| Van Kirk, MA | 2 |
| Secic, M | 2 |
| Wanamaker, JR | 3 |
| Tuason, L | 1 |
| Sanguineti, G | 5 |
| Iop, A | 2 |
| Cartei, G | 2 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Diaz-Rubio, E | 1 |
| Satoh, N | 1 |
| Dinges, S | 1 |
| Boehmer, D | 1 |
| Schrader, M | 1 |
| Griem, KL | 2 |
| Recine, DC | 1 |
| Kiel, K | 3 |
| Blendowski, C | 1 |
| Hurst, PB | 1 |
| Showel, JT | 1 |
| Campanella, RS | 1 |
| Chen, S | 1 |
| Rowinsky, EK | 1 |
| Meluch, AA | 2 |
| Salwen, W | 2 |
| Gentile, A | 1 |
| Ray-Coquard, I | 1 |
| Bolla, M | 3 |
| Brochon, D | 1 |
| Lebeau, J | 2 |
| Colonna, M | 1 |
| Kolodié, H | 2 |
| Vincent, F | 2 |
| Chinal-Provencal, J | 1 |
| Bień, S | 1 |
| Szendo, J | 1 |
| Zyłka, S | 1 |
| Synowiec, J | 1 |
| Matsubara, T | 1 |
| Ueda, M | 1 |
| Nagao, N | 1 |
| Takahashi, T | 1 |
| Nakajima, T | 1 |
| Nishi, M | 1 |
| Fasanmade, A | 1 |
| Glisson, B | 2 |
| Sulzen, L | 5 |
| Klepsch, A | 1 |
| Johnson, J | 1 |
| Jiminez, U | 1 |
| Gore, M | 2 |
| Szpirglas, H | 1 |
| Robbins, K | 1 |
| Oliveira, J | 1 |
| Lewensohn, R | 1 |
| Schüller, J | 1 |
| Riviere, A | 2 |
| Arvay, C | 1 |
| Langecker, P | 1 |
| Jacob, H | 1 |
| Wendt, TG | 8 |
| Grabenbauer, GG | 2 |
| Rödel, CM | 1 |
| Thiel, HJ | 1 |
| Aydin, H | 1 |
| Rohloff, R | 2 |
| Wustrow, TP | 6 |
| Popella, C | 1 |
| Schalhorn, A | 3 |
| Fried, M | 1 |
| Poulin, M | 1 |
| Fabian, RL | 2 |
| Fitzgerald, TJ | 1 |
| Dreyfuss, A | 1 |
| Peters, ES | 1 |
| Barton, JJ | 2 |
| Isaia, A | 1 |
| Makishima, K | 1 |
| Bryce, TJ | 1 |
| Dewhirst, MW | 1 |
| Floyd, CE | 1 |
| Hars, V | 2 |
| Yuyama, S | 1 |
| Itoh, K | 1 |
| Lavit, M | 1 |
| Pujol, A | 1 |
| Canal, P | 1 |
| Numico, GM | 2 |
| Danova, M | 1 |
| Santelli, A | 4 |
| Ameli, F | 1 |
| Albers, ME | 1 |
| Richtsmeier, WJ | 1 |
| George, SL | 1 |
| Huang, AT | 2 |
| Prosnitz, LR | 1 |
| Schaebler, D | 1 |
| Sauter, E | 1 |
| DeMaria, D | 1 |
| Johnson, C | 1 |
| Reilly, DM | 1 |
| Leighton, J | 1 |
| Aks, C | 1 |
| Litwin, S | 1 |
| Teicher, BA | 1 |
| Ara, G | 1 |
| Chen, YN | 1 |
| Recht, A | 1 |
| Coleman, CN | 1 |
| Westra, WH | 1 |
| Lee, DJ | 1 |
| Hardouin, A | 1 |
| Campion, L | 1 |
| Conroy, T | 1 |
| Perrocheau, G | 1 |
| Feldmann, HJ | 1 |
| Creighton, C | 1 |
| Kau, R | 1 |
| Molls, M | 1 |
| Giaretti, W | 1 |
| Geido, E | 1 |
| Preisler, HD | 1 |
| Kotelnikov, VM | 1 |
| LaFollette, S | 1 |
| Mundle, S | 1 |
| Wood, N | 1 |
| Coon, JS | 1 |
| Hutchinson, J | 1 |
| Griem, K | 1 |
| Bumma, C | 2 |
| Contu, P | 1 |
| Dessì, D | 1 |
| Lampis, B | 1 |
| Lai, P | 1 |
| Mulas, C | 2 |
| Testa, A | 3 |
| Cadeddu, G | 1 |
| Tore, G | 2 |
| Humerickhouse, R | 2 |
| Uchida, N | 1 |
| Takeda, Y | 1 |
| Kasai, H | 1 |
| Hojo, K | 1 |
| Wada, T | 1 |
| Nishida, K | 1 |
| Maekawa, R | 1 |
| Sugita, K | 1 |
| Yoshioka, T | 1 |
| Peters, GE | 4 |
| Beenken, SW | 1 |
| Smith, J | 1 |
| Conner, W | 1 |
| Salter, MM | 4 |
| Sánchez Parra, M | 1 |
| Churruca, C | 1 |
| Paredes, A | 1 |
| Lacasta, A | 1 |
| López de Argumedo, G | 1 |
| Alvárez, I | 1 |
| Abad, T | 1 |
| Egana, L | 1 |
| Guimón, E | 1 |
| Piera, JM | 1 |
| Humerickhouse, RA | 1 |
| Giatromanolaki, A | 2 |
| Koukourakis, MI | 2 |
| Georgoulias, V | 2 |
| Gatter, KC | 2 |
| Harris, AL | 2 |
| Marcolin, P | 1 |
| Russo Spena, F | 1 |
| Biglietto, M | 1 |
| Cartenì, G | 2 |
| Gravina, A | 2 |
| Poissonnet, G | 1 |
| Fontana, X | 1 |
| Sormani, M | 1 |
| Roncallo, F | 1 |
| Mereu, P | 1 |
| Hennequin, C | 1 |
| Maylin, C | 1 |
| Schlemmer, HP | 1 |
| Bachert, P | 1 |
| Wollensack, P | 1 |
| Zuna, I | 1 |
| Knopp, MV | 1 |
| van Kaick, G | 1 |
| Cabelguenne, A | 2 |
| Carnot, F | 2 |
| de Waziers, I | 2 |
| Hamelin, R | 1 |
| McGuire, JJ | 1 |
| Gamelin, E | 1 |
| Su, CL | 1 |
| Liao, CT | 1 |
| Chen, IH | 1 |
| Fried, MP | 2 |
| Gomolin, HI | 1 |
| Amrein, P | 2 |
| Lamb, C | 1 |
| Barton, J | 1 |
| Read, R | 2 |
| Tomita, T | 2 |
| Morrison, WH | 1 |
| Byers, RM | 3 |
| Geara, F | 1 |
| Clayman, GL | 1 |
| Callender, DL | 1 |
| Goepfert, H | 3 |
| Cox, NH | 1 |
| Eedy, DJ | 1 |
| Morton, CA | 1 |
| Lammering, G | 1 |
| Carl, UM | 1 |
| Pape, H | 1 |
| Hartmann, KA | 1 |
| Altmann, S | 1 |
| Hoffmanns, H | 1 |
| Gadgeel, S | 1 |
| Du, W | 1 |
| McLeod, H | 1 |
| De Vita, F | 1 |
| Casaretti, R | 1 |
| Morsman, J | 1 |
| Blackie, R | 1 |
| Shiga, H | 2 |
| Heath, EI | 1 |
| Rasmussen, AA | 2 |
| Trock, B | 1 |
| Langmacher, M | 2 |
| Baylor, A | 2 |
| Lee, M | 2 |
| Flahault, A | 1 |
| Périé, S | 1 |
| Monceaux, G | 1 |
| Coulet, F | 1 |
| Callard, P | 1 |
| Bernaudin, JF | 1 |
| Ohmuma, T | 1 |
| Monney, M | 1 |
| Rosset, A | 1 |
| Ozsahin, M | 1 |
| Guillemin, C | 1 |
| Nishino, H | 2 |
| Miyata, M | 2 |
| Morita, M | 1 |
| Björk-Eriksson, T | 1 |
| West, C | 1 |
| Karlsson, E | 1 |
| Sørensen, P | 1 |
| Larto, MA | 1 |
| Sivridis, E | 1 |
| D'Costa, IA | 1 |
| Huges, PG | 1 |
| Sexton, MA | 1 |
| Lyons, B | 1 |
| Janinis, J | 3 |
| Panagos, G | 3 |
| Soussi, T | 1 |
| Hsieh, YC | 1 |
| Papadakou, M | 2 |
| Xidakis, E | 1 |
| Boukis, H | 1 |
| Poulis, A | 1 |
| Lefantzis, D | 2 |
| Aref, A | 1 |
| Berkey, BA | 1 |
| Okamoto, M | 1 |
| Ohe, G | 1 |
| Oshikawa, T | 1 |
| Nishikawa, H | 1 |
| Furuichi, S | 1 |
| Yoshida, H | 1 |
| Nakanoboh, M | 2 |
| Kawada, M | 1 |
| Amrein, PC | 3 |
| Rivellini, F | 2 |
| Mozzillo, N | 1 |
| Manzione, L | 1 |
| Schaefer, U | 1 |
| Schueller, P | 1 |
| Canaparo, R | 1 |
| Casale, F | 1 |
| Muntoni, E | 1 |
| Zara, GP | 1 |
| Della Pepa, C | 1 |
| Berno, E | 1 |
| Pons, N | 1 |
| Fornari, G | 1 |
| Eandi, M | 1 |
| Ganly, I | 1 |
| Arseneau, J | 1 |
| Tannock, IF | 1 |
| Romel, L | 1 |
| Ironside, J | 1 |
| MacDougall, RH | 1 |
| Heise, C | 1 |
| Randlev, B | 1 |
| Gillenwater, AM | 1 |
| Bruso, P | 1 |
| Kaye, SB | 1 |
| Kirn, DH | 1 |
| Schmerber, S | 1 |
| Cuisnie, O | 1 |
| Backus, HH | 1 |
| Wouters, D | 1 |
| Padrón, JM | 1 |
| Molders, N | 1 |
| van Groeningen, CJ | 1 |
| Jansen, G | 1 |
| Yanoma, S | 2 |
| Mizuno, H | 1 |
| Lamont, JP | 1 |
| Kuhn, JA | 1 |
| Landers, SA | 1 |
| McCarty, TM | 1 |
| Schmidinger, M | 1 |
| Budinsky, AC | 1 |
| Wenzel, C | 1 |
| Piribauer, M | 1 |
| Brix, R | 1 |
| Kautzky, M | 1 |
| Oder, W | 1 |
| Locker, GJ | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Eifel, PJ | 1 |
| Itoh, Y | 1 |
| Murata, Y | 1 |
| Peyrat, JP | 1 |
| Abecassis, J | 1 |
| Millon, R | 1 |
| Fujisawa, Y | 1 |
| Ichimura, K | 1 |
| Abe, K | 1 |
| Tanaka, H | 1 |
| Orús, C | 1 |
| Sancho, FJ | 1 |
| de Juan, M | 1 |
| Nakamura, Y | 2 |
| Lewis, NL | 1 |
| Meropol, NJ | 1 |
| Frenette, G | 1 |
| Seroskie, JD | 1 |
| Garay, CA | 1 |
| Chung, T | 1 |
| Weichselbaum, R | 2 |
| Sommer, K | 1 |
| Peters, SO | 1 |
| Robins, IH | 1 |
| Raap, M | 1 |
| Wiedemann, GJ | 1 |
| Remmert, S | 1 |
| Sieg, P | 1 |
| Bittner, C | 1 |
| Feyerabend, T | 1 |
| Eberlein, K | 1 |
| Jackel, MC | 1 |
| De Crevoisier, R | 1 |
| Koscielny, S | 1 |
| Lusinchi, A | 1 |
| Bobin, S | 1 |
| De Stefani, A | 1 |
| Marchionatti, S | 1 |
| Pedani, F | 2 |
| Gabriele, P | 2 |
| Panousaki, A | 1 |
| Hatzidaki, D | 1 |
| Dokianakis, G | 1 |
| Yanagisawa, T | 1 |
| Kishimoto, H | 1 |
| Yoshioka, W | 1 |
| Teranobu, O | 1 |
| Shigeta, Y | 1 |
| Komori, T | 1 |
| Shimada, K | 1 |
| Ohnishi, M | 1 |
| Tanaka, Y | 1 |
| Kamiya, Y | 1 |
| Akazawa, N | 1 |
| Oko, T | 1 |
| Takahashi, N | 1 |
| Adachi, R | 1 |
| Tanigaki, S | 1 |
| Hirata, Y | 1 |
| Yakushiji, N | 1 |
| Kitamura, R | 1 |
| Hashikawa, N | 1 |
| Staar, S | 1 |
| Stuetzer, H | 1 |
| Schroeder, M | 1 |
| Mueller, RP | 1 |
| Akervall, J | 1 |
| Brun, E | 1 |
| Dictor, M | 1 |
| Wennerberg, J | 3 |
| Baker, MN | 1 |
| Morrissey, LH | 1 |
| Knowling, M | 1 |
| Browman, G | 1 |
| Siu, L | 1 |
| Khoo, K | 1 |
| Cooke, A | 1 |
| Tannock, I | 1 |
| Klaassen, D | 1 |
| Goss, G | 1 |
| Matthews, S | 1 |
| Clarke, R | 1 |
| Seymour, L | 1 |
| Carinci, F | 1 |
| Cassano, L | 1 |
| Farina, A | 1 |
| Pelucchi, S | 1 |
| Calearo, C | 1 |
| Modugno, V | 1 |
| Nielsen, I | 1 |
| Api, P | 1 |
| Pastore, A | 1 |
| Yamaoka, H | 1 |
| Nagahara, T | 1 |
| Munro, AJ | 1 |
| Poole, ME | 1 |
| Sailer, SL | 2 |
| Rosenman, JG | 2 |
| Tepper, JE | 1 |
| Weissler, MC | 2 |
| Shockley, WW | 1 |
| Yarbrough, WG | 1 |
| Pillsbury, HC | 2 |
| Schell, MJ | 1 |
| Bernard, SA | 1 |
| Madeddu, C | 1 |
| Mura, L | 1 |
| Mudu, MC | 1 |
| Astara, G | 1 |
| Murgia, V | 1 |
| Gramignano, G | 1 |
| Ferreli, L | 1 |
| Camboni, P | 1 |
| Lusso, MR | 1 |
| Mocci, M | 1 |
| Mura, M | 1 |
| Amichetti, M | 1 |
| Maccio, A | 1 |
| Pallestrini, E | 2 |
| Marchetti, G | 1 |
| Hathaway, B | 1 |
| Piccirillo, JF | 1 |
| Snyderman, CH | 1 |
| Labriola, S | 1 |
| Marcié, S | 1 |
| Toh, S | 1 |
| Koike, K | 1 |
| Suzui, M | 1 |
| Deguchi, A | 1 |
| Komiyama, S | 5 |
| Weinstein, IB | 1 |
| Gopal, HV | 1 |
| Xu, D | 1 |
| Chen, G | 1 |
| Li, S | 1 |
| Cai, Y | 1 |
| Ling, H | 1 |
| Xu, L | 1 |
| Poluri, A | 1 |
| Patel, S | 1 |
| Shaha, AR | 1 |
| Pfister, D | 1 |
| Sherman, E | 1 |
| Goberdhan, A | 1 |
| Hoffman, RM | 2 |
| Rodrigues, MA | 1 |
| Hamilton-Nelson, KL | 1 |
| Calvert, AH | 1 |
| Shaw, HJ | 2 |
| Hughes, KB | 1 |
| DeWys, WD | 2 |
| Boston, B | 1 |
| Capizzi, RL | 1 |
| Goldsmith, MA | 1 |
| Carter, SK | 2 |
| Schwab, W | 2 |
| zum Winkel, K | 1 |
| Ammon, J | 2 |
| Donegan, WL | 3 |
| Harris, P | 1 |
| Stathopoulos, G | 1 |
| Wiltshaw, E | 1 |
| Armstrong, AL | 1 |
| Meeker, WR | 1 |
| Holoye, PY | 3 |
| Gard, DA | 1 |
| Guillamondegui, OM | 2 |
| Bianco, A | 1 |
| Reich, S | 1 |
| Merrill, JM | 1 |
| Nitze, HR | 2 |
| Oberfield, RA | 3 |
| Dietz, R | 2 |
| Wilhelm, HJ | 1 |
| Bohno, K | 1 |
| Muto, J | 1 |
| Nishiyama, A | 1 |
| Osawa, H | 1 |
| Ryan, RF | 2 |
| Mootz, W | 1 |
| Hiroto, I | 1 |
| Ryu, S | 1 |
| Kuwano, M | 2 |
| Endo, H | 1 |
| Hill, GJ | 3 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 2 |
| Grage, T | 1 |
| Fletcher, WS | 1 |
| Golomb, FM | 1 |
| Dowell, KE | 1 |
| Armstrong, DM | 1 |
| Aust, JB | 2 |
| Slack, NH | 1 |
| Bross, ID | 1 |
| Stiop, LD | 1 |
| Sikov, VG | 1 |
| Nikolaev, GI | 1 |
| Brunin, F | 1 |
| Rodriguez, J | 1 |
| Jaulerry, C | 1 |
| Mosseri, V | 1 |
| Jouve, M | 1 |
| Point, D | 1 |
| Asselain, B | 1 |
| Validire, P | 1 |
| Blaszka, B | 1 |
| Zafrani, B | 1 |
| Saito, H | 1 |
| Ohtsubo, T | 1 |
| Fujieda, S | 1 |
| Tanigawa, N | 1 |
| Karaseva, VV | 1 |
| Stepanov, VG | 1 |
| Korolev, VV | 1 |
| Badellino, F | 1 |
| Mahé, E | 1 |
| Filleul, A | 1 |
| Sachwald, J | 1 |
| Bertrand, F | 1 |
| Berlie, J | 1 |
| Banal, A | 1 |
| Zojaji, A | 1 |
| Tubiana-Hulin, M | 1 |
| Valenza, R | 2 |
| Zerillo, G | 3 |
| Restivo, S | 1 |
| Cupido, G | 1 |
| Ingria, F | 3 |
| Spadafora, G | 2 |
| Barbaccia, C | 1 |
| Cannata, G | 1 |
| Spielmann, M | 1 |
| Kac, J | 1 |
| Tellez-Bernal, E | 3 |
| Munck, JN | 1 |
| Bachouchi, M | 1 |
| Watanabe, S | 1 |
| Sawaki, S | 3 |
| Frassineti, GL | 1 |
| Flamini, E | 1 |
| Falcini, F | 1 |
| Maltoni, M | 1 |
| Nanni, O | 1 |
| Riccobon, A | 1 |
| Piccinini, C | 1 |
| Bauer, FP | 1 |
| Westhofen, M | 1 |
| Kehrl, W | 1 |
| Baillet, F | 1 |
| Dubreuil, C | 1 |
| Pellae Cosset, B | 1 |
| Rausa, L | 3 |
| Sharan, VM | 5 |
| Damm, C | 5 |
| Earle, AS | 5 |
| Shah, AC | 5 |
| Haria, CD | 5 |
| Trey, JE | 1 |
| Carter, SG | 5 |
| Hines, JD | 5 |
| Stephens, S | 2 |
| Kim, RY | 3 |
| Weppelmann, B | 3 |
| Beckett, M | 1 |
| Karrison, T | 1 |
| Weinstein, G | 1 |
| Chabardes, E | 1 |
| Housset, M | 1 |
| Laccourreye, H | 2 |
| Fisher, SG | 1 |
| Hamasaki, VK | 1 |
| Narasimha, K | 1 |
| Kusumoto, T | 1 |
| White, RM | 1 |
| Myers, EM | 1 |
| Ashayeri, E | 1 |
| Gumbs, RV | 1 |
| Pressoir, R | 1 |
| Smith, IM | 1 |
| Robinson, D | 1 |
| Thomson, D | 1 |
| Coman, WB | 1 |
| Sridhar, K | 2 |
| Brandon, AH | 1 |
| Houdek, PV | 1 |
| Serago, C | 1 |
| Miller, DJ | 1 |
| Maurer, J | 1 |
| Welkoborsky, HJ | 1 |
| Mann, W | 1 |
| Goldman, MD | 3 |
| Clendeninn, NJ | 1 |
| Collier, MA | 1 |
| Cassuto-Viguier, E | 1 |
| Santini, J | 7 |
| Frenay, M | 1 |
| Scott, CB | 1 |
| Gahbauer, RA | 1 |
| Spatafora, G | 1 |
| Cimino, A | 1 |
| Pastorello, T | 1 |
| Ferrara, P | 1 |
| Metch, B | 1 |
| Hutchins, LF | 1 |
| Triozzi, P | 1 |
| McClure, S | 1 |
| VonFeldt, E | 1 |
| Williamson, SK | 1 |
| Schilsky, RL | 10 |
| Melin, S | 1 |
| Qaqish, BF | 1 |
| Valone, FH | 1 |
| Gandara, DR | 1 |
| Deisseroth, AB | 1 |
| Perez, EA | 1 |
| Rayner, A | 1 |
| Aronson, FR | 1 |
| Luce, J | 1 |
| Paradise, C | 1 |
| Economidou-Karaoglou, A | 2 |
| Opsomer, M | 1 |
| Lans, M | 2 |
| Taper, HS | 1 |
| Deckers, C | 1 |
| Roberfroid, MB | 1 |
| Pfeiffer, P | 1 |
| Madsen, EL | 1 |
| May, O | 1 |
| Sombolos, K | 2 |
| Destouni-Salem, E | 1 |
| Tourkantonis, A | 2 |
| Belehradek, M | 2 |
| Leridant, AM | 1 |
| Vericel, R | 1 |
| Kawabe, Y | 1 |
| Yamagiwa, M | 2 |
| Suzuki, T | 2 |
| Mizuno, A | 1 |
| Mineda, H | 1 |
| De Vathaire, F | 2 |
| Richard, JM | 3 |
| Kawasaki, K | 1 |
| Marandas, P | 2 |
| Benahmed, M | 1 |
| Tononi, A | 1 |
| Occhiuzzi, L | 1 |
| Caliceti, U | 1 |
| Dall'Olio, D | 1 |
| Laudadio, P | 1 |
| Lyman, G | 1 |
| Velez-García, E | 2 |
| Knight, W | 1 |
| Hochster, H | 1 |
| Goodnough, LT | 1 |
| Mortimer, JE | 1 |
| Einhorn, LH | 2 |
| Schacter, L | 1 |
| Moormeier, JA | 1 |
| Egorin, MJ | 1 |
| Terazono, T | 1 |
| Oshima, W | 1 |
| Kihira, S | 1 |
| Takegami, E | 1 |
| Kume, T | 1 |
| Nakao, M | 1 |
| Takada, A | 1 |
| Altendorf-Hofmann, A | 1 |
| Makrantonakis, P | 1 |
| Themelis, C | 1 |
| Beer, M | 1 |
| Tepmongkol, P | 1 |
| Panichevalux, A | 1 |
| Skulchan, V | 1 |
| Thanaphum, V | 1 |
| Sangruchi, S | 1 |
| Thansakul, A | 1 |
| Jirapanuwat, S | 1 |
| Janisch, L | 1 |
| Hoffman, PC | 1 |
| Golomb, HM | 1 |
| Visser, GW | 1 |
| Stringer, I | 1 |
| Kaasa, S | 1 |
| Thorud, E | 1 |
| Tausjø, J | 1 |
| Wist, E | 2 |
| Gundersen, S | 1 |
| Høst, H | 1 |
| Grunberg, SM | 1 |
| Clay, C | 1 |
| Spicer, DV | 1 |
| Norum, J | 1 |
| Bonaventura, A | 1 |
| Stewart, JF | 1 |
| Schratter-Sehn, AU | 1 |
| Handl-Zeller, L | 1 |
| Strassl, H | 2 |
| Braun, OM | 2 |
| Dobrowsky, W | 2 |
| Braun, SD | 1 |
| Gemer, LS | 1 |
| McIntee, RA | 1 |
| Baugh, R | 1 |
| Thomas, JH | 1 |
| Evans, RG | 1 |
| Bouffard, P | 1 |
| Vert, M | 1 |
| Caty, A | 1 |
| Vilain, MO | 1 |
| Vanseymortier, L | 1 |
| Merle, S | 1 |
| Krikorian, A | 1 |
| Turner, SL | 1 |
| Kalnins, I | 1 |
| Gebski, V | 1 |
| Tiver, KW | 1 |
| Donald, PJ | 1 |
| Macmillan, CH | 1 |
| Carrick, K | 1 |
| Bradley, PJ | 1 |
| Morgan, DA | 1 |
| Robbins, KT | 2 |
| Varki, NM | 1 |
| Storniolo, AM | 1 |
| Hoffman, H | 1 |
| Gradishar, W | 1 |
| Schilsky, R | 1 |
| Fu, KK | 1 |
| Lowry, LD | 1 |
| Scotte Doggett, RL | 1 |
| Denham, JW | 1 |
| Abbott, RL | 1 |
| Bernard, S | 1 |
| Gioanni, J | 1 |
| Tennvall, J | 1 |
| Anderson, H | 1 |
| Elner, A | 1 |
| Perey, L | 1 |
| Capasso, P | 1 |
| Savary, M | 1 |
| Vincent, A | 1 |
| Staumont, M | 1 |
| Dupuis, B | 1 |
| Gautier, P | 1 |
| Adenis, L | 1 |
| Migdał, K | 1 |
| Korzeniowski, S | 1 |
| Skołyszewski, J | 1 |
| Beauduin, M | 1 |
| Longueville, J | 1 |
| Majois, F | 1 |
| Remacle, FM | 1 |
| Rousseau, F | 1 |
| Salamon, E | 1 |
| Wambersie, A | 1 |
| Sharma, SC | 1 |
| Sharma, AK | 1 |
| Singhal, KC | 1 |
| Teatini, G | 1 |
| Meloni, F | 1 |
| Bisail, M | 1 |
| Milia, V | 1 |
| Sanna, G | 1 |
| Sarobba, MG | 1 |
| Massidda, B | 1 |
| Scotto, T | 1 |
| Ogasawara, H | 1 |
| Kaneko, S | 1 |
| Sugita, M | 1 |
| Davis, RK | 3 |
| Gibbs, FA | 2 |
| Sapozink, MD | 1 |
| Farver, M | 1 |
| Harker, G | 2 |
| Palmieri, G | 1 |
| Gridelli, C | 1 |
| Airoma, G | 1 |
| Balestrino, M | 1 |
| Bisogno, A | 1 |
| Incoronato, P | 1 |
| Bianco, AR | 1 |
| Chen, MC | 1 |
| Sebille, A | 1 |
| St-Guily, JL | 1 |
| Angelard, B | 1 |
| de Stabenrath, A | 1 |
| Sutton, HG | 2 |
| Tybor, AG | 2 |
| Roullet, B | 1 |
| Labadie, M | 1 |
| Taper, H | 1 |
| Dewez, B | 1 |
| Roberfroid, M | 1 |
| Berdah, JF | 1 |
| Bachellerie-Rhein, B | 1 |
| Clavere, P | 1 |
| Hazan, A | 1 |
| Sénéchaut, JP | 1 |
| Hussein, AM | 1 |
| Vlastou, C | 4 |
| Jevremovic, S | 1 |
| Djuric, L | 1 |
| Mijatovic, L | 1 |
| Kodym, R | 1 |
| Szepesi, T | 1 |
| O'Dwyer, PJ | 1 |
| Cornfeld, MJ | 1 |
| Peter, R | 1 |
| Comis, RL | 1 |
| Planting, AS | 1 |
| van Sichem, CK | 1 |
| Schmitz, PI | 1 |
| Meeuwis, CM | 1 |
| Stoter, G | 1 |
| Colombo, A | 1 |
| Crispino, S | 1 |
| Tancini, G | 1 |
| Personeni, A | 1 |
| Taino, R | 1 |
| Sarti, E | 1 |
| Barni, S | 1 |
| Lissoni, P | 1 |
| Placa, F | 1 |
| Mazzola, P | 1 |
| Wright, JE | 1 |
| Fallon, BG | 1 |
| Casey, D | 1 |
| Klein, R | 1 |
| Petruzzelli, GJ | 1 |
| de Vries, EJ | 1 |
| Grimaldi, A | 7 |
| Cacace, F | 1 |
| Pappagallo, GL | 1 |
| Zorat, P | 1 |
| Fosser, VP | 1 |
| De Besi, P | 1 |
| Fornasiero, A | 1 |
| Fiorentino, MV | 1 |
| Mayernik, DG | 3 |
| Nolan, TA | 3 |
| Sigler, BA | 3 |
| Panis, X | 2 |
| Panasci, L | 1 |
| Gravenor, D | 1 |
| Black, M | 1 |
| Frenkiel, S | 1 |
| Margolese, R | 1 |
| Stolwijk, C | 1 |
| Wagener, DJ | 1 |
| Van den Broek, P | 1 |
| Levendag, PC | 1 |
| Kazem, I | 1 |
| Bruaset, I | 1 |
| Ardiet, JM | 1 |
| Gignoux, B | 1 |
| Perry, DJ | 1 |
| Duttenhaver, JR | 1 |
| Zajtchuk, JT | 1 |
| Hauck, KH | 1 |
| Major, WB | 1 |
| Baumann, JC | 1 |
| Paterson, IC | 2 |
| Quilty, PM | 1 |
| Weitzman, SA | 1 |
| Williams, SD | 1 |
| Essessee, I | 1 |
| Ratkin, G | 1 |
| Birch, R | 1 |
| Odell, P | 1 |
| Danjoux, C | 1 |
| Nichol, J | 1 |
| de la Bastide, Y | 1 |
| Barron, P | 1 |
| Hardie, J | 1 |
| Vogl, SE | 1 |
| Komisar, A | 1 |
| Kaplan, BH | 1 |
| Engstrom, PF | 1 |
| Kasule, OH | 1 |
| Stolbach, L | 1 |
| Lerner, H | 1 |
| Muggia, F | 1 |
| Ziegler, P | 1 |
| Klotch, D | 1 |
| Lee, K | 1 |
| Lore, J | 1 |
| Grossman, TW | 3 |
| Toohill, RJ | 3 |
| Kun, LE | 2 |
| Byhardt, RW | 3 |
| Duncavage, JA | 3 |
| Teplin, RW | 1 |
| Ritch, PS | 2 |
| Hoffman, RG | 1 |
| Malin, TC | 1 |
| Hoffmann, RG | 1 |
| Cox, JD | 2 |
| Malin, T | 1 |
| Newton, M | 1 |
| Wulf, BG | 1 |
| Navarro Vila, C | 1 |
| Martínez-Alegría, J | 1 |
| Suñer Machado, M | 1 |
| Lacau St Guily, J | 1 |
| Bassot, V | 1 |
| Weil, M | 1 |
| Jacquillat, C | 1 |
| Ahmad, K | 1 |
| Kida, A | 2 |
| Iizuka, N | 1 |
| Kikuchi, K | 2 |
| Tomita, H | 2 |
| Al-Kourainy, K | 1 |
| Tapazoglou, E | 3 |
| Malaker, K | 1 |
| Triozzi, PL | 1 |
| Brantley, A | 1 |
| Fisher, S | 1 |
| Cole, TB | 1 |
| Crocker, I | 1 |
| Tsuji, H | 1 |
| Tsujii, H | 1 |
| Kamada, T | 1 |
| Takamura, A | 1 |
| Matsuoka, Y | 1 |
| Irie, G | 1 |
| Gardin, G | 2 |
| Ganzer, U | 3 |
| Bier, H | 1 |
| Bachert, C | 1 |
| Campbell, JB | 1 |
| Dorman, EB | 1 |
| Helliwell, TR | 2 |
| McCormick, M | 1 |
| Miles, J | 1 |
| Morton, RP | 1 |
| Rugman, F | 1 |
| Stell, PM | 2 |
| Stoney, PJ | 1 |
| Vauhan, ED | 1 |
| Steindorfer, P | 1 |
| Germann, R | 1 |
| Schneider, G | 1 |
| Berger, A | 1 |
| Mischinger, HJ | 1 |
| Rehak, P | 1 |
| Sertoli, MR | 1 |
| Scarpati, D | 2 |
| Apostolidis, T | 1 |
| Foladore, S | 1 |
| Bidoli, E | 1 |
| Innocente, R | 1 |
| Caruso, G | 1 |
| Monfardini, S | 1 |
| Ruggeri, EM | 1 |
| Perrino, A | 1 |
| Calabresi, F | 1 |
| Chilelli, MG | 1 |
| Schantz, SP | 1 |
| Savage, HE | 1 |
| Racz, T | 1 |
| Liu, FJ | 1 |
| Brown, BW | 1 |
| Rossen, RD | 1 |
| Kemeny, N | 1 |
| Schneider, A | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
| Nishio, M | 1 |
| Kagami, Y | 1 |
| Narimatsu, N | 1 |
| Sanbe, S | 1 |
| Scherlacher, A | 1 |
| Haas, J | 1 |
| Nicolaou, A | 1 |
| Sideras, T | 1 |
| Haritanti, A | 1 |
| Anastasakis, C | 1 |
| Delis, V | 1 |
| Benhamed, M | 1 |
| Ishii, Y | 1 |
| Mochizuki, F | 1 |
| Yamagata, M | 1 |
| Moriya, Y | 1 |
| Abiko, Y | 1 |
| Sakabe, T | 1 |
| Atkinson, MW | 1 |
| Cooke, TG | 1 |
| Cooke, LD | 1 |
| Neumeister, B | 1 |
| Popp, W | 1 |
| Scherrer, R | 1 |
| Dobrowsky, E | 1 |
| Rausch, EM | 1 |
| Krisch, K | 1 |
| Holzner, JH | 1 |
| Stetz, J | 1 |
| Davis, LW | 1 |
| Leibel, S | 2 |
| de Bruijn, EA | 1 |
| Laurensse, EJ | 2 |
| van Walsum, M | 1 |
| Stoker, K | 1 |
| Davis, K | 1 |
| Harnsberger, HR | 1 |
| Stevens, MH | 1 |
| Parkin, JL | 1 |
| Johnson, LP | 1 |
| Gordon, LI | 1 |
| Hauck, WW | 1 |
| Krespi, Y | 1 |
| Ossoff, RH | 1 |
| Pecaro, BC | 1 |
| Yuska, C | 1 |
| Lamut, CH | 1 |
| Brand, WN | 1 |
| Chang, SK | 1 |
| Bitran, JD | 1 |
| Goldman, M | 2 |
| Tanaka, J | 2 |
| Takaoka, T | 2 |
| Hosoda, H | 2 |
| Palmeri, S | 1 |
| Oliveri, D | 1 |
| Ferro, A | 1 |
| Vitriolo, S | 1 |
| Veins, P | 1 |
| Chauvel, P | 4 |
| Kearsley, JH | 1 |
| Dalley, D | 1 |
| Woods, R | 1 |
| Aroney, R | 1 |
| Hughes, P | 1 |
| Cruickshank, D | 1 |
| Hartenstein, RC | 4 |
| Kastenbauer, ER | 2 |
| Trott, KR | 2 |
| Rauschning, W | 2 |
| Achterrath, W | 2 |
| Stennert, E | 2 |
| Bernal, AG | 1 |
| Calle, R | 1 |
| Gómez, JL | 1 |
| Awan, AM | 3 |
| Bennett, JA | 2 |
| Parnes, SM | 2 |
| Holinger, LD | 4 |
| Lim, F | 1 |
| Duncan, L | 1 |
| Coates, A | 2 |
| Sagerman, P | 1 |
| Choi, KE | 3 |
| Guaspari, A | 2 |
| Guarnieri, C | 1 |
| Whaling, S | 1 |
| Liebner, MA | 1 |
| Guarnieri, CM | 4 |
| Whaling, SM | 2 |
| Lissner, J | 1 |
| Carlson, LS | 1 |
| Stuart, R | 1 |
| Osguthorpe, JD | 1 |
| de Jong, PC | 1 |
| van der Broek, P | 1 |
| Alexieva-Figusch, J | 1 |
| van Putten, WL | 1 |
| Ravasz, LA | 1 |
| Snow, GB | 4 |
| Paredes, J | 1 |
| Felder, TB | 1 |
| Choksi, AJ | 2 |
| Newman, RA | 1 |
| Castellanos, AM | 1 |
| McCarthy, K | 1 |
| Atkinson, N | 1 |
| Goren, MP | 2 |
| Wright, RK | 1 |
| Horowitz, ME | 1 |
| Dodge, RK | 1 |
| Kamen, BA | 1 |
| Viar, MJ | 1 |
| Pratt, CB | 1 |
| Magid, DM | 1 |
| Imano, Y | 1 |
| Hayashizaki, K | 1 |
| Kaneko, T | 1 |
| Viens, P | 1 |
| Ayela, P | 1 |
| Legha, SS | 2 |
| Iida, H | 1 |
| Yokode, Y | 1 |
| Lebrun, D | 1 |
| Lucas, P | 1 |
| Garbe, E | 1 |
| Mackintosh, JF | 1 |
| Nagel, G | 1 |
| Loeffler, TM | 1 |
| Lindemann, J | 1 |
| Luckhaupt, H | 1 |
| Rose, KG | 1 |
| Hausamen, TU | 1 |
| John, M | 1 |
| Flam, M | 1 |
| Wittlinger, P | 1 |
| Podolsky, W | 1 |
| Padmanabhan, A | 1 |
| Mowry, PA | 1 |
| Okamoto, Y | 1 |
| Ohkawa, T | 1 |
| Kakiuchi, H | 1 |
| Tabata, T | 1 |
| Uchida, K | 1 |
| Abe, T | 1 |
| Garaventa, G | 1 |
| Binns, P | 1 |
| Thomas, GD | 1 |
| Yosida, T | 1 |
| Miyata, K | 1 |
| Hattori, T | 1 |
| Tashiro, T | 1 |
| Toyota, S | 1 |
| Hirano, T | 1 |
| Sakakura, Y | 2 |
| Murata, M | 1 |
| Thongprasert, S | 1 |
| Tonusin, A | 2 |
| Phandphae, P | 1 |
| Changwaiwit, W | 1 |
| Chaimongkol, B | 1 |
| Hartenstein, R | 1 |
| Goodyear, MD | 1 |
| Jackson, BS | 1 |
| Basrur, V | 1 |
| Johanson, C | 1 |
| Atkinson, D | 1 |
| Ahmed, K | 1 |
| Mathog, R | 1 |
| Goffinet, L | 1 |
| Kohler, M | 1 |
| Biller, HF | 1 |
| Tropé, C | 1 |
| James, P | 1 |
| Showel, J | 3 |
| Borgel, J | 2 |
| Guenoun, A | 1 |
| Junien-Lavillauroy, C | 1 |
| Dionet, C | 2 |
| Vrousos, C | 1 |
| Rozan, R | 1 |
| Achard, JL | 1 |
| Dumesnil, Y | 1 |
| Russier, M | 1 |
| Lemesle, P | 1 |
| Theron, H | 1 |
| de Latour, M | 1 |
| Mondie, JM | 1 |
| VaLlicioni, J | 4 |
| Brando, V | 1 |
| Giordano, C | 1 |
| Chang, H | 1 |
| Leone, LA | 1 |
| Tefft, M | 1 |
| Nigri, PT | 1 |
| Jin, BL | 1 |
| Davis, L | 1 |
| Hanks, GA | 1 |
| Weigensberg, I | 1 |
| Natale, RB | 1 |
| Takasugi, BJ | 1 |
| Vogel, WC | 1 |
| Kudla-Hatch, V | 1 |
| Schramm, VL | 2 |
| Chevallier, B | 1 |
| Lefur, R | 1 |
| Dehesdin, D | 1 |
| Bastit, P | 1 |
| Seng, SH | 1 |
| Greenberg, B | 1 |
| Ahmann, F | 1 |
| Garewal, H | 1 |
| Koopmann, C | 1 |
| Coulthard, S | 1 |
| Berzes, H | 1 |
| Alberts, D | 1 |
| Shimm, D | 1 |
| Slymen, D | 1 |
| Brunetti, I | 1 |
| Modenesi, M | 1 |
| Scala, M | 1 |
| Scasso, F | 2 |
| Castiglia, G | 1 |
| Anderson, T | 1 |
| Haas, CD | 1 |
| Haas, JS | 1 |
| Hartz, AJ | 1 |
| Libnoch, JA | 1 |
| Choi, TK | 1 |
| Wei, W | 1 |
| Lau, WF | 1 |
| Lam, KH | 1 |
| Mercier, RJ | 1 |
| Neal, GD | 1 |
| Mattox, DE | 1 |
| Pomeroy, TC | 1 |
| Von Hoff, DD | 1 |
| Witt, TR | 1 |
| Hoover, S | 1 |
| Rowland, KM | 1 |
| Spiers, AS | 1 |
| O'Donnell, MR | 1 |
| Stott, PB | 1 |
| Milner, LM | 1 |
| Marsh, JC | 1 |
| Stewart, DJ | 1 |
| Maroun, JA | 1 |
| Young, V | 1 |
| Laframboise, G | 1 |
| Gerin-Lajoie, J | 1 |
| Taketa, C | 2 |
| Dodion, P | 1 |
| van Rymenant, M | 2 |
| Dalesio, O | 1 |
| Kirkpatrick, A | 2 |
| Rozencweig, M | 1 |
| Punpae, P | 1 |
| Sumitrasawan, Y | 1 |
| Changwiwit, W | 1 |
| Yanagita, T | 2 |
| Kudo, S | 1 |
| Kuwano, N | 1 |
| Boerrigter, GH | 1 |
| Heinerman, EC | 1 |
| Harada, T | 1 |
| Kubo, M | 1 |
| Fukukita, K | 1 |
| Nielsen, ES | 1 |
| Rygård, J | 1 |
| Vermorken, J | 1 |
| Rossi, A | 1 |
| Dalesic, O | 1 |
| Sefi, A | 1 |
| Guenons, A | 1 |
| Caldani, C | 1 |
| Kudoh, S | 1 |
| Srodes, CH | 1 |
| Kramer, T | 1 |
| Tamamushi, N | 1 |
| Yao, K | 1 |
| Takeyama, I | 1 |
| Otake, H | 1 |
| Hattori, Y | 1 |
| Murakami, T | 1 |
| Matsuura, S | 1 |
| Makino, S | 1 |
| Satake, B | 1 |
| Shimizu, R | 1 |
| Sakaino, K | 1 |
| Maehara, Y | 1 |
| Miyama, J | 1 |
| Kaplan, MJ | 1 |
| Hahn, SS | 1 |
| Johns, ME | 1 |
| Stewart, FM | 1 |
| Constable, WC | 1 |
| Rooney, M | 1 |
| Dasmahapatra, KS | 1 |
| Citrin, P | 1 |
| Yee, R | 1 |
| Mohit-Tabatabai, MA | 1 |
| Rush, BF | 2 |
| Mayer, M | 1 |
| Colon, J | 1 |
| Harris, HS | 1 |
| Sancho, H | 1 |
| Sindram, PJ | 1 |
| Simmonds, WP | 1 |
| Bagshaw, MA | 1 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Giesen, M | 1 |
| Palme, G | 1 |
| Nervi, C | 1 |
| Casale, C | 1 |
| Cortese, M | 1 |
| Cady, B | 1 |
| Booth, JC | 1 |
| Watt, J | 1 |
| Kenis, Y | 1 |
| McInnis, WD | 1 |
| Lychev, VA | 1 |
| Freckman, HA | 1 |
| Larsen, RR | 1 |
| Priestman, TJ | 1 |
| Esser, E | 1 |
| Glupe, J | 2 |
| Schumann, J | 1 |
| Nathanson, L | 1 |
| Hall, TC | 1 |
| Schilling, A | 1 |
| Miller, S | 1 |
| Burdette, WJ | 1 |
| Krementz, ET | 2 |
| Kokame, GM | 1 |
| Scherer, E | 1 |
| Rassow, J | 1 |
| Kraus, H | 1 |
| Wannenmacher, E | 1 |
| Jewell, WR | 1 |
| Lawton, RL | 1 |
| Gulesserian, HP | 1 |
| Sharzer, LA | 1 |
| Vaughn, CB | 1 |
| Reed, ML | 1 |
| Vaitkevicious, VK | 1 |
| Hanham, IW | 1 |
| Newton, KA | 1 |
| Westbury, G | 1 |
| Miura, T | 1 |
| Ishida, M | 1 |
| Hatano, S | 1 |
| Yonemoto, RH | 1 |
| Byron, RL | 1 |
| Riihimaki, DU | 1 |
| Keating, JL | 1 |
| Bréhant, J | 1 |
| Montagnier, J | 1 |
| Meunier, JP | 1 |
| Imamura, K | 1 |
| Sugahara, K | 1 |
| Fujii, Y | 1 |
| Ramirez, G | 2 |
| Korbitz, BC | 1 |
| Vosteen, KH | 1 |
| Egawa, J | 1 |
| Humphrey, LJ | 1 |
| Wirtanen, GW | 1 |
| Bernhardt, LC | 1 |
| Mackman, S | 1 |
| Curreri, AR | 1 |
| Lindberg, RD | 1 |
| Johnson, RH | 1 |
| Litwin, MS | 1 |
| Reed, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma[NCT02358031] | Phase 3 | 882 participants (Actual) | Interventional | 2015-03-19 | Completed | ||
| Phase II Clinical Study of Sintilimab Combined With Platinum-based Chemotherapy and SBRT in the First-line Treatment of Limited Metastatic Head and Neck Squamous Cell Carcinoma[NCT05136768] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma[NCT05213884] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | ||
| TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)[NCT06163534] | 500 participants (Anticipated) | Observational [Patient Registry] | 2024-01-30 | Not yet recruiting | |||
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| Immune Biomarker Study for Head and Neck Cancer[NCT05375266] | 1,100 participants (Anticipated) | Observational | 2022-05-16 | Recruiting | |||
| Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck[NCT05644457] | 50 participants (Anticipated) | Observational | 2022-03-09 | Recruiting | |||
| A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT04815720] | Phase 1/Phase 2 | 65 participants (Anticipated) | Interventional | 2021-08-09 | Recruiting | ||
| Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)[NCT05517330] | Phase 2 | 23 participants (Anticipated) | Interventional | 2022-12-20 | Recruiting | ||
| A Single-arm, Prospective, Phase II Study of PABLIXIMAB Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous-cell Carcinoma[NCT06125223] | 45 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| A Window Trial of 5-Azacytidine or Nivolumab or Combination Nivolumab Plus 5-Azacytidine in Resectable HPV-Associated Head and Neck Squamous Cell Cancer[NCT05317000] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2023-03-23 | Recruiting | ||
| A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck[NCT00261703] | Phase 2/Phase 3 | 439 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma[NCT02913066] | Phase 2 | 88 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| A Phase II Study of Biweekly Induction Regimen With Docetaxel, Cisplatin and Fluorouracil for Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck[NCT04397341] | Phase 2 | 58 participants (Actual) | Interventional | 2014-03-01 | Completed | ||
| Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy[NCT03700905] | Phase 3 | 276 participants (Anticipated) | Interventional | 2018-08-21 | Active, not recruiting | ||
| An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the [NCT02741570] | Phase 3 | 947 participants (Actual) | Interventional | 2016-10-05 | Completed | ||
| A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients[NCT02551159] | Phase 3 | 823 participants (Actual) | Interventional | 2015-10-15 | Completed | ||
| A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With[NCT02383966] | Phase 3 | 243 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)[NCT00828386] | Phase 3 | 83 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Low accrual) | ||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomize[NCT01086826] | Phase 3 | 320 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Assessment of Circulating Tumor Cells as an Early Predictive Marker of Response to a First Line Treatment Based on an Anti-Human Epidermal Growth Factor Receptor (HER), Cetuximab, in Patients With Inoperable Recurrent and/or Metastatic Head-and-neck Squam[NCT02119559] | 115 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | |||
| A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL][NCT00095875] | Phase 3 | 145 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02460887] | Phase 3 | 236 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Open-label, Single-arm, Multicenter, Phase II Study Investigating Cetuximab in Combination With Chemotherapy in the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Japanese Subjects[NCT00971932] | Phase 2 | 33 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00460265] | Phase 3 | 658 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma[NCT03558035] | Phase 2 | 96 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue[NCT02985255] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints[NCT00400205] | Phase 2 | 14 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Safety reasons) | ||
| Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer[NCT01609114] | 30 participants (Actual) | Observational | 2012-04-30 | Active, not recruiting | |||
| [NCT01755585] | 40 participants (Anticipated) | Observational | 2011-07-31 | Enrolling by invitation | |||
| Open-label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Canc[NCT00705016] | Phase 1/Phase 2 | 184 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the He[NCT01177956] | Phase 3 | 73 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)[NCT00731380] | Phase 1 | 12 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSC[NCT00774319] | Phase 2 | 70 participants (Anticipated) | Interventional | 2008-12-31 | Recruiting | ||
| Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma[NCT04995120] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally R[NCT01081041] | Phase 2 | 187 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia Induced by Targeted Therapy and Immunotherapy Combination Treatment[NCT04896528] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-06-06 | Recruiting | ||
| Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122] | 400 participants (Anticipated) | Observational | 2017-02-02 | Recruiting | |||
| A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck[NCT04107103] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-03-19 | Recruiting | ||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial[NCT06109207] | Phase 1 | 12 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies[NCT06061705] | 100 participants (Anticipated) | Interventional | 2023-12-30 | Not yet recruiting | |||
| 1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK[NCT04150900] | Phase 2 | 7 participants (Actual) | Interventional | 2020-01-13 | Active, not recruiting | ||
| A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion [NCT03356223] | Phase 2 | 25 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck[NCT00122460] | Phase 3 | 442 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck[NCT00193284] | Phase 2 | 50 participants | Interventional | 2003-10-31 | Completed | ||
| Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.[NCT05832593] | 52 participants (Anticipated) | Observational | 2023-05-01 | Not yet recruiting | |||
| Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With Gem-based Doublets and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer[NCT02416609] | 44 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Docetaxel (NSC-628503), Cisplatin (NSC-119875), And 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed By Accelerated Fractionation/Concomitant Boost Radiation And Concurrent Single Agent Cisplatin (NSC-119875), In Patients With Advanced Squamous [NCT00054054] | Phase 2 | 0 participants | Interventional | 2003-04-30 | Completed | ||
| Phase I Trial of Induction Paraplatin® and Xeloda® Followed by Concurrent Paraplatin and Xeloda With Intensity Modulated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT00114153] | Phase 1 | 48 participants (Anticipated) | Interventional | 2003-06-30 | Completed | ||
| Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer[NCT00002476] | Phase 3 | 0 participants | Interventional | 1990-01-31 | Completed | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies[NCT00266279] | Phase 2 | 17 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278] | 60 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer[NCT00462735] | Phase 2 | 33 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck[NCT00003888] | Phase 3 | 359 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase II Study Comparing Gemcitabine Plus Cisplatin to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT02016417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma: A Randomized Phase III Trial[NCT04898374] | Phase 3 | 120 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02096380] | 120 participants (Anticipated) | Observational [Patient Registry] | 2014-05-31 | Not yet recruiting | |||
| A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progressio[NCT00273546] | Phase 3 | 500 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients[NCT05590650] | Phase 1 | 21 participants (Actual) | Interventional | 2018-07-07 | Completed | ||
| Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer[NCT03998696] | Phase 4 | 60 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| A Phase I/II Study of Taxotere, Cisplatin, 5-Fluorouracil and Leucovorin for Squamous Cell Carcinoma of the Head and Neck[NCT00139243] | Phase 1/Phase 2 | 30 participants | Interventional | 1997-10-31 | Completed | ||
| TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma[NCT00139230] | Phase 2 | 30 participants | Interventional | 1997-01-31 | Completed | ||
| Phase I/II Pilot Study of Induction Chemotherapy With Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00139269] | Phase 1/Phase 2 | 38 participants | Interventional | 1998-02-28 | Completed | ||
| Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Ca[NCT01181401] | Phase 2 | 94 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT03047265] | Phase 2 | 164 participants (Anticipated) | Interventional | 2017-02-04 | Active, not recruiting | ||
| A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol[NCT06087614] | Phase 2 | 124 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER[NCT00002888] | Phase 3 | 0 participants | Interventional | 1997-03-31 | Completed | ||
| Surgery and Adjuvant Radiotherapy Versus Concurrent Chemo-Radiotherapy for Resectable (Non-Metastatic) Stage III/IV Head and Neck Squamous Cell Cancer[NCT00003576] | Phase 3 | 200 participants (Anticipated) | Interventional | 1997-01-31 | Completed | ||
| Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy[NCT00736944] | Phase 2 | 30 participants (Actual) | Interventional | 2008-12-19 | Completed | ||
| Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection[NCT02546895] | 2,000 participants (Anticipated) | Observational | 2015-09-30 | Recruiting | |||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| Changes in Sense of Taste of Patients Submitted to Hematopoietic Stem Cell Transplantation[NCT03498950] | 80 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer[NCT00002774] | Phase 2 | 63 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial[NCT02282839] | Phase 3 | 60 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Evaluation of Three Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00006248] | Phase 2 | 78 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck[NCT00002951] | Phase 2 | 53 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01540136] | Phase 3 | 402 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial[NCT02940925] | Phase 3 | 241 participants (Actual) | Interventional | 2016-10-20 | Completed | ||
| Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01245959] | Phase 3 | 476 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders[NCT01525927] | Phase 2 | 2 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Principal Investigator left institution. IRB approval lapsed.) | ||
| Phase II Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil Followed by Weekly Docetaxel and Cetuximab in Concurrence With Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NPC)[NCT01326559] | Phase 2 | 33 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer[NCT03532737] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-10-07 | Recruiting | ||
| Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial[NCT05144100] | Phase 2/Phase 3 | 498 participants (Anticipated) | Interventional | 2021-12-01 | Not yet recruiting | ||
| Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial[NCT01467115] | Phase 2 | 1 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Helping Cancer Patients Quit Smoking Using Brief Advice Based on Risk Communication: a Randomized Controlled Trial[NCT01685723] | 528 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Validity and Reliability of the Turkish Version of the McMaster University Head and Neck Radiotherapy Questionnaire[NCT04269148] | 90 participants (Anticipated) | Observational | 2020-03-13 | Recruiting | |||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers[NCT00797446] | 10 participants (Actual) | Observational | 2007-09-30 | Terminated (stopped due to Slow enrollment, feasibility issues) | |||
| Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer[NCT00140556] | Early Phase 1 | 28 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Phase Ⅲ Trial of Transcatheter Arterial Chemoembolization(TACE) Plus Recombinant Human Adenovirus Type 5 Injection for Unresectable Hepatocellular Carcinoma (HCC)[NCT01869088] | Phase 3 | 266 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01417390] | Phase 2 | 80 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer[NCT00001442] | Phase 1 | 35 participants | Interventional | 1995-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 290 |
| Pembrolizumab + Chemotherapy (Pembro Combo) | 271 |
| Cetuximab + Chemotherapy (Control) | 286 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued study drug due to an AE was reported for each treatment arm. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 36 |
| Pembrolizumab + Chemotherapy (Pembro Combo) | 90 |
| Cetuximab + Chemotherapy (Control) | 79 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared between all participants of the pembro combo arm and the control arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Baseline, Week 15
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 1.17 |
| Cetuximab + Chemotherapy (Control) | 0.77 |
ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro combo arm and control arm. Per protocol, ORR was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 35.6 |
| Cetuximab + Chemotherapy (Control) | 36.3 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro combo arm and control arm. Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 36.4 |
| Cetuximab + Chemotherapy (Control) | 35.7 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro combo arm and control arm. Per protocol, ORR was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 42.9 |
| Cetuximab + Chemotherapy (Control) | 38.2 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥1. Per protocol, OS was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 13.6 |
| Cetuximab + Chemotherapy (Control) | 10.4 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥20. Per protocol, OS was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 14.7 |
| Cetuximab + Chemotherapy (Control) | 11.0 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro combo arm and control arm. Per protocol, OS was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 13.0 |
| Cetuximab + Chemotherapy (Control) | 10.7 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 17.2 |
| Cetuximab + Chemotherapy (Control) | 13.6 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 19.7 |
| Cetuximab + Chemotherapy (Control) | 12.5 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 23.9 |
| Cetuximab + Chemotherapy (Control) | 14.0 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 44.7 |
| Cetuximab + Chemotherapy (Control) | 44.9 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 44.9 |
| Cetuximab + Chemotherapy (Control) | 43.3 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro combo arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 49.4 |
| Cetuximab + Chemotherapy (Control) | 47.2 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by IHC as Combined Positive Score ≥20 (hereafter referred to as CPS ≥20). Per protocol, PFS was compared separately between CPS ≥20 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 5.8 |
| Cetuximab + Chemotherapy (Control) | 5.3 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro combo arm and control arm with PD-L1 biomarker positive expression defined by immunohistochemistry (IHC) as Combined Positive Score ≥1 (hereafter referred to as CPS ≥1). Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 5.1 |
| Cetuximab + Chemotherapy (Control) | 5.0 |
"PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro combo arm was compared to the control arm as a pre-specified primary analysis of the Intent-To-Treat (ITT) population. PFS is reported here for all participants in the pembro combo arm and control arm. Per protocol, PFS was compared separately between all participants of the pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | 4.9 |
| Cetuximab + Chemotherapy (Control) | 5.2 |
"EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the GHS question How would you rate your overall health during the past week? (Item 29) and the QoL question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD in GHS/QoL defined as the time from baseline to the first onset of a ≥10 point decrease from baseline in GHS/QoL combined score, with confirmation. Per protocol, TTD in GHS/QoL combined score was compared between all participants of pembro combo arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in GHS/QoL combined score was compared separately between all participants of pembro mono arm and control arm and is presented later in the record." (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Swallowing scale (Items 35-38) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Swallowing Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared between all participants of pembro combo arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared separately between all participants of pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Pain scale (Items 31-34) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Pain Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared between all participants of pembro combo arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared separately between all participants of pembro mono arm and control arm and is presented later in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab + Chemotherapy (Pembro Combo) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the GHS question How would you rate your overall health during the past week? (Item 29) and the QoL question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared between all participants of the pembro mono arm and the control arm as a pre-specified secondary analysis. As specified by the protocol, change from baseline to Week 15 in the GHS/QoL combined score was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Baseline, Week 15
| Intervention | Score on a Scale (Least Squares Mean) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 0.85 |
| Cetuximab + Chemotherapy (Control) | 0.60 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants in the pembro mono arm and control arm. Per protocol, ORR was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 16.9 |
| Cetuximab + Chemotherapy (Control) | 36.0 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro mono arm and control arm. Per protocol, ORR was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 19.1 |
| Cetuximab + Chemotherapy (Control) | 34.9 |
ORR was defined as the percentage of participants in the analysis population who have a CR (disappearance of all target lesions) or a PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. based upon BICR. Per protocol, ORR in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants who experienced CR or PR is reported here as the ORR for all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro mono arm and control arm. Per protocol, ORR was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 23.3 |
| Cetuximab + Chemotherapy (Control) | 36.1 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm. Per protocol, OS was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 11.5 |
| Cetuximab + Chemotherapy (Control) | 10.7 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥1. Per protocol, OS was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 12.3 |
| Cetuximab + Chemotherapy (Control) | 10.3 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. OS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥20. Per protocol, OS was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 14.8 |
| Cetuximab + Chemotherapy (Control) | 10.7 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 17.6 |
| Cetuximab + Chemotherapy (Control) | 15.0 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 20.6 |
| Cetuximab + Chemotherapy (Control) | 13.6 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 12 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 12 months was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 12
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 23.5 |
| Cetuximab + Chemotherapy (Control) | 15.1 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 26.2 |
| Cetuximab + Chemotherapy (Control) | 45.7 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥1 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 28.7 |
| Cetuximab + Chemotherapy (Control) | 43.9 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified secondary analysis of the ITT population. The percentage of participants with PFS (PFS rate) at 6 months is reported here out of all participants with PD-L1 biomarker positive expression defined by IHC as CPS ≥20 in the pembro mono arm and control arm. Per protocol, the percentage of participants with PFS at 6 months was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Month 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 33.0 |
| Cetuximab + Chemotherapy (Control) | 46.6 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm. Per protocol, PFS was compared separately between all participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 2.3 |
| Cetuximab + Chemotherapy (Control) | 5.2 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥1. Per protocol, PFS was compared separately between CPS ≥1 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 3.2 |
| Cetuximab + Chemotherapy (Control) | 5.0 |
"PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD.~Per protocol, PFS in the pembro mono arm was compared to the control arm as a pre-specified primary analysis of the ITT population. PFS is reported here for all participants in the pembro mono arm and control arm with PD-L1 biomarker positive expression defined by IHC as CPS ≥20. Per protocol, PFS was compared separately between CPS ≥20 participants of the pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Up to approximately 47 months (through Final Analysis cut-off date of 25-Feb-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | 3.4 |
| Cetuximab + Chemotherapy (Control) | 5.3 |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Pain scale (Items 31-34) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Pain Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared between all participants of pembro mono arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Pain Score was compared separately between all participants of pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
EORTC QLQ-H&N35 is a 35-item questionnaire developed to assess QoL of head and neck cancer participants and consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. Participant responses to the Swallowing scale (Items 35-38) were scored on a 4-point scale (1=Not at all to 4=Very much). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating more problems. TTD in EORTC QLQ-H&N35 Swallowing Score defined as the time from baseline to the first onset of a ≥10 point decrease from baseline, with confirmation. Per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared between all participants of pembro mono arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in EORTC QLQ-H&N35 Swallowing Score was compared separately between all participants of pembro combo arm and control arm and is presented earlier in the record. (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
"EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients. Participant responses to the GHS question How would you rate your overall health during the past week? (Item 29) and the QoL question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Raw scores were standardized by linear transformation so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. TTD in GHS/QoL defined as the time from baseline to the first onset of a ≥10 point decrease from baseline in GHS/QoL combined score, with confirmation. Per protocol, TTD in GHS/QoL combined score was compared between all participants of pembro mono arm and control arm as a pre-specified secondary analysis. Also per protocol, TTD in GHS/QoL combined score was compared separately between all participants of pembro combo arm and control arm and is presented earlier in the record." (NCT02358031)
Timeframe: Baseline up to approximately 12 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab Monotherapy (Pembro Mono) | NA |
| Cetuximab + Chemotherapy (Control) | NA |
Overall survival (OS) is defined as the time between randomization and death. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after participants off-treatment date. (Based on Kaplan-Meier estimates) (NCT02741570)
Timeframe: From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)
| Intervention | Months (Median) |
|---|---|
| Nivolumab + Ipilimumab | 13.90 |
| EXTREME Regimen | 13.50 |
Overall survival (OS) is defined as the time between randomization and death. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after participants off-treatment date. (Based on Kaplan-Meier estimates) (NCT02741570)
Timeframe: From randomization to date of death or date the participant was last known to be alive (Up to approximately 65 months)
| Intervention | Months (Median) |
|---|---|
| Nivolumab + Ipilimumab | 13.90 |
| EXTREME Regimen | 13.50 |
Overall survival (OS) is defined as the time between randomization and death. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after participants off-treatment date. (Based on Kaplan-Meier estimates) (NCT02741570)
Timeframe: From randomization to date of death or date the participant was last known to be alive (Up to approximately 55 months)
| Intervention | Months (Median) |
|---|---|
| Nivolumab + Ipilimumab | 17.58 |
| EXTREME Regimen | 14.59 |
Overall survival (OS) is defined as the time between randomization and death. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after participants off-treatment date. (Based on Kaplan-Meier estimates) (NCT02741570)
Timeframe: From randomization to date of death or date the participant was last known to be alive (Up to approximately 65 months)
| Intervention | Months (Median) |
|---|---|
| Nivolumab + Ipilimumab | 17.74 |
| EXTREME Regimen | 14.59 |
Overall survival (OS) is defined as the time between randomization and death. For participants without documentation of death, OS will be censored on the last date the participant was known to be alive. Overall survival will be censored at the date of randomization for participants who were randomized but had no follow-up. Survival follow-up will be conducted every 3 months after participants off-treatment date. (Based on Kaplan-Meier estimates) (NCT02741570)
Timeframe: From randomization to date of death or date the participant was last known to be alive (Up to approximately 65 months)
| Intervention | Months (Median) |
|---|---|
| Nivolumab + Ipilimumab | 15.67 |
| EXTREME Regimen | 13.24 |
"The time between the first documented response (Complete response (CR) or partial response (PR)) and progression or death, per RECIST 1.1 by blinded independent central review (BICR) assessment. (Based on Kaplan-Meier Estimates)~Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters." (NCT02741570)
Timeframe: From randomization to the first documented response (CR or PR) and progression (up to approximately 65 months)
| Intervention | Months (Median) | |
|---|---|---|
| All randomized participants | Randomized PD-L1 CPS >= 20 participants | |
| EXTREME Regimen | 5.88 | 6.97 |
| Nivolumab + Ipilimumab | 16.59 | 33.51 |
"Objective Response Rate (ORR) is defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria by blinded independent central review (BICR) assessment.~Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters." (NCT02741570)
Timeframe: From randomization up to approximately 65 months
| Intervention | Percent (Number) | |
|---|---|---|
| All randomized participants | Randomized PD-L1 CPS >= 20 participants | |
| EXTREME Regimen | 37.1 | 35.4 |
| Nivolumab + Ipilimumab | 24.2 | 34.1 |
"PFS is defined as the time between the date of randomization and the date of first documented tumor progression, based on Blinded Independent Central Review (BICR) assessments (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria), or death due to any cause, whichever occurs first. Participants who neither progress nor die will be censored on the date of their last tumor assessment. Participants who receive subsequent anti-cancer therapy prior to documented progression, will be censored on the date of their last tumor assessment prior to subsequent therapy. (Based on Kaplan-Meier Estimates)~Progression is defined as at least a 20% increase in the sum of diameters of target lesions, in addition the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)." (NCT02741570)
Timeframe: From randomization to disease progression or death (Up to approximately 65 months)
| Intervention | Months (Median) | |
|---|---|---|
| Randomized participants | Randomized PD-L1 CPS >= 20 participants | |
| EXTREME Regimen | 6.77 | 6.97 |
| Nivolumab + Ipilimumab | 3.29 | 5.39 |
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (NCT02551159)
Timeframe: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
| Intervention | Months (Median) |
|---|---|
| Durvalumab + Tremelimumab | 9.2 |
| Durvalumab | 11.9 |
| Standard of Care (SOC) | 4.2 |
Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (NCT02551159)
Timeframe: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
| Intervention | Months (Median) |
|---|---|
| Durvalumab + Tremelimumab | 6.5 |
| Durvalumab | 12.3 |
| Standard of Care (SOC) | 4.2 |
Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1) (NCT02551159)
Timeframe: From date of randomization until time of final analysis, an average of approximately 4 years
| Intervention | Months (Median) |
|---|---|
| Durvalumab + Tremelimumab | 10.7 |
| Durvalumab | 9.9 |
| Standard of Care (SOC) | 10.3 |
Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1) (NCT02551159)
Timeframe: From date of randomization until time of final analysis, an average of approximately 4 years
| Intervention | Months (Median) |
|---|---|
| Durvalumab + Tremelimumab | 11.2 |
| Durvalumab | 10.9 |
| Standard of Care (SOC) | 10.9 |
Number of participants with Overall Survival (OS) (NCT02551159)
Timeframe: From date of randomization until time of final analysis, an average of approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Durvalumab + Tremelimumab | 162 |
| Durvalumab | 84 |
| Standard of Care (SOC) | 77 |
"Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression).~Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT02551159)
Timeframe: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
| Intervention | Months (Median) |
|---|---|
| Durvalumab + Tremelimumab | 2.8 |
| Durvalumab | 2.8 |
| Standard of Care (SOC) | 5.4 |
Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT02551159)
Timeframe: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years
| Intervention | Months (Median) |
|---|---|
| Durvalumab + Tremelimumab | 2.8 |
| Durvalumab | 2.8 |
| Standard of Care (SOC) | 5.3 |
Percentage of patients alive (NCT02551159)
Timeframe: 12, 18 and 24 months after randomization
| Intervention | % of participants (Number) | ||
|---|---|---|---|
| at 12 months | at 18 months | at 24 months | |
| Durvalumab | 42.8 | 31.2 | 24.7 |
| Durvalumab + Tremelimumab | 46.5 | 30.7 | 22.9 |
| Standard of Care (SOC) | 43.8 | 29.7 | 23.2 |
Percentage of patients alive (NCT02551159)
Timeframe: 12, 18 and 24 months after randomization
| Intervention | % of participants (Number) | ||
|---|---|---|---|
| at 12 months | at 18 months | at 24 months | |
| Durvalumab | 48.0 | 34.7 | 27.6 |
| Durvalumab + Tremelimumab | 49.3 | 31.8 | 23.9 |
| Standard of Care (SOC) | 44.0 | 30.8 | 26.4 |
The Best ORR was based on imaging and classified according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. The BOR rate was defined as the number of participants whose BOR was either complete response (CR) or partial response (PR), relative to the number of participants belonging to the trial set of interest. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 50 |
| Cisplatin/Carboplatin + 5-Flurouracil | 26.6 |
The DCR was based on imaging and classified according to RECIST Version 1.1 criteria. The DCR was defined as the number of participants whose Best Overall Response is either CR, PR or stable disease (SD), divided by the number of participants belonging to the trial set of interest multiplied by 100. CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on trial. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 75.6 |
| Cisplatin/Carboplatin + 5-Flurouracil | 59.5 |
DOR was determined for participants whose BOR was either CR or PR. It was defined as the time from the first assessment of CR or PR until the event defining PFS time. PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). CR was defined as disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | Weeks (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 18.1 |
| Cisplatin/Carboplatin + 5-Flurouracil | 13.9 |
The OS time was defined as the time from randomization to the date of death. If a participant was alive at the time of analysis, survival time was censored at the last date when the participant was known to be alive. If this date was after data cut-off, participants were censored at the date of data cut-off. OS was measured using Kaplan-Meier (KM) estimates. (NCT02383966)
Timeframe: Time from date of randomization up to data cutoff (assessed up to 904 days)
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 10.2 |
| Cisplatin/Carboplatin + 5-Flurouracil | 8.4 |
PFS time was defined as the time in months from the date of randomization until first observation of PD (based on imaging as assessed by IRC), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 5.5 |
| Cisplatin/Carboplatin + 5-Flurouracil | 4.2 |
PFS time was defined as the time in months from the date of randomization until first observation of PD (radiologically confirmed by Investigator), or death due to any cause when death occurs within 60 days after the last tumor assessment or randomization (whichever is later). PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on trial; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions. The sum must also demonstrate an absolute increase of at least 5 millimeter. PFS was measured using Kaplan-Meier (KM) estimates. (NCT02383966)
Timeframe: Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 5.5 |
| Cisplatin/Carboplatin + 5-Flurouracil | 4.6 |
An Adverse event (AE) was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs. (NCT02383966)
Timeframe: Time from date of randomization up to data cutoff (assessed up to 904 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| TEAEs | TESAEs | TEAEs Leading to Death | AEs Leading to Discontinuation | |
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil | 163 | 46 | 11 | 27 |
| Cisplatin/Carboplatin + 5-Flurouracil | 75 | 21 | 8 | 8 |
To compare the 3-year survival achieved by docetaxel/cisplatin/5-FU based sequential therapy with platinum based chemo radiotherapy in patients with locally advanced SCCHN. Overall survival is defined as the time from date of randomisation to death from any cause. Patients alive at the time of current analysis were censored at the date last known to be alive.Kaplan-Meier method was used to estimate overall survival (NCT00095875)
Timeframe: 3-years
| Intervention | percent of patients (Number) |
|---|---|
| Arm I | 73 |
| Arm II | 78 |
Progression free survival was defined as the time from date of randomisation to disease progression or death from any cause without progression whichever occurred first; otherwise, patients were censored at the date last known to be free of progression. (NCT00095875)
Timeframe: 5 years
| Intervention | percent of patients (Number) |
|---|---|
| Arm I | 67 |
| Arm II | 69 |
Percentage of participants experiencing a complete response [CR] (complete disappearance of measurable and evaluable disease without new lesions) or partial response [PR] (greater than or equal to 50 percent decrease in the sum of the products of diameters [SOPD] of index lesions compared to the baseline SOPD, with no evidence of PD) confirmed by a subsequent assessment no less than 28 days after criteria for response were first met based on modified WHO criteria as assessed by Independent Review Committee (IRC). (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until progressive disease (PD) reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 36.4 |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST as assessed by IRC. CR are those that persist on repeat imaging study at least 28 days after initial documentation of response. PR are those with greater than or equal to 30 percent decrease in the SOPD of index lesions compared to the baseline SOPD, with no evidence of PD. (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 45.5 |
Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (>=50 percent decrease in sum of the products of diameters [SOPD] of index lesions compared to baseline SOPD, with no evidence of PD) confirmed by subsequent assessment no less than 28 days after criteria for response were first met) or stable disease [SD] (neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD) at least once no less than 42 days after first dose of trial treatment based on modified WHO criteria as assessed by IRC. (NCT00971932)
Timeframe: Evaluations performed every 6 weeks until PD reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 87.9 |
Duration of response according to modified WHO criteria as assessed by IRC was defined as the time from the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death when death occurred within 60 days of the last tumor assessment or first administration of trial treatment (whichever was last). (NCT00971932)
Timeframe: Time from first assessment of CR or PR to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 2.8 |
Time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00971932)
Timeframe: Time from first administration of trial treatment or last day known to be alive, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 12.8 |
The PFS time according to modified WHO criteria as assessed by IRC was defined as duration from first administration of trial treatment until PD (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT00971932)
Timeframe: Time from first administration of trial treatment to PD, death or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 4.1 |
Time to treatment failure according to modified WHO criteria as assessed by IRC was defined as the time from first administration of trial treatment until the date of the first occurrence of one of the events defining treatment failure: PD assessed by the investigator, discontinuation of treatment due to PD, discontinuation of treatment due to an adverse event (AE), start of any new anticancer therapy, or withdrawal of consent or death within 60 days of the last tumor assessment or first administration of trial treatment. (NCT00971932)
Timeframe: Time from first administration of trial treatment to treatment failure or last tumor assessment, reported between day of first participant treated, until cut-off date, 02 March 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil (5-FU) | 4.2 |
Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H). (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 5.7 |
An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | subjects (Number) |
|---|---|
| Panitumumab Plus Chemotherapy | 101 |
| Chemotherapy Alone | 73 |
Time from randomization to death (NCT00460265)
Timeframe: Upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 11.1 |
| Chemotherapy Alone | 9.0 |
Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death. (NCT00460265)
Timeframe: Every 6 weeks until disease progression or deaths, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.8 |
| Chemotherapy Alone | 4.6 |
Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H) (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 6.8 |
| Chemotherapy Alone | 5.6 |
Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 1.4 |
| Chemotherapy Alone | 1.5 |
Complete remission (complete disappearance of disease), partial remission [more than 30% decrease in tumor measurement by RECIST (Response evaluation criteria in solid tumors)]. (NCT00400205)
Timeframe: every 3 months
| Intervention | participants (Number) |
|---|---|
| Recipients of Docetaxel, Cisplatin, 5-Fluorouracil | 8 |
"Percent change in TNM stage of tumors after three cycles of study treatment was assessed to see if baseline acetylated tubulin (AT) expression predicts treatment success. Decreasing tumor stage change (a negative number) indicates that the tumor is responding to treatment while an increase means that the severity of the tumor is not decreasing. Immunohistochemistry (IHC) analysis of AT expression was performed in formalin-fixed, paraffin-embedded, pre-treatment tissues. The staining was scored based upon intensity according to the following criteria: 0=no staining, 1+=weak tumor staining, 2+=moderate tumor staining, 3+=moderate to high tumor staining, and 4+=high tumor staining.~Data presented are adopted from Saba, NF, et. al. Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck. Head and Neck Pathology (2014) 8:66-72." (NCT00400205)
Timeframe: Baseline, After 3 cycles of study treatment
| Intervention | percentage of tumor stage change (Mean) | |
|---|---|---|
| AT score less than or equal to 2 | AT score greater than 2 | |
| Recipients of Docetaxel, Cisplatin, 5-Fluorouracil | -0.8 | -0.36 |
The BOR rate is defined as the percentage of the participants having achieved confirmed complete response (CR) or partial response (PR) as the best overall response according to radiological assessments (based on RECIST Version 1.0). (NCT00705016)
Timeframe: Evaluations will be performed every 6 weeks until progression reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | percentage of participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 46.8 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 26.7 |
| Cetuximab+5-FU+Cisplatin | 35.5 |
The disease control rate is defined as the percentage of participants having achieved confirmed CR, PR or stable disease (SD) as best overall response according to radiological assessments (based on RECIST Version 1.0). (NCT00705016)
Timeframe: Evaluations will be performed every 6 weeks until progression reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | percentage of participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 85.5 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 73.3 |
| Cetuximab+5-FU+Cisplatin | 80.6 |
Duration of response is defined as the time from the first assessment of CR or PR until the date of the first occurrence of progressive disease (PD), or until the date of death. (NCT00705016)
Timeframe: Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.8 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.1 |
| Cetuximab+5-FU+Cisplatin | 6.4 |
The OS time is defined as the time from randomization to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. (NCT00705016)
Timeframe: Time from randomization to death, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 12.4 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 10.6 |
| Cetuximab+5-FU+Cisplatin | 11.6 |
The PFS is defined as the duration from randomization until radiological progression (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) or death due to any cause. Only deaths within 84 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. Investigator read is the assessment of all imaging by the treating physician at the local trial site. (NCT00705016)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 6.4 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 5.6 |
| Cetuximab+5-FU+Cisplatin | 5.7 |
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00705016)
Timeframe: Time from first assessment of CR or PR until PD, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | participants (Number) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 61 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 59 |
| Cetuximab+5-FU+Cisplatin | 61 |
TTF is defined as the time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 84 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. (NCT00705016)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, 03 July 2009, until cut-off date (03 September 2011)
| Intervention | months (Median) |
|---|---|
| Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin | 5.6 |
| Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin | 4.5 |
| Cetuximab+5-FU+Cisplatin | 4.3 |
BOR: Percentage of participants experiencing a CR (complete disappearance of measurable and evaluable disease without new lesions) or PR (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified WHO criteria), divided by the number of participants belonging to ITT or safety population. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 55.9 |
BOR: Percentage of participants experiencing a Complete Response (CR) (complete disappearance of measurable and evaluable disease without new lesions) or Partial Response (PR) (greater than or equal to 50 percent decrease of sum of product diameters of measurable disease, evaluable disease not worsening or progressing, no new lesions confirmed by a subsequent assessment no less than 28 days after criteria for response were first met) (based on modified World Health Organization [WHO] criteria), divided by the number of participants belonging to intention to treat (ITT) or safety population. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 54.4 |
Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.1 |
Time from first assessment of CR or PR to disease progression or death (within 60 days of last tumor assessment). Participants without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 5.7 |
The OS time was defined as the time from first administration of trial treatment to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT01177956)
Timeframe: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 12.6 |
Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.6 |
Duration from first administration of trial treatment until progression (radiological or clinical, if radiological progression is not available) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.2 |
Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 15 November 2012
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 7.0 |
Time from first administration of trial treatment to disease progression (radiological or clinical, if radiological progression is not available). Participants without event are censored on the date of last tumor assessment. (NCT01177956)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first participant randomized, 25 December 2009, until cut-off date 25 January 2011
| Intervention | months (Median) |
|---|---|
| Cetuximab + Cisplatin + 5-FU | 6.8 |
A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Weekly from Cycle 1, Day 1 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Intervention | micrograms*hours/milliliter (μg*h/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 21900 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 18800 |
A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Weekly from Cycle 1, Week 3 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 225 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 199 |
The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy. (NCT01081041)
Timeframe: Part 2: Cycle 1, Day 1: 0 hours [(h); immediately postdose], 1 h, 2 h, and 24 h postdose
| Intervention | micrograms per milliliter (μg/mL) (Geometric Mean) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 208 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 208 |
January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality. (NCT01081041)
Timeframe: Part 2: Baseline to end of combination therapy or date first participant switched to US commercial cetuximab (up to 18 weeks)
| Intervention | participants (Number) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 75 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI), | 68 |
September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality. (NCT01081041)
Timeframe: Part 2: Baseline to end of combination therapy (up to 18 weeks)
| Intervention | participants (Number) |
|---|---|
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 76 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 68 |
(NCT01081041)
Timeframe: Day 1, Week 1 of Cycles 3 and 5 (postbaseline samples were collected prior to infusion).
| Intervention | participants (Number) |
|---|---|
| All Participants (Cetuximab) | 4 |
OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Date of Death from any Cause (Up to 36.3 Months)
| Intervention | Months (Median) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 9.13 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 9.23 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 9.46 |
Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 69.7 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 58.4 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 62.0 |
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version [v]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)*100. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
| Intervention | percentage of participants (Number) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 24.2 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 32.5 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 36.6 |
PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch. (NCT01081041)
Timeframe: Parts 1 and 2: Randomization to Progression of Disease or Death from any Cause (Up to 32.7 Months)
| Intervention | Months (Median) |
|---|---|
| Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU) | 4.57 |
| Part 2: Combination Therapy: Cetuximab (US Commercial) | 4.34 |
| Part 2: Combination Therapy: Cetuximab (Manufactured by BI) | 5.59 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 35.6 |
| Chemotherapy Alone | 19.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments according to investigator (based on modified WHO criteria). (NCT00122460)
Timeframe: evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 81.1 |
| Chemotherapy Alone | 60.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00122460)
Timeframe: time from first assessment of Complete Response or Partial Response to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 4.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00122460)
Timeframe: time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 10.1 |
| Chemotherapy Alone | 7.4 |
"Duration from randomization until radiological progression according to investigator (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 3.3 |
Please refer to Adverse Events section for further details (NCT00122460)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first dose of study treatment, 22 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus Chemotherapy | 218 |
| Chemotherapy Alone | 208 |
"Time from randomization to date of the first occurrence of; progression, discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment." (NCT00122460)
Timeframe: Time from randomization to treatment failure or last tumor assessment, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus Chemotherapy | 4.8 |
| Chemotherapy Alone | 3.0 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 50.74 | 52.68 | 55.30 |
| Chemotherapy Alone | 45.15 | 45.48 | 42.49 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of social functioning. (NCT00122460)
Timeframe: at baseline, day 1 of cycle 3, first 6-weekly evaluation following completion of chemotherapy, 6 & 12 months after randomization, reported between day of first patient randomised, 21 Dec 2004,until cut-off date, 12 Mar 2007
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| At baseline | At cycle 3 | Month 6 | |
| Cetuximab Plus Chemotherapy | 62.14 | 64.64 | 61.27 |
| Chemotherapy Alone | 62.05 | 60.67 | 65.72 |
Number of patients that developed common side effect of diarrhea. (NCT00266279)
Timeframe: At study enrollment, Every two 28 day treatment cycles, and at end of treatment due to disease progression
| Intervention | participants (Number) |
|---|---|
| Treatment With Study Drugs | 2 |
"Among the 15 patients treated, 2 (13%) achieved partial response (PR), and 5 (33%) achieved stable disease (SD), for a Overall Response Rate (ORR) of 46% measured by RECIST criteria.~Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.~Overall Response Rate (ORR)=PR+CR." (NCT00266279)
Timeframe: Every two 28 day treatment cycles until subject no longer on treatment due to disease progression
| Intervention | Participants (Number) | |
|---|---|---|
| Partial Response | Stable Disease | |
| Treatment With Study Drugs | 2 | 5 |
Percentage of participants who did not have distant control (NCT00462735)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Advanced Head and Neck Cancer | 21 |
Percentage of Participants with Loco-regional recurrence. (NCT00462735)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Advanced Head and Neck Cancer | 27 |
Grade 3 toxicities events (NCT00462735)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Advanced Head and Neck Cancer | 32 |
University of Washington Quality of Life (UW-QOLR) questionnaire - covers 12 domains - pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood and anxiety. Each domain have between 3 and 6 response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response and reported as one composite score from 0 (worst) to 100 (best). (NCT00462735)
Timeframe: 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Advanced Head and Neck Cancer | 80 |
Overall Survival - Percentage of Participants who survived Disease-Free Survival - measured from the initiation of nonsurgical treatment to either the last follow-up, disease progression, or death using intent-to-treat methodology (NCT00462735)
Timeframe: 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Overall Survival | Disease-Free Survival | |
| Advanced Head and Neck Cancer | 86 | 69 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
| Intervention | participants (Number) |
|---|---|
| Celecoxib 200mg | 0 |
| Celecoxib 400mg | 1 |
| Celecoxib 600mg | 2 |
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
| Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| locoregional control | progress-free survival | overall survival rates | long term toxicity | |
| Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
| Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
"Clinical exam included laryngoscopy in office or operating room.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 16 |
"Clinical exam included laryngoscopy in office or operating room.~Partial response rate (PR) defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 |
Time from complete response to death from any cause, to disease progression or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 93.529 |
Time from diagnosis to death or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 83.960 |
Time from initiation of induction chemotherapy to death due to disease progression, to disease progression, or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 38.675 |
(NCT00736944)
Timeframe: completion of the first 10 patients induction chemotherapy
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction/hypersensitivity | Other allergic reaction:cipro | Other allergic reaction:hives | Hypotension | INR | Fatigue | Alopecia | Chelitis | Dry skin | Rash | Rash:acneiform | Rash:penile (unconfirmed HSV) | Anorexia | Colitis | Constipation | Dehydration | Dental:teeth | Diarrhea | Hemorrhoids | Nausea | Taste alteration | Vomiting | Other:soft stools | Hemoglobin | Leukocytes (WBC) | Lymphopenia | Neutrophils (ANC) | Platelets | Hemmorrhage:nose | Alkaline phosphatase | SGPT (ALT) | Infection other:sinus infection | Edema:limb | Albumin, low | Calcium, low | Magnesium, low | Potassium, low | Potassium, high | Sodium, low | Phosphorus | Dizziness | Mood alteration:anger | Neuropathy:sensory (peripheral) | Vision-photophobia | Pain:thigh | Pain:tumor pain | Hiccoughs (hiccups) | Obstruction/stenosis of airway:trachea | Creatinine | GFR | Renal failure | Thrombosis/thrombus/embolism | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 1 | 1 | 1 | 1 | 1 | 10 | 5 | 1 | 1 | 1 | 7 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 8 | 8 | 8 | 8 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 4 | 3 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 |
"Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 11 | 7 |
"Clinical exam included laryngoscopy in office or operating room.~Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 13 | 17 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 14 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 17 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 61 | 39 | 0 |
| CT Scan | 30 | 48 | 22 |
| FDG-PET/CT | 36 | 56 | 8 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 43 | 57 | 0 |
| CT Scan | 14 | 50 | 36 |
| FDG-PET/CT | 24 | 66 | 10 |
"In the future, primary tumor site, nodal, and OTR by VCR (CR-x or PR-x = Y or N) will be compared with response based on CT scan (CR-x or PR-x = Y or N) using a test for difference in paired, binary values. Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests.~We are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 53 | 47 | 0 |
| CT Scan | 33 | 41 | 26 |
| FDG-PET/CT | 32 | 61 | 7 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 2 | 4 | 1 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 | 0 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 4 | 1 | 2 | 0 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 19 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 12 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 10 | 11 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 4 | 14 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
Complete response (resolution) of tumor on clinical exam. (NCT00140556)
Timeframe: Within 30 days of completing RT
| Intervention | Participants (Number) |
|---|---|
| Entire Study Population | 25 |
103 reviews available for fluorouracil and Head and Neck Neoplasms
| Article | Year |
|---|---|
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Lo | 2022 |
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Lo | 2022 |
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Lo | 2022 |
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Lo | 2022 |
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Induction chemotherapy in locally advanced head and neck cancers, is there a best choice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2021 |
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2021 |
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2021 |
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2021 |
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Feasibility | 2017 |
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Feasibility | 2017 |
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Feasibility | 2017 |
Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Feasibility | 2017 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2018 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2018 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2018 |
Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2018 |
[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conscious | 2018 |
[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conscious | 2018 |
[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conscious | 2018 |
[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Conscious | 2018 |
Induction chemotherapy in head and neck cancers: Results and controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; | 2019 |
Induction chemotherapy in head and neck cancers: Results and controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; | 2019 |
Induction chemotherapy in head and neck cancers: Results and controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; | 2019 |
Induction chemotherapy in head and neck cancers: Results and controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; | 2019 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Disease-Free Surv | 2013 |
Is there still a role for induction chemotherapy in locally advanced head and neck cancer?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2014 |
Is there still a role for induction chemotherapy in locally advanced head and neck cancer?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2014 |
Is there still a role for induction chemotherapy in locally advanced head and neck cancer?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2014 |
Is there still a role for induction chemotherapy in locally advanced head and neck cancer?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2014 |
Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Databases, Factual; Disease-Free Survival; Female; Fl | 2013 |
Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Databases, Factual; Disease-Free Survival; Female; Fl | 2013 |
Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Databases, Factual; Disease-Free Survival; Female; Fl | 2013 |
Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Databases, Factual; Disease-Free Survival; Female; Fl | 2013 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2015 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2015 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2015 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2015 |
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Topics: Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship | 2016 |
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Topics: Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship | 2016 |
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Topics: Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship | 2016 |
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Topics: Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship | 2016 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy | 2015 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy | 2015 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy | 2015 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy | 2015 |
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
[Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a Meta-analysis of the efficacy and safety].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Fluorouracil; Hea | 2016 |
[Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a Meta-analysis of the efficacy and safety].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Fluorouracil; Hea | 2016 |
[Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a Meta-analysis of the efficacy and safety].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Fluorouracil; Hea | 2016 |
[Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a Meta-analysis of the efficacy and safety].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Fluorouracil; Hea | 2016 |
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisp | 2008 |
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisp | 2008 |
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisp | 2008 |
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisp | 2008 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2008 |
Induction chemotherapy for head and neck cancer: recent data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2010 |
Induction chemotherapy for head and neck cancer: recent data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2010 |
Induction chemotherapy for head and neck cancer: recent data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2010 |
Induction chemotherapy for head and neck cancer: recent data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2010 |
TPF sequential therapy: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2010 |
TPF sequential therapy: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2010 |
TPF sequential therapy: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2010 |
TPF sequential therapy: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2010 |
TPF: a rational choice for larynx preservation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2010 |
TPF: a rational choice for larynx preservation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2010 |
TPF: a rational choice for larynx preservation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2010 |
TPF: a rational choice for larynx preservation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2010 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
Management of recurrent head and neck cancer: recent progress and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Management of recurrent head and neck cancer: recent progress and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Management of recurrent head and neck cancer: recent progress and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Management of recurrent head and neck cancer: recent progress and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
[Induction chemotherapy for head and neck epidermoid carcinomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Induction chemotherapy for head and neck epidermoid carcinomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Induction chemotherapy for head and neck epidermoid carcinomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Induction chemotherapy for head and neck epidermoid carcinomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Current treatment options for metastatic head and neck cancer.
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2012 |
Current treatment options for metastatic head and neck cancer.
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2012 |
Current treatment options for metastatic head and neck cancer.
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2012 |
Current treatment options for metastatic head and neck cancer.
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2012 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Molecular targeting agents in the context of primary chemoradiation strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2013 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Car | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Car | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Car | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Car | 2012 |
New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorou | 2012 |
New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorou | 2012 |
New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorou | 2012 |
New aspects of induction chemotherapy for head and neck cancer: POSTASCO 2011.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorou | 2012 |
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2012 |
Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2012 |
Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2012 |
Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2012 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2003 |
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
[Docetaxel and squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2004 |
[Docetaxel and squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2004 |
[Docetaxel and squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2004 |
[Docetaxel and squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2004 |
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
[Decision making in non resectable head and neck tumours].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[Decision making in non resectable head and neck tumours].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[Decision making in non resectable head and neck tumours].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[Decision making in non resectable head and neck tumours].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2005 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2005 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2005 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2005 |
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2007 |
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2007 |
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2007 |
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2007 |
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
The changing face of p53 in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; DNA Damage; DNA-Binding Proteins; Fluorouracil; Genes, p | 2007 |
The changing face of p53 in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; DNA Damage; DNA-Binding Proteins; Fluorouracil; Genes, p | 2007 |
The changing face of p53 in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; DNA Damage; DNA-Binding Proteins; Fluorouracil; Genes, p | 2007 |
The changing face of p53 in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; DNA Damage; DNA-Binding Proteins; Fluorouracil; Genes, p | 2007 |
[The present situation of neoadjuvant therapy for head and neck carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2007 |
[The present situation of neoadjuvant therapy for head and neck carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2007 |
[The present situation of neoadjuvant therapy for head and neck carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2007 |
[The present situation of neoadjuvant therapy for head and neck carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2007 |
Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2007 |
[Recent progress on radiotherapy for head and neck neoplasms].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Ele | 2007 |
[Recent progress on radiotherapy for head and neck neoplasms].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Ele | 2007 |
[Recent progress on radiotherapy for head and neck neoplasms].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Ele | 2007 |
[Recent progress on radiotherapy for head and neck neoplasms].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Ele | 2007 |
Recurrent head and neck cancer: current treatment and future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Recurrent head and neck cancer: current treatment and future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Recurrent head and neck cancer: current treatment and future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Recurrent head and neck cancer: current treatment and future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
Treatment of skin cancer using multiple modalities.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F | 1982 |
Treatment of skin cancer using multiple modalities.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F | 1982 |
Treatment of skin cancer using multiple modalities.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F | 1982 |
Treatment of skin cancer using multiple modalities.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F | 1982 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
Fluorouracil modulation in head and neck cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; | 1993 |
Fluorouracil modulation in head and neck cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; | 1993 |
Fluorouracil modulation in head and neck cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; | 1993 |
Fluorouracil modulation in head and neck cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; | 1993 |
The promise of biochemical modulation in combined modality therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1994 |
The promise of biochemical modulation in combined modality therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1994 |
The promise of biochemical modulation in combined modality therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1994 |
The promise of biochemical modulation in combined modality therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; | 1994 |
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Mitomycin; Neop | 1995 |
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Mitomycin; Neop | 1995 |
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Mitomycin; Neop | 1995 |
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Mitomycin; Neop | 1995 |
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1995 |
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1995 |
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1995 |
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1995 |
[Role of neoadjuvant chemotherapy for management of resectable head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1994 |
[Role of neoadjuvant chemotherapy for management of resectable head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1994 |
[Role of neoadjuvant chemotherapy for management of resectable head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1994 |
[Role of neoadjuvant chemotherapy for management of resectable head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1994 |
[A critical consideration of the combined radiochemotherapy of head and neck tumors].
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1994 |
[A critical consideration of the combined radiochemotherapy of head and neck tumors].
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1994 |
[A critical consideration of the combined radiochemotherapy of head and neck tumors].
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1994 |
[A critical consideration of the combined radiochemotherapy of head and neck tumors].
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1994 |
5-fluorouracil plus radiation for head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; H | 1995 |
5-fluorouracil plus radiation for head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; H | 1995 |
5-fluorouracil plus radiation for head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; H | 1995 |
5-fluorouracil plus radiation for head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; H | 1995 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1996 |
[Chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1996 |
[Chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1996 |
[Chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 1996 |
[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinom | 1996 |
[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinom | 1996 |
[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinom | 1996 |
[Predictive value of the hemogram for myelotoxicity induced by the association of carboplatin-fluorouracil on the 4th day of the therapeutic regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carcinom | 1996 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1997 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1997 |
[Chemoradiotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Chemoradiotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Chemoradiotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Chemoradiotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols | 1997 |
[Treatment for recurrent head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Ce | 1998 |
[Treatment for recurrent head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Ce | 1998 |
[Treatment for recurrent head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Ce | 1998 |
[Treatment for recurrent head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Ce | 1998 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Head and Neck | 1999 |
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Head and Neck | 1999 |
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Head and Neck | 1999 |
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Head and Neck | 1999 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Doce | 2000 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Doce | 2000 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Doce | 2000 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Doce | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2000 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
[Role of Chemotherapy in head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2001 |
[Role of Chemotherapy in head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2001 |
[Role of Chemotherapy in head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2001 |
[Role of Chemotherapy in head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Anticipating the future role of radiotherapy and chemotherapy in the treatment of head and neck cancer: a lesson from Manchester.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Chemotherapy, Adjuvant; Cli | 2001 |
Anticipating the future role of radiotherapy and chemotherapy in the treatment of head and neck cancer: a lesson from Manchester.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Chemotherapy, Adjuvant; Cli | 2001 |
Anticipating the future role of radiotherapy and chemotherapy in the treatment of head and neck cancer: a lesson from Manchester.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Chemotherapy, Adjuvant; Cli | 2001 |
Anticipating the future role of radiotherapy and chemotherapy in the treatment of head and neck cancer: a lesson from Manchester.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Chemotherapy, Adjuvant; Cli | 2001 |
[Preoperative chemotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carci | 2001 |
[Preoperative chemotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carci | 2001 |
[Preoperative chemotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carci | 2001 |
[Preoperative chemotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carci | 2001 |
[Current and future state of chemoradiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
[Current and future state of chemoradiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
[Current and future state of chemoradiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
[Current and future state of chemoradiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
[Chemo-radiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Er | 2002 |
[Chemo-radiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Er | 2002 |
[Chemo-radiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Er | 2002 |
[Chemo-radiotherapy for head and neck cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Er | 2002 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion | 1977 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion | 1977 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion | 1977 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion | 1977 |
Regional infusion chemotherapy for cancer of the head and neck.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Carcinoma, S | 1975 |
Regional infusion chemotherapy for cancer of the head and neck.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Carcinoma, S | 1975 |
Regional infusion chemotherapy for cancer of the head and neck.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Carcinoma, S | 1975 |
Regional infusion chemotherapy for cancer of the head and neck.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Carcinoma, S | 1975 |
Current role of chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combine | 1992 |
Current role of chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combine | 1992 |
Current role of chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combine | 1992 |
Current role of chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combine | 1992 |
Chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
Chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
Chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
Chemotherapy in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl | 1992 |
Locally advanced (stage III and IV) head and neck cancer: Westmead Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1991 |
Locally advanced (stage III and IV) head and neck cancer: Westmead Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1991 |
Locally advanced (stage III and IV) head and neck cancer: Westmead Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1991 |
Locally advanced (stage III and IV) head and neck cancer: Westmead Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1991 |
Advanced malignancy in the young marijuana smoker.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ar | 1991 |
Advanced malignancy in the young marijuana smoker.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ar | 1991 |
Advanced malignancy in the young marijuana smoker.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ar | 1991 |
Advanced malignancy in the young marijuana smoker.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ar | 1991 |
Current chemotherapy of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Current chemotherapy of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Current chemotherapy of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Current chemotherapy of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck | 1985 |
Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck | 1985 |
Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck | 1985 |
Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck | 1985 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
Current progress in the management of cancer. A collective review.
Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem | 1969 |
405 trials available for fluorouracil and Head and Neck Neoplasms
| Article | Year |
|---|---|
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorourac | 2022 |
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorourac | 2022 |
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorourac | 2022 |
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Docetaxel; Fatigue; Fluorourac | 2022 |
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2022 |
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2022 |
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2022 |
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiothera | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Comparative study of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Imm | 2019 |
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2021 |
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2021 |
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2021 |
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2021 |
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2020 |
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2020 |
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2020 |
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2020 |
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2020 |
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2020 |
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2020 |
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2020 |
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2021 |
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2021 |
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2021 |
Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2021 |
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Cetuximab; Cisplatin; Docetaxe | 2021 |
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Cetuximab; Cisplatin; Docetaxe | 2021 |
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Cetuximab; Cisplatin; Docetaxe | 2021 |
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Cetuximab; Cisplatin; Docetaxe | 2021 |
A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2021 |
A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2021 |
A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2021 |
A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2021 |
Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; F | 2021 |
Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; F | 2021 |
Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; F | 2021 |
Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; F | 2021 |
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2021 |
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2021 |
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2021 |
First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2021 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA, Viral; Doc | 2017 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA, Viral; Doc | 2017 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA, Viral; Doc | 2017 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA, Viral; Doc | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2017 |
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2017 |
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2017 |
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Cisplatin; Female; Fluorouracil; Head an | 2018 |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Cisplatin; Female; Fluorouracil; Head an | 2018 |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Cisplatin; Female; Fluorouracil; Head an | 2018 |
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Cisplatin; Female; Fluorouracil; Head an | 2018 |
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modalit | 2013 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2014 |
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2014 |
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; | 2015 |
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; | 2015 |
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; | 2015 |
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Squamous Cell; | 2015 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2014 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2014 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2014 |
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2015 |
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2015 |
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2015 |
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2015 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluor | 2015 |
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2016 |
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2016 |
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2016 |
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemor | 2016 |
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ci | 2016 |
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ci | 2016 |
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ci | 2016 |
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ci | 2016 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2016 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2016 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2016 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Ch | 2016 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel | 2018 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel | 2018 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel | 2018 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel | 2018 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2009 |
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2010 |
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2010 |
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2010 |
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2010 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Combined Modality Therapy | 2009 |
Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Combined Modality Therapy | 2009 |
Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Combined Modality Therapy | 2009 |
Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Combined Modality Therapy | 2009 |
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2010 |
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2010 |
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2010 |
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2010 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Drug Admi | 2010 |
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Drug Admi | 2010 |
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Drug Admi | 2010 |
Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Drug Admi | 2010 |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2011 |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2011 |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2011 |
DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2011 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2011 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2011 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2011 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2011 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progres | 2010 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progres | 2010 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progres | 2010 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progres | 2010 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Carcinoma, Squamous Cell; Com | 2011 |
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2010 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Continuous infusion of 5-FU with split-dose cisplatin: an effective treatment for advanced squamous-cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
Topics: Adult; Aged; Alginates; Antineoplastic Combined Chemotherapy Protocols; Carnosine; Cisplatin; Doceta | 2011 |
[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
Topics: Adult; Aged; Alginates; Antineoplastic Combined Chemotherapy Protocols; Carnosine; Cisplatin; Doceta | 2011 |
[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
Topics: Adult; Aged; Alginates; Antineoplastic Combined Chemotherapy Protocols; Carnosine; Cisplatin; Doceta | 2011 |
[Preventive effect of polaprezinc suspension dispersed in sodium alginate solution (P-AG) for stomatitis induced by Docetaxel/Cisplatin/Fluorouracil (DCF) chemotherapy in patients with head and neck cancer].
Topics: Adult; Aged; Alginates; Antineoplastic Combined Chemotherapy Protocols; Carnosine; Cisplatin; Doceta | 2011 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem | 2012 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined | 2012 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined | 2012 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined | 2012 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined | 2012 |
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2012 |
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2012 |
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2012 |
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2012 |
Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Squa | 2012 |
Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Squa | 2012 |
Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Squa | 2012 |
Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carboplatin; Carcinoma, Squa | 2012 |
Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Is neck dissection necessary after induction plus concurrent chemoradiotherapy in complete responder head and neck cancer patients with pretherapy advanced nodal disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-F | 2012 |
[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
[Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2013 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2013 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2013 |
A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2013 |
A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes.
Topics: Adult; Aged; Cisplatin; Fluorouracil; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasm | 2012 |
A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes.
Topics: Adult; Aged; Cisplatin; Fluorouracil; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasm | 2012 |
A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes.
Topics: Adult; Aged; Cisplatin; Fluorouracil; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasm | 2012 |
A head and neck cancer tumor response-specific gene signature for cisplatin, 5-fluorouracil induction chemotherapy fails with added taxanes.
Topics: Adult; Aged; Cisplatin; Fluorouracil; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasm | 2012 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 2002 |
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 2002 |
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 2002 |
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cy | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 2002 |
Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2002 |
Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2002 |
Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2002 |
Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2002 |
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Accelerated hyperfractionated radiotherapy and concurrent protracted venous infusion chemotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2002 |
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2002 |
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2002 |
Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and eecommended dose of NDP administered after 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 2002 |
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combine | 2003 |
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combine | 2003 |
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combine | 2003 |
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combine | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 2003 |
Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 2003 |
Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 2003 |
Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 2003 |
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
Carcinoma of the head and neck: a 5- to 20-year experience with preoperative chemotherapy, uncompromised surgery, and selective radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 2003 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Ge | 2003 |
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatogr | 2003 |
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatogr | 2003 |
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatogr | 2003 |
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatogr | 2003 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2004 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2004 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2004 |
Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2004 |
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2004 |
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2004 |
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2004 |
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2004 |
Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deo | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deo | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deo | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deo | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2004 |
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2004 |
Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2004 |
Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2004 |
Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2004 |
Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2004 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2004 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2004 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2004 |
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous | 2004 |
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous | 2004 |
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous | 2004 |
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous | 2004 |
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2005 |
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2005 |
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2005 |
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2005 |
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2005 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Mitomycin and fluorouracil in combination with concomitant radiotherapy: a potentially curable approach for locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2005 |
Mitomycin and fluorouracil in combination with concomitant radiotherapy: a potentially curable approach for locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2005 |
Mitomycin and fluorouracil in combination with concomitant radiotherapy: a potentially curable approach for locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2005 |
Mitomycin and fluorouracil in combination with concomitant radiotherapy: a potentially curable approach for locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; | 2005 |
Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
Late chemo-intensification with cisplatin and 5-fluorouracil as an adjunct to radiotherapy: a pragmatic approach for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2006 |
Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy | 2006 |
Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy | 2006 |
Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy | 2006 |
Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy | 2006 |
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
[Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2006 |
[Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2006 |
[Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2006 |
[Adjuvant chemotherapy (nedaplatin/UFT) after concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2006 |
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carb | 2006 |
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carb | 2006 |
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carb | 2006 |
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carb | 2006 |
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2006 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2006 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2006 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2006 |
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipeptides; Double-Blind Met | 2006 |
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipeptides; Double-Blind Met | 2006 |
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipeptides; Double-Blind Met | 2006 |
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dipeptides; Double-Blind Met | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2006 |
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2006 |
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2006 |
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2006 |
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Modified radical neck dissection and minimal invasive tumor surgery in the middle of split course of concomitant chemoradiotherapy of advanced HNSCC.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Modified radical neck dissection and minimal invasive tumor surgery in the middle of split course of concomitant chemoradiotherapy of advanced HNSCC.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Modified radical neck dissection and minimal invasive tumor surgery in the middle of split course of concomitant chemoradiotherapy of advanced HNSCC.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Modified radical neck dissection and minimal invasive tumor surgery in the middle of split course of concomitant chemoradiotherapy of advanced HNSCC.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2007 |
Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2007 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2007 |
Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2007 |
Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2007 |
Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2007 |
Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
Dose escalation study of nedaplatin with 5-fluorouracil in combination with alternating radiotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2007 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2007 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2007 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2007 |
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2008 |
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2008 |
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2008 |
Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2008 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2008 |
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy strategies in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Integration of safe initial combination chemotherapy (without cisplatin) with a high response rate and local therapy for untreated stage III and IV epidermoid cancer of the head and neck: 5-year survival data.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; D | 1983 |
Integration of safe initial combination chemotherapy (without cisplatin) with a high response rate and local therapy for untreated stage III and IV epidermoid cancer of the head and neck: 5-year survival data.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; D | 1983 |
Integration of safe initial combination chemotherapy (without cisplatin) with a high response rate and local therapy for untreated stage III and IV epidermoid cancer of the head and neck: 5-year survival data.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; D | 1983 |
Integration of safe initial combination chemotherapy (without cisplatin) with a high response rate and local therapy for untreated stage III and IV epidermoid cancer of the head and neck: 5-year survival data.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; D | 1983 |
Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1984 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Synergism; Dr | 1983 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Clinical trials and cancer risk in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and Neck | 1984 |
Clinical trials and cancer risk in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and Neck | 1984 |
Clinical trials and cancer risk in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and Neck | 1984 |
Clinical trials and cancer risk in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and Neck | 1984 |
Selective cytotoxic effect of topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind | 1983 |
Selective cytotoxic effect of topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind | 1983 |
Selective cytotoxic effect of topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind | 1983 |
Selective cytotoxic effect of topical 5-fluorouracil.
Topics: Administration, Topical; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Double-Blind | 1983 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells.
Topics: Animals; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug The | 1983 |
Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells.
Topics: Animals; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug The | 1983 |
Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells.
Topics: Animals; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug The | 1983 |
Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells.
Topics: Animals; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug The | 1983 |
Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Female; Fluorouracil; He | 1982 |
Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Female; Fluorouracil; He | 1982 |
Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Female; Fluorouracil; He | 1982 |
Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Female; Fluorouracil; He | 1982 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Improved survival with preoperative chemotherapy followed by resection uncompromised by tumor response for advanced squamous cell carcinoma of the head and neck.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa | 1995 |
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa | 1995 |
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa | 1995 |
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squa | 1995 |
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St | 1995 |
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St | 1995 |
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St | 1995 |
A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over St | 1995 |
Palliative intra-arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port-systems.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1995 |
Palliative intra-arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port-systems.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1995 |
Palliative intra-arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port-systems.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1995 |
Palliative intra-arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port-systems.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cathete | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1995 |
[High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories].
Topics: Chemotherapy, Adjuvant; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplas | 1995 |
[High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories].
Topics: Chemotherapy, Adjuvant; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplas | 1995 |
[High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories].
Topics: Chemotherapy, Adjuvant; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplas | 1995 |
[High tissue concentration of 5-FU reduced local recurrence after administration of tegafur suppositories].
Topics: Chemotherapy, Adjuvant; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplas | 1995 |
Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1995 |
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Su | 1995 |
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Su | 1995 |
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Su | 1995 |
Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Su | 1995 |
Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1995 |
Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1995 |
Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1995 |
Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1995 |
Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; H | 1994 |
Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; H | 1994 |
Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; H | 1994 |
Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; H | 1994 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1994 |
Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1994 |
Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1994 |
Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1994 |
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 1994 |
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 1994 |
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 1994 |
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 1994 |
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoth | 1994 |
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoth | 1994 |
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoth | 1994 |
[Cisplatin/5-FU versus carboplatin/5-FU. 5 year follow-up].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoth | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1994 |
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1994 |
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1994 |
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1994 |
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1994 |
Chemotherapy as predictor of compliance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
Chemotherapy as predictor of compliance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
Chemotherapy as predictor of compliance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
Chemotherapy as predictor of compliance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1994 |
[A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administr | 1994 |
[A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administr | 1994 |
[A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administr | 1994 |
[A comparative clinical study on the treatment of head and neck tumors by adjuvant chemotherapy with HCFU--Second Study by Kinki Head and Neck Tumor Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administr | 1994 |
Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1993 |
Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1993 |
A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Follow-Up Stu | 1994 |
A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Follow-Up Stu | 1994 |
A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Follow-Up Stu | 1994 |
A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Follow-Up Stu | 1994 |
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1994 |
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Fluorour | 1993 |
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Fluorour | 1993 |
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Fluorour | 1993 |
Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Female; Fluorour | 1993 |
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diabetes Complic | 1993 |
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diabetes Complic | 1993 |
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diabetes Complic | 1993 |
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diabetes Complic | 1993 |
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head an | 1993 |
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head an | 1993 |
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head an | 1993 |
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Head an | 1993 |
Four days' continuous infusion of cisplatin-5-fluorouracil and short daily infusion of high-dose leucovorin as induction chemotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; | 1995 |
Four days' continuous infusion of cisplatin-5-fluorouracil and short daily infusion of high-dose leucovorin as induction chemotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; | 1995 |
Four days' continuous infusion of cisplatin-5-fluorouracil and short daily infusion of high-dose leucovorin as induction chemotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; | 1995 |
Four days' continuous infusion of cisplatin-5-fluorouracil and short daily infusion of high-dose leucovorin as induction chemotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; | 1995 |
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1995 |
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1996 |
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1996 |
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1996 |
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1996 |
[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
[Adjuvant chemotherapy in advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1995 |
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1996 |
Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Local hyperthermia of N2/N3 cervical lymph node metastases: correlationof technical/thermal parameters and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Local hyperthermia of N2/N3 cervical lymph node metastases: correlationof technical/thermal parameters and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Local hyperthermia of N2/N3 cervical lymph node metastases: correlationof technical/thermal parameters and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Local hyperthermia of N2/N3 cervical lymph node metastases: correlationof technical/thermal parameters and response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorour | 1996 |
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorour | 1996 |
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorour | 1996 |
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorour | 1996 |
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1996 |
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1996 |
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1996 |
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1996 |
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1996 |
Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Accelerated fractionation radiotherapy and concomitant chemotherapy in patients with stage IV inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1995 |
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1996 |
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1996 |
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1996 |
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1996 |
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Mo | 1996 |
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Mo | 1996 |
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Mo | 1996 |
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Mo | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1996 |
[Systemic neoadjuvant chemotherapy in advanced head and neck tumors: a randomized study of the combination of 5-FU/carboplatin versus 5-FU/cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemot | 1996 |
[Systemic neoadjuvant chemotherapy in advanced head and neck tumors: a randomized study of the combination of 5-FU/carboplatin versus 5-FU/cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemot | 1996 |
[Systemic neoadjuvant chemotherapy in advanced head and neck tumors: a randomized study of the combination of 5-FU/carboplatin versus 5-FU/cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemot | 1996 |
[Systemic neoadjuvant chemotherapy in advanced head and neck tumors: a randomized study of the combination of 5-FU/carboplatin versus 5-FU/cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemot | 1996 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1994 |
Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1994 |
Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1994 |
Neo-adjuvant chemotherapy +/- immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1994 |
[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1996 |
[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1996 |
[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1996 |
[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 1996 |
Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1996 |
Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1996 |
Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1996 |
Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1996 |
Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; | 1996 |
Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; | 1996 |
Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; | 1996 |
Carboplatin, 5-fluorouracil and folinic acid: a 48-hour chemotherapy regimen in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Female; | 1996 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1997 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 1997 |
Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1997 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1997 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1997 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1997 |
Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Locally advanced head and neck cancer: combined chemotherapy and radical radiation therapy for organ and function preservation (interim report).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1997 |
Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1997 |
Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1997 |
Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1997 |
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1997 |
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1997 |
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1997 |
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 1997 |
Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 1997 |
Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 1997 |
Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 1997 |
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; F | 1997 |
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; F | 1997 |
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; F | 1997 |
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; F | 1997 |
Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Concurrent chemoradiotherapy for salvage in relapsed squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combine | 1997 |
Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Chemo-radiotherapy for locally advanced head and neck cancer--long-term results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined | 1997 |
Chemo-radiotherapy for locally advanced head and neck cancer--long-term results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined | 1997 |
Chemo-radiotherapy for locally advanced head and neck cancer--long-term results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined | 1997 |
Chemo-radiotherapy for locally advanced head and neck cancer--long-term results of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: preliminary results of phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1997 |
Paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1997 |
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1997 |
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1997 |
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1997 |
Chemotherapy for relapsed head and neck cancer: paclitaxel, cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1997 |
[Preliminary evaluation of the effects of chemotherapy (cisplatin + 5-fluorouracil) for advanced head and neck neoplasms].
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Hu | 1995 |
[Preliminary evaluation of the effects of chemotherapy (cisplatin + 5-fluorouracil) for advanced head and neck neoplasms].
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Hu | 1995 |
[Preliminary evaluation of the effects of chemotherapy (cisplatin + 5-fluorouracil) for advanced head and neck neoplasms].
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Hu | 1995 |
[Preliminary evaluation of the effects of chemotherapy (cisplatin + 5-fluorouracil) for advanced head and neck neoplasms].
Topics: Adult; Aged; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Hu | 1995 |
[Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1998 |
[Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1998 |
[Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1998 |
[Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1998 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1998 |
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1998 |
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1998 |
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1998 |
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1998 |
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1998 |
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1998 |
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1998 |
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1998 |
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1998 |
Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1998 |
Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Artificial neural network model of survival in patients treated with irradiation with and without concurrent chemotherapy for advanced carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1998 |
Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Drug Adm | 1998 |
Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Drug Adm | 1998 |
Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Drug Adm | 1998 |
Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Drug Adm | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1998 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinoma, Squamous Cell | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1998 |
Squamous cell granulomas of the neck: histologic regression of metastatic squamous cell carcinoma following chemotherapy and/or radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1998 |
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1998 |
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1998 |
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1998 |
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1998 |
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area U | 1998 |
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area U | 1998 |
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area U | 1998 |
Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area U | 1998 |
Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; | 1997 |
Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; | 1997 |
Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; | 1997 |
Chemoradiotherapy as an alternative to radiotherapy alone in fast proliferating head and neck squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; | 1997 |
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous | 1996 |
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous | 1996 |
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous | 1996 |
Continued malignant cell proliferation in head and neck tumors during cytotoxic therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous | 1996 |
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1998 |
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1998 |
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1998 |
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1998 |
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1999 |
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1999 |
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1999 |
Phase II clinical trial of cisplatin, 5-fluorouracil, and ifosfamide as treatment for advanced locoregional head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fl | 1999 |
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combin | 1999 |
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combin | 1999 |
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combin | 1999 |
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combin | 1999 |
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1999 |
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1999 |
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1999 |
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1999 |
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1999 |
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1999 |
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1999 |
A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Ci | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 1999 |
Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 1999 |
Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 1999 |
Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; C | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
[Low-dose CDDP and 5-FU for head and neck cancer patients].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
[Low-dose CDDP and 5-FU for head and neck cancer patients].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
[Low-dose CDDP and 5-FU for head and neck cancer patients].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
[Low-dose CDDP and 5-FU for head and neck cancer patients].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1999 |
Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne | 1999 |
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 1999 |
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 1999 |
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 1999 |
Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1999 |
An original accelerated radiotherapy schedule in stage III to IV head and neck cancers. Results in a multicenter setting.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2000 |
An original accelerated radiotherapy schedule in stage III to IV head and neck cancers. Results in a multicenter setting.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2000 |
An original accelerated radiotherapy schedule in stage III to IV head and neck cancers. Results in a multicenter setting.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2000 |
An original accelerated radiotherapy schedule in stage III to IV head and neck cancers. Results in a multicenter setting.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2000 |
[A clinical study of inoperable head and neck cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Flu | 1999 |
[A clinical study of inoperable head and neck cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Flu | 1999 |
[A clinical study of inoperable head and neck cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Flu | 1999 |
[A clinical study of inoperable head and neck cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Flu | 1999 |
Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Head and Neck Neopla | 1999 |
Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Head and Neck Neopla | 1999 |
Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Head and Neck Neopla | 1999 |
Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Head and Neck Neopla | 1999 |
Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2000 |
The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2000 |
The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2000 |
The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2000 |
The influence of beam energy on the outcome of postoperative radiotherapy in head and neck cancer patients: secondary analysis of RTOG 85-03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progr | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progr | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progr | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progr | 2000 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2000 |
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2000 |
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2000 |
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adenoviruses, Human; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2000 |
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2000 |
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2000 |
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).
Topics: Adenoviruses, Human; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2000 |
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma, Non-Small-Cell | 2000 |
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma, Non-Small-Cell | 2000 |
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma, Non-Small-Cell | 2000 |
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma, Non-Small-Cell | 2000 |
[Concurrent chemoradiotherapy for locally unresectable head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; C | 2000 |
[Concurrent chemoradiotherapy for locally unresectable head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; C | 2000 |
[Concurrent chemoradiotherapy for locally unresectable head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; C | 2000 |
[Concurrent chemoradiotherapy for locally unresectable head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; C | 2000 |
Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2000 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorou | 2001 |
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorou | 2001 |
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorou | 2001 |
Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorou | 2001 |
[Multi-institutional cooperative study on combination chemotherapy with THP, CDDP and 5-FU for squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2001 |
[Multi-institutional cooperative study on combination chemotherapy with THP, CDDP and 5-FU for squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2001 |
[Multi-institutional cooperative study on combination chemotherapy with THP, CDDP and 5-FU for squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2001 |
[Multi-institutional cooperative study on combination chemotherapy with THP, CDDP and 5-FU for squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 2001 |
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2001 |
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2001 |
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2001 |
Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2001 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
A National Cancer Institute of Canada clinical trials group phase II study of eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada | 2001 |
Unresectable primary tumor of head and neck: does neck dissection combined with chemoradiotherapy improve survival?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Unresectable primary tumor of head and neck: does neck dissection combined with chemoradiotherapy improve survival?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Unresectable primary tumor of head and neck: does neck dissection combined with chemoradiotherapy improve survival?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
Unresectable primary tumor of head and neck: does neck dissection combined with chemoradiotherapy improve survival?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2001 |
[Effect of combination chemotherapy with nedaplatin and 5-FU for head and neck squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2001 |
[Effect of combination chemotherapy with nedaplatin and 5-FU for head and neck squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2001 |
[Effect of combination chemotherapy with nedaplatin and 5-FU for head and neck squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2001 |
[Effect of combination chemotherapy with nedaplatin and 5-FU for head and neck squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2001 |
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2001 |
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2001 |
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2001 |
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2001 |
Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2001 |
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2001 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
[Combined high dose leucovorin and 5-fluorouracil continuous infusion for head-neck and digestive tract cancers].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Th | 2002 |
[Combined high dose leucovorin and 5-fluorouracil continuous infusion for head-neck and digestive tract cancers].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Th | 2002 |
[Combined high dose leucovorin and 5-fluorouracil continuous infusion for head-neck and digestive tract cancers].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Th | 2002 |
[Combined high dose leucovorin and 5-fluorouracil continuous infusion for head-neck and digestive tract cancers].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Th | 2002 |
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2002 |
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2002 |
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2002 |
Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2002 |
Combination chemotherapy pilot studies in head and neck squamous cell cancer.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug T | 1979 |
Combination chemotherapy pilot studies in head and neck squamous cell cancer.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug T | 1979 |
Combination chemotherapy pilot studies in head and neck squamous cell cancer.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug T | 1979 |
Combination chemotherapy pilot studies in head and neck squamous cell cancer.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyclophosphamide; Drug T | 1979 |
[Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Fem | 1992 |
[Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Fem | 1992 |
[Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Fem | 1992 |
[Role of neoadjuvant chemotherapy in the treatment of advanced head and neck tumors. Results of two randomized therapeutical trials conducted at the Institut Curie on 208 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Fem | 1992 |
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cell | 1992 |
Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cell | 1992 |
Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cell | 1992 |
Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cell | 1992 |
Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Fl | 1992 |
Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Fl | 1992 |
Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Fl | 1992 |
Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Fl | 1992 |
Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1992 |
A phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
A phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
A phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
A phase I study of high-dose cisplatin, prolonged infusion 5-fluorouracil, and concomitant conventional fraction radiation therapy in patients with inoperable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1992 |
Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1992 |
Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1992 |
Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1992 |
Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Hyperfractionated radiation therapy and concurrent 5-fluorouracil, cisplatin and mitomycin-C in head and neck carcinoma. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1992 |
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1992 |
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1992 |
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1992 |
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1992 |
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1992 |
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1992 |
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1992 |
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1992 |
Simultaneous chemoradiation in the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head | 1992 |
Simultaneous chemoradiation in the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head | 1992 |
Simultaneous chemoradiation in the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head | 1992 |
Simultaneous chemoradiation in the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Female; Fluorouracil; Head | 1992 |
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1991 |
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1991 |
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1991 |
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dr | 1991 |
Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Double-Blind Meth | 1990 |
Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Double-Blind Meth | 1990 |
Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Double-Blind Meth | 1990 |
Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Double-Blind Meth | 1990 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1991 |
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1991 |
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1991 |
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 1992 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
[A comparative clinical study of adjuvant chemotherapy of tumors in the head and neck areas by means of HCFU].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluoro | 1991 |
[A comparative clinical study of adjuvant chemotherapy of tumors in the head and neck areas by means of HCFU].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluoro | 1991 |
[A comparative clinical study of adjuvant chemotherapy of tumors in the head and neck areas by means of HCFU].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluoro | 1991 |
[A comparative clinical study of adjuvant chemotherapy of tumors in the head and neck areas by means of HCFU].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluoro | 1991 |
Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
Phase I/II study of carboplatin and 5-fluorouracil in patients with advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors.
Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship | 1991 |
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors.
Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship | 1991 |
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors.
Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship | 1991 |
Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors.
Topics: Adult; Animals; Antineoplastic Agents; Delayed-Action Preparations; Dogs; Dose-Response Relationship | 1991 |
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Admini | 1991 |
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Admini | 1991 |
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Admini | 1991 |
A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Admini | 1991 |
5-year results of cisplatin and fluorouracil infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
5-year results of cisplatin and fluorouracil infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
5-year results of cisplatin and fluorouracil infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
5-year results of cisplatin and fluorouracil infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1991 |
Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1991 |
Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1991 |
Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1991 |
Induction chemotherapy (cisplatin + 5-fluorouracil) and radiotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1991 |
[Preliminary evaluation of the effectiveness of induction chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1991 |
[Preliminary evaluation of the effectiveness of induction chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1991 |
[Preliminary evaluation of the effectiveness of induction chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1991 |
[Preliminary evaluation of the effectiveness of induction chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; | 1991 |
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1991 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1990 |
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1990 |
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1990 |
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1990 |
Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: a preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1990 |
[The results of simultaneous radio-chemotherapy in advanced head and neck tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
[The results of simultaneous radio-chemotherapy in advanced head and neck tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
[The results of simultaneous radio-chemotherapy in advanced head and neck tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
[The results of simultaneous radio-chemotherapy in advanced head and neck tumors].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1990 |
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1990 |
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1990 |
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1990 |
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1990 |
Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1990 |
Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1990 |
Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1990 |
Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1990 |
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1985 |
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1985 |
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1985 |
Randomized neo-adjuvant chemotherapy trial for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1985 |
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Randomized study of adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1985 |
Randomized study of adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1985 |
Randomized study of adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1985 |
Randomized study of adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1985 |
A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract.
Topics: Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Head | 1986 |
A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract.
Topics: Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Head | 1986 |
A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract.
Topics: Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Head | 1986 |
A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract.
Topics: Bleomycin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclophosphamide; Fluorouracil; Head | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
Short-term results of the combination of cis-platinum, 5-fluorouracil and bleomycin in advanced upper aerodigestive tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Comb | 1986 |
A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1986 |
A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1986 |
A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1986 |
A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. South-East Co-operative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1986 |
Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials a | 1987 |
Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials a | 1987 |
Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials a | 1987 |
Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials a | 1987 |
Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1987 |
Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1987 |
Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1987 |
Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Clin | 1987 |
Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1988 |
Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1988 |
Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1988 |
Sequential versus alternating chemotherapy and radiotherapy in stage III-IV squamous cell carcinoma of the head and neck: a phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials | 1988 |
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1989 |
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1989 |
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1989 |
Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1989 |
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1989 |
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1989 |
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1989 |
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1989 |
Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1989 |
Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1989 |
Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1989 |
Morphometric analysis, ploidy and response to chemotherapy in squamous carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1989 |
Chemotherapy following surgery for head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Chemotherapy following surgery for head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Chemotherapy following surgery for head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Chemotherapy following surgery for head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Head and Nec | 1989 |
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1989 |
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1989 |
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1989 |
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1989 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Carcinoma, Squa | 1989 |
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Carcinoma, Squa | 1989 |
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Carcinoma, Squa | 1989 |
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Carcinoma, Squa | 1989 |
Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Sequential trial of initial chemotherapy for advanced cancer of the head and neck. DDP versus DDP + 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouracil; Head | 1988 |
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouracil; Head | 1988 |
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouracil; Head | 1988 |
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Female; Fluorouracil; Head | 1988 |
Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1988 |
Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1988 |
Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1988 |
Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1988 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1988 |
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1988 |
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1988 |
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1988 |
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1987 |
Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1987 |
Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1987 |
Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1987 |
Sequential MTX and 5-FU: advance or myth?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Clinical Trials as Topic; | 1986 |
Sequential MTX and 5-FU: advance or myth?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Clinical Trials as Topic; | 1986 |
Sequential MTX and 5-FU: advance or myth?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Clinical Trials as Topic; | 1986 |
Sequential MTX and 5-FU: advance or myth?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Clinical Trials as Topic; | 1986 |
Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1987 |
Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1987 |
Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1987 |
Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1987 |
Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1987 |
Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1987 |
Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1987 |
Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1987 |
Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1987 |
Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1987 |
Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1987 |
Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report.
Topics: Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasm | 1987 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
Clinical trials on UFT in the treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1985 |
Clinical trials on UFT in the treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1985 |
Clinical trials on UFT in the treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1985 |
Clinical trials on UFT in the treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1985 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
762 other studies available for fluorouracil and Head and Neck Neoplasms
| Article | Year |
|---|---|
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fat | 2023 |
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fat | 2023 |
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fat | 2023 |
FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B1; Fat | 2023 |
[Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2021 |
[Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2021 |
[Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2021 |
[Analysis of curative effect of ultrasonic hyperthermia combined with TPF chemotherapy on 19 elderly with advanced oral squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 2021 |
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; He | 2022 |
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; He | 2022 |
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; He | 2022 |
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; He | 2022 |
[Utility of GPR68 and TIL in TPF-induced chemotherapy and prognosis evaluation in middle-advanced hypopharyngeal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2022 |
[Utility of GPR68 and TIL in TPF-induced chemotherapy and prognosis evaluation in middle-advanced hypopharyngeal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2022 |
[Utility of GPR68 and TIL in TPF-induced chemotherapy and prognosis evaluation in middle-advanced hypopharyngeal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2022 |
[Utility of GPR68 and TIL in TPF-induced chemotherapy and prognosis evaluation in middle-advanced hypopharyngeal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2022 |
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2023 |
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2022 |
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2022 |
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2022 |
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Prognosis; T | 2022 |
Treatment efficacy of low-dose 5-fluorouracil with ultrasound in mediating 5-fluorouracil-loaded microbubble cavitation in head and neck cancer.
Topics: Animals; Fluorouracil; Head and Neck Neoplasms; Mice; Microbubbles; Tissue Distribution; Treatment O | 2023 |
Treatment efficacy of low-dose 5-fluorouracil with ultrasound in mediating 5-fluorouracil-loaded microbubble cavitation in head and neck cancer.
Topics: Animals; Fluorouracil; Head and Neck Neoplasms; Mice; Microbubbles; Tissue Distribution; Treatment O | 2023 |
Treatment efficacy of low-dose 5-fluorouracil with ultrasound in mediating 5-fluorouracil-loaded microbubble cavitation in head and neck cancer.
Topics: Animals; Fluorouracil; Head and Neck Neoplasms; Mice; Microbubbles; Tissue Distribution; Treatment O | 2023 |
Treatment efficacy of low-dose 5-fluorouracil with ultrasound in mediating 5-fluorouracil-loaded microbubble cavitation in head and neck cancer.
Topics: Animals; Fluorouracil; Head and Neck Neoplasms; Mice; Microbubbles; Tissue Distribution; Treatment O | 2023 |
Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Fluorouracil; Head and | 2023 |
Docetaxel plus radiotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2023 |
Docetaxel plus radiotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2023 |
Docetaxel plus radiotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2023 |
Docetaxel plus radiotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouraci | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrenc | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrenc | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrenc | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrenc | 2023 |
A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluoroura | 2023 |
A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluoroura | 2023 |
A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluoroura | 2023 |
A novel intra-tumoral drug delivery carrier for treatment of oral squamous cell carcinoma.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluoroura | 2023 |
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2023 |
[Analysis of efficacy and prognosis of neoadjuvant chemotherapy and （or） surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma].
Topics: Cetuximab; China; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Prognosis; Ret | 2023 |
[Analysis of efficacy and prognosis of neoadjuvant chemotherapy and （or） surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma].
Topics: Cetuximab; China; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Prognosis; Ret | 2023 |
[Analysis of efficacy and prognosis of neoadjuvant chemotherapy and （or） surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma].
Topics: Cetuximab; China; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Prognosis; Ret | 2023 |
[Analysis of efficacy and prognosis of neoadjuvant chemotherapy and （or） surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma].
Topics: Cetuximab; China; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Prognosis; Ret | 2023 |
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Agents; Cetuximab; Cost-Benefit Analysis; Fluorouracil; Head and Neck Neoplasms; Huma | 2019 |
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Agents; Cetuximab; Cost-Benefit Analysis; Fluorouracil; Head and Neck Neoplasms; Huma | 2019 |
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Agents; Cetuximab; Cost-Benefit Analysis; Fluorouracil; Head and Neck Neoplasms; Huma | 2019 |
Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Agents; Cetuximab; Cost-Benefit Analysis; Fluorouracil; Head and Neck Neoplasms; Huma | 2019 |
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Drug Administration Sche | 2019 |
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Drug Administration Sche | 2019 |
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Drug Administration Sche | 2019 |
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Drug Administration Sche | 2019 |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brazil; Bridged-Ring Compounds; Can | 2020 |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brazil; Bridged-Ring Compounds; Can | 2020 |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brazil; Bridged-Ring Compounds; Can | 2020 |
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brazil; Bridged-Ring Compounds; Can | 2020 |
Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2020 |
Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2020 |
Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2020 |
Accelerated Radiotherapy with Concurrent Chemotherapy in Locally Advanced Head and Neck Cancers: Evaluation of Response and Compliance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2020 |
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cis | 2020 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cis | 2020 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cis | 2020 |
Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cis | 2020 |
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2021 |
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2021 |
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2021 |
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase | 2021 |
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunologica | 2020 |
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunologica | 2020 |
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunologica | 2020 |
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunologica | 2020 |
Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Exosomes; Fluo | 2020 |
Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Exosomes; Fluo | 2020 |
Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Exosomes; Fluo | 2020 |
Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Exosomes; Fluo | 2020 |
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2020 |
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2020 |
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2020 |
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2020 |
The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Dental Prophylaxis; Female; Fluorouracil; Head | 2021 |
The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Dental Prophylaxis; Female; Fluorouracil; Head | 2021 |
The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Dental Prophylaxis; Female; Fluorouracil; Head | 2021 |
The impact of timing and modalities of dental prophylaxis on the risk of 5-fluorouracil-related oral mucositis in patients with head and neck cancer: a nationwide population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Dental Prophylaxis; Female; Fluorouracil; Head | 2021 |
Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Cell Survival; Chemotactic Factors; Chromatography, Liquid; Cis | 2020 |
Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Cell Survival; Chemotactic Factors; Chromatography, Liquid; Cis | 2020 |
Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Cell Survival; Chemotactic Factors; Chromatography, Liquid; Cis | 2020 |
Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Cell Survival; Chemotactic Factors; Chromatography, Liquid; Cis | 2020 |
When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2021 |
When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2021 |
When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2021 |
When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.
Topics: Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Deh | 2021 |
Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice.
Topics: Animals; Cell Proliferation; Cisplatin; Disease Models, Animal; Docetaxel; Fluorouracil; Head and Ne | 2020 |
Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice.
Topics: Animals; Cell Proliferation; Cisplatin; Disease Models, Animal; Docetaxel; Fluorouracil; Head and Ne | 2020 |
Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice.
Topics: Animals; Cell Proliferation; Cisplatin; Disease Models, Animal; Docetaxel; Fluorouracil; Head and Ne | 2020 |
Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice.
Topics: Animals; Cell Proliferation; Cisplatin; Disease Models, Animal; Docetaxel; Fluorouracil; Head and Ne | 2020 |
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiothera | 2021 |
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiothera | 2021 |
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiothera | 2021 |
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiothera | 2021 |
Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2020 |
Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2020 |
Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2020 |
Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2020 |
MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Head and Neck Neoplasms; Humans; MicroRNAs; Prot | 2021 |
MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Head and Neck Neoplasms; Humans; MicroRNAs; Prot | 2021 |
MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Head and Neck Neoplasms; Humans; MicroRNAs; Prot | 2021 |
MicroRNA‑149‑3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma.
Topics: Cell Line, Tumor; Cell Proliferation; Fluorouracil; Head and Neck Neoplasms; Humans; MicroRNAs; Prot | 2021 |
Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Survival; Chitosan; Drug | 2021 |
Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Survival; Chitosan; Drug | 2021 |
Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Survival; Chitosan; Drug | 2021 |
Chitosan/PCL nanoparticles can improve anti-neoplastic activity of 5-fluorouracil in head and neck cancer through autophagy activation.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Survival; Chitosan; Drug | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Plati | 2021 |
Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2021 |
Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2021 |
Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2021 |
Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 2021 |
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug | 2021 |
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug | 2021 |
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug | 2021 |
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug | 2021 |
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Resistance, | 2022 |
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Resistance, | 2022 |
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Resistance, | 2022 |
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Resistance, | 2022 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidenc | 2021 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidenc | 2021 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidenc | 2021 |
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Confidenc | 2021 |
Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Topics: Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doc | 2021 |
Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Topics: Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doc | 2021 |
Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Topics: Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doc | 2021 |
Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Topics: Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doc | 2021 |
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Fluo | 2022 |
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Fluo | 2022 |
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Fluo | 2022 |
Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Fluo | 2022 |
Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Therapy, Combination; Fluorouracil; | 2022 |
Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Therapy, Combination; Fluorouracil; | 2022 |
Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Therapy, Combination; Fluorouracil; | 2022 |
Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Therapy, Combination; Fluorouracil; | 2022 |
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2021 |
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2021 |
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2021 |
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2021 |
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic | 2021 |
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic | 2021 |
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic | 2021 |
Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic | 2021 |
Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoi | 2021 |
Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoi | 2021 |
Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoi | 2021 |
Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoi | 2021 |
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2017 |
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2017 |
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2017 |
Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
Topics: Acute Kidney Injury; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopla | 2017 |
Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
Topics: AC133 Antigen; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cisplatin; Fluo | 2017 |
Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
Topics: AC133 Antigen; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cisplatin; Fluo | 2017 |
Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
Topics: AC133 Antigen; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cisplatin; Fluo | 2017 |
Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
Topics: AC133 Antigen; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cisplatin; Fluo | 2017 |
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2017 |
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2017 |
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2017 |
Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2017 |
Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Pr | 2017 |
Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Pr | 2017 |
Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Pr | 2017 |
Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Pr | 2017 |
Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Comparison cisplatin with cisplatin plus 5FU in head and neck cancer patients received postoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuxi | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuxi | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuxi | 2017 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuxi | 2017 |
[Role and interest of induction chemotherapy for head and neck cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2017 |
[Role and interest of induction chemotherapy for head and neck cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2017 |
[Role and interest of induction chemotherapy for head and neck cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2017 |
[Role and interest of induction chemotherapy for head and neck cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2017 |
Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2017 |
Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolifera | 2017 |
Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolifera | 2017 |
Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolifera | 2017 |
Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Prolifera | 2017 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2018 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2018 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2018 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2018 |
A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carcinoma; Chemoradiotherapy; China; Cisplatin; Dise | 2018 |
A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carcinoma; Chemoradiotherapy; China; Cisplatin; Dise | 2018 |
A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carcinoma; Chemoradiotherapy; China; Cisplatin; Dise | 2018 |
A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carcinoma; Chemoradiotherapy; China; Cisplatin; Dise | 2018 |
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line | 2018 |
Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line | 2018 |
Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line | 2018 |
Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line | 2018 |
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorouracil; | 2018 |
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorouracil; | 2018 |
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorouracil; | 2018 |
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorouracil; | 2018 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2019 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2019 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2019 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2019 |
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluoroura | 2019 |
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluoroura | 2019 |
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluoroura | 2019 |
Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Female; Fluoroura | 2019 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, | 2019 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, | 2019 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, | 2019 |
Towards risk-stratified induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Clinical Trials, | 2019 |
Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-F | 2019 |
Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-F | 2019 |
Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-F | 2019 |
Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-F | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Thermosensitive nanohydrogel of 5-fluorouracil for head and neck cancer: preparation, characterization and cytotoxicity assay.
Topics: Cell Death; Cell Line, Tumor; Fluorouracil; Head and Neck Neoplasms; Humans; Hydrogels; Temperature | 2018 |
Thermosensitive nanohydrogel of 5-fluorouracil for head and neck cancer: preparation, characterization and cytotoxicity assay.
Topics: Cell Death; Cell Line, Tumor; Fluorouracil; Head and Neck Neoplasms; Humans; Hydrogels; Temperature | 2018 |
Thermosensitive nanohydrogel of 5-fluorouracil for head and neck cancer: preparation, characterization and cytotoxicity assay.
Topics: Cell Death; Cell Line, Tumor; Fluorouracil; Head and Neck Neoplasms; Humans; Hydrogels; Temperature | 2018 |
Thermosensitive nanohydrogel of 5-fluorouracil for head and neck cancer: preparation, characterization and cytotoxicity assay.
Topics: Cell Death; Cell Line, Tumor; Fluorouracil; Head and Neck Neoplasms; Humans; Hydrogels; Temperature | 2018 |
Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2019 |
Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2019 |
Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2019 |
Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2019 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2019 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2019 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2019 |
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax | 2019 |
Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Prot | 2019 |
Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Prot | 2019 |
Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Prot | 2019 |
Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; C-Reactive Prot | 2019 |
DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 2019 |
DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 2019 |
DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 2019 |
DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpor | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Induction chemotherapy challenges for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; | 2013 |
Induction chemotherapy challenges for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; | 2013 |
Induction chemotherapy challenges for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; | 2013 |
Induction chemotherapy challenges for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; | 2013 |
Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Animals; Colonic Neoplasms; Female; Fluorine Radioisotopes; Fluorour | 2013 |
Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Animals; Colonic Neoplasms; Female; Fluorine Radioisotopes; Fluorour | 2013 |
Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Animals; Colonic Neoplasms; Female; Fluorine Radioisotopes; Fluorour | 2013 |
Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Animals; Colonic Neoplasms; Female; Fluorine Radioisotopes; Fluorour | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Survival impact of pulmonary metastasectomy for patients with head and neck cancer.
Topics: Adenoma; Antineoplastic Agents; Carcinoma; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck | 2013 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dru | 2013 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dru | 2013 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dru | 2013 |
Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dru | 2013 |
Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.
Topics: Adolescent; Adult; Biomarkers, Pharmacological; Cisplatin; Female; Fluorouracil; Genetic Association | 2013 |
Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.
Topics: Adolescent; Adult; Biomarkers, Pharmacological; Cisplatin; Female; Fluorouracil; Genetic Association | 2013 |
Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.
Topics: Adolescent; Adult; Biomarkers, Pharmacological; Cisplatin; Female; Fluorouracil; Genetic Association | 2013 |
Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.
Topics: Adolescent; Adult; Biomarkers, Pharmacological; Cisplatin; Female; Fluorouracil; Genetic Association | 2013 |
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms | 2013 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colonic Neoplasms | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine | 2013 |
Cisplatin plus capecitabine as first-line chemotherapy for recurrent or metastatic head and neck squamous cell cancer: experience outside of a trial setting.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine | 2013 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, West | 2013 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, West | 2013 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, West | 2013 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, West | 2013 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
5% fluorouracil chemowraps in the management of widespread lower leg solar keratoses and squamous cell carcinoma.
Topics: Administration, Cutaneous; Antimetabolites, Antineoplastic; Bandages; Carcinoma, Squamous Cell; Fluo | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-B | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-B | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-B | 2013 |
Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cost-B | 2013 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni | 2013 |
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni | 2013 |
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni | 2013 |
Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Do | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Do | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Do | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Do | 2013 |
Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Fluorouracil; G | 2013 |
Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Fluorouracil; G | 2013 |
Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Fluorouracil; G | 2013 |
Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Fluorouracil; G | 2013 |
Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2014 |
Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2013 |
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2013 |
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2013 |
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2013 |
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluoroura | 2014 |
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluoroura | 2014 |
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluoroura | 2014 |
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Female; Fluoroura | 2014 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.
Topics: Animals; Area Under Curve; Bile; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Male; Radiometry; | 2013 |
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema | 2014 |
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema | 2014 |
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema | 2014 |
Changes of oral microcirculation in chemotherapy patients: A possible correlation with mucositis?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fema | 2014 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers.
Topics: Administration, Buccal; Animals; Antimetabolites, Antineoplastic; Cattle; Diffusion; Fluorouracil; H | 2014 |
Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers.
Topics: Administration, Buccal; Animals; Antimetabolites, Antineoplastic; Cattle; Diffusion; Fluorouracil; H | 2014 |
Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers.
Topics: Administration, Buccal; Animals; Antimetabolites, Antineoplastic; Cattle; Diffusion; Fluorouracil; H | 2014 |
Targeted local simultaneous iontophoresis of chemotherapeutics for topical therapy of head and neck cancers.
Topics: Administration, Buccal; Animals; Antimetabolites, Antineoplastic; Cattle; Diffusion; Fluorouracil; H | 2014 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyr | 2014 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyr | 2014 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyr | 2014 |
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Dihydropyr | 2014 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; | 2013 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; | 2013 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; | 2013 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; | 2013 |
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squam | 2013 |
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squam | 2013 |
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squam | 2013 |
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squam | 2013 |
Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Cisplatin | 2014 |
Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Cisplatin | 2014 |
Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Cisplatin | 2014 |
Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Cisplatin | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2014 |
Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2014 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Impending Carotid Blowout Syndrome.
Topics: Angiography; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Caro | 2015 |
Impending Carotid Blowout Syndrome.
Topics: Angiography; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Caro | 2015 |
Impending Carotid Blowout Syndrome.
Topics: Angiography; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Caro | 2015 |
Impending Carotid Blowout Syndrome.
Topics: Angiography; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Caro | 2015 |
Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Cisplatin; Docetaxel; Drug Therapy, Combinati | 2014 |
Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Cisplatin; Docetaxel; Drug Therapy, Combinati | 2014 |
Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Cisplatin; Docetaxel; Drug Therapy, Combinati | 2014 |
Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Cisplatin; Docetaxel; Drug Therapy, Combinati | 2014 |
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; C | 2014 |
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; C | 2014 |
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; C | 2014 |
Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; C | 2014 |
INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synerg | 2014 |
INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synerg | 2014 |
INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synerg | 2014 |
INF-γ sensitizes head and neck squamous cell carcinoma cells to chemotherapy-induced apoptosis and necroptosis through up-regulation of Egr-1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Synerg | 2014 |
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Car | 2014 |
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Car | 2014 |
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Car | 2014 |
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Car | 2014 |
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relatio | 2014 |
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relatio | 2014 |
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relatio | 2014 |
Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relatio | 2014 |
Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proli | 2014 |
Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proli | 2014 |
Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proli | 2014 |
Cell-cycle distribution and Thymidilate Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Proli | 2014 |
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Sq | 2014 |
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Sq | 2014 |
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Sq | 2014 |
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Sq | 2014 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su | 2015 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2014 |
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2014 |
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2014 |
Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2014 |
Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2014 |
Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2014 |
Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2014 |
Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response | 2014 |
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2014 |
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2014 |
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2014 |
Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2014 |
Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CD3 Complex; Cell | 2015 |
Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CD3 Complex; Cell | 2015 |
Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CD3 Complex; Cell | 2015 |
Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3β inhibitors.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CD3 Complex; Cell | 2015 |
Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor | 2014 |
Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor | 2014 |
Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor | 2014 |
Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor | 2014 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2015 |
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cisplatin; Drug Resist | 2015 |
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplati | 2015 |
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplati | 2015 |
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplati | 2015 |
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplati | 2015 |
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival | 2015 |
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival | 2015 |
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival | 2015 |
Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival | 2015 |
Effectiveness of CT assists for intraarterial chemotherapy: therapeutic outcome of chemoradiation for advanced head and neck cancer extending across the anatomical midline.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Antineoplas | 2014 |
Effectiveness of CT assists for intraarterial chemotherapy: therapeutic outcome of chemoradiation for advanced head and neck cancer extending across the anatomical midline.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Antineoplas | 2014 |
Effectiveness of CT assists for intraarterial chemotherapy: therapeutic outcome of chemoradiation for advanced head and neck cancer extending across the anatomical midline.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Antineoplas | 2014 |
Effectiveness of CT assists for intraarterial chemotherapy: therapeutic outcome of chemoradiation for advanced head and neck cancer extending across the anatomical midline.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Antineoplas | 2014 |
Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bridged Bicyclo Compound | 2015 |
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bridged Bicyclo Compound | 2015 |
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bridged Bicyclo Compound | 2015 |
Enhanced anticancer activity of a protein phosphatase 2A inhibitor on chemotherapy and radiation in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bridged Bicyclo Compound | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2015 |
Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2015 |
Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2015 |
Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2015 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 2014 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 2014 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 2014 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 2014 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
[5-FU+CDDP(FP) +cetuximab in recurrence/metastasis head and neck cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cispla | 2015 |
[5-FU+CDDP(FP) +cetuximab in recurrence/metastasis head and neck cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cispla | 2015 |
[5-FU+CDDP(FP) +cetuximab in recurrence/metastasis head and neck cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cispla | 2015 |
[5-FU+CDDP(FP) +cetuximab in recurrence/metastasis head and neck cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cispla | 2015 |
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; C | 2015 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2015 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2015 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2015 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2015 |
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2016 |
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2016 |
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2016 |
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2016 |
Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doc | 2015 |
Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doc | 2015 |
Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doc | 2015 |
Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doc | 2015 |
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2015 |
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2015 |
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2015 |
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma | 2015 |
Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Dise | 2016 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Dise | 2016 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Dise | 2016 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Dise | 2016 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2015 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2015 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2015 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2015 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2016 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2016 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2016 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2016 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Topics: Adult; Aged; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Genotype; Head and N | 2015 |
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Topics: Adult; Aged; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Genotype; Head and N | 2015 |
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Topics: Adult; Aged; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Genotype; Head and N | 2015 |
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Topics: Adult; Aged; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Genotype; Head and N | 2015 |
[Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin（Divided Doses for 5 Days), and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Docetaxel; Female; Fluorouracil; H | 2015 |
[Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin（Divided Doses for 5 Days), and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Docetaxel; Female; Fluorouracil; H | 2015 |
[Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin（Divided Doses for 5 Days), and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Docetaxel; Female; Fluorouracil; H | 2015 |
[Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin（Divided Doses for 5 Days), and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Docetaxel; Female; Fluorouracil; H | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2015 |
Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamou | 2016 |
Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamou | 2016 |
Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamou | 2016 |
Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamou | 2016 |
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Ca | 2015 |
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Ca | 2015 |
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Ca | 2015 |
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Ca | 2015 |
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Sequential Curettage, 5-Fluorouracil, and Photodynamic Therapy for Field Cancerization of the Scalp and Face in Solid Organ Transplant Recipients.
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Ther | 2016 |
Comparative evaluation of PLGA nanoparticle delivery system for 5-fluorouracil and curcumin on squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug | 2016 |
Comparative evaluation of PLGA nanoparticle delivery system for 5-fluorouracil and curcumin on squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug | 2016 |
Comparative evaluation of PLGA nanoparticle delivery system for 5-fluorouracil and curcumin on squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug | 2016 |
Comparative evaluation of PLGA nanoparticle delivery system for 5-fluorouracil and curcumin on squamous cell carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug | 2016 |
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisp | 2017 |
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisp | 2017 |
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisp | 2017 |
Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisp | 2017 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2016 |
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2016 |
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2016 |
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemor | 2016 |
[Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherap | 2016 |
[Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherap | 2016 |
[Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherap | 2016 |
[Observance and results of concurrent chemoradiotherapy after induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil for locally advanced head and neck cancers].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherap | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Biomarkers, Tumor; Carcinoma, Sq | 2016 |
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Biomarkers, Tumor; Carcinoma, Sq | 2016 |
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Biomarkers, Tumor; Carcinoma, Sq | 2016 |
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Biomarkers, Tumor; Carcinoma, Sq | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuxi | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuxi | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuxi | 2016 |
Induction chemotherapy before surgery for unresectable head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuxi | 2016 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemor | 2017 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemor | 2017 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemor | 2017 |
Clinical management of squamous cell carcinoma associated with sinonasal inverted papilloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemor | 2017 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2016 |
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2016 |
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2016 |
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2016 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuxima | 2016 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuxima | 2016 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuxima | 2016 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuxima | 2016 |
Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2016 |
Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2016 |
Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2016 |
Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2016 |
Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplat | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplat | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplat | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplat | 2016 |
Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasm | 2016 |
Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasm | 2016 |
Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasm | 2016 |
Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Neck Neoplasm | 2016 |
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; | 2016 |
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; | 2016 |
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; | 2016 |
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; | 2016 |
Capecitabine and lapatinib treatment in head and neck cancer.
Topics: Capecitabine; Cisplatin; Disease-Free Survival; Early Growth Response Protein 1; Early Growth Respon | 2016 |
Capecitabine and lapatinib treatment in head and neck cancer.
Topics: Capecitabine; Cisplatin; Disease-Free Survival; Early Growth Response Protein 1; Early Growth Respon | 2016 |
Capecitabine and lapatinib treatment in head and neck cancer.
Topics: Capecitabine; Cisplatin; Disease-Free Survival; Early Growth Response Protein 1; Early Growth Respon | 2016 |
Capecitabine and lapatinib treatment in head and neck cancer.
Topics: Capecitabine; Cisplatin; Disease-Free Survival; Early Growth Response Protein 1; Early Growth Respon | 2016 |
Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospital.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Nec | 2016 |
Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospital.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Nec | 2016 |
Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospital.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Nec | 2016 |
Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospital.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Head and Nec | 2016 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2016 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Topics: 3' Untranslated Regions; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Arecoline; | 2016 |
Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Topics: 3' Untranslated Regions; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Arecoline; | 2016 |
Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Topics: 3' Untranslated Regions; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Arecoline; | 2016 |
Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Topics: 3' Untranslated Regions; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Arecoline; | 2016 |
Exclusive concurrent radiochemotherapy for advanced head and neck cancers with 'fractionated' 5-fluorouracil and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Exclusive concurrent radiochemotherapy for advanced head and neck cancers with 'fractionated' 5-fluorouracil and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Exclusive concurrent radiochemotherapy for advanced head and neck cancers with 'fractionated' 5-fluorouracil and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Exclusive concurrent radiochemotherapy for advanced head and neck cancers with 'fractionated' 5-fluorouracil and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies | 2016 |
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies | 2016 |
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies | 2016 |
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies | 2016 |
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplements; Docetaxel; Fem | 2017 |
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplements; Docetaxel; Fem | 2017 |
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplements; Docetaxel; Fem | 2017 |
Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplements; Docetaxel; Fem | 2017 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, | 2016 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2017 |
Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells.
Topics: Acrylic Resins; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Mem | 2017 |
Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells.
Topics: Acrylic Resins; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Mem | 2017 |
Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells.
Topics: Acrylic Resins; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Mem | 2017 |
Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells.
Topics: Acrylic Resins; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Mem | 2017 |
Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemo | 2008 |
Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemo | 2008 |
Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemo | 2008 |
Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemo | 2008 |
Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2008 |
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Dihydrour | 2009 |
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Dihydrour | 2009 |
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Dihydrour | 2009 |
The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Dihydrour | 2009 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2008 |
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2008 |
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2008 |
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2008 |
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Proliferation; Fluorouracil; Head an | 2009 |
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Proliferation; Fluorouracil; Head an | 2009 |
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Proliferation; Fluorouracil; Head an | 2009 |
Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Proliferation; Fluorouracil; Head an | 2009 |
5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Fluoroura | 2009 |
5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Fluoroura | 2009 |
5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Fluoroura | 2009 |
5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Fluoroura | 2009 |
[Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolizati | 2008 |
[Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolizati | 2008 |
[Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolizati | 2008 |
[Intra-arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoembolizati | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Topics: Animals; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Deh | 2009 |
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Topics: Animals; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Deh | 2009 |
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Topics: Animals; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Deh | 2009 |
The predictive and therapeutic value of thymidine phosphorylase and dihydropyrimidine dehydrogenase in capecitabine (Xeloda)-based chemotherapy for head and neck cancer.
Topics: Animals; Biomarkers, Tumor; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Dihydrouracil Deh | 2009 |
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2009 |
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2009 |
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2009 |
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2009 |
Targeting EGFR in head and neck cancer: a decade of progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Targeting EGFR in head and neck cancer: a decade of progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Targeting EGFR in head and neck cancer: a decade of progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Targeting EGFR in head and neck cancer: a decade of progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2009 |
Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2009 |
Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2009 |
Neoadjuvant chemotherapy followed by limited surgery in a mouse model of head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diseas | 2009 |
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2009 |
Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose Fra | 2009 |
Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose Fra | 2009 |
Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose Fra | 2009 |
Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Dose Fra | 2009 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Assoc | 2009 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Assoc | 2009 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Assoc | 2009 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Assoc | 2009 |
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplat | 2009 |
Cutaneous human papillomavirus in head and neck squamous cell carcinomas.
Topics: Aged; Alcohol Drinking; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2009 |
Cutaneous human papillomavirus in head and neck squamous cell carcinomas.
Topics: Aged; Alcohol Drinking; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2009 |
Cutaneous human papillomavirus in head and neck squamous cell carcinomas.
Topics: Aged; Alcohol Drinking; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2009 |
Cutaneous human papillomavirus in head and neck squamous cell carcinomas.
Topics: Aged; Alcohol Drinking; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carbopl | 2009 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2010 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2010 |
[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Cisplatin; Cli | 2009 |
[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Cisplatin; Cli | 2009 |
[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Cisplatin; Cli | 2009 |
[Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Cisplatin; Cli | 2009 |
[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2009 |
[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2009 |
[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2009 |
[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2009 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Altered glucose metabolism during chemoradiation for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cispl | 2009 |
Altered glucose metabolism during chemoradiation for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cispl | 2009 |
Altered glucose metabolism during chemoradiation for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cispl | 2009 |
Altered glucose metabolism during chemoradiation for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cispl | 2009 |
Diagnosis of lymph node metastases of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2010 |
Diagnosis of lymph node metastases of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2010 |
Diagnosis of lymph node metastases of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2010 |
Diagnosis of lymph node metastases of head and neck cancer and evaluation of effects of chemoradiotherapy using ultrasonography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2010 |
[In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770].
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplat | 2010 |
[In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770].
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplat | 2010 |
[In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770].
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplat | 2010 |
[In reference to the article: "Neck dissection following chemoradiation for node positive head and neck carcinomas" by Thariat et al. Cancer Radiother 2009;13:758-770].
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplat | 2010 |
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl | 2010 |
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl | 2010 |
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl | 2010 |
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl | 2010 |
[Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
[Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
[Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
[Concurrent chemoradiotherapy for resectable locoregionally advanced squamous cell carcinoma of the head and neck-analysis of factors associated with toxicity and efficacy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2010 |
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Topics: Adenoviridae; Animals; Cell Line; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Female; Flucy | 2010 |
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Topics: Adenoviridae; Animals; Cell Line; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Female; Flucy | 2010 |
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Topics: Adenoviridae; Animals; Cell Line; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Female; Flucy | 2010 |
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Topics: Adenoviridae; Animals; Cell Line; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Female; Flucy | 2010 |
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Fluorouracil; Head and Neck N | 2010 |
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Fluorouracil; Head and Neck N | 2010 |
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Fluorouracil; Head and Neck N | 2010 |
High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Fluorouracil; Head and Neck N | 2010 |
Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2011 |
Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2011 |
Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2011 |
Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2011 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
In regards to Barkati et al. (Int J Radiat Oncol Biol Phys 2010;76:410-416).
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; He | 2010 |
In regards to Barkati et al. (Int J Radiat Oncol Biol Phys 2010;76:410-416).
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; He | 2010 |
In regards to Barkati et al. (Int J Radiat Oncol Biol Phys 2010;76:410-416).
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; He | 2010 |
In regards to Barkati et al. (Int J Radiat Oncol Biol Phys 2010;76:410-416).
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Fluorouracil; He | 2010 |
Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2010 |
Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2010 |
Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2010 |
Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2010 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
[Treatment of advanced head and neck cancer by TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2010 |
[Treatment of advanced head and neck cancer by TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2010 |
[Treatment of advanced head and neck cancer by TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2010 |
[Treatment of advanced head and neck cancer by TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Ne | 2010 |
[Effectiveness of concurrent chemoradiation therapy using TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2010 |
[Effectiveness of concurrent chemoradiation therapy using TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2010 |
[Effectiveness of concurrent chemoradiation therapy using TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2010 |
[Effectiveness of concurrent chemoradiation therapy using TPF].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2010 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West | 2010 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West | 2010 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West | 2010 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous | 2011 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous | 2011 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous | 2011 |
Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous | 2011 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract | 2011 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplat | 2010 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplat | 2010 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplat | 2010 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplat | 2010 |
The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati | 2011 |
The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati | 2011 |
The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati | 2011 |
The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy; Cisplati | 2011 |
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Topics: Capecitabine; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Comet Assay; Deoxycytidine; D | 2011 |
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Topics: Capecitabine; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Comet Assay; Deoxycytidine; D | 2011 |
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Topics: Capecitabine; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Comet Assay; Deoxycytidine; D | 2011 |
Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cells.
Topics: Capecitabine; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Comet Assay; Deoxycytidine; D | 2011 |
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 2010 |
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 2010 |
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 2010 |
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 2010 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas.
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Female; Flow Cyt | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell | 2011 |
Induction chemotherapy in head and neck cancer: closer to an answer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; Humans; Immun | 2011 |
Induction chemotherapy in head and neck cancer: closer to an answer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; Humans; Immun | 2011 |
Induction chemotherapy in head and neck cancer: closer to an answer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; Humans; Immun | 2011 |
Induction chemotherapy in head and neck cancer: closer to an answer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; Humans; Immun | 2011 |
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Squam | 2012 |
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Squam | 2012 |
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Squam | 2012 |
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Squam | 2012 |
Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2011 |
Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2011 |
Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2011 |
Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2011 |
Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Decision | 2012 |
The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Decision | 2012 |
The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Decision | 2012 |
The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Decision | 2012 |
Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
Low-dose preoperative chemoradiation therapy compared with surgery alone with or without postoperative radiotherapy in patients with head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confounding Fac | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confounding Fac | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confounding Fac | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confounding Fac | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2011 |
High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brachytherapy; Carci | 2011 |
High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brachytherapy; Carci | 2011 |
High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brachytherapy; Carci | 2011 |
High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brachytherapy; Carci | 2011 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
[Current status of TPF therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; F | 2011 |
[Current status of TPF therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; F | 2011 |
[Current status of TPF therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; F | 2011 |
[Current status of TPF therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Fluorouracil; F | 2011 |
Optimizing treatments of locally advanced squamous cell carcinoma: where to go from here?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2011 |
Optimizing treatments of locally advanced squamous cell carcinoma: where to go from here?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2011 |
Optimizing treatments of locally advanced squamous cell carcinoma: where to go from here?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2011 |
Optimizing treatments of locally advanced squamous cell carcinoma: where to go from here?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2011 |
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2011 |
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2011 |
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2011 |
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2011 |
Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2011 |
Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Enzym | 2011 |
Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Enzym | 2011 |
Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Enzym | 2011 |
Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Enzym | 2011 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2011 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2011 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2011 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2011 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2012 |
A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Pr | 2012 |
A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Pr | 2012 |
A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Pr | 2012 |
A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Carcinoma, Squamous Cell; Cell Pr | 2012 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; | 2012 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; | 2012 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; | 2012 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; | 2012 |
Neoadjuvant chemotherapy prior to surgery in head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2012 |
Neoadjuvant chemotherapy prior to surgery in head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2012 |
Neoadjuvant chemotherapy prior to surgery in head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2012 |
Neoadjuvant chemotherapy prior to surgery in head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2012 |
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorocebus aethiops; Cytosine Deaminase; ErbB | 2012 |
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorocebus aethiops; Cytosine Deaminase; ErbB | 2012 |
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorocebus aethiops; Cytosine Deaminase; ErbB | 2012 |
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorocebus aethiops; Cytosine Deaminase; ErbB | 2012 |
Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, T | 2012 |
Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, T | 2012 |
Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, T | 2012 |
Synthesis and in vitro anti-tumor activity of novel HPMA copolymer-drug conjugates with potential cell surface targeting property for carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, T | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit An | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit An | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit An | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit An | 2012 |
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.
Topics: Aged; Antibodies, Bispecific; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.
Topics: Aged; Antibodies, Bispecific; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.
Topics: Aged; Antibodies, Bispecific; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment.
Topics: Aged; Antibodies, Bispecific; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols | 2011 |
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2012 |
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2012 |
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2012 |
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2012 |
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2012 |
Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chro | 2012 |
Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chro | 2012 |
Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chro | 2012 |
Chromosomal rearrangements in lymphocytes of head and neck squamous cell carcinoma treated with chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chro | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; | 2012 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; | 2012 |
Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Blotting, Western; Car | 2012 |
Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Blotting, Western; Car | 2012 |
Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Blotting, Western; Car | 2012 |
Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Blotting, Western; Car | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
Efficacy analysis of simplified intensity-modulated radiotherapy with high or conventional dose and concurrent chemotherapy for patients with neck and upper thoracic esophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neop | 2012 |
[Usefulness and indication of superselective intra-arterial chemotherapy via the radial artery for advanced head and neck cancer--aN indication for inaccessible to treatment with seldingers method].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; F | 2012 |
[Usefulness and indication of superselective intra-arterial chemotherapy via the radial artery for advanced head and neck cancer--aN indication for inaccessible to treatment with seldingers method].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; F | 2012 |
[Usefulness and indication of superselective intra-arterial chemotherapy via the radial artery for advanced head and neck cancer--aN indication for inaccessible to treatment with seldingers method].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; F | 2012 |
[Usefulness and indication of superselective intra-arterial chemotherapy via the radial artery for advanced head and neck cancer--aN indication for inaccessible to treatment with seldingers method].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Female; F | 2012 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2013 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Digestive symptoms as side effects of combination chemotherapy of docetaxel, nedaplatin and 5-fluorouracil for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Head and Neck | 2012 |
Digestive symptoms as side effects of combination chemotherapy of docetaxel, nedaplatin and 5-fluorouracil for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Head and Neck | 2012 |
Digestive symptoms as side effects of combination chemotherapy of docetaxel, nedaplatin and 5-fluorouracil for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Head and Neck | 2012 |
Digestive symptoms as side effects of combination chemotherapy of docetaxel, nedaplatin and 5-fluorouracil for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Head and Neck | 2012 |
Induction docetaxel, Cisplatin, and 5-Fluorouracil precludes definitive chemoradiotherapy in a substantial proportion of patients with head and neck cancer in a low socioeconomic status population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2014 |
Induction docetaxel, Cisplatin, and 5-Fluorouracil precludes definitive chemoradiotherapy in a substantial proportion of patients with head and neck cancer in a low socioeconomic status population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2014 |
Induction docetaxel, Cisplatin, and 5-Fluorouracil precludes definitive chemoradiotherapy in a substantial proportion of patients with head and neck cancer in a low socioeconomic status population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2014 |
Induction docetaxel, Cisplatin, and 5-Fluorouracil precludes definitive chemoradiotherapy in a substantial proportion of patients with head and neck cancer in a low socioeconomic status population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2014 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa | 2013 |
Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa | 2013 |
Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa | 2013 |
Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa | 2013 |
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin | 2002 |
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin | 2002 |
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin | 2002 |
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin | 2002 |
Radiation could induce p53-independent and cell cycle--unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line; Coloring Agents; Flow | 2002 |
Radiation could induce p53-independent and cell cycle--unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line; Coloring Agents; Flow | 2002 |
Radiation could induce p53-independent and cell cycle--unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line; Coloring Agents; Flow | 2002 |
Radiation could induce p53-independent and cell cycle--unrelated apoptosis in 5-fluorouracil radiosensitized head and neck carcinoma cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line; Coloring Agents; Flow | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2002 |
Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2002 |
Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2002 |
Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2002 |
Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2002 |
Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Hypoxia; Female; Fluorouracil; Head | 2003 |
Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Hypoxia; Female; Fluorouracil; Head | 2003 |
Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Hypoxia; Female; Fluorouracil; Head | 2003 |
Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cell Hypoxia; Female; Fluorouracil; Head | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Non-Q-Wave acute anterior myocardial infarction associated with 5-fluorouracil and cisplatin chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; F | 2003 |
Non-Q-Wave acute anterior myocardial infarction associated with 5-fluorouracil and cisplatin chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; F | 2003 |
Non-Q-Wave acute anterior myocardial infarction associated with 5-fluorouracil and cisplatin chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; F | 2003 |
Non-Q-Wave acute anterior myocardial infarction associated with 5-fluorouracil and cisplatin chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; F | 2003 |
[Preoperative concurrent chemoradiotherapy with intra-arterial infusion of pirarubicin and continuous intravenous instillation of 5-fluorouracil for resectable advanced head and neck squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2003 |
[Preoperative concurrent chemoradiotherapy with intra-arterial infusion of pirarubicin and continuous intravenous instillation of 5-fluorouracil for resectable advanced head and neck squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2003 |
[Preoperative concurrent chemoradiotherapy with intra-arterial infusion of pirarubicin and continuous intravenous instillation of 5-fluorouracil for resectable advanced head and neck squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2003 |
[Preoperative concurrent chemoradiotherapy with intra-arterial infusion of pirarubicin and continuous intravenous instillation of 5-fluorouracil for resectable advanced head and neck squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2003 |
[Combined MTX.5-FU.CDGP for the treatment of head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
[Combined MTX.5-FU.CDGP for the treatment of head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
[Combined MTX.5-FU.CDGP for the treatment of head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
[Combined MTX.5-FU.CDGP for the treatment of head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2003 |
Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2003 |
Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2003 |
Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2003 |
[Chronobiological considerations for the management of human head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case Ma | 2003 |
[Chronobiological considerations for the management of human head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case Ma | 2003 |
[Chronobiological considerations for the management of human head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case Ma | 2003 |
[Chronobiological considerations for the management of human head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case Ma | 2003 |
Treatment outcome of N3 nodal head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 2003 |
Treatment outcome of N3 nodal head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 2003 |
Treatment outcome of N3 nodal head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 2003 |
Treatment outcome of N3 nodal head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 2003 |
Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dihydr | 2003 |
Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dihydr | 2003 |
Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dihydr | 2003 |
Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dihydr | 2003 |
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cispla | 2003 |
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cispla | 2003 |
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cispla | 2003 |
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cispla | 2003 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Bl | 2003 |
[Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2003 |
[Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2003 |
[Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2003 |
[Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2003 |
Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 2003 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.
Topics: Angiography; Arm; Brachiocephalic Trunk; Brain Neoplasms; Carotid Arteries; Chemotherapy, Cancer, Re | 1964 |
INTRA-ARTERIAL INFUSION FOR HEAD AND NECK CANCER.
Topics: Antineoplastic Agents; Brain Neoplasms; Dactinomycin; Facial Neoplasms; Fluorouracil; Head and Neck | 1964 |
INTRA-ARTERIAL INFUSION FOR HEAD AND NECK CANCER.
Topics: Antineoplastic Agents; Brain Neoplasms; Dactinomycin; Facial Neoplasms; Fluorouracil; Head and Neck | 1964 |
INTRA-ARTERIAL INFUSION FOR HEAD AND NECK CANCER.
Topics: Antineoplastic Agents; Brain Neoplasms; Dactinomycin; Facial Neoplasms; Fluorouracil; Head and Neck | 1964 |
INTRA-ARTERIAL INFUSION FOR HEAD AND NECK CANCER.
Topics: Antineoplastic Agents; Brain Neoplasms; Dactinomycin; Facial Neoplasms; Fluorouracil; Head and Neck | 1964 |
INTRA-ARTERIAL CHEMOTHERAPY.
Topics: Brain Neoplasms; Drug Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Parenteral; | 1964 |
INTRA-ARTERIAL CHEMOTHERAPY.
Topics: Brain Neoplasms; Drug Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Parenteral; | 1964 |
INTRA-ARTERIAL CHEMOTHERAPY.
Topics: Brain Neoplasms; Drug Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Parenteral; | 1964 |
INTRA-ARTERIAL CHEMOTHERAPY.
Topics: Brain Neoplasms; Drug Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Parenteral; | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
COMBINED CHEMOTHERAPY AND RADIATION THERAPY IN ADVANCED MALIGNANCIES.
Topics: Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neoplasms; Humans; La | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
[REGIONAL INTRA-ARTERIAL CYTOSTATIC THERAPY OF MALIGNANT TUMORS OF THE HEAD AND NECK].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
REGIONAL ARTERIAL INFUSION OF ANTIMETABOLITES. AN ANALYSIS OF THE RESULTS OBTAINED IN 33 PATIENTS WITH MALIGNANT TUMORS OF THE HEAD AND NECK.
Topics: Antimetabolites; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; H | 1965 |
Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2003 |
Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cal | 2003 |
Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cal | 2003 |
Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cal | 2003 |
Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma.
Topics: Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cal | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous C | 2003 |
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous C | 2003 |
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous C | 2003 |
Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous C | 2003 |
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cycl | 2004 |
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cycl | 2004 |
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cycl | 2004 |
Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas.
Topics: Aged; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Cyclin E; Cycl | 2004 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Head an | 2004 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Head an | 2004 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Head an | 2004 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Head an | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2004 |
Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2004 |
Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2004 |
Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2004 |
Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2004 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
Topics: Aged; Alleles; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Fas Ligand Protein; fas | 2004 |
Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
Topics: Aged; Alleles; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Fas Ligand Protein; fas | 2004 |
Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
Topics: Aged; Alleles; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Fas Ligand Protein; fas | 2004 |
Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
Topics: Aged; Alleles; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Fas Ligand Protein; fas | 2004 |
Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Caspase 1; Cell Line, | 2004 |
Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Caspase 1; Cell Line, | 2004 |
Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Caspase 1; Cell Line, | 2004 |
Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Squamous Cell; Caspase 1; Cell Line, | 2004 |
Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Carcinoma, | 2004 |
Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Carcinoma, | 2004 |
Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Carcinoma, | 2004 |
Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Carcinoma, | 2004 |
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2004 |
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2004 |
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2004 |
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2004 |
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2004 |
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2004 |
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2004 |
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2004 |
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; | 2004 |
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; | 2004 |
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; | 2004 |
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; | 2004 |
Functional outcomes following chemoradiotherapy for head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Functional outcomes following chemoradiotherapy for head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Functional outcomes following chemoradiotherapy for head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Functional outcomes following chemoradiotherapy for head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2004 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, | 2004 |
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2005 |
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2005 |
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2005 |
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2005 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Cycle; C | 2004 |
[Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Concurrent chemoradiotherapy for head and neck squamous cell carcinoma with indication of total laryngectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 2005 |
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 2005 |
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 2005 |
Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Analysis of Variance; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma | 2005 |
[Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
[Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
[Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
[Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
Results of treatment intensification for progressive locoregional disease in head-and-neck cancer patients undergoing postoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2005 |
Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2005 |
Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2005 |
Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2005 |
[A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
[A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
[A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
[A case of head and neck squamous cell carcinoma suffering from acute renal failure after methotrexate administrator].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2005 |
Post-operative adjuvant chemoradiotherapy with carboplatin and 5-fluorouracil for primary branchiogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Branchioma; Carboplatin; Carcinoma, Squamous Cell; C | 2005 |
Post-operative adjuvant chemoradiotherapy with carboplatin and 5-fluorouracil for primary branchiogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Branchioma; Carboplatin; Carcinoma, Squamous Cell; C | 2005 |
Post-operative adjuvant chemoradiotherapy with carboplatin and 5-fluorouracil for primary branchiogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Branchioma; Carboplatin; Carcinoma, Squamous Cell; C | 2005 |
Post-operative adjuvant chemoradiotherapy with carboplatin and 5-fluorouracil for primary branchiogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Branchioma; Carboplatin; Carcinoma, Squamous Cell; C | 2005 |
Revisiting induction chemotherapy for head and neck cancer. References and reviews.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2005 |
Revisiting induction chemotherapy for head and neck cancer. References and reviews.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2005 |
Revisiting induction chemotherapy for head and neck cancer. References and reviews.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2005 |
Revisiting induction chemotherapy for head and neck cancer. References and reviews.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ci | 2005 |
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin | 2005 |
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin | 2005 |
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin | 2005 |
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin | 2005 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
[A case of unknown primary squamous cell carcinoma in the neck showing a high response with combined chemotherapy including nedaplatin, adriamycin and 5-fluorouracil].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Induction redux: once more with taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2005 |
Adjuvant chemotherapy for Merkel cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Chemotherapy, Adjuvant | 2005 |
Adjuvant chemotherapy for Merkel cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Chemotherapy, Adjuvant | 2005 |
Adjuvant chemotherapy for Merkel cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Chemotherapy, Adjuvant | 2005 |
Adjuvant chemotherapy for Merkel cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Chemotherapy, Adjuvant | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2005 |
Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cell Count; Cisplatin; Epithelium; Female; Fluorouracil; Head an | 2005 |
Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cell Count; Cisplatin; Epithelium; Female; Fluorouracil; Head an | 2005 |
Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cell Count; Cisplatin; Epithelium; Female; Fluorouracil; Head an | 2005 |
Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cell Count; Cisplatin; Epithelium; Female; Fluorouracil; Head an | 2005 |
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Topics: Albuterol; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atenolol; Cispla | 2006 |
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Topics: Albuterol; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atenolol; Cispla | 2006 |
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Topics: Albuterol; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atenolol; Cispla | 2006 |
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Topics: Albuterol; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atenolol; Cispla | 2006 |
Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; DNA Mutational Analysis; DNA, Mitochondrial; Female; Fluorourac | 2006 |
Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; DNA Mutational Analysis; DNA, Mitochondrial; Female; Fluorourac | 2006 |
Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; DNA Mutational Analysis; DNA, Mitochondrial; Female; Fluorourac | 2006 |
Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
Topics: Carcinoma, Squamous Cell; Cisplatin; DNA Mutational Analysis; DNA, Mitochondrial; Female; Fluorourac | 2006 |
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2006 |
Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell | 2006 |
Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell | 2006 |
Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell | 2006 |
Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell | 2006 |
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cell | 2006 |
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cell | 2006 |
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cell | 2006 |
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cell | 2006 |
[Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2006 |
[Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2006 |
[Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2006 |
[Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; | 2006 |
[Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2006 |
[Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2006 |
[Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2006 |
[Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2006 |
Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Caspase 8 | 2006 |
Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Caspase 8 | 2006 |
Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Caspase 8 | 2006 |
Role of caspase 8 as a determinant in chemosensitivity of p53-mutated head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Caspase 8 | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2006 |
Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Density; Bone Matrix; Bone Remode | 2006 |
Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Density; Bone Matrix; Bone Remode | 2006 |
Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Density; Bone Matrix; Bone Remode | 2006 |
Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Density; Bone Matrix; Bone Remode | 2006 |
Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
Topics: Adult; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Cisplatin; Electrocardiography; Fluoro | 2006 |
Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
Topics: Adult; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Cisplatin; Electrocardiography; Fluoro | 2006 |
Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
Topics: Adult; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Cisplatin; Electrocardiography; Fluoro | 2006 |
Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
Topics: Adult; Antimetabolites, Antineoplastic; Arrhythmias, Cardiac; Cisplatin; Electrocardiography; Fluoro | 2006 |
Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2006 |
[Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
[Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
[Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
[Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2006 |
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carci | 2006 |
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carci | 2006 |
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carci | 2006 |
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carci | 2006 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2007 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2007 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2007 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2007 |
Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
Successful treatment of syncope in head and neck cancer with induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 2006 |
Successful treatment of syncope in head and neck cancer with induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 2006 |
Successful treatment of syncope in head and neck cancer with induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 2006 |
Successful treatment of syncope in head and neck cancer with induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Hea | 2006 |
Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2006 |
Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2006 |
Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2006 |
Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispl | 2006 |
Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Pilot study of intraoperative chemotherapy with cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; D | 2007 |
Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; D | 2007 |
Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; D | 2007 |
Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; D | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce | 2007 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec | 2008 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec | 2008 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec | 2008 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec | 2008 |
Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; | 2008 |
Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; | 2008 |
Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; | 2008 |
Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; | 2008 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil; | 2007 |
[Head and neck: concurrent chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Fluorouracil; | 2007 |
[Head and neck: concurrent chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Fluorouracil; | 2007 |
[Head and neck: concurrent chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Fluorouracil; | 2007 |
[Head and neck: concurrent chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Fluorouracil; | 2007 |
Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 2007 |
Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 2007 |
Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 2007 |
Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a | 2007 |
Change of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Pri | 2007 |
Change of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Pri | 2007 |
Change of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Pri | 2007 |
Change of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Pri | 2007 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Car | 2008 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Car | 2008 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Car | 2008 |
Long-term survival of resectable subset after induction chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Car | 2008 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tu | 2008 |
Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tu | 2008 |
Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tu | 2008 |
Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tu | 2008 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Chemotherapy in unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Chemotherapy in unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Chemotherapy in unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Chemotherapy in unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Flu | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; D | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; D | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; D | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; D | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III a | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III a | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III a | 2008 |
Treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III a | 2008 |
Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamou | 2007 |
Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamou | 2007 |
Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamou | 2007 |
Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Squamou | 2007 |
Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square Distribution; C | 2008 |
Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square Distribution; C | 2008 |
Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square Distribution; C | 2008 |
Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square Distribution; C | 2008 |
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[Drug therapy in advanced squamous cell carcinoma of the ORL region].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1984 |
[Drug therapy in advanced squamous cell carcinoma of the ORL region].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1984 |
[Drug therapy in advanced squamous cell carcinoma of the ORL region].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1984 |
[Drug therapy in advanced squamous cell carcinoma of the ORL region].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 1984 |
Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1984 |
Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1984 |
Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1984 |
Combined radiotherapy and CMF-B cytotoxic regimen in stage III-IV head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1984 |
Safe and effective combination chemotherapy for squamous cell carcinomas of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1980 |
Safe and effective combination chemotherapy for squamous cell carcinomas of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1980 |
Safe and effective combination chemotherapy for squamous cell carcinomas of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1980 |
Safe and effective combination chemotherapy for squamous cell carcinomas of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1980 |
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; | 1980 |
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; | 1980 |
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; | 1980 |
Combination chemotherapy for advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; | 1980 |
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Administr | 1980 |
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Administr | 1980 |
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Administr | 1980 |
Advanced recurrent squamous cell carcinoma of the head and neck. Results of a chemotherapeutic regimen with adriamycin, bleomycin, 5-fluorouracil, methotrextate, and vitamin A.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Administr | 1980 |
Simultaneous combination radiotherapy and multidrug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, | 1980 |
Simultaneous combination radiotherapy and multidrug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, | 1980 |
Simultaneous combination radiotherapy and multidrug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, | 1980 |
Simultaneous combination radiotherapy and multidrug chemotherapy for stage III and stage IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, | 1980 |
Chemotherapy for head and neck cancer relapsing after radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Ther | 1981 |
Chemotherapy for head and neck cancer relapsing after radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Ther | 1981 |
Chemotherapy for head and neck cancer relapsing after radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Ther | 1981 |
Chemotherapy for head and neck cancer relapsing after radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Ther | 1981 |
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N | 1981 |
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N | 1981 |
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N | 1981 |
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N | 1981 |
[2 cases of sebaceous cancer observed at the Holy Spirit Hospital in Casale Monferrato in 1980].
Topics: Adenoma; Aged; Anal Gland Neoplasms; Animals; Bleomycin; Diagnosis, Differential; Dinitrochlorobenze | 1982 |
[2 cases of sebaceous cancer observed at the Holy Spirit Hospital in Casale Monferrato in 1980].
Topics: Adenoma; Aged; Anal Gland Neoplasms; Animals; Bleomycin; Diagnosis, Differential; Dinitrochlorobenze | 1982 |
[2 cases of sebaceous cancer observed at the Holy Spirit Hospital in Casale Monferrato in 1980].
Topics: Adenoma; Aged; Anal Gland Neoplasms; Animals; Bleomycin; Diagnosis, Differential; Dinitrochlorobenze | 1982 |
[2 cases of sebaceous cancer observed at the Holy Spirit Hospital in Casale Monferrato in 1980].
Topics: Adenoma; Aged; Anal Gland Neoplasms; Animals; Bleomycin; Diagnosis, Differential; Dinitrochlorobenze | 1982 |
Treatment of carcinoma of the head and neck with combined irradiation and chemotherapy.
Topics: Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Human | 1981 |
Treatment of carcinoma of the head and neck with combined irradiation and chemotherapy.
Topics: Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Human | 1981 |
Treatment of carcinoma of the head and neck with combined irradiation and chemotherapy.
Topics: Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Human | 1981 |
Treatment of carcinoma of the head and neck with combined irradiation and chemotherapy.
Topics: Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Human | 1981 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Non-platinum-containing combination chemotherapy for stage III-IV head and neck squamous carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamid | 1983 |
Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cy | 1984 |
Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cy | 1984 |
Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cy | 1984 |
Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cy | 1984 |
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1984 |
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1984 |
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1984 |
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; | 1984 |
[Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
[Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
[Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
[Results of drug therapy with cisplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck region].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1984 |
[Evaluation of tissue concentrations of FT-207 and 5-FU in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Fluorouracil; Head | 1983 |
[Evaluation of tissue concentrations of FT-207 and 5-FU in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Fluorouracil; Head | 1983 |
[Evaluation of tissue concentrations of FT-207 and 5-FU in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Fluorouracil; Head | 1983 |
[Evaluation of tissue concentrations of FT-207 and 5-FU in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Female; Fluorouracil; Head | 1983 |
[Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorourac | 1983 |
[Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorourac | 1983 |
[Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorourac | 1983 |
[Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorourac | 1983 |
[Silicone elastomers for the local administration of antineoplastic drugs].
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Doxorubicin; Fluorouracil; Head and Nec | 1983 |
[Silicone elastomers for the local administration of antineoplastic drugs].
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Doxorubicin; Fluorouracil; Head and Nec | 1983 |
[Silicone elastomers for the local administration of antineoplastic drugs].
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Doxorubicin; Fluorouracil; Head and Nec | 1983 |
[Silicone elastomers for the local administration of antineoplastic drugs].
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Doxorubicin; Fluorouracil; Head and Nec | 1983 |
[Combined treatment of advanced head and neck cancer using 5-fluorouracil and irradiation in the so-called synchronized cell cycle].
Topics: Cell Cycle; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Radiotherapy D | 1984 |
[Combined treatment of advanced head and neck cancer using 5-fluorouracil and irradiation in the so-called synchronized cell cycle].
Topics: Cell Cycle; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Radiotherapy D | 1984 |
[Combined treatment of advanced head and neck cancer using 5-fluorouracil and irradiation in the so-called synchronized cell cycle].
Topics: Cell Cycle; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Radiotherapy D | 1984 |
[Combined treatment of advanced head and neck cancer using 5-fluorouracil and irradiation in the so-called synchronized cell cycle].
Topics: Cell Cycle; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Radiotherapy D | 1984 |
The role of chemotherapy in untreated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham | 1984 |
The role of chemotherapy in untreated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham | 1984 |
The role of chemotherapy in untreated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham | 1984 |
The role of chemotherapy in untreated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophospham | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1984 |
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1984 |
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1984 |
Ineffectiveness of 5-fluorouracil and cis-platin as second-line chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1984 |
Methotrexate and 5-fluorouracil in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fluoro | 1983 |
Methotrexate and 5-fluorouracil in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fluoro | 1983 |
Methotrexate and 5-fluorouracil in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fluoro | 1983 |
Methotrexate and 5-fluorouracil in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy; Fluoro | 1983 |
Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Head and Neck | 1983 |
Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Head and Neck | 1983 |
Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Head and Neck | 1983 |
Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Head and Neck | 1983 |
Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
A nontoxic adjuvant treatment for advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1983 |
A nontoxic adjuvant treatment for advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1983 |
A nontoxic adjuvant treatment for advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1983 |
A nontoxic adjuvant treatment for advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluoroura | 1983 |
Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck.
Topics: Combined Modality Therapy; Drug Administration Schedule; Evaluation Studies as Topic; Fluorouracil; | 1984 |
Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck.
Topics: Combined Modality Therapy; Drug Administration Schedule; Evaluation Studies as Topic; Fluorouracil; | 1984 |
Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck.
Topics: Combined Modality Therapy; Drug Administration Schedule; Evaluation Studies as Topic; Fluorouracil; | 1984 |
Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck.
Topics: Combined Modality Therapy; Drug Administration Schedule; Evaluation Studies as Topic; Fluorouracil; | 1984 |
[Clinical application of futraful suppositories in malignant head and neck cancer--effects of the therapy combined with radiation].
Topics: Aged; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Suppositories; Tegaf | 1982 |
[Clinical application of futraful suppositories in malignant head and neck cancer--effects of the therapy combined with radiation].
Topics: Aged; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Suppositories; Tegaf | 1982 |
[Clinical application of futraful suppositories in malignant head and neck cancer--effects of the therapy combined with radiation].
Topics: Aged; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Suppositories; Tegaf | 1982 |
[Clinical application of futraful suppositories in malignant head and neck cancer--effects of the therapy combined with radiation].
Topics: Aged; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Suppositories; Tegaf | 1982 |
[Clinical study of HCFU and radiation therapy for head and neck cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Ne | 1983 |
[Clinical study of HCFU and radiation therapy for head and neck cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Ne | 1983 |
[Clinical study of HCFU and radiation therapy for head and neck cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Ne | 1983 |
[Clinical study of HCFU and radiation therapy for head and neck cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Ne | 1983 |
Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck | 1982 |
Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck | 1982 |
Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck | 1982 |
Cis-platinum and 5-fluorouracil as induction therapy for advanced head and neck cancer.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck | 1982 |
[Clinical results of FAR (5-FU, vitamin A, and radiation) therapy in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and Nec | 1982 |
[Clinical results of FAR (5-FU, vitamin A, and radiation) therapy in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and Nec | 1982 |
[Clinical results of FAR (5-FU, vitamin A, and radiation) therapy in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and Nec | 1982 |
[Clinical results of FAR (5-FU, vitamin A, and radiation) therapy in head and neck cancer].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and Nec | 1982 |
Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1994 |
Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1994 |
Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1994 |
Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1994 |
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Topics: Animals; Carcinoma, Squamous Cell; Circadian Rhythm; Colonic Neoplasms; Delayed-Action Preparations; | 1995 |
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Topics: Animals; Carcinoma, Squamous Cell; Circadian Rhythm; Colonic Neoplasms; Delayed-Action Preparations; | 1995 |
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Topics: Animals; Carcinoma, Squamous Cell; Circadian Rhythm; Colonic Neoplasms; Delayed-Action Preparations; | 1995 |
Antitumour activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice.
Topics: Animals; Carcinoma, Squamous Cell; Circadian Rhythm; Colonic Neoplasms; Delayed-Action Preparations; | 1995 |
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and Neck Neoplasms; Huma | 1995 |
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and Neck Neoplasms; Huma | 1995 |
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and Neck Neoplasms; Huma | 1995 |
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
Topics: Adult; Aged; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and Neck Neoplasms; Huma | 1995 |
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1993 |
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1993 |
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1993 |
Folinic acid plus 5-FU based chemotherapy in squamous cell carcinoma of the head and neck: Bologna experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Fine needle aspiration (FNA) in diagnosing recurrent squamous cell carcinoma of the head and neck: truth or consequences?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cobalt Rad | 1993 |
Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line; Cell Survival | 1995 |
Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line; Cell Survival | 1995 |
Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line; Cell Survival | 1995 |
Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line; Cell Survival | 1995 |
[Local chemotherapy by a sustained-release preparation with fibrin seal against the operative wound in head and neck cancer].
Topics: Animals; Delayed-Action Preparations; Fibrin Tissue Adhesive; Fluorouracil; Head and Neck Neoplasms; | 1995 |
[Local chemotherapy by a sustained-release preparation with fibrin seal against the operative wound in head and neck cancer].
Topics: Animals; Delayed-Action Preparations; Fibrin Tissue Adhesive; Fluorouracil; Head and Neck Neoplasms; | 1995 |
[Local chemotherapy by a sustained-release preparation with fibrin seal against the operative wound in head and neck cancer].
Topics: Animals; Delayed-Action Preparations; Fibrin Tissue Adhesive; Fluorouracil; Head and Neck Neoplasms; | 1995 |
[Local chemotherapy by a sustained-release preparation with fibrin seal against the operative wound in head and neck cancer].
Topics: Animals; Delayed-Action Preparations; Fibrin Tissue Adhesive; Fluorouracil; Head and Neck Neoplasms; | 1995 |
Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy.
Topics: Aged; Bone Marrow Diseases; Bone Neoplasms; Carcinoma, Signet Ring Cell; Facial Neoplasms; Fluoroura | 1995 |
Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy.
Topics: Aged; Bone Marrow Diseases; Bone Neoplasms; Carcinoma, Signet Ring Cell; Facial Neoplasms; Fluoroura | 1995 |
Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy.
Topics: Aged; Bone Marrow Diseases; Bone Neoplasms; Carcinoma, Signet Ring Cell; Facial Neoplasms; Fluoroura | 1995 |
Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy.
Topics: Aged; Bone Marrow Diseases; Bone Neoplasms; Carcinoma, Signet Ring Cell; Facial Neoplasms; Fluoroura | 1995 |
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Topics: Breast Neoplasms; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorourac | 1994 |
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Topics: Breast Neoplasms; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorourac | 1994 |
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Topics: Breast Neoplasms; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorourac | 1994 |
A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.
Topics: Breast Neoplasms; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluorourac | 1994 |
Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.
Topics: Breast Neoplasms; Cell Division; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug | 1994 |
Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.
Topics: Breast Neoplasms; Cell Division; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug | 1994 |
Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.
Topics: Breast Neoplasms; Cell Division; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug | 1994 |
Wide range for optimal concentration of folinic acid in fluorouracil modulation--experimental data on human tumour cell lines.
Topics: Breast Neoplasms; Cell Division; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug | 1994 |
[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Carbazilquinone; Carcinoma, Squam | 1994 |
[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Carbazilquinone; Carcinoma, Squam | 1994 |
[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Carbazilquinone; Carcinoma, Squam | 1994 |
[Flow cytometric DNA analysis and chemosensitivity in squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Carbazilquinone; Carcinoma, Squam | 1994 |
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity?
Topics: Adult; Aged; Blood Viscosity; Carcinoma, Squamous Cell; Fibrinogen; Fluorouracil; Head and Neck Neop | 1995 |
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity?
Topics: Adult; Aged; Blood Viscosity; Carcinoma, Squamous Cell; Fibrinogen; Fluorouracil; Head and Neck Neop | 1995 |
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity?
Topics: Adult; Aged; Blood Viscosity; Carcinoma, Squamous Cell; Fibrinogen; Fluorouracil; Head and Neck Neop | 1995 |
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity?
Topics: Adult; Aged; Blood Viscosity; Carcinoma, Squamous Cell; Fibrinogen; Fluorouracil; Head and Neck Neop | 1995 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1995 |
Population study of dihydropyrimidine dehydrogenase in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1994 |
Population study of dihydropyrimidine dehydrogenase in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1994 |
Population study of dihydropyrimidine dehydrogenase in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1994 |
Population study of dihydropyrimidine dehydrogenase in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1994 |
[Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neopla | 1994 |
[Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neopla | 1994 |
[Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neopla | 1994 |
[Tissue concentration of tegafur suppository in patients with head and neck cancer--concentration of 5-FU in cancer tissue].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neopla | 1994 |
Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1994 |
Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1994 |
Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1994 |
Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1994 |
[The effect of induction chemotherapy with CBDCA, 5-FU and UFT in head and neck cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admini | 1994 |
[The effect of induction chemotherapy with CBDCA, 5-FU and UFT in head and neck cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admini | 1994 |
[The effect of induction chemotherapy with CBDCA, 5-FU and UFT in head and neck cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admini | 1994 |
[The effect of induction chemotherapy with CBDCA, 5-FU and UFT in head and neck cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admini | 1994 |
Concomitant chemoradiotherapy for advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cobal | 1994 |
Concomitant chemoradiotherapy for advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cobal | 1994 |
Concomitant chemoradiotherapy for advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cobal | 1994 |
Concomitant chemoradiotherapy for advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cobal | 1994 |
[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
[Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1993 |
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
Relationship between fluorouracil systemic exposure and tumor response and patient survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1994 |
[Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
[Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
[Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
[Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1993 |
Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Combined Modality Therapy; | 1993 |
Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Combined Modality Therapy; | 1993 |
Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Combined Modality Therapy; | 1993 |
Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Combined Modality Therapy; | 1993 |
The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1993 |
The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1993 |
The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1993 |
The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F | 1993 |
Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1993 |
Histocultures of patient head and neck tumors for pharmacodynamics studies.
Topics: Adult; Aged; Cisplatin; Culture Techniques; Drug Screening Assays, Antitumor; Female; Fluorouracil; | 1993 |
Histocultures of patient head and neck tumors for pharmacodynamics studies.
Topics: Adult; Aged; Cisplatin; Culture Techniques; Drug Screening Assays, Antitumor; Female; Fluorouracil; | 1993 |
Histocultures of patient head and neck tumors for pharmacodynamics studies.
Topics: Adult; Aged; Cisplatin; Culture Techniques; Drug Screening Assays, Antitumor; Female; Fluorouracil; | 1993 |
Histocultures of patient head and neck tumors for pharmacodynamics studies.
Topics: Adult; Aged; Cisplatin; Culture Techniques; Drug Screening Assays, Antitumor; Female; Fluorouracil; | 1993 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 1994 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 1994 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 1994 |
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil, both in continuous 96-hour infusion, in the treatment of locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fluoroura | 1994 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
[Tissue and serum levels of 5-FU in the patients with head and neck malignant tumors--influence of a streptococcal preparation OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Head and Neck Neo | 1993 |
[Tissue and serum levels of 5-FU in the patients with head and neck malignant tumors--influence of a streptococcal preparation OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Head and Neck Neo | 1993 |
[Tissue and serum levels of 5-FU in the patients with head and neck malignant tumors--influence of a streptococcal preparation OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Head and Neck Neo | 1993 |
[Tissue and serum levels of 5-FU in the patients with head and neck malignant tumors--influence of a streptococcal preparation OK-432].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Head and Neck Neo | 1993 |
Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administ | 1993 |
Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administ | 1993 |
Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administ | 1993 |
Carboplatin and 5-fluorouracil in advanced and recurrent squamous carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Drug Administ | 1993 |
Dihydropyrimidine dehydrogenase activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1993 |
Dihydropyrimidine dehydrogenase activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1993 |
Dihydropyrimidine dehydrogenase activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1993 |
Dihydropyrimidine dehydrogenase activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1993 |
Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.
Topics: Ambulatory Care; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Infusion Pumps | 1993 |
Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.
Topics: Ambulatory Care; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Infusion Pumps | 1993 |
Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.
Topics: Ambulatory Care; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Infusion Pumps | 1993 |
Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.
Topics: Ambulatory Care; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Infusion Pumps | 1993 |
[Population study of dihydropyrimidine dehydrogenase in cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD+); | 1995 |
[Population study of dihydropyrimidine dehydrogenase in cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD+); | 1995 |
[Population study of dihydropyrimidine dehydrogenase in cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD+); | 1995 |
[Population study of dihydropyrimidine dehydrogenase in cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NAD+); | 1995 |
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1996 |
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1996 |
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1996 |
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1996 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Primary chemotherapy of advanced head and neck cancer: where do we go from here?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
Primary chemotherapy of advanced head and neck cancer: where do we go from here?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
Primary chemotherapy of advanced head and neck cancer: where do we go from here?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
Primary chemotherapy of advanced head and neck cancer: where do we go from here?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 1996 |
Peritumoral angiogenesis in carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Flow Cytometry; Fluorouracil; | 1996 |
Peritumoral angiogenesis in carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Flow Cytometry; Fluorouracil; | 1996 |
Peritumoral angiogenesis in carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Flow Cytometry; Fluorouracil; | 1996 |
Peritumoral angiogenesis in carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Flow Cytometry; Fluorouracil; | 1996 |
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bronchial Neoplasms; | 1996 |
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bronchial Neoplasms; | 1996 |
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bronchial Neoplasms; | 1996 |
[Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bronchial Neoplasms; | 1996 |
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1997 |
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1997 |
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1997 |
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1997 |
[Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1996 |
[Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1996 |
[Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1996 |
[Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1996 |
Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1997 |
Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1997 |
Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1997 |
Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil; | 1997 |
Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1997 |
Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1997 |
Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1997 |
Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1997 |
Intensive chemotherapy using cisplatin and fluorouracil followed by radiotherapy in advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 1997 |
[Therapy pf cervical lymph node metastases of unknown primary tumor].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[Therapy pf cervical lymph node metastases of unknown primary tumor].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[Therapy pf cervical lymph node metastases of unknown primary tumor].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[Therapy pf cervical lymph node metastases of unknown primary tumor].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1997 |
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1997 |
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1997 |
Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Fem | 1997 |
Effectiveness of selective neck dissection for management of the clinically negative neck.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1997 |
Effectiveness of selective neck dissection for management of the clinically negative neck.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1997 |
Effectiveness of selective neck dissection for management of the clinically negative neck.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1997 |
Effectiveness of selective neck dissection for management of the clinically negative neck.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1997 |
Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1997 |
Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1997 |
Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1997 |
[Combination of induction chemotherapy with surgery and/or radiotherapy in locally advanced head and neck cancers. A retrospective analysis of a series of 125 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Combination of induction chemotherapy with surgery and/or radiotherapy in locally advanced head and neck cancers. A retrospective analysis of a series of 125 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Combination of induction chemotherapy with surgery and/or radiotherapy in locally advanced head and neck cancers. A retrospective analysis of a series of 125 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
[Combination of induction chemotherapy with surgery and/or radiotherapy in locally advanced head and neck cancers. A retrospective analysis of a series of 125 patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
Surgical treatment for carcinoma of the thoracic esophagus with major involvement in the neck or upper mediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 1998 |
[Importance of AUC of carboplatin in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous C | 1998 |
[Importance of AUC of carboplatin in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous C | 1998 |
[Importance of AUC of carboplatin in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous C | 1998 |
[Importance of AUC of carboplatin in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous C | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Dih | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
Interaction of tomudex with radiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Surv | 1998 |
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1998 |
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1998 |
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1998 |
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 1998 |
[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Squamous | 1998 |
[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Squamous | 1998 |
[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Squamous | 1998 |
[Augmented antitumor efficacy of combination chemotherapy of nedaplatin with 5-fluorouracil in in vivo murine and human tumor model].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Squamous | 1998 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1999 |
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1999 |
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1999 |
Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1999 |
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydrouracil Dehydrogenase | 1999 |
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydrouracil Dehydrogenase | 1999 |
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydrouracil Dehydrogenase | 1999 |
A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydrouracil Dehydrogenase | 1999 |
Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cispl | 1999 |
Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cispl | 1999 |
Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cispl | 1999 |
Management of the neck after alternating chemoradiotherapy for advanced head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cispl | 1999 |
Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-A | 1999 |
Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-A | 1999 |
Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-A | 1999 |
Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-A | 1999 |
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Floxur | 1999 |
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Floxur | 1999 |
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Floxur | 1999 |
Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Administration Schedule; Female; Floxur | 1999 |
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Topics: Adult; Aged; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adv | 1999 |
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Topics: Adult; Aged; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adv | 1999 |
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Topics: Adult; Aged; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adv | 1999 |
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
Topics: Adult; Aged; Breast Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adv | 1999 |
Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Asia, Southeastern; Cisplatin; F | 1999 |
Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Asia, Southeastern; Cisplatin; F | 1999 |
Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Asia, Southeastern; Cisplatin; F | 1999 |
Impact of oral submucous fibrosis on chemotherapy-induced mucositis for head and neck cancer in a geographic area in which betel quid chewing is prevalent.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Asia, Southeastern; Cisplatin; F | 1999 |
Guidelines for management of Bowen's disease. British Association of Dermatologists.
Topics: Antimetabolites; Bowen's Disease; Carcinoma, Squamous Cell; Cautery; Cryotherapy; Disease Progressio | 1999 |
Guidelines for management of Bowen's disease. British Association of Dermatologists.
Topics: Antimetabolites; Bowen's Disease; Carcinoma, Squamous Cell; Cautery; Cryotherapy; Disease Progressio | 1999 |
Guidelines for management of Bowen's disease. British Association of Dermatologists.
Topics: Antimetabolites; Bowen's Disease; Carcinoma, Squamous Cell; Cautery; Cryotherapy; Disease Progressio | 1999 |
Guidelines for management of Bowen's disease. British Association of Dermatologists.
Topics: Antimetabolites; Bowen's Disease; Carcinoma, Squamous Cell; Cautery; Cryotherapy; Disease Progressio | 1999 |
[Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors].
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
[Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors].
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
[Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors].
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
[Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors].
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2000 |
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2000 |
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2000 |
p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous | 2000 |
Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 2000 |
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 2000 |
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2000 |
Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2000 |
Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2000 |
Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2000 |
Docetaxel, cisplatin, fluorouracil, and leucovorin in locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2000 |
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; F | 2000 |
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; F | 2000 |
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; F | 2000 |
p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; F | 2000 |
Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Fluorouracil; Head and Neck Ne | 2000 |
Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Fluorouracil; Head and Neck Ne | 2000 |
Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Fluorouracil; Head and Neck Ne | 2000 |
Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytokines; Fluorouracil; Head and Neck Ne | 2000 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypridine-1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
Histologically negative specimens after induction therapy: frequency and impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2000 |
Histologically negative specimens after induction therapy: frequency and impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2000 |
Histologically negative specimens after induction therapy: frequency and impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2000 |
Histologically negative specimens after induction therapy: frequency and impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cel | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
[Chemoprevention and FAR therapy regimen comprised of 5-fluorouracil, vitamin A and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Carotene; Cell Division; Combined Mo | 2001 |
[Chemoprevention and FAR therapy regimen comprised of 5-fluorouracil, vitamin A and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Carotene; Cell Division; Combined Mo | 2001 |
[Chemoprevention and FAR therapy regimen comprised of 5-fluorouracil, vitamin A and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Carotene; Cell Division; Combined Mo | 2001 |
[Chemoprevention and FAR therapy regimen comprised of 5-fluorouracil, vitamin A and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Carotene; Cell Division; Combined Mo | 2001 |
[Development of new treatment modalities for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacterial Proteins; Bridged-Ring Compound | 2001 |
[Development of new treatment modalities for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacterial Proteins; Bridged-Ring Compound | 2001 |
[Development of new treatment modalities for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacterial Proteins; Bridged-Ring Compound | 2001 |
[Development of new treatment modalities for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bacterial Proteins; Bridged-Ring Compound | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2001 |
Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2001 |
Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2001 |
Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoth | 2001 |
Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoth | 2001 |
Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoth | 2001 |
Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoth | 2001 |
Chemoradiation for metastatic SCCA: role of comorbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comorbidity; Fluorouracil; | 2001 |
Chemoradiation for metastatic SCCA: role of comorbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comorbidity; Fluorouracil; | 2001 |
Chemoradiation for metastatic SCCA: role of comorbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comorbidity; Fluorouracil; | 2001 |
Chemoradiation for metastatic SCCA: role of comorbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comorbidity; Fluorouracil; | 2001 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2002 |
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2002 |
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2002 |
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2002 |
The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, Western; Cell | 2002 |
The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, Western; Cell | 2002 |
The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, Western; Cell | 2002 |
The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, Western; Cell | 2002 |
Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cis | 2002 |
Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cis | 2002 |
Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cis | 2002 |
Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cis | 2002 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
The role of chemotherapy in the management of cancer of the head and neck: a review.
Topics: Bleomycin; Dinitrochlorobenzene; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Head and Neck | 1975 |
The role of chemotherapy in the management of cancer of the head and neck: a review.
Topics: Bleomycin; Dinitrochlorobenzene; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Head and Neck | 1975 |
The role of chemotherapy in the management of cancer of the head and neck: a review.
Topics: Bleomycin; Dinitrochlorobenzene; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Head and Neck | 1975 |
The role of chemotherapy in the management of cancer of the head and neck: a review.
Topics: Bleomycin; Dinitrochlorobenzene; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Head and Neck | 1975 |
[Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Fluorouracil; Head and Neck Neoplasms; Humans; Methods; Neoplasm M | 1976 |
[Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Fluorouracil; Head and Neck Neoplasms; Humans; Methods; Neoplasm M | 1976 |
[Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Fluorouracil; Head and Neck Neoplasms; Humans; Methods; Neoplasm M | 1976 |
[Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Fluorouracil; Head and Neck Neoplasms; Humans; Methods; Neoplasm M | 1976 |
Regional chemotherapy with combined drugs in cancer of the head and neck.
Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and | 1976 |
Regional chemotherapy with combined drugs in cancer of the head and neck.
Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and | 1976 |
Regional chemotherapy with combined drugs in cancer of the head and neck.
Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and | 1976 |
Regional chemotherapy with combined drugs in cancer of the head and neck.
Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Head and | 1976 |
Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Fluorouracil; Head and Nec | 1976 |
Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Fluorouracil; Head and Nec | 1976 |
Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Fluorouracil; Head and Nec | 1976 |
Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Fluorouracil; Head and Nec | 1976 |
Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Carotid Artery, External; | 1978 |
Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Carotid Artery, External; | 1978 |
Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Carotid Artery, External; | 1978 |
Palliation of inoperable head and heck cancer: combined intra-arterial infusion chemotherapy and irradiation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Carotid Artery, External; | 1978 |
Combination chemotherapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow; Carcinoma, Squamous Cell; Cy | 1978 |
Combination chemotherapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow; Carcinoma, Squamous Cell; Cy | 1978 |
Combination chemotherapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow; Carcinoma, Squamous Cell; Cy | 1978 |
Combination chemotherapy of head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Bone Marrow; Carcinoma, Squamous Cell; Cy | 1978 |
[Current status of chemotherapy in malignant head and neck neoplasms (proceedings)].
Topics: Animals; Bleomycin; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Humans; Methot | 1979 |
[Current status of chemotherapy in malignant head and neck neoplasms (proceedings)].
Topics: Animals; Bleomycin; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Humans; Methot | 1979 |
[Current status of chemotherapy in malignant head and neck neoplasms (proceedings)].
Topics: Animals; Bleomycin; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Humans; Methot | 1979 |
[Current status of chemotherapy in malignant head and neck neoplasms (proceedings)].
Topics: Animals; Bleomycin; Drug Therapy, Combination; Fluorouracil; Head and Neck Neoplasms; Humans; Methot | 1979 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
[Experiences with radiotherapy of malignant tumors in the head-neck-esophagus area using the synchronization effect of 5-FU].
Topics: Esophageal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Remission, Spontaneous | 1978 |
[Experiences with radiotherapy of malignant tumors in the head-neck-esophagus area using the synchronization effect of 5-FU].
Topics: Esophageal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Remission, Spontaneous | 1978 |
[Experiences with radiotherapy of malignant tumors in the head-neck-esophagus area using the synchronization effect of 5-FU].
Topics: Esophageal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Remission, Spontaneous | 1978 |
[Experiences with radiotherapy of malignant tumors in the head-neck-esophagus area using the synchronization effect of 5-FU].
Topics: Esophageal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Remission, Spontaneous | 1978 |
[Recent result of simultaneous irradiation and 5-fluorouracil arterial infusion for cancer of the head and neck].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusi | 1977 |
[Recent result of simultaneous irradiation and 5-fluorouracil arterial infusion for cancer of the head and neck].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusi | 1977 |
[Recent result of simultaneous irradiation and 5-fluorouracil arterial infusion for cancer of the head and neck].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusi | 1977 |
[Recent result of simultaneous irradiation and 5-fluorouracil arterial infusion for cancer of the head and neck].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusi | 1977 |
Could 5-FU therapy replace, or supplement, radical surgery in the treatment of squamous cancer of the head and neck?
Topics: Administration, Topical; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans | 1978 |
Could 5-FU therapy replace, or supplement, radical surgery in the treatment of squamous cancer of the head and neck?
Topics: Administration, Topical; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans | 1978 |
Could 5-FU therapy replace, or supplement, radical surgery in the treatment of squamous cancer of the head and neck?
Topics: Administration, Topical; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans | 1978 |
Could 5-FU therapy replace, or supplement, radical surgery in the treatment of squamous cancer of the head and neck?
Topics: Administration, Topical; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans | 1978 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors.
Topics: Cobalt Radioisotopes; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Head and Neck N | 1978 |
Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors.
Topics: Cobalt Radioisotopes; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Head and Neck N | 1978 |
Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors.
Topics: Cobalt Radioisotopes; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Head and Neck N | 1978 |
Synergistic combination therapy of 5-fluorouracil, vitamin A and cobalt-60 radiation upon head and neck tumors.
Topics: Cobalt Radioisotopes; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Head and Neck N | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
Systemic chemotherapy of advanced head and neck malignancies.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
[Tele-gamma irradiation and regional chemotherapy in the treatment of patients with widespread head and neck tumours (author's transl)].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorou | 1975 |
[Tele-gamma irradiation and regional chemotherapy in the treatment of patients with widespread head and neck tumours (author's transl)].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorou | 1975 |
[Tele-gamma irradiation and regional chemotherapy in the treatment of patients with widespread head and neck tumours (author's transl)].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorou | 1975 |
[Tele-gamma irradiation and regional chemotherapy in the treatment of patients with widespread head and neck tumours (author's transl)].
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorou | 1975 |
[Radiotherapy combined with halogenated pyrimidines--fundamental and clinical studies (author's transl)].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Halogens; Head and Neck Neoplasm | 1975 |
[Radiotherapy combined with halogenated pyrimidines--fundamental and clinical studies (author's transl)].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Halogens; Head and Neck Neoplasm | 1975 |
[Radiotherapy combined with halogenated pyrimidines--fundamental and clinical studies (author's transl)].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Halogens; Head and Neck Neoplasm | 1975 |
[Radiotherapy combined with halogenated pyrimidines--fundamental and clinical studies (author's transl)].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Female; Fluorouracil; Halogens; Head and Neck Neoplasm | 1975 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cisplatin; Colonic Neopl | 1992 |
[The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eva | 1992 |
[The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eva | 1992 |
[The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eva | 1992 |
[The efficacy of polychemotherapy with cisplatin, methotrexate and 5-fluorouracil in inoperable forms of squamous cell cancer of the head and neck area].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Eva | 1992 |
[Retrospective study of 139 cases of epidermoid carcinoma of the upper respiratory and digestive tracts treated by induction chemotherapy with cisplatin-5FU. Influence of the result on the therapeutic protocol].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Retrospective study of 139 cases of epidermoid carcinoma of the upper respiratory and digestive tracts treated by induction chemotherapy with cisplatin-5FU. Influence of the result on the therapeutic protocol].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Retrospective study of 139 cases of epidermoid carcinoma of the upper respiratory and digestive tracts treated by induction chemotherapy with cisplatin-5FU. Influence of the result on the therapeutic protocol].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Retrospective study of 139 cases of epidermoid carcinoma of the upper respiratory and digestive tracts treated by induction chemotherapy with cisplatin-5FU. Influence of the result on the therapeutic protocol].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; D | 1992 |
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; D | 1992 |
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; D | 1992 |
Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; D | 1992 |
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchial Neoplasms; Carcinoma, Squamous | 1992 |
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchial Neoplasms; Carcinoma, Squamous | 1992 |
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchial Neoplasms; Carcinoma, Squamous | 1992 |
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchial Neoplasms; Carcinoma, Squamous | 1992 |
[Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1992 |
[Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1992 |
[Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1992 |
[Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1992 |
[The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Conduction; Carboplatin; Dose-Response Re | 1992 |
[The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Conduction; Carboplatin; Dose-Response Re | 1992 |
[The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Conduction; Carboplatin; Dose-Response Re | 1992 |
[The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Conduction; Carboplatin; Dose-Response Re | 1992 |
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
Topics: Blood Proteins; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Hum | 1992 |
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
Topics: Blood Proteins; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Hum | 1992 |
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
Topics: Blood Proteins; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Hum | 1992 |
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
Topics: Blood Proteins; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Hum | 1992 |
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1992 |
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1992 |
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1992 |
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1992 |
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
Topics: Cell Survival; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea | 1992 |
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
Topics: Cell Survival; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea | 1992 |
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
Topics: Cell Survival; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea | 1992 |
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
Topics: Cell Survival; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
T1 squamous cell carcinoma of the arytenoid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arytenoid Cartilage; | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
Chemotherapy of solid tumors in private practice in Malaysia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Drug | 1992 |
[Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
[Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Triple therapy for advanced squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Triple therapy for advanced squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Triple therapy for advanced squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Triple therapy for advanced squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Head and N | 1992 |
[Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Cisplatin | 1992 |
[Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Cisplatin | 1992 |
[Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Cisplatin | 1992 |
[Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Cisplatin | 1992 |
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1992 |
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1992 |
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1992 |
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1992 |
Influence of sex and age on fluorouracil clearance.
Topics: Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Carcinoma, Squamous Cell; Female; Fluor | 1992 |
Influence of sex and age on fluorouracil clearance.
Topics: Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Carcinoma, Squamous Cell; Female; Fluor | 1992 |
Influence of sex and age on fluorouracil clearance.
Topics: Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Carcinoma, Squamous Cell; Female; Fluor | 1992 |
Influence of sex and age on fluorouracil clearance.
Topics: Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Carcinoma, Squamous Cell; Female; Fluor | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Mo | 1990 |
Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Mo | 1990 |
Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Mo | 1990 |
Predictive value of serum alkaline DNase activity variations in treatment of head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Mo | 1990 |
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1991 |
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1991 |
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1991 |
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1991 |
[Neoadjuvant chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Flu | 1991 |
[Neoadjuvant chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Flu | 1991 |
[Neoadjuvant chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Flu | 1991 |
[Neoadjuvant chemotherapy of head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Flu | 1991 |
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
5-fluorouracil + folinic acid with cisplatinum and bleomycin in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1991 |
[Neo-adjuvant chemotherapy with cisplatin, 5-fluorouracil, vindesine in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
[Neo-adjuvant chemotherapy with cisplatin, 5-fluorouracil, vindesine in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
[Neo-adjuvant chemotherapy with cisplatin, 5-fluorouracil, vindesine in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
[Neo-adjuvant chemotherapy with cisplatin, 5-fluorouracil, vindesine in head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 1992 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug A | 1991 |
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug A | 1991 |
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug A | 1991 |
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug A | 1991 |
Neoadjuvant carboplatin & 5 fluorouracil combination chemotherapy and radiotherapy in the treatment of locally advanced head and neck cancer: primary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 1991 |
Neoadjuvant carboplatin & 5 fluorouracil combination chemotherapy and radiotherapy in the treatment of locally advanced head and neck cancer: primary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 1991 |
Neoadjuvant carboplatin & 5 fluorouracil combination chemotherapy and radiotherapy in the treatment of locally advanced head and neck cancer: primary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 1991 |
Neoadjuvant carboplatin & 5 fluorouracil combination chemotherapy and radiotherapy in the treatment of locally advanced head and neck cancer: primary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co | 1991 |
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu | 1991 |
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu | 1991 |
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu | 1991 |
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu | 1991 |
In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides.
Topics: Colonic Neoplasms; Deoxyuridine; DNA; Fluorouracil; Head and Neck Neoplasms; Humans; Mitosis; Stereo | 1991 |
In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides.
Topics: Colonic Neoplasms; Deoxyuridine; DNA; Fluorouracil; Head and Neck Neoplasms; Humans; Mitosis; Stereo | 1991 |
In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides.
Topics: Colonic Neoplasms; Deoxyuridine; DNA; Fluorouracil; Head and Neck Neoplasms; Humans; Mitosis; Stereo | 1991 |
In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides.
Topics: Colonic Neoplasms; Deoxyuridine; DNA; Fluorouracil; Head and Neck Neoplasms; Humans; Mitosis; Stereo | 1991 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
[Infusor--an aid in cytostatic therapy].
Topics: Antineoplastic Agents; Evaluation Studies as Topic; Fluorouracil; Head and Neck Neoplasms; Humans; I | 1991 |
[Infusor--an aid in cytostatic therapy].
Topics: Antineoplastic Agents; Evaluation Studies as Topic; Fluorouracil; Head and Neck Neoplasms; Humans; I | 1991 |
[Infusor--an aid in cytostatic therapy].
Topics: Antineoplastic Agents; Evaluation Studies as Topic; Fluorouracil; Head and Neck Neoplasms; Humans; I | 1991 |
[Infusor--an aid in cytostatic therapy].
Topics: Antineoplastic Agents; Evaluation Studies as Topic; Fluorouracil; Head and Neck Neoplasms; Humans; I | 1991 |
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil; | 1991 |
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil; | 1991 |
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil; | 1991 |
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil; | 1991 |
[Incidence of osteoradionecrosis after combined radiotherapy-chemotherapy of head and neck tumors].
Topics: Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; | 1991 |
[Incidence of osteoradionecrosis after combined radiotherapy-chemotherapy of head and neck tumors].
Topics: Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; | 1991 |
[Incidence of osteoradionecrosis after combined radiotherapy-chemotherapy of head and neck tumors].
Topics: Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; | 1991 |
[Incidence of osteoradionecrosis after combined radiotherapy-chemotherapy of head and neck tumors].
Topics: Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; | 1991 |
Intraoperative radiation therapy in the treatment of recurrent carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Intraoperative radiation therapy in the treatment of recurrent carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Intraoperative radiation therapy in the treatment of recurrent carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Intraoperative radiation therapy in the treatment of recurrent carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1991 |
Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1991 |
Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1991 |
Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1991 |
Concomitant chemo/radiotherapy for advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 1991 |
Drug response of head and neck tumors in native-state histoculture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cell Division; | 1991 |
Drug response of head and neck tumors in native-state histoculture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cell Division; | 1991 |
Drug response of head and neck tumors in native-state histoculture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cell Division; | 1991 |
Drug response of head and neck tumors in native-state histoculture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cell Division; | 1991 |
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Electrocardiog | 1991 |
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Electrocardiog | 1991 |
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Electrocardiog | 1991 |
Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Electrocardiog | 1991 |
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
Concurrent cisplatin, infusional fluorouracil, and conventionally fractionated radiation therapy in head and neck cancer: dose-limiting mucosal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1991 |
Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1991 |
Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1991 |
Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1991 |
Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1991 |
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1991 |
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1991 |
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1991 |
Cisplatin, vindesine, and 96-h continuous infusion of 5-fluorouracil as initial chemotherapy for locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1991 |
[Continuous Holter cardiac monitoring and chemotherapy by combination with platinum and fluoro-uracil].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Electrocardiography, Am | 1991 |
[Continuous Holter cardiac monitoring and chemotherapy by combination with platinum and fluoro-uracil].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Electrocardiography, Am | 1991 |
[Continuous Holter cardiac monitoring and chemotherapy by combination with platinum and fluoro-uracil].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Electrocardiography, Am | 1991 |
[Continuous Holter cardiac monitoring and chemotherapy by combination with platinum and fluoro-uracil].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Electrocardiography, Am | 1991 |
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1991 |
Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1990 |
Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1990 |
Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1990 |
Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1990 |
Neoadjuvant chemotherapy with cisplatinum and 5-fluorouracil in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1990 |
Neoadjuvant chemotherapy with cisplatinum and 5-fluorouracil in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1990 |
Neoadjuvant chemotherapy with cisplatinum and 5-fluorouracil in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1990 |
Neoadjuvant chemotherapy with cisplatinum and 5-fluorouracil in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1990 |
[Usage of urine FT levels for medication compliance in head and neck cancer with administration of UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 1990 |
[Usage of urine FT levels for medication compliance in head and neck cancer with administration of UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 1990 |
[Usage of urine FT levels for medication compliance in head and neck cancer with administration of UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 1990 |
[Usage of urine FT levels for medication compliance in head and neck cancer with administration of UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; | 1990 |
Thermochemotherapy in inoperable head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheters, Indwellin | 1990 |
Thermochemotherapy in inoperable head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheters, Indwellin | 1990 |
Thermochemotherapy in inoperable head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheters, Indwellin | 1990 |
Thermochemotherapy in inoperable head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheters, Indwellin | 1990 |
What is the optimal regimen of cisplatin plus 5-FU for head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1990 |
What is the optimal regimen of cisplatin plus 5-FU for head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1990 |
What is the optimal regimen of cisplatin plus 5-FU for head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1990 |
What is the optimal regimen of cisplatin plus 5-FU for head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1990 |
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El | 1990 |
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El | 1990 |
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El | 1990 |
Low prevalence of cisplatin-induced neuropathy after 4-day continuous infusion in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; El | 1990 |
[Possible value of variations in the serum alkaline DNAse activity in the prognosis of cancers of the upper respiratory-digestive tract treated by chemotherapy].
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxyribonucleases; Female; Fluorouracil; Head and Neck Neoplasms | 1990 |
[Possible value of variations in the serum alkaline DNAse activity in the prognosis of cancers of the upper respiratory-digestive tract treated by chemotherapy].
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxyribonucleases; Female; Fluorouracil; Head and Neck Neoplasms | 1990 |
[Possible value of variations in the serum alkaline DNAse activity in the prognosis of cancers of the upper respiratory-digestive tract treated by chemotherapy].
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxyribonucleases; Female; Fluorouracil; Head and Neck Neoplasms | 1990 |
[Possible value of variations in the serum alkaline DNAse activity in the prognosis of cancers of the upper respiratory-digestive tract treated by chemotherapy].
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxyribonucleases; Female; Fluorouracil; Head and Neck Neoplasms | 1990 |
Hypercalcemia in head and neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 1990 |
Hypercalcemia in head and neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 1990 |
Hypercalcemia in head and neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 1990 |
Hypercalcemia in head and neck squamous-cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Fluorou | 1990 |
Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin.
Topics: Arrhythmias, Cardiac; Carcinoma, Squamous Cell; Chest Pain; Cisplatin; Electrocardiography; Esophage | 1990 |
[The effect of 5-fluorouracil on the radiosensitivity of granulocytopoietic stem cells in the bone marrow and the blood].
Topics: Combined Modality Therapy; Fluorouracil; Granulocytes; Head and Neck Neoplasms; Hematopoietic Stem C | 1990 |
[The effect of 5-fluorouracil on the radiosensitivity of granulocytopoietic stem cells in the bone marrow and the blood].
Topics: Combined Modality Therapy; Fluorouracil; Granulocytes; Head and Neck Neoplasms; Hematopoietic Stem C | 1990 |
[The effect of 5-fluorouracil on the radiosensitivity of granulocytopoietic stem cells in the bone marrow and the blood].
Topics: Combined Modality Therapy; Fluorouracil; Granulocytes; Head and Neck Neoplasms; Hematopoietic Stem C | 1990 |
[The effect of 5-fluorouracil on the radiosensitivity of granulocytopoietic stem cells in the bone marrow and the blood].
Topics: Combined Modality Therapy; Fluorouracil; Granulocytes; Head and Neck Neoplasms; Hematopoietic Stem C | 1990 |
Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1990 |
Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1990 |
Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1990 |
Efficacy and side effects of two chemotherapy regimens with cisplatin plus fluorouracil in advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1990 |
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1990 |
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1990 |
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1990 |
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 1990 |
Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
Neutropenic enterocolitis. A new complication of head and neck cancer chemotherapy.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin | 1990 |
5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 1990 |
5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 1990 |
5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 1990 |
5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; D | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Adjuvant methotrexate-5-fluorouracil for extracapsular squamous cell carcinoma in cervical metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
Adjuvant methotrexate-5-fluorouracil for extracapsular squamous cell carcinoma in cervical metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
Adjuvant methotrexate-5-fluorouracil for extracapsular squamous cell carcinoma in cervical metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
Adjuvant methotrexate-5-fluorouracil for extracapsular squamous cell carcinoma in cervical metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1990 |
Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Relation between responses to induction chemotherapy and subsequent radiotherapy in advanced or multicentric squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1990 |
Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1985 |
Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1985 |
Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1985 |
Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1985 |
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Multimodality therapy for unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Cisplatin-containing chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Cisplatin-containing chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Cisplatin-containing chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Cisplatin-containing chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl | 1985 |
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Induction therapy in head and neck cancer. A comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Induction therapy in head and neck cancer. A comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Induction therapy in head and neck cancer. A comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Induction therapy in head and neck cancer. A comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Nursing implications related to chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Methotre | 1985 |
Nursing implications related to chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Methotre | 1985 |
Nursing implications related to chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Methotre | 1985 |
Nursing implications related to chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Methotre | 1985 |
Preoperative chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1986 |
Preoperative chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1986 |
Preoperative chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1986 |
Preoperative chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carci | 1986 |
Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1986 |
Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1986 |
Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1986 |
Combined modality therapy utilizing a cisplatin combination for effective chemotherapy in patients with previously untreated head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1986 |
Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
Long-term results of a pilot study for the treatment of advanced unresectable head and neck tumors by combination chemotherapy and split course radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; Fluoro | 1986 |
Long-term results of a pilot study for the treatment of advanced unresectable head and neck tumors by combination chemotherapy and split course radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; Fluoro | 1986 |
Long-term results of a pilot study for the treatment of advanced unresectable head and neck tumors by combination chemotherapy and split course radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; Fluoro | 1986 |
Long-term results of a pilot study for the treatment of advanced unresectable head and neck tumors by combination chemotherapy and split course radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; Fluoro | 1986 |
5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neopla | 1987 |
5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neopla | 1987 |
5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neopla | 1987 |
5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Cyclophosphamide; Female; Fluorouracil; Head and Neck Neopla | 1987 |
[Combined chemotherapy and radiotherapy in recurrent tumors of the head and neck region].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1987 |
[Combined chemotherapy and radiotherapy in recurrent tumors of the head and neck region].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1987 |
[Combined chemotherapy and radiotherapy in recurrent tumors of the head and neck region].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1987 |
[Combined chemotherapy and radiotherapy in recurrent tumors of the head and neck region].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1987 |
CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
[Critical remarks on chemotherapy of malignant tumors of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1987 |
[Critical remarks on chemotherapy of malignant tumors of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1987 |
[Critical remarks on chemotherapy of malignant tumors of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1987 |
[Critical remarks on chemotherapy of malignant tumors of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluo | 1987 |
Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1987 |
Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1987 |
Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1987 |
Hyperthermia as an adjuvant to radiation- and/or chemotherapy in far advanced recurrences of the head and neck region.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1987 |
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1988 |
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1988 |
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1988 |
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1988 |
Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, | 1988 |
Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, | 1988 |
Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, | 1988 |
Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, | 1988 |
Induction cytotoxic chemotherapy: the significance of apparent complete clinical regression after using the Price Hill Schedule A protocol for squamous carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1988 |
Induction cytotoxic chemotherapy: the significance of apparent complete clinical regression after using the Price Hill Schedule A protocol for squamous carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1988 |
Induction cytotoxic chemotherapy: the significance of apparent complete clinical regression after using the Price Hill Schedule A protocol for squamous carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1988 |
Induction cytotoxic chemotherapy: the significance of apparent complete clinical regression after using the Price Hill Schedule A protocol for squamous carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1988 |
Immunologic determinants of head and neck cancer response to induction chemotherapy.
Topics: Adult; Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinom | 1989 |
Immunologic determinants of head and neck cancer response to induction chemotherapy.
Topics: Adult; Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinom | 1989 |
Immunologic determinants of head and neck cancer response to induction chemotherapy.
Topics: Adult; Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinom | 1989 |
Immunologic determinants of head and neck cancer response to induction chemotherapy.
Topics: Adult; Aged; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinom | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
[Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1989 |
[Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1989 |
[Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1989 |
[Treatment of squamous cell carcinoma of the head and neck with multi-drug chemotherapy and radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb | 1989 |
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1989 |
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1989 |
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1989 |
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1989 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous | 1989 |
[Chemosensitivity of human head and neck tumors detected by human tumor clonogenic assay].
Topics: Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, | 1989 |
[Chemosensitivity of human head and neck tumors detected by human tumor clonogenic assay].
Topics: Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, | 1989 |
[Chemosensitivity of human head and neck tumors detected by human tumor clonogenic assay].
Topics: Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, | 1989 |
[Chemosensitivity of human head and neck tumors detected by human tumor clonogenic assay].
Topics: Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Histiocytoma, | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1989 |
Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Drug Resistance; Female; Floxuridine; | 1989 |
Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Drug Resistance; Female; Floxuridine; | 1989 |
Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Drug Resistance; Female; Floxuridine; | 1989 |
Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
Topics: Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Drug Resistance; Female; Floxuridine; | 1989 |
Fluoropyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Head and Ne | 1989 |
Fluoropyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Head and Ne | 1989 |
Fluoropyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Head and Ne | 1989 |
Fluoropyrimidine metabolism in human head and neck cancer xenografts and murine colon tumors.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Head and Ne | 1989 |
Prognostic indicators in head and neck cancer patients receiving combined therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Prognostic indicators in head and neck cancer patients receiving combined therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Prognostic indicators in head and neck cancer patients receiving combined therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Prognostic indicators in head and neck cancer patients receiving combined therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
[Synchronization therapy as a palliative measure in incurable head and neck tumors].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and | 1985 |
[Synchronization therapy as a palliative measure in incurable head and neck tumors].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and | 1985 |
[Synchronization therapy as a palliative measure in incurable head and neck tumors].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and | 1985 |
[Synchronization therapy as a palliative measure in incurable head and neck tumors].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Head and | 1985 |
Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
[Preoperative chemotherapy for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Ne | 1985 |
[Preoperative chemotherapy for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Ne | 1985 |
[Preoperative chemotherapy for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Ne | 1985 |
[Preoperative chemotherapy for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Fluorouracil; Head and Neck Ne | 1985 |
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck | 1989 |
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck | 1989 |
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck | 1989 |
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
[Optimization using the pharmacokinetics of the therapeutic index of CDDP-5 FU treatment over 5 continuous days].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1989 |
[Optimization using the pharmacokinetics of the therapeutic index of CDDP-5 FU treatment over 5 continuous days].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1989 |
[Optimization using the pharmacokinetics of the therapeutic index of CDDP-5 FU treatment over 5 continuous days].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1989 |
[Optimization using the pharmacokinetics of the therapeutic index of CDDP-5 FU treatment over 5 continuous days].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 1989 |
Treatment of advanced squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1989 |
Treatment of advanced squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1989 |
Treatment of advanced squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1989 |
Treatment of advanced squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1989 |
Simultaneous chemo-radiotherapy with 5-FU/folinic acid/cis-platinum and accelerated split-course radiation in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Simultaneous chemo-radiotherapy with 5-FU/folinic acid/cis-platinum and accelerated split-course radiation in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Simultaneous chemo-radiotherapy with 5-FU/folinic acid/cis-platinum and accelerated split-course radiation in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Simultaneous chemo-radiotherapy with 5-FU/folinic acid/cis-platinum and accelerated split-course radiation in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Carboplatin. The better platinum in head and neck cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood; Carboplatin; Cisplatin | 1989 |
Carboplatin. The better platinum in head and neck cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood; Carboplatin; Cisplatin | 1989 |
Carboplatin. The better platinum in head and neck cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood; Carboplatin; Cisplatin | 1989 |
Carboplatin. The better platinum in head and neck cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood; Carboplatin; Cisplatin | 1989 |
Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1989 |
Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1989 |
Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1989 |
Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclosporins; Fluorouracil; Hea | 1989 |
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclosporins; Fluorouracil; Hea | 1989 |
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclosporins; Fluorouracil; Hea | 1989 |
Growth and chemosensitivity of human head and neck cancers implanted under the kidney capsule of cyclosporine-immunosuppressed mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclosporins; Fluorouracil; Hea | 1989 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule | 1989 |
Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1989 |
[The use of neo-adjuvant chemotherapy in the treatment of carcinoma of the upper aero-digestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1989 |
[The use of neo-adjuvant chemotherapy in the treatment of carcinoma of the upper aero-digestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1989 |
[The use of neo-adjuvant chemotherapy in the treatment of carcinoma of the upper aero-digestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1989 |
[The use of neo-adjuvant chemotherapy in the treatment of carcinoma of the upper aero-digestive tract].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 1989 |
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1989 |
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1989 |
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1989 |
Treatment of advanced squamous cell carcinoma of head and neck with cisplatin and continuous 96 hour infusion of 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1989 |
Accuracy of the subrenal capsule xenograft assay in predicting the clinical growth and chemosensitivity of human squamous head and neck carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Male; M | 1989 |
Accuracy of the subrenal capsule xenograft assay in predicting the clinical growth and chemosensitivity of human squamous head and neck carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Male; M | 1989 |
Accuracy of the subrenal capsule xenograft assay in predicting the clinical growth and chemosensitivity of human squamous head and neck carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Male; M | 1989 |
Accuracy of the subrenal capsule xenograft assay in predicting the clinical growth and chemosensitivity of human squamous head and neck carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Male; M | 1989 |
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1989 |
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1989 |
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1989 |
Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1989 |
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1989 |
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Multimodality treatment of advanced head and neck carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Multimodality treatment of advanced head and neck carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Multimodality treatment of advanced head and neck carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Multimodality treatment of advanced head and neck carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1989 |
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
[Treatment of head and neck neoplasms].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neopl | 1989 |
[Treatment of head and neck neoplasms].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neopl | 1989 |
[Treatment of head and neck neoplasms].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neopl | 1989 |
[Treatment of head and neck neoplasms].
Topics: Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neopl | 1989 |
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1989 |
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1989 |
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1989 |
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1989 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst | 1986 |
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst | 1986 |
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst | 1986 |
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst | 1986 |
[Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1988 |
[Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1988 |
[Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1988 |
[Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1988 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
[Influence of OK-432 on the concentration of active substance of fluoropyrimidine carcinostatics in the living body].
Topics: Biological Products; Fluorouracil; Head and Neck Neoplasms; Humans; Picibanil; Tegafur | 1986 |
[Influence of OK-432 on the concentration of active substance of fluoropyrimidine carcinostatics in the living body].
Topics: Biological Products; Fluorouracil; Head and Neck Neoplasms; Humans; Picibanil; Tegafur | 1986 |
[Influence of OK-432 on the concentration of active substance of fluoropyrimidine carcinostatics in the living body].
Topics: Biological Products; Fluorouracil; Head and Neck Neoplasms; Humans; Picibanil; Tegafur | 1986 |
[Influence of OK-432 on the concentration of active substance of fluoropyrimidine carcinostatics in the living body].
Topics: Biological Products; Fluorouracil; Head and Neck Neoplasms; Humans; Picibanil; Tegafur | 1986 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
[Balloon occluded arterial infusion with direct hemoperfusion in recurrent cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolization | 1988 |
[Balloon occluded arterial infusion with direct hemoperfusion in recurrent cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolization | 1988 |
[Balloon occluded arterial infusion with direct hemoperfusion in recurrent cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolization | 1988 |
[Balloon occluded arterial infusion with direct hemoperfusion in recurrent cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolization | 1988 |
Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplas | 1988 |
Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplas | 1988 |
Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplas | 1988 |
Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplas | 1988 |
Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined | 1988 |
Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined | 1988 |
Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined | 1988 |
Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined | 1988 |
Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac | 1988 |
Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac | 1988 |
Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac | 1988 |
Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac | 1988 |
[Alteration of immunological parameters following CDDP-5-FU chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Alteration of immunological parameters following CDDP-5-FU chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Alteration of immunological parameters following CDDP-5-FU chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Alteration of immunological parameters following CDDP-5-FU chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Continuous superselective intra-arterial infusion with BUdR and 5 FU in combination with radiotherapy in the treatment of head and neck tumors].
Topics: Bromodeoxyuridine; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1988 |
[Continuous superselective intra-arterial infusion with BUdR and 5 FU in combination with radiotherapy in the treatment of head and neck tumors].
Topics: Bromodeoxyuridine; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1988 |
[Continuous superselective intra-arterial infusion with BUdR and 5 FU in combination with radiotherapy in the treatment of head and neck tumors].
Topics: Bromodeoxyuridine; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1988 |
[Continuous superselective intra-arterial infusion with BUdR and 5 FU in combination with radiotherapy in the treatment of head and neck tumors].
Topics: Bromodeoxyuridine; Combined Modality Therapy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1988 |
Effectiveness of cis-platinum and 5-fluorouracil as induction chemotherapy prior to radiation therapy in advanced head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Effectiveness of cis-platinum and 5-fluorouracil as induction chemotherapy prior to radiation therapy in advanced head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Effectiveness of cis-platinum and 5-fluorouracil as induction chemotherapy prior to radiation therapy in advanced head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Effectiveness of cis-platinum and 5-fluorouracil as induction chemotherapy prior to radiation therapy in advanced head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
[Results of simultaneous radio-polychemotherapy in advanced inoperable cancer of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
[Results of simultaneous radio-polychemotherapy in advanced inoperable cancer of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
[Results of simultaneous radio-polychemotherapy in advanced inoperable cancer of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
[Results of simultaneous radio-polychemotherapy in advanced inoperable cancer of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1988 |
5-Fluorouracil/folinic acid/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Evaluatio | 1988 |
5-Fluorouracil/folinic acid/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Evaluatio | 1988 |
5-Fluorouracil/folinic acid/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Evaluatio | 1988 |
5-Fluorouracil/folinic acid/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Evaluatio | 1988 |
Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1988 |
Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1988 |
Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1988 |
Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; | 1988 |
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Ci | 1988 |
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Ci | 1988 |
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Ci | 1988 |
The effect of cisplatin and fluorouracil on xenografted human squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Survival; Ci | 1988 |
Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1988 |
Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1988 |
Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1988 |
Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1988 |
Simultaneous radiotherapy and chemotherapy with 5-fluorouracil and cisplatin for locally confined squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Simultaneous radiotherapy and chemotherapy with 5-fluorouracil and cisplatin for locally confined squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Simultaneous radiotherapy and chemotherapy with 5-fluorouracil and cisplatin for locally confined squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Simultaneous radiotherapy and chemotherapy with 5-fluorouracil and cisplatin for locally confined squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1988 |
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1988 |
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1988 |
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1988 |
Chemotherapy with low doses of radiation followed by definitive radiotherapy for advanced unresectable carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Chemotherapy with low doses of radiation followed by definitive radiotherapy for advanced unresectable carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Chemotherapy with low doses of radiation followed by definitive radiotherapy for advanced unresectable carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Chemotherapy with low doses of radiation followed by definitive radiotherapy for advanced unresectable carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation. 1. Advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1988 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation. 1. Advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1988 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation. 1. Advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1988 |
Sequential combination of 5-fluorouracil, cis-platinum and irradiation. 1. Advanced head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 1988 |
[Cisplatin-5 fluorouracil in cervicofacial cancer recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Facial Neoplasms; Fluorouracil; Head and | 1988 |
[Cisplatin-5 fluorouracil in cervicofacial cancer recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Facial Neoplasms; Fluorouracil; Head and | 1988 |
[Cisplatin-5 fluorouracil in cervicofacial cancer recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Facial Neoplasms; Fluorouracil; Head and | 1988 |
[Cisplatin-5 fluorouracil in cervicofacial cancer recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Facial Neoplasms; Fluorouracil; Head and | 1988 |
Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
Advanced head and neck cancer: response to and toxicity of multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Advanced head and neck cancer: response to and toxicity of multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Advanced head and neck cancer: response to and toxicity of multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
Advanced head and neck cancer: response to and toxicity of multimodality therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1988 |
[Induction chemotherapy with cisplatin-5 fluorouracil. Current results in cervicofacial carcinology].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
[Induction chemotherapy with cisplatin-5 fluorouracil. Current results in cervicofacial carcinology].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
[Induction chemotherapy with cisplatin-5 fluorouracil. Current results in cervicofacial carcinology].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
[Induction chemotherapy with cisplatin-5 fluorouracil. Current results in cervicofacial carcinology].
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 1987 |
Accelerated split-course radiotherapy and simultaneous cis-dichlorodiammine-platinum and 5-fluorouracil chemotherapy with folinic acid enhancement for unresectable carcinoma of the head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cobalt R | 1987 |
Accelerated split-course radiotherapy and simultaneous cis-dichlorodiammine-platinum and 5-fluorouracil chemotherapy with folinic acid enhancement for unresectable carcinoma of the head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cobalt R | 1987 |
Accelerated split-course radiotherapy and simultaneous cis-dichlorodiammine-platinum and 5-fluorouracil chemotherapy with folinic acid enhancement for unresectable carcinoma of the head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cobalt R | 1987 |
Accelerated split-course radiotherapy and simultaneous cis-dichlorodiammine-platinum and 5-fluorouracil chemotherapy with folinic acid enhancement for unresectable carcinoma of the head and neck.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cobalt R | 1987 |
[Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[Clinical efficacy of combined treatment in a late-stage malignant tumor of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1987 |
[Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1987 |
[Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1987 |
[Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1987 |
[Principles of the simultaneous radiation and polychemotherapy in advanced head and neck carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1987 |
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1987 |
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1987 |
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1987 |
A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1987 |
[Sequential administration of methotrexate and 5-fluorouracil in epidermoid carcinomas of the head and neck. Results of a prospective study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and | 1986 |
[Sequential administration of methotrexate and 5-fluorouracil in epidermoid carcinomas of the head and neck. Results of a prospective study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and | 1986 |
[Sequential administration of methotrexate and 5-fluorouracil in epidermoid carcinomas of the head and neck. Results of a prospective study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and | 1986 |
[Sequential administration of methotrexate and 5-fluorouracil in epidermoid carcinomas of the head and neck. Results of a prospective study].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; Head and | 1986 |
Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1987 |
Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1987 |
Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1987 |
Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. A phase I-II study.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; | 1987 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Regional chemotherapy through a saphenous vein graft for the treatment of head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer | 1987 |
Regional chemotherapy through a saphenous vein graft for the treatment of head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer | 1987 |
Regional chemotherapy through a saphenous vein graft for the treatment of head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer | 1987 |
Regional chemotherapy through a saphenous vein graft for the treatment of head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer | 1987 |
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
Treatment of advanced head and neck cancer with concomitant radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1987 |
Treatment of advanced head and neck cancer with concomitant radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1987 |
Treatment of advanced head and neck cancer with concomitant radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1987 |
Treatment of advanced head and neck cancer with concomitant radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1987 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Synergism; Fluorourac | 1986 |
Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Synergism; Fluorourac | 1986 |
Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Synergism; Fluorourac | 1986 |
Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Synergism; Fluorourac | 1986 |
[Clinical effect of HCFU therapy of head and neck cancer].
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Fluorour | 1986 |
[Clinical effect of HCFU therapy of head and neck cancer].
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Fluorour | 1986 |
[Clinical effect of HCFU therapy of head and neck cancer].
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Fluorour | 1986 |
[Clinical effect of HCFU therapy of head and neck cancer].
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Fluorour | 1986 |
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1986 |
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1986 |
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1986 |
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1986 |
[Clinical study of HCFU and radiation therapy in head and neck cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil | 1986 |
[Clinical study of HCFU and radiation therapy in head and neck cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil | 1986 |
[Clinical study of HCFU and radiation therapy in head and neck cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil | 1986 |
[Clinical study of HCFU and radiation therapy in head and neck cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil | 1986 |
Combination chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1986 |
Combination chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1986 |
Combination chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1986 |
Combination chemotherapy in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1986 |
[Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application].
Topics: Adult; Aged; Combined Modality Therapy; Drug Resistance; Drug Therapy, Combination; Esophageal Neopl | 1986 |
[Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application].
Topics: Adult; Aged; Combined Modality Therapy; Drug Resistance; Drug Therapy, Combination; Esophageal Neopl | 1986 |
[Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application].
Topics: Adult; Aged; Combined Modality Therapy; Drug Resistance; Drug Therapy, Combination; Esophageal Neopl | 1986 |
[Multidisciplinary treatment of the head and neck cancer--FAR therapy and its modification and application].
Topics: Adult; Aged; Combined Modality Therapy; Drug Resistance; Drug Therapy, Combination; Esophageal Neopl | 1986 |
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice.
Topics: Animals; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance | 1986 |
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice.
Topics: Animals; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance | 1986 |
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice.
Topics: Animals; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance | 1986 |
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice.
Topics: Animals; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Chemoradiotherapy as initial management in patients with squamous cell carcinoma of the head and neck.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
[Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; He | 1986 |
[Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; He | 1986 |
[Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; He | 1986 |
[Clinical study of HCFU in combination with irradiation therapy in squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Fluorouracil; He | 1986 |
[Advanced head and neck carcinoma treated with combined cisplatin and fluorouracil infusions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1986 |
[Advanced head and neck carcinoma treated with combined cisplatin and fluorouracil infusions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1986 |
[Advanced head and neck carcinoma treated with combined cisplatin and fluorouracil infusions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1986 |
[Advanced head and neck carcinoma treated with combined cisplatin and fluorouracil infusions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Head a | 1986 |
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
[Combination cisplatin, 5-FU and low-dose radiotherapy in recurrent carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1986 |
[Combination cisplatin, 5-FU and low-dose radiotherapy in recurrent carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1986 |
[Combination cisplatin, 5-FU and low-dose radiotherapy in recurrent carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1986 |
[Combination cisplatin, 5-FU and low-dose radiotherapy in recurrent carcinomas of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1986 |
Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1986 |
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1985 |
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1985 |
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1985 |
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
Maintenance chemotherapy for high-risk patients. A preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Moda | 1985 |
Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Female; Fluorouracil | 1985 |
Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Female; Fluorouracil | 1985 |
Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Female; Fluorouracil | 1985 |
Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Female; Fluorouracil | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
[An evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy of head and neck cancer].
Topics: Brachytherapy; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, | 1985 |
[An evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy of head and neck cancer].
Topics: Brachytherapy; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, | 1985 |
[An evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy of head and neck cancer].
Topics: Brachytherapy; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, | 1985 |
[An evaluation of multi-disciplinary treatment combined with intra-arterial chemotherapy of head and neck cancer].
Topics: Brachytherapy; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, | 1985 |
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 1986 |
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 1986 |
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 1986 |
Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Female; Fluoroura | 1986 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
The activity of a single-agent 5-fluorouracil infusion in advanced and recurrent head and neck cancer.
Topics: Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasm | 1986 |
Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Fluorouracil; Head and Neck | 1985 |
Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Fluorouracil; Head and Neck | 1985 |
Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Fluorouracil; Head and Neck | 1985 |
Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Combinations; Fluorouracil; Head and Neck | 1985 |
Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1985 |
Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1985 |
Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1985 |
Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
Phase I-II trial with cisplatin and 5-FU in recurrent head and neck cancer: an effective outpatient schedule.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Ce | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1985 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |
[Chemotherapy by intra-arterial path in cancer of the "head and neck" region].
Topics: Antineoplastic Agents; Bleomycin; Facial Neoplasms; Fluorouracil; Head; Head and Neck Neoplasms; Hum | 1971 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
Factors influencing the success of arterial infusion chemotherapy for cancer of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell | 1972 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
[Intra-arterial chemotherapy of head and neck tumors: statistical study of 129 cases treated at the Institut Gustave Roussy].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Facial Neoplasms | 1973 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
Protracted intra-arterial chemotherapy with sequential courses of antimitotics and hydrogen peroxyde in the treatment of head and neck tumors.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
Protracted intra-arterial chemotherapy with sequential courses of antimitotics and hydrogen peroxyde in the treatment of head and neck tumors.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
Protracted intra-arterial chemotherapy with sequential courses of antimitotics and hydrogen peroxyde in the treatment of head and neck tumors.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
Protracted intra-arterial chemotherapy with sequential courses of antimitotics and hydrogen peroxyde in the treatment of head and neck tumors.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Regional arterial chemotherapy for advanced carcinoma of the head and neck. A ten-year review.
Topics: Antimetabolites; Antineoplastic Agents; Carotid Arteries; Catheterization; Digestive System; Dose-Re | 1973 |
Triple drug intra-arterial infusion combined with x-ray therapy and surgery for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Head and N | 1974 |
Triple drug intra-arterial infusion combined with x-ray therapy and surgery for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Head and N | 1974 |
Triple drug intra-arterial infusion combined with x-ray therapy and surgery for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Head and N | 1974 |
Triple drug intra-arterial infusion combined with x-ray therapy and surgery for head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; Fluorouracil; Head and N | 1974 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
[Characteristics of the cell mitotic cycle and the possibility of enhancing the effect of radiotherapy].
Topics: Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Deoxyuridine; DNA, Neoplasm; Esopha | 1974 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy.
Topics: Antineoplastic Agents; Brachial Artery; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Art | 1972 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Intra-arterial infusion for head and neck cancers.
Topics: Aged; Antineoplastic Agents; Brachiocephalic Trunk; Carcinoma, Squamous Cell; Carotid Arteries; Cath | 1973 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
[Clinical and experimental studies on radiotherapy of inoperable tumors following partial synchronization].
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; DNA, Neoplasm; Fluorouracil; Head and Nec | 1974 |
[Clinical and experimental studies on radiotherapy of inoperable tumors following partial synchronization].
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; DNA, Neoplasm; Fluorouracil; Head and Nec | 1974 |
[Clinical and experimental studies on radiotherapy of inoperable tumors following partial synchronization].
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; DNA, Neoplasm; Fluorouracil; Head and Nec | 1974 |
[Clinical and experimental studies on radiotherapy of inoperable tumors following partial synchronization].
Topics: Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; DNA, Neoplasm; Fluorouracil; Head and Nec | 1974 |
Regional chemotherapy of cancer of the head and neck.
Topics: Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head; Head | 1966 |
Regional chemotherapy of cancer of the head and neck.
Topics: Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head; Head | 1966 |
Regional chemotherapy of cancer of the head and neck.
Topics: Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head; Head | 1966 |
Regional chemotherapy of cancer of the head and neck.
Topics: Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head; Head | 1966 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
[Combined cytostatic and irradiation treatment of head and neck tumors using the synchronization effect].
Topics: Aged; Cobalt Isotopes; Ear Neoplasms; Female; Fluorouracil; Head; Head and Neck Neoplasms; Humans; M | 1972 |
[Combined cytostatic and irradiation treatment of head and neck tumors using the synchronization effect].
Topics: Aged; Cobalt Isotopes; Ear Neoplasms; Female; Fluorouracil; Head; Head and Neck Neoplasms; Humans; M | 1972 |
[Combined cytostatic and irradiation treatment of head and neck tumors using the synchronization effect].
Topics: Aged; Cobalt Isotopes; Ear Neoplasms; Female; Fluorouracil; Head; Head and Neck Neoplasms; Humans; M | 1972 |
[Combined cytostatic and irradiation treatment of head and neck tumors using the synchronization effect].
Topics: Aged; Cobalt Isotopes; Ear Neoplasms; Female; Fluorouracil; Head; Head and Neck Neoplasms; Humans; M | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Intra-arterial infusion. A seven-year study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; Injections, Intra-Art | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; | 1972 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Seventy-five cases of solid tumours treated by a modified quadruple chemotherapy regime.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Child; Cyclophosphamide; Female; Flu | 1971 |
Intra-arterial chemotherapy with surgery or radiotherapy in tumours of the head-neck region.
Topics: Fluorouracil; Head; Head and Neck Neoplasms; Injections, Intra-Arterial; Methotrexate; Neoplasms | 1971 |
Intra-arterial chemotherapy with surgery or radiotherapy in tumours of the head-neck region.
Topics: Fluorouracil; Head; Head and Neck Neoplasms; Injections, Intra-Arterial; Methotrexate; Neoplasms | 1971 |
Intra-arterial chemotherapy with surgery or radiotherapy in tumours of the head-neck region.
Topics: Fluorouracil; Head; Head and Neck Neoplasms; Injections, Intra-Arterial; Methotrexate; Neoplasms | 1971 |
Intra-arterial chemotherapy with surgery or radiotherapy in tumours of the head-neck region.
Topics: Fluorouracil; Head; Head and Neck Neoplasms; Injections, Intra-Arterial; Methotrexate; Neoplasms | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
Historic and current intra-arterial chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catheterization; Chemotherapy, Cancer, Regional Per | 1970 |
[Intracarotid chemotherapy in the treatment of advanced cancers of the head and neck. Study of 100 cases].
Topics: Facial Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans | 1965 |
[Intracarotid chemotherapy in the treatment of advanced cancers of the head and neck. Study of 100 cases].
Topics: Facial Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans | 1965 |
[Intracarotid chemotherapy in the treatment of advanced cancers of the head and neck. Study of 100 cases].
Topics: Facial Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans | 1965 |
[Intracarotid chemotherapy in the treatment of advanced cancers of the head and neck. Study of 100 cases].
Topics: Facial Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans | 1965 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
[Clinical use of 5-fluorouracil in surgical field].
Topics: Adult; Aged; Animals; Breast Neoplasms; Dogs; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1969 |
Treatment of advanced cancer of the head and neck.
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal | 1970 |
Treatment of advanced cancer of the head and neck.
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal | 1970 |
Treatment of advanced cancer of the head and neck.
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal | 1970 |
Treatment of advanced cancer of the head and neck.
Topics: Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal | 1970 |
[Radiotherapy of synchronized tumors; 1st results].
Topics: Aged; Cell Division; Cell Transformation, Neoplastic; Female; Fluorouracil; Head; Head and Neck Neop | 1970 |
[Radiotherapy of synchronized tumors; 1st results].
Topics: Aged; Cell Division; Cell Transformation, Neoplastic; Female; Fluorouracil; Head; Head and Neck Neop | 1970 |
[Radiotherapy of synchronized tumors; 1st results].
Topics: Aged; Cell Division; Cell Transformation, Neoplastic; Female; Fluorouracil; Head; Head and Neck Neop | 1970 |
[Radiotherapy of synchronized tumors; 1st results].
Topics: Aged; Cell Division; Cell Transformation, Neoplastic; Female; Fluorouracil; Head; Head and Neck Neop | 1970 |
[Innovation in radiotherapy of advanced malignant tumors].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Lar | 1967 |
[Innovation in radiotherapy of advanced malignant tumors].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Lar | 1967 |
[Innovation in radiotherapy of advanced malignant tumors].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Lar | 1967 |
[Innovation in radiotherapy of advanced malignant tumors].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Hyperbaric Oxygenation; Lar | 1967 |
Chemotherapy for tumors of chest wall and base of neck by arterial infusion.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head and Neck Neoplasms; He | 1968 |
Chemotherapy for tumors of chest wall and base of neck by arterial infusion.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head and Neck Neoplasms; He | 1968 |
Chemotherapy for tumors of chest wall and base of neck by arterial infusion.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head and Neck Neoplasms; He | 1968 |
Chemotherapy for tumors of chest wall and base of neck by arterial infusion.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Head and Neck Neoplasms; He | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Topical chemotherapy of cutaneous malignancy of the head and neck.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Kera | 1969 |
Topical chemotherapy of cutaneous malignancy of the head and neck.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Kera | 1969 |
Topical chemotherapy of cutaneous malignancy of the head and neck.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Kera | 1969 |
Topical chemotherapy of cutaneous malignancy of the head and neck.
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fluorouracil; Head and Neck Neoplasms; Humans; Kera | 1969 |